1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
PUBLIC RELEASE DRAFT
May 2024
EPA Document #EPA-740-D-24-010
May 2024
United States Office of Chemical Safety and
Environmental Protection Agency Pollution Prevention
Draft Non-cancer Human Health Hazard Assessment for
Diisononyl Phthalate (DINP)
Technical Support Document for the Draft Risk Evaluation
CASRNs: 28553-12-0 and 68515-48-0
(Representative Structure)
May 2024
-------
PUBLIC RELEASE DRAFT
May 2024
27 TABLE OF CONTENTS
28 SUMMARY 9
29 1 INTRODUCTION 11
30 1.1 Human Epidemiologic Data: Approach and Preliminary Conclusions 11
31 1.2 Laboratory Animal Findings: Summary of Existing Assessments from Other Regulatory
32 Organizations 13
33 1.3 Laboratory Animal Data: Approach and Methodology 16
34 1.3,1 Approach to Identifying and Integrating Laboratory Animal Data 16
35 1,3,2 New Literature Identified and Hazards of Focus for DINP 18
36 2 TOXICOKINETICS 19
37 2.1 Oral Route 19
38 2.2 Inhalation Route 21
39 2.3 Dermal Route 21
40 2.4 Summary 22
41 3 HAZARD IDENTIFICATION 23
42 3.1 Developmental and Reproductive Toxicity 23
43 3.1.1 Summary of Available Epidemiological Studies 23
44 3,1,2 Summary of Laboratory Animals Studies 23
45 3.1.2.1 Developing Male Reproductive System 24
46 3.1.2.1.1 Summary of Studies Evaluating Effects on the Developing Male Reproductive
47 System 24
48 3.1.2.1.2 Mode of Action for Phthalate Syndrome 29
49 3.1.2.2 Other Developmental and Reproductive Outcomes 30
50 3.1.2.3 Conclusions on Reproductive and Developmental Toxicity 41
51 3.2 Liver Toxicity 42
52 3.3 Kidney Toxicity 44
53 3.4 Neurotoxicity 51
54 3.5 Cardiovascular Health Effects 58
55 3.6 Immune Sy stem Toxi city 61
56 3.7 Musculoskeletal Toxicity 67
57 4 DOSE-REPONSE ASSESSMENT 69
58 4.1 Selection of Studies and Endpoints for Non-cancer and Threshold Cancer Health Effects 69
59 4.1.1 Non-cancer Oral Points of Departure for Acute Exposures 69
60 4,1,2 Non-cancer Oral Points of Departure for Intermediate Exposures 76
61 4.1.3 Non-cancer Oral Points of Departure for Chronic Exposures 81
62 4.2 Weight of Scientific Evidence 88
63 4.2.1 POD for Acute and Intermediate Durations 88
64 4,2,2 POD for Chronic Durations 89
65 5 CONSIDERATION OF PESS AND AGGEGRATE EXPOSURE 91
66 5.1 Hazard Considerations for Aggregate Exposure 91
67 5.2 PESS Based on Greater Susceptibility 91
68 6 POINTS OF DEPARTURE USED TO ESTIMATE RISKS FROM DINP EXPOSURE 99
69 REFERENCES 101
Page 2 of 184
-------
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
PUBLIC RELEASE DRAFT
May 2024
Appendix A EXISTING ASSESSMENTS FROM OTHER REGULATORY AGENCIES OF
DINP 116
Appendix B SUMMARY OF LIVER TOXICITY STUDIES 120
Appendix C FETAL TESTICULAR TESTOSTERONE AS AN ACUTE EFFECT 137
Appendix D SUMMARY OF EPIDEMIOLOGY STUDIES ON REPRODUCTIVE
OUTCOMES 138
Appendix E BENCHMARK DOSE ANALYSIS OF LINGTON ET AL. (1997) 141
E.l Background 141
E.2 Summary of BMD Modeling Approach 141
E,3 Summary of BMD Modeling Results 142
E.4 Continuous Endpoints 143
E.4.1 Relative Liver Weight - Terminal Sacrifice 143
E.4.1.1 Male F344 Rats 143
E.4.1.2 Female F344 Rats 148
E.4.2 Serum ALT - Male F344 Rats 151
E.4.2.1 6-Month Sacrifice 151
E.4.2.2 18-Month Sacrifice 156
E,5 Dichotomous Endpoints 161
E.5.1 Focal Necrosis in the liver 161
E.5.1.1 Male F344 Rats 161
E.5.1.2 Female F344 Rats 167
E.5.2 Spongiosis hepatis in the liver - Male F344 Rats 172
E.5.3 Sinusoid Ectasia in the Liver Male F344 Rats 177
Appendix F CALCULATING DAILY ORAL HUMAN EQUIVALENT DOSES AND
HUMAN EQUIVALENT CONCENTRATIONS 182
F.l DINP Non-cancer HED and HEC Calculations for Acute and Intermediate Duration
Exposures 183
F.2 DINP Non-cancer HED and HEC Calculations for Chronic Exposures 184
LIST OF TABLES
Table 1-1. Summary of DINP Non-cancer PODs Selected for Use by other Regulatory Organizations. 14
Table 2-1. Absorption and Excretion Summary of DINP 20
Table 2-2. Metabolites of DINP Identified in Urine from Rats and Humans after Oral Administration. 21
Table 3-1. Summary of DINP Studies Evaluating Effects on the Developing Male Reproductive System
25
Table 3-2. Summary of DINP Studies Evaluating Effects on Reproduction and Development 31
Table 3-3. Mean Percent of Fetuses in Litter with Skeletal Variations (Waterman et al., 1999) 35
Table 3-4. Incidence of Visceral, Skeletal, and Soft Tissue Variations (Hellwig et al., 1997) 36
Table 3-5. Mean Measured Doses (mg/kg-day) from the One-Generation Study of DINP in SD Rats
(Waterman et al., 2000; Exxon Biomedical, 1996a) 37
Table 3-6. F1 Offspring Postnatal Body Weight (Grams) from the One-Generation Study of
Reproduction in SD Rats (Waterman et al., 2000; Exxon Biomedical, 1996a) 38
Table 3-7. Mean Measured Doses (mg/kg-day) from the Two-Generation Study of DINP in SD Rats
(Waterman et al., 2000; Exxon Biomedical, 1996b) 39
Page 3 of 184
-------
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
PUBLIC RELEASE DRAFT
May 2024
Table 3-8. F1 and F2 Offspring Postnatal Body Weight (Grams) from the Two-Generation Study of
Reproduction in SD Rats (Waterman et al., 2000; Exxon Biomedical, 1996b) 39
Table 3-9. Incidence and Severity of Selected Non-neoplastic Lesions in the Kidneys of Male and
Female F344 Rats Fed DINP for 2 Years (Covance Labs, 1998c) 48
Table 3-10. Summary of Study Evaluating Cardiovascular Outcomes 60
Table 4-1. Summary of NASEM (2017) Meta-Analysis and BMD Modeling for Effects of DINP in Fetal
Testosterone 72
Table 4-2. Dose-Response Analysis of Selected Developmental Studies Considered for Deriving the
Acute Non-cancer POD 74
Table 4-3. Dose-Response Analysis of Selected Studies Considered for Deriving the Intermediate Non-
ancer POD 79
Table 4-4. Summary of BMD Model Results from Lington et al. (1997) 83
Table 4-5. Dose-Response Analysis of Selected Studies Considered for Deriving the Chronic Non-
cancer POD 85
Table 5-1. PESS Evidence Crosswalk for Biological Susceptibility Considerations 93
Table 6-1. Non-cancer HECs and HEDs Used to Estimate Risks 100
LIST OF FIGURES
Figure 1-1. Overview of DINP Human Health Hazard Assessment Approach 17
Figure 2-1. Postulated DINP Metabolism in Humans (Koch and Angerer, 2007) 19
Figure 3-1. Hypothesized Phthalate Syndrome Mode of Action Following Gestational Exposure 29
Figure 4-1. Dose-Response Array of Studies Considered for Deriving the Acute Duration Non-cancer
POD 71
Figure 4-2. Dose-Response Array of Studies Considered for Deriving the Intermediate Duration Non-
cancer POD 78
Figure 4-3. Dose Response Array of Studies Considered for Considered for Deriving the Chronic Non-
cancer POD 84
LIST OF APPENDIX TABLES
TableApx A-l. Summary of Peer Review, Public Comments, and Systematic Review for Existing
Assessments of DINP 116
Table Apx B-l. Summary of Liver Effects Reported in Animal Toxicological Studies Following Short-
Term Exposure to DINP 123
Table Apx B-2. Summary of Liver Effects Reported in Animal Toxicological Studies Following
Subchronic Exposure to DINP 127
Table Apx B-3. Incidence of Selected Non-neoplastic Hepatic Lesions in F344 Rats Exposed to DINP
for 24 Months (Lington et al., 1997) 130
Table Apx B-4. Incidence of Selected Hepatic Lesions in F344 Rats Exposed to DINP in the Diet for 2
Years (Covance Labs, 1998c) 131
Table Apx B-5. Overall Incidence of Selected Tumors in Male and Female Sprague Dawley Rats
Exposed to DINP for 2 Years (Bio/dynamics, 1987) 133
Table Apx B-6. Incidence of Selected Non-neoplastic Lesions in B6C3F1 Mice Exposed to DINP in the
Diet for 2 Years (Covance Labs, 1998b) 134
Table Apx B-7. Summary of Liver Effects Reported in Animal Toxicological Studies Following
Chronic Exposure to DINP 135
Table Apx E-l. Summary of Benchmark Dose Modeling Results from Selected Endpoints in Male and
Female F344 Rats Following 2-Year Exposure to DINP (Lington et al., 1997) 142
Page 4 of 184
-------
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
PUBLIC RELEASE DRAFT
May 2024
TableApx E-2. Dose-Response Modeling Data for Relative Liver Weight at Terminal Sacrifice in Male
F344 Rats Following 2-Year Exposure to DINP (Lington et al., 1997) 143
Table Apx E-3. Summary of Benchmark Dose Modeling Results for Relative Liver Weight at Terminal
Sacrifice in Male F344 Rats Following 2-Year Exposure to DINP (Constant Variance)
(Lington et al., 1997) 144
Table Apx E-4. Dose-Response Modeling Data for Relative Liver Weight at Terminal Sacrifice in
Female F344 Rats Following 2-Year Exposure to DINP (Lington et al., 1997) 148
Table Apx E-5. Summary of Benchmark Dose Modeling Results for Relative Liver Weight at Terminal
Sacrifice in Female F344 Rats Following 2-Year Exposure to DINP (Non-Constant
Variance) (Lington et al., 1997) 149
Table Apx E-6. Dose-Response Modeling Data for Serum ALT Levels in Male F344 Rats Following 6-
Month Exposure to DINP (Lington et al., 1997) 151
Table Apx E-7. Summary of Benchmark Dose Modeling Results for Serum ALT Levels in Male F344
Rats Following 6-Month Exposure to DINP (Non-constant Variance) (Lington et al.,
1997) 152
Table Apx E-8. Dose-Response Modeling Data for Serum ALT Levels in Male F344 Rats Following
18-Month Exposure to DINP (Lington et al., 1997) 156
Table Apx E-9. Summary of Benchmark Dose Modeling Results for Serum ALT Levels in Male F344
Rats Following 18-Month Exposure to DINP (Non-constant Variance) (Lington et al.,
1997) 157
Table Apx E-10. Dose-Response Modeling Data for Focal Necrosis of the Liver in Male F344 Rats
Following 2-Year Exposure to DINP (Lington et al., 1997) 161
Table Apx E-l 1. Summary of Benchmark Dose Modeling Results for Focal Necrosis of the Liver in
Male F344 Rats Following 2-Year Exposure to DINP (Lington et al., 1997) 162
Table Apx E-12. Dose-Response Modeling Data for Focal Necrosis of the Liver in Female F344 Rats
Following 2-Year Exposure to DINP (Lington et al., 1997) 167
TableApx E-13. Summary of Benchmark Dose Modeling Results for Focal Necrosis of the Liver in
Female F344 Rats Following 2-year Exposure to DINP (Lington et al., 1997) 168
Table Apx E-14. Dose-Response Modeling Data for Spongiosis Hepatis of the Liver in Male F344 Rats
Following 2-Year Exposure to DINP (Lington et al., 1997) 172
TableApx E-15. Summary of Benchmark Dose Modeling Results for Spongiosis Hepatis of the Liver
in Male F344 Rats Following 2-Year Exposure to DINP (Lington et al., 1997) 173
Table Apx E-16. Dose-Response Modeling Data for Sinusoid Ectasia of the Liver in Male F344 Rats
Following 2-Year Exposure to DINP (Lington et al., 1997) 177
Table Apx E-17. Summary of Benchmark Dose Modeling Results for Sinusoid Ectasia of the Liver in
Male F344 Rats Following 2-Year Exposure to DINP (Lington et al., 1997) 178
Page 5 of 184
-------
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
PUBLIC RELEASE DRAFT
May 2024
ABBREVIATIONS AND ACRONYMS
a2u-globulin
ACE
ADME
AGD
ALP
ALT
AST
AT1R
BMD
BMDL
CASRN
CPSC
DINP
ECB
ECHA
EFSA
eNOS
EPA
F344
GD
GLP
GSH
HEC
HED
IFN
Ig
IL
LABC
LOAEL
LOEL
MNG
MOA
MOE
MWM
NFkB
NICNAS
NOAEL
NOEL
Nrf2
NTP-CERHR
OCSPP
OECD
8-OH-dG
OPPT
PECO
PESS
PND
POD
Alpha 2u-globulin
Angiotensin converting enzyme
Absorption, distribution, metabolism, and excretion
Anogenital distance
Alkaline phosphatase
Alanine aminotransferase
Aspartate aminotransferase
Angiotensin-II type 1 receptor
Benchmark dose
Benchmark dose (lower confidence limit)
Chemical Abstracts Service registry number
Consumer Product Safety Commission (U.S.)
Diisononyl phthalate
European Chemicals Bureau
European Chemicals Agency
European Food Safety Authority
Endothelial nitric oxide synthase
Environmental Protection Agency (U.S.)
Fischer 344 (rat)
Gestation day
Good Laboratory Practice
Glutathione
Human equivalent concentration
Human equivalent dose
Interferon
Immunoglobulin
Interleukin
Levator ani-bulbocavernosus muscle
Lowest-ob served-adverse-effect level
Lowest-ob served-effect level
Multinucleated gonocytes
Mode of action
Margin of exposure
Morris Water Maze
Nuclear factor kappa B
National Industrial Chemicals Notification and Assessment Scheme
No-observed-adverse-effect level
No-observed-effect level
Nuclear factor erythroid 2-related factor 2
National Toxicology Program Center for the Evaluation of Risks to Human Reproduction
Office of Chemical Safety and Pollution Prevention
Organisation for Economic Co-operation and Development
8-Hydroxydeoxyguanosine
Office of Pollution Prevention and Toxics
Population, exposure, comparator, and outcome
Potentially exposed or susceptible subpopulations
Postnatal day
Point of departure
Page 6 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
247
PPARa
Peroxisome proliferator activated receptor alpha
248
ROS
Reactive oxygen species
249
SACC
Science Advisory Committee on Chemicals
250
SD
Sprague-Dawley (rat)
251
TNFa
Tumor necrosis factor alpha
252
TSCA
Toxic Substances Control Act
253
UF
Uncertainty factor
254
U.S.
United States
Page 7 of 184
-------
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
PUBLIC RELEASE DRAFT
May 2024
ACKNOWLEDGEMENTS
This report was developed by the United States Environmental Protection Agency (U.S. EPA or the
Agency), Office of Chemical Safety and Pollution Prevention (OCSPP), Office of Pollution Prevention
and Toxics (OPPT).
Acknowledgements
The Assessment Team gratefully acknowledges the participation, input, and review comments from
OPPT and OCSPP senior managers and science advisors and assistance from EPA contractors SRC
(Contract Number 68HERH19D0022). Special acknowledgement is given for the contributions of
technical experts from EPA's Office of Research and Development (ORD), including Jeff Gift, and
Geoffrey Collin Peterson for their benchmark dose modeling support.
As part of an intra-agency review, the draft DINP Risk Evaluation was provided to multiple EPA
Program Offices for review. Comments were submitted by Comments were submitted by EPA's Office
of Air and Radiation (OAR.), Office of Children's Health Protection (OCHP), Office of General Counsel
(OGC), ORD, and Office of Water (OW).
Docket
Supporting information can be found in the public docket, Docket ID (EPA.-H.Q-OPPT-2018-0436).
Disclaimer
Reference herein to any specific commercial products, process or service by trade name, trademark,
manufacturer, or otherwise does not constitute or imply its endorsement, recommendation, or favoring
by the United States Government.
Authors: John Allran, Anthony Luz, Ashley Peppriell, Myles Hodge, Sailesh Surapureddi, Christelene
Horton, Brandall Ingle-Carlson, Collin Beachum (Branch Chief)
Contributors: Susanna Wegner, Abhilash Sasidharan
Technical Support: Mark Gibson, Hillary Hollinger
This report was reviewed and cleared by OPPT and OCSPP leadership.
Page 8 of 184
-------
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
PUBLIC RELEASE DRAFT
May 2024
SUMMARY
This technical support document for diisononyl phthalate (DINP) summarizes the non-cancer hazards
associated with exposure to DINP and identifies the proposed points of departure (PODs) to be used to
estimate risks from DINP exposures in the draft risk evaluation of DINP. EPA summarizes the cancer
hazards associated with exposure to DINP in a separate technical support document, the Draft Cancer
Human Health Hazard Assessment for Diisononyl Phthalate (DINP) ( 2024a).
EPA identified developmental, liver, and kidney toxicity as the most sensitive and robust non-cancer
hazards associated with oral exposure to DINP in experimental animal models (Section 3.1 through 3.3).
Liver, kidney, and developmental toxicity were also identified as the most sensitive and robust non-
cancer effects following oral exposure to DINP by existing assessments of DINP—including those by
the U.S. Consumer Product Safety Commission ( 3. 2014). Health Canada (ECCC/HC. 2020).
European Chemicals Agency (ECHA. 2013b). European Food Safety Authority ( ), and the
Australian National Industrial Chemicals Notification and Assessment Scheme (NICNA.S. 2015). EPA
is proposing a point of departure (POD) of 49 mg/kg-day (human equivalent dose [HED] of 12 mg/kg-
day) to estimate non-cancer risks from oral exposure to DINP for acute and intermediate durations of
exposure in the draft risk evaluation of DINP. The proposed POD was derived through meta-regression
analysis and benchmark dose (BMD) modeling of fetal testicular testosterone data from two prenatal
exposure studies of rats by the National Academies of Sciences, Engineering, and Medicine (NA.SEM.
2017). The POD of 49 mg/kg-day is the 95 percent lower confidence limit of the BMD associated with a
benchmark response (BMR) of 5 percent.
As discussed further in Sections 4.1.1 and 4.1.2, several additional acute and intermediate duration
studies of DINP provide similar, although less-sensitive, candidate PODs, which further support EPA's
proposal to use the selected POD of 12 mg/kg-day for decreased fetal testicular testosterone production.
The Agency has performed % body weight scaling to yield the HED and is applying the animal to
human extrapolation factor {i.e., interspecies extrapolation; UFa) of 3x and an within human variability
extrapolation factor {i.e., intraspecies extrapolation; UFh) of 10x. Thus, a total uncertainty factor (UF)
of 30x is applied for use as the benchmark margin of exposure (MOE). Based on the strengths,
limitations, and uncertainties discussed Section 4.2.1, EPA has robust overall confidence in the
proposed POD based on fetal testicular testosterone for use in characterizing risk from exposure
to DINP for acute and intermediate exposure scenarios. For purposes of assessing non-cancer risks,
the selected POD is considered most applicable to women of reproductive age, pregnant women, and
infants. Use of this POD to assess risk for other age groups {e.g., older children and adult males) is
conservative.
EPA is proposing a no-observed-adverse-effect level (NOAEL) of 15 mg/kg-day (HED of 3.5 mg/kg-
day) from a high quality 2-year study of rats based on liver toxicity to estimate non-cancer risks from
oral exposure to DINP for chronic durations of exposure in the draft risk evaluation of DINP. More
specifically, liver toxicity in the key study (Lington et ai. 1997; Bio/dynamics. 1986) was characterized
by increased liver weight, increased serum alanine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), and histopathological findings {e.g., focal necrosis, spongiosis
hepatis). EPA considers the observed liver effects to be adverse and relevant for extrapolating human
risk from chronic exposures ( 1002a). As discussed further in Sections 4.1.1 through 4.1.3,
several additional studies of DINP provide similar, although less-sensitive, candidate PODs, which
further support EPA's decision to use the selected POD of 3.5 mg/kg-day for chronic exposures. The
Agency has performed 3/4 body weight scaling to yield the HED and is applying the animal to human
extrapolation factor {i.e., interspecies extrapolation; UFA) of 3/ and an within human variability
extrapolation factor {i.e., intraspecies extrapolation; UFH) of 10x. Thus, a total UF of 30x is applied for
Page 9 of 184
-------
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
PUBLIC RELEASE DRAFT
May 2024
use as the benchmark MOE. Overall, based on the strengths, limitations, and uncertainties discussed in
Section 4.2.2, EPA has robust overall confidence in the proposed POD based on hepatic outcomes
for use in characterizing risk from exposure to DINP for chronic exposure scenarios.
No data were available for the dermal or inhalation routes that were suitable for deriving route-specific
PODs. Therefore, EPA used the acute/intermediate and chronic oral PODs to evaluate risks from dermal
exposure to DINP. Differences in absorption will be accounted for in dermal exposure estimates in the
draft risk evaluation for DINP. For the inhalation route, EPA extrapolated the oral HED to an inhalation
human equivalent concentration (HEC) using a human body weight and breathing rate relevant to a
continuous exposure of an individual at rest ( 94). The oral HED and inhalation HEC values
selected by EPA to estimate non-cancer risk from acute/intermediate and chronic exposure to DINP in
the draft risk evaluation of DINP are summarized in Table ES-1 and Section 6.
EPA is soliciting comments from the Science Advisory Committee on Chemicals (SACC) on charge
questions and comments from the public for the upcoming SACC meeting.
Table ES-1. Non-cancer HECs and HEDs Uset
to Estimate
iisks
Exposure
Scenario
Target
Organ
System
Species
(Sex)
Duration
POD
(mg/kg-
day)
Effect
HEC
(mg/m3)
[ppm]
HED
(mg/
kg-day)
Benchmark
MOE
Reference
Acute and
Intermediate
Development
Rat
5 to 14 days
throughout
gestation
BMDLs
= 49"
i fetal testicular
testosterone
63
[3.7]
12
UFa= 3
UFh=10
Total UF=30
(NASEM.
2017)
Chronic
Liver
Rat
2 years
NOAEL
= 15
t liver weight,
t serum
chemistry,
histopathology''
19
[1.1]
3.5
UFa= 3
UFh=10
Total UF=30
(Lington et
al. 1997;
Bio/dynamics
6)c
HEC = human equivalent concentration; HED = human equivalent dose; POD = point of departure; MOE = margin of exposure;
BMDL = benchmark dose lower limit; UF = uncertainty factor; NOAEL = no observable adverse effect level
" The BMDL^ was derived by NASEM (2017) through meta-regression and BMD modeling of fetal testicular testosterone data from
two studies of DINP with rats (Boberg et al, 2011; Hannas et al, 2011). R code supporting NASEM's meta-regression and BMD
analysis of DINP is publicly available through GitlTiib.
4 Liver toxicity included increased relative liver weight, increased serum chemistry {i.e., AST, ALT, ALP), and histopathologic
findings (e.g., focal necrosis, spongiosis hepatis) in F344 rats following 2 years of dietary exposure to DINP (Lington et al, 1997;
Bio/dynamics, 1986).
c The Lington study presents a portion of the data from a larger good laboratory practice (GLP)-certified study by Bio/dynamics
(1986).
Page 10 of 184
-------
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
PUBLIC RELEASE DRAFT
May 2024
1 INTRODUCTION
On May 24, 2019, EPA received a request, pursuant to 40 CFR 702.37, from ExxonMobil Chemical
Company, through the American Chemistry Council's High Phthalates Panel (ACC HPP. 2019). to
conduct a risk evaluation for diisononyl phthalate (DINP) (CASRNs 28553-12-0 and 68515-48-0)
(Docket ID: EPA-HQ-OPPT-2018-0436). EPA determined that these two CASRNs should be treated as
a category of chemical substances as defined in 15 U.S.C § 2625(c). On August 19, 2019, EPA opened a
45-day public comment period to gather information relevant to the requested risk evaluation. EPA
reviewed the request (along with additional information received during the public comment period) and
assessed whether the circumstances identified in the request constitute conditions of use under 40 CFR
702.33, and whether those conditions of use warrant inclusion within the scope of a risk evaluation for
DINP. EPA determined that the request meets the applicable regulatory criteria and requirements, as
prescribed under 40 CFR 702.37. The Agency granted the request on December 2, 2019, and published
the draft and final scope documents for DINP in August 2020 and 2021, respectively (I v << \
2020).
Following publication of the final scope document, one of the next steps in the TSCA risk evaluation
process is to identify and characterize the human health hazards of DINP and conduct a dose-response
assessment to determine the toxicity values to be used to estimate risks from DINP exposures. This
technical support document for DINP summarizes the non-cancer hazards associated with exposure to
DINP and proposes toxicity values to be used to estimate non-cancer risks from DINP exposures. EPA
summarizes the cancer hazards associated with exposure to DINP in a separate technical support
document, the Draft Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP) (U.S.
EPA. 2024aY
Over the past several decades the human health effects of DINP have been reviewed by several
regulatory and authoritative agencies, including the: U.S. Consumer Product Safety Commission (U.S.
CPSC); Health Canada; U.S. National Toxicology Program Center for the Evaluation of Risks to Human
Reproduction (NTP-CERHR); European Chemicals Bureau (ECB); European Chemicals Agency
(ECHA); European Food Safety Authority (EFSA); the Australian National Industrial Chemicals
Notification and Assessment Scheme (NICNAS); The National Academies of Sciences, Engineering,
and Medicine (NASEM); and U.S EPA. EPA relied on information published in existing assessments by
these regulatory and authoritative agencies as a starting point for its human health hazard assessment of
DINP. Additionally, EPA considered new literature published since the most recent existing assessments
of DINP to determine if newer information might support the identification of new human health
hazards or lower PODs for use in estimating human risk. EPA's process for considering and
incorporating new DINP literature is described in the Draft Risk Evaluation for Diisononyl Phthalate
(DINP) - Systematic Review Protocol (also referred to as the Draft DINP Systematic Review Protocol)
(I E024b). EPA's approach and methodology for identifying and using human epidemiologic
data and experimental laboratory animal data is described in Section 1.1.
1.1 Human Epidemiologic Data: Approach and Preliminary Conclusions
To identify and integrate human epidemiologic data into the draft DINP Risk Evaluation, EPA first
reviewed existing assessments of DINP conducted by regulatory and authoritative agencies, as well as
several systematic reviews of epidemiologic studies of DINP published by U.S. EPA Integrated Risk
Information System (IRIS) program. Existing assessments reviewed by EPA are listed below. As
described further in Appendix A, most of these assessments have been subjected to peer-review and/or
public comment periods and have employed formal systematic review protocols.
Page 11 of 184
-------
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
PUBLIC RELEASE DRAFT
May 2024
• Supporting documentation: Evaluation of epidemiologic studies on phthalate compounds and
their metabolites for hormonal effects, growth and development and reproductive parameters
(Health Canada. 2018b);
• Supporting documentation: Evaluation of epidemiologic studies on phthalate compounds and
their metabolites for effects on behaviour and neurodevelopment, allergies, cardiovascular
function, oxidative stress, breast cancer, obesity, and metabolic disorders (Health Canada.
2018a):
• Phthalate exposure and male reproductive outcomes: A systematic review of the human
epidemiological evidence (Radke et ah. 2018);
• Phthalate exposure andfemale reproductive and developmental outcomes: A systematic review
of the human epidemiological evidence (Radke et ah. 2019b);
• Phthalate exposure and metabolic effects: A systematic review of the human epidemiological
evidence (Radke et ah. 2019a); and
• Phthalate exposure and neurodevelopment: A systematic review and meta-analysis of human
epidemiological evidence (Radke et ah. 2020a).
Next, EPA sought to identify new population, exposure, comparator, and outcome (PECO)-relevant
literature published since the most recent existing assessments) of DINP by applying a literature
inclusion cutoff date. For DINP, the applied cutoff date was based on existing assessments of
epidemiologic studies of phthalates by Health Canada (2018a. b), which included literature up to
January 2018. The Health Canada (2018a. b) epidemiologic evaluations were considered the most
appropriate existing assessments for setting a literature inclusion cutoff date because those assessments
provided the most robust and recent evaluation of human epidemiologic data for DINP. Health Canada
evaluated epidemiologic study quality using the Downs and Black method (Downs i ck. 1998) and
reviewed the database of epidemiologic studies for consistency, temporality, exposure-response,
strength of association, and database quality to determine the level of evidence for association between
urinary DINP metabolites and health outcomes. New PECO-relevant literature published between 2018
to 2019 was identified through the literature search conducted by EPA in 2019, as well as references
published between 2018 to 2023 that were submitted with public comments to the DINP Docket (
HQ-QPPT-2018-0436). were evaluated for data quality and extracted consistent with EPA's Draft
Systematic Review Protocol Supporting TSCA Risk Evaluations for Chemical Substances (U.S. EPA.
2021a). Data quality evaluations for new studies reviewed by EPA are provided in the Draft Risk
Evaluation for Diisononyl Phthalate (DINP) - Systematic Review Supplemental File: Data Quality
Evaluation Information for Human Health Hazard Epidemiology ( 24d).
As described further in the Draft DINP Systematic Review Protocol ( 2024b). EPA considers
phthalate metabolite concentrations in urine to be an appropriate proxy of exposure from all sources—
including exposure through ingestion, dermal absorption, and inhalation. As described in thq Application
of US EPA IRIS systematic review methods to the health effects ofphthalates: Lessons learned and path
forward (Radke et ah. 2020b). from EPA's IRIS program, the "problem with measuring phthalate
metabolites in blood and other tissues is the potential for contamination from outside sources (Calafat et
ah. 2015). Phthalate diesters present from exogenous contamination can be metabolized to the
monoester metabolites by enzymes present in blood and other tissues, but not urine." Therefore, EPA
has focused its epidemiologic evaluation on urinary biomonitoring data; new epidemiologic studies that
examined DINP metabolites in matrices other than urine were considered supplemental and not
evaluated for data quality.
The Agency is proposing to use epidemiologic studies of DINP qualitatively; this proposal is consistent
with Health Canada, U.S. CPSC, ECHA, EFSA, and Australia NICNAS. The Agency did not use
Page 12 of 184
-------
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
PUBLIC RELEASE DRAFT
May 2024
epidemiology studies quantitatively for dose-response assessment, primarily due to uncertainty
associated with exposure characterization. Primary sources of uncertainty include the source(s) of
exposure; timing of exposure assessment that may not be reflective of exposure during outcome
measurements; and use of spot-urine samples, which due to rapid elimination kinetics may not be
representative of average urinary concentrations that are collected over a longer term or calculated using
pooled samples. Additional uncertainty results from co-exposure to mixtures of multiple phthalates that
may confound results for the majority of epidemiologic studies, which examine one phthalate and one
exposure period at a time such that they are treated as if they occur in isolation (Shin et at.. 2019;
Aylward et at.. 2016). Conclusions from Health Canada (2018a. b) and U.S. EPA systematic review
articles (Radke et at.. 2020a; Radke et at.. 2019b; Radke et at.. 2019a; Radke et at.. 2018) regarding the
level of evidence for association between urinary DINP metabolites and each health outcome were
reviewed by EPA and used as a starting point for its human health hazard assessment. The Agency also
evaluated and summarized new epidemiologic studies identified by EPA's systematic review process to
use qualitatively during evidence integration to inform hazard identification and the weight of scientific
evidence (Shin et at.. 2019; Aylward et at.. 2016).
1.2 Laboratory Animal Findings: Summary of Existing Assessments from
Other Regulatory Organizations
The human health hazards of DINP have been evaluated in existing assessments by U.S. CPSC (2014.
2010). Health Canada (ECCC/HC. 2020; EC/HC. 2015). NTP-CERHR (2003). ECB (2003). ECHA
(201 ' 10 g/kg), dermal
(LD50 > 3g/kg), or inhalation (LC50 > 4.4 mg/L) routes of exposure. DINP only resulted in slight
irritation in primary skin and eye irritation studies in rabbits. Dermal sensitization studies with rodent
models (e.g., Buehler tests) indicate that DINP is not a dermal sensitizer. EPA identified no new
information that would change these conclusions; therefore, these hazards are not discussed further in
this draft hazard assessment.
Page 13 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
480 Table 1-1. Summary of DINP Non-cancer POPs Selected for Use by other Regulatory Organizations
Brief Study Description
TSCA Data
Quality
NOAEL/
LOAEL
(mg/kg-day)
Critical Effect
U.S. CPSC
(MM)
u
u ^
r \ ©J
W fSl
w
03 3
Uh ®
w d
NICNAS
(2012)
^ 2|
S3 ^
U ©1
y (S|J
Male and female F344 rats (110/sex/dose) fed diets containing
0, 300, 3,000, 6,000 ppm DINP (CASRN 68515-48-0) for two
years (equivalent to 15, 152, 307 mg/kg-day for males; 18,
184, 375 mg/kg-day for females) (GLP-compliant, non-
guideline studv) (Lington et aL 1997; Bio/dynamics, 1986)
High
15/152
t in absolute and relative
liver and kidney weight
with increase in
histopathological changes
(e.g., spongiosis hepatis)
and other signs of
hepatotoxicity
y/a
yb
•/c
^/d
•/e
Male and female F344 rats (70-85/sex/dose) administered 0,
500, 1500, 6000, 12,000 ppm in the diet for 104 weeks
(equivalent to 29, 88, 358, 733 mg/kg-day in males; 36, 108,
4422, 885 mg/kg-day in females) (GLP-compliant, adhered to
40 CFR Part 798 (S 798.330)) (Covance Labs. 1998c)
High
88/ 358
t Liver and kidney weight,
biochemical changes (f
serum ALT, AST), and
histopathological findings
^/d
Pregnant female SD rats (6/dose) gavaged with 0, 10, 100,
500, 1,000 mg/kg-day DINP on GDs 12-21. Dams were
allowed to give birth naturally, and then dams and pups were
sacrificed (non-euideline studv) (Li et al.. 2015)
Medium
10 (LOEL)/
100
(LOAEL)
t MNGs and Leydig cell
clusters/ aggregation
Hershberger assay: young (6-week old) castrated male SD rats
treated with testosterone propionate (0.4 mg/kg-day) were
gavaged with 0, 20, 100, 500 mg/kg-day DINP for 10 days and
then sacrificed (non-euideline studv) (Lee and Koo. 2007)
Medium
100/500
i absolute seminal vesicle
and LABC weights
Pregnant SD rats (8/dose) gavaged with 0, 50, 250, 500 mg/kg-
dav DIINP on GDs 12-19 (non-euideline studv) (Clewell et aL.
2013a)
High
50/ 250
Transient reduced fetal
testosterone level and
histopathological changes
(MNGs)
y/a
•/c
Jd
¦/e
Pregnant Wistar rats (16/dose) gavaged with 0, 300, 600, 750,
900 mg/kg-day DINP from GD 7 to PND 17 (non-guideline
studv) (Bobere et aL. 2011)
Medium
300/600
t Nipple retention
y/a
Jd
Pregnant Harlan SD rats (5-9/group) gavaged with 0, 500, 750,
1000, 1500 mg/kg-day DINP from GD 14 to 18 (non-guideline
studv) (Hannas et aL. 2011)
Medium
-/500
i fetal testicular
testosterone production
y/a
Jd
Pregnant SD rats (20-24/group) fed diets containing 0, 760,
3800, 11,400 ppm DINP from GD 12 to PND 14 (target doses:
Medium
250/750
i male pup AGD on PND
14
y/a
Page 14 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
TSCA Data
Quality
NOAEL/
LOAEL
(mg/kg-day)
Critical Effect
U.S. CPSC
( )
ECCC/HC
(2020)
¦^5 Q
Ifl vH|
U, O
3 GJ
t/l
< f5j
LJ ©1
a d
ECHA
(2013b)
0, 50, 250, 750 mg/kg-day; received doses: 56, 288, 720,
me/ke-dav on CDs 13-20) (non-euideline studv) (Clewell et
al.. 20Obi
50/250
i male pup body weight on
PND 14
¦/e
Male and female SD rats fed diets containing 0, 0.2, 0.4, 0.8%
(Received doses in units of mg/kg-day shown in Table 3-7)
DINP 10 weeks prior to mating, and throughout mating,
gestation and lactation continuously for two generations (GLP-
coniDliant. adhered to 40 CFR 798 (§ 798.4700)) (Waterman et
al.. 2000; Exxon Biomedical 1996b")
High
-/114-395
| F1 and F2 pup body
weight on PND7 and 21
•/e
CPSC = Consumer Product Safety Commission (U.S.); ECCC/HC = Environment and Climate Change Canada/Health Canada; ECHA = European Chemicals Agency;
EFSA = European Food Safety Authority; NICNAS = Australia National Industrial Chemicals Notification and Assessment Scheme; ALT = Alanine
aminotransferase; AGD = Anogenital distance; AST = Aspartate aminotransferase; LABC = Levator ani/bulbocavernosus; MNG = Multinucleated gonocytes; PND =
Post-natal day
" NOAELs from antiandroeenic endooints (i.e., nioDlc retention, fetal testosterone dinduction. MNGs) across several studies ((Clewell et al.. 2013a; Clewell et al..
2013b; Bobere et al. 2011; Hannas et al.. 2011)) were used bv U.S. CPSC to assien a NOAEL for developmental toxicity of 50 me/ke-dav based on antiandroeenic
endooints (see d. 98 of (U.S. CPSC. 2014)).
h NOAELs from Lineton et al. (1997) and Li et al. (2015) were used bv Health Canada to calculate MOEs for individual DINP exposure scenarios (see Table 9-58 of
(ECCC/HC. 2020)). NOAELs from Li et al. and Lee and Koo (2007) were used to estimate hazard quotients for DINP as part of the cumulative risk assessment (see
Tables F-5 throuehF-9 in (ECCC/HC. 2020)).
c NOAEL from Lington et al. (1997) was used by EFSA to derive a stand-alone tolerable daily intake (TDI) for DINP based on liver and kidney effects, while the
NOAEL from Clewell et al. (2013a) was used to establish a erouo-TDI for several nhthalates (e.s., DEHP. DBP. BBP. and DINP) based on developmental effects
related to a plausible common mechanism (i.e., reduced fetal testosterone).
¦'NIC AS derived a NOAEL for svstemic effects (liver and kidney toxicity) based on the results from two 2-year dietary studies of F344 rats (Covance Labs. 1998c;
Lineton et al. 1997). which were similar in desien and collectively suDDorted a NOAEL of 88 me/ke-dav. Similarly. NICNAS derived a NOAEL of 50 me/ke-dav for
fertility-related effects (i.e., reduced fetal testosterone) based on results from three studies (Clewell et al. 2013a; Bobere et al. 2011; Hannas et al. 2011) and a
NOAEL of 50 me/ke-dav for developmental effects (i.e., reduced dud weieht) based on results from two studies (Clewell et al. 2013b; Waterman et al.. 2000) (see
Table 7.1 in (NICNAS. 2012)).
• NOAELs used bv ECHA to calculate derived no effect levels (DNELs) (see Section 4.4.11.2 of (ECHA. 2013b)).
' Studies evaluated for data duality consistent with the Draft DINP Systematic Review Protocol (U.S. EPA. 2024b) and EPA's Draft Systematic Review Protocol (U.S.
EPA. 2021a).
481
Page 15 of 184
-------
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
PUBLIC RELEASE DRAFT
May 2024
1.3 Laboratory Animal Data: Approach and Methodology
1.3.1 Approach to Identifying and Integrating Laboratory Animal Data
Figure 1-1 provides an overview of EPA's approach to identifying and integrating laboratory animal
data into the draft DINP Risk Evaluation. EPA first reviewed existing assessments of DINP conducted
by various regulatory and authoritative agencies. Existing assessments reviewed by EPA are listed
below. The purpose of this review was to identify sensitive and human relevant hazard outcomes
associated with exposure to DINP, and identify key studies used to establish PODs for estimating human
risk. As described further in Appendix A, most of these assessments have been subjected to external
peer-review and/or public comment periods but have not employed formal systematic review protocols.
• Toxicity review of DiisononylPhthalate (DINP) (U.S. CPSC. 2010);
• Chronic Hazard Advisory Panel on phthalates and phthalate alternatives (U.S. CPSC. 2014);
• State of the science report: Phthalate substance grouping 1,2-Benzenedicarboxylic acid,
diisononyl ester; 1,2-Benzenedicarboxylic acid, di-C8-10-branchedalkyl esters, C9-rich
(Diisononyl Phthalate; DINP). Chemical Abstracts Service Registry Numbers: 28553-12-0 and
68515-48-0 (EC/HC. 2015);
• Supporting documentation: Carcinogenicity ofphthalates - mode of action and human relevance
(Health Canada. 2015);
• Screening assessment - Phthalate substance grouping (ECCC/HC. 2020);
• NTP-CERHR monograph on the potential human reproductive and developmental effects of di-
isononyl phthalate (DINP) (NTP-CERHR. 2003);
• European union risk assessment report: DINP (ECB. 2003);
• Evaluation of new scientific evidence concerning DINP and DIDP in relation to entry 52 of
Annex XVII to REACH Regulation (EC) No 1907/2006 (EC ));
• Committee for Risk Assessment (RAC) Opinion on the ECHA 's draft review report on
"Evaluation of new scientific evidence concerning DINP and DIDP in relation to entry 52 of
AnnexXVII to Regulation (EC) No 1907/2006 (REACH) " ECHA/RAC/A77-0-0000001412-86-
10/F (EC a);
• Committee for Risk Assessment (RAC) Opinion proposing harmonised classification and
labelling at EUlevel of 1,2-Benzenedicarboxylic acid, di-C8-10-branchedalkylesters, C9- rich;
[1] di- "isononyl"phthalate; [2] [DINP] (ECHA.. 2018);
• Opinion of the scientific panel on food additives, flavourings, processing aids and materials in
contact with food (AFC) on a request from the commission related to di-isononylphthalate
(DINP) for use in food contact materials. (EFSA. 2005);
• Update of the risk assessment of di-butylphthalate (DBP), butyl-benzyl-phthalate (BBP), bis(2-
ethylhexyl)phthalate (DEHP), di-isononylphthalate (DINP) and di-isodecylphthalate (DIDP) for
use in food contact materials (EFSA. );
• Priority existing chemical assessment report no. 35: Diisononyl phthalate (NICNAS. 2012);
• Application of systematic review methods in an overall strategy for evaluating low-dose toxicity
from endocrine active chemicals (NASEM. 2017);
• Revised technical review of diisononyl phthalate ( 305b); and
• Technical review of diisononyl phthalate (Final assessment) ( 1023c).
Page 16 of 184
-------
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
PUBLIC RELEASE DRAFT
May 2024
Figure 1-1. Overview of DINP Human Health Hazard Assessment Approach
11 Any study that was considered for dose-response assessment, not necessarily limited to the study used for POD
selection.
h Extracted information includes PECO relevance, species, exposure route and type, study duration, number of
dose groups, target organ/systems evaluated, study-wide LOEL, and PESS categories.
EPA used the 2015 Health Canada assessment (EC/HC. 2015) as the key starting point for this draft
document. The Health Canada assessment included scientific literature up to August 2014, and
considered a range of human health hazards (e.g., developmental and reproductive toxicity, systemic
toxicity to major organ systems, genotoxicity, carcinogenicity) across all durations (i.e., acute, short-
term, subchronic, chronic) and routes of exposure (i.e., oral, dermal, inhalation). The EFSA (2019)
assessment was limited in scope (i.e., considered a limited range of human health hazards) and was not
subject to external peer-review, whereas the Health Canada (ECCC/HC. 2020) assessment did not
provide a specific literature inclusion cutoff date and the U.S. EPA (2023c) assessment did not describe
its approach to identifying literature. Therefore, EPA considered literature published between 2014 to
2019 further as shown in Figure 1-1. EPA first screened titles and abstracts and then full texts for
relevancy using PECO screening criteria described in the Draft DINP Systematic Review Protocol (U.S.
EPA. 2024b). EPA then identified PECO-relevant literature published since the most recent and
comprehensive existing assessment of DINP by applying a literature inclusion cutoff date from this
assessment.
Next, EPA reviewed new studies published between 2014 and 2019 and extracted key study information
as described in the Draft DINP Systematic Review Protocol (U.S. EPA. 2024b). Extracted information
included: PECO relevance; species tested; exposure route, method, and duration of exposure; number of
dose groups; target organ/systems evaluated; information related to potentially exposed or susceptible
subpopulations (PESS); and the study-wide lowest-observable-effect level (LOEL) (Figure 1-1).
New information for DINP was primarily limited to oral exposure studies, and study LOELs were
converted to HEDs by scaling allometrically across species using the 3A power of body weight (BW3/4)
for oral data, which is the approach recommended by U.S. EPA when physiologically based
pharmacokinetic models or other information to support a chemical-specific quantitative extrapolation is
absent (U.S. EPA. 2011b). EPA's use of allometric body weight scaling is described further in Appendix
F. EPA did not conduct data quality evaluations for studies with HEDs based on LOELs that were
greater than an order of magnitude of the lowest HED based on the lowest-observable-adverse-effect
level (LOAEL) across existing assessments because they were not considered sensitive for subsequent
POD selection. However, these studies were still reviewed and integrated into the hazard identification
process. Studies with HEDs for LOELs within an order of magnitude of the lowest LOAEL-based HED
Page 17 of 184
-------
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
PUBLIC RELEASE DRAFT
May 2024
identified across existing assessments were considered sensitive and potentially relevant for POD
selection. These studies were further reviewed by EPA to determine if they provide information that
supports a human health hazard not identified in previous assessments or to determine if they contain
sufficient dose-response information to support a potentially lower POD than identified in existing
assessments of DINP.
Data quality evaluations for DINP animal toxicity studies reviewed by EPA are provided in the Draft
Risk Evaluation for Diisononyl Phthalate (DINP) - Systematic Review Supplemental File: Data Quality
Evaluation Information for Human Health Hazard Animal Toxicology ( 324c).
1,3.2 New Literature Identified and Hazards of Focus for DINP
As described in Section 1.3.1, EPA reviewed literature published between 2014 to 2019 for new
information on sensitive human health hazards not previously identified in existing assessments,
including information that may indicate a more sensitive POD. As described further in the Draft DINP
Systematic Review Protocol ( 2024b). EPA identified 13 new PECO-relevant studies that
provided information pertaining to 5 primary hazard outcomes, including reproduction/development,
neurological, cardiovascular, immune system, and the musculoskeletal system. Further details regarding
EPA's handling of this new information are provided below.
• Reproductive/Developmental. EPA identified six new studies evaluating reproductive/
developmental outcome (Chiang and Flaws. 2019; Neief et ai. 2019; Neier et ai. 2018; Setti
Ahmed et ai. 2018; Li et at . v edha et ai. I ) These new studies of DINP are discussed
further in Section 3.1.
• Neurotoxicity. EPA identified four new studies evaluating neurological outcomes, including two
that evaluate neurobehavioral outcomes (Ma et ai. 201 ^eng. 2015) and two that evaluate brain
weight (Neier et ai. 2018; Setti Ahmed et ai. 2018). Neurotoxicity is a new health outcome that
has not been seen in previous studies of DINP or discussed in existing assessments of DINP. The
neurologic effects of DINP are discussed further in Section 3.4.
• Cardiovascular. EPA identified one new study evaluating cardiovascular outcomes (Dene et ai.
2019). Results from Deng et ai provide evidence of a new health hazard associated with
exposure to DINP that has not been previously seen in studies of DINP. The cardiovascular
effects of DINP are discussed further in Section 3.5.
• Immune System EPA identified three new studies evaluating immune system effects (Kane et
ai. 2016; Wu et ai. 2015; Sadakane et ai. 2014). Results from these studies indicate that DINP
can have adjuvant-like effects on immune responses. The immune adjuvant effects of DINP are
discussed further in Section 3.6.
• Musculoskeletal. EPA identified one new study evaluating effects on the musculoskeletal system
(Hwane et ai. 2017). Results from Hwang et ai provide evidence of a new health hazard
associated with exposure to DINP that has not been previously seen in studies of DINP.
Musculoskeletal effects of DINP are discussed further in Section 3.7.
Based on information provided in existing assessments of DINP for liver, kidney, and developmental
effects in combination with new information identified by EPA that encompasses additional hazard
outcomes, the Agency focused its non-cancer human health hazard assessment on developmental
toxicity (Section 3.1); liver toxicity (Section 3.2); kidney toxicity (Section 3.3); neurotoxicity (Section
3.4); cardiovascular health effects (Section 3.5); immune system toxicity (Section 3.6); and
musculoskeletal toxicity (Section 3.7).
Genotoxicity and carcinogenicity data for DINP are summarized in EPA's Draft Cancer Human Health
Hazard Assessment for Diisononyl Phthalate (DINP) (U.S. EPA. 2024a).
Page 18 of 184
-------
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
PUBLIC RELEASE DRAFT
May 2024
2 TOXICOKINETICS
2A Oral Route
Three experimental animal studies are available that provide useful data in evaluating absorption,
distribution, metabolism, and excretion (ADME) of DINP for the oral route. DINP is shown to be
predominantly metabolized in the liver in rodents, and urinary excretion is the primary route of
elimination for metabolites. In one of the few studies designed to investigate the metabolism of
phthalates in humans, a male volunteer (aged 63) was given a single oral dose of 1.27 mg of deuterium-
labeled DINP/kg bodyweight. DINP was found to be rapidly eliminated in a manner similar to rats
(Koch and Angerer. 2007). The postulated metabolic pathway of DINP in humans is shown in Figure
2-1. Results indicated that approximately 44 percent of the administered dose was recovered in urine
over 48 hours in the form of the following metabolites: (1) 20.2 percent as OFI-MINP (MHINP; based
on measured standard of 70H-MMeOP); (2) 10.7 percent as carboxy-MINP (MCiOP; based on
measured standard of 7-carboxy-MMeHP); (3) 10.6 percent as oxo-MINP (MOINP; based on measured
standard of 7oxo -MMeOP); and (4) 2.2 percent as MINP (Koch and Armerer. 2007).
D4-7o*o-MMeOP
R:
D4-OINP:
D+-MMCOP:
D4-70H- MMcOP:
D4-7o*o-MMcOP:
D4-7c»bo*v-MMcl IP:
iMvrnms I ;ilk) Ichain
IM-di-iso-nonylphtlu laic
l>4-mv»inM 4-rocthy loc t> I )pt> Aalutc
4-methyl-7-hydroxyociyI )phlhal-(4-mcthyl*7-oxoocty 1 )phlhaJatc
l>4 -mono «< 4- mcthy I• 7-oxy hepty 1 )ph dul.itc
Figure 2-1. Postulated DINP Metabolism in Humans (Koch and Angerer, 2007)
In Anderson et al, 20 volunteers were given two doses of DINP (0.78 mg and 7.3 mg) to examine its
metabolism and excretion. More than 33 percent of the labelled DINP was found as metabolites in urine
after 48 hours (Anderson et al., 2011).
Several studies investigated the toxicokinetics of DINP in animals. McKee et al. (2002) examined the
ADME of DINP in male and female F344 rats. Rats were administered single oral doses of 50 or 500
mg/kg 114C]DINP, and data on tissue distribution indicated that 2 to 4 hours following administration,
Page 19 of 184
-------
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
PUBLIC RELEASE DRAFT
May 2024
the highest levels of radioactivity were found to be in the blood, liver, and kidneys. The distribution of
radiolabeled DINP to other tissues after 7 days of exposure, was gastrointenstinal (GI) tract (0.097
percent), fat (0.053 percent), muscle (0.024 percent), and other organs (<0.009 percent). No differences
in excretion were apparent in either sex at either dose. In the single dose studies, 50 percent of the
radioactivity was recovered in the urine and the remainder in the feces at the low dose; whereas at the
high dose, 35 to 40 percent of the radioactivity was excreted in the urine and the remainder in the feces,
suggesting an inverse relationship between dose level and absorption. In repeated dose studies, rats were
administered 50, 150, and 500 mg/kg-day [14C]DINP for 5 days, and excretion was evaluated (McKee et
at.. 2002). In the repeated dose studies, about 60 percent of the administered dose was excreted at all
doses, suggesting an elevation of esterase activity and more rapid conversion to monoester following
repeated treatment. The elimination (half-life) of absorbed [14C]DINP was about 7 hours.
In another study by Clewell et al. (2013a). pregnant Sprague-Dawley (SD) rats received 50, 250, and
750 mg/kg-day of DINP from gestation day (GD) 12 to 19 via oral gavage. The percentage of DINP
absorbed following oral exposure was lower at the higher doses of 750 mg/kg-day compared to the 250
mg/kg-day group. Additionally, Clewell et al. (2013a) characterized the metabolite disposition of DINP
in the fetus and demonstrated that MINP and its oxidative metabolites along with its glucuronidated
form (MINP-Gluc) were all present in the fetal plasma, testes, and amniotic fluid. MINP-Gluc was
present at higher concentrations in the fetal plasma than the maternal plasma (in contradiction with what
was observed with the other metabolites), indicating potential placental transfer of MINP-Gluc, or, more
likely, that conjugation could occur in the fetus by phase II detoxification enzyme systems. Because
these metabolites were localized in maternal plasma and MINP was present at similar concentrations as
MCiOP, it was suggested that (1) urinary clearance of both MINP and MINP-Gluc is limited, and (2)
these metabolites were poor predictors of plasma and tissue disposition for DINP.
A summary of different metabolites found in human and rat urine after oral administration of DINP is
presented in Table 2-1.
Table 2-1. Absorption and Excretion Summary of DINP
Species
Dose
Source
Absorption
Reference
Human
1.28 mg/kg
Urine
44% over 48 hours
(Koch a terer.
2007)
Human
0.78 and 7.3 mg/kg
Urine
33 ± 6.4% over 48 hours
(Anderson et al..
201 I)
Rat
50 mg/kg
500 mg/kg
50-500 mg/kg
Urine
Urine
Estimated
urine + bile
49% over 72 hours
39% over 72 hours
75% over 72 hours
(McKee et al.. 2002)
50, 150, or 500
mg/kg-day for 5
days
Urine
Estimated
urine + bile
56-62% over 24 hours, 62-64%
over 72 hours
90% over 72 hours
Rat
(non-
pregnant)
Single dose of 300
mg/kg
Urine
Mono(carboxy-isooctyl)phthalate
(MciOP) 82%
Other metabolites 18%
(Silva et al.. 2006)
Page 20 of 184
-------
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
PUBLIC RELEASE DRAFT
May 2024
Silva et al. (2006) administered a single oral gavage dose of 300 mg/kg DINP to non-pregnant SD rats
and quantified the metabolites in urine daily for 4 days. MciOP accounted for 82 percent of the
identified metabolites, and the other metabolites constituted 18 percent. This study characterized the
different co- and co-1-oxidation metabolites found in urine and found that MciOP was the major urinary
metabolite recovered, while MINP and DINP were not found in significant amounts in the urine.
Based on the available data, EPA assumes an oral absorption of 100 percent for the draft DINP risk
evaluation.
Table 2-2. Metabolites of DINP Identified in Urine from Rats and Humans after Oral
Administration
Metabolite(s)
Abbreviation(s)
Reference(s) (Species)
Monoisobutyl phtlialate
MINP
(Anderson et al., .V1 () (human)
(Suzuki et al.. 2012) (human)
(Koch and Aneerer, 2007) (human)
(Calafat et al., 2006a) (rat)
Glucuronidated MINP
MINP-Glue
(Clewell et al., 2013a) (rat)
[mono-(4-methyl-7-carboxyheptyl)
phtlialate] representing:
Mono(carboxyisooctyl) phtlialate
[D4-7carboxy-MmeHP]
C02-MINP; MCIOP
(Anderson et al.. .'01 0 (human)
(Koch and Aneerer. 2007) (human)
[D4-mono-(4-methyl-7-
hydroxyoctyl) phthalate]
representing:
Mono(hydroxyisononyl) phthalate
[70H-MmeOP]
for OH-MINP; MHINP
(Anderson et al., .'01 () (human)
(Koch et al.. 2012) (human)
(Koch and Aneerer. 2007) (human)
(Silva et al., 2006) (rat)
[D4-mono-(4-methyl-7-
oxooctyl)phthalate] repre senting:
Mono(oxoisononyl) phthalate
[7oxo-MmeOP] for Oxo-MINP;
MOINP
(Anderson et al., .'01 () (human)
(Koch et al.. 2012) (human)
(Koch and Aneerer. 2007) (human)
(Silva et al., 2006) (rat)
Monocarboxylisononyl phthalate
cx-MINP
(Koch et al., 2012) (human)
Mono-carboxy-isooctyl phthalate
MCIOP (MCOP is sometimes
used to represent MCIOP)
(Silva et al., 2006) (rat)
Mono(carboxy-isoheptyl) phthalate
MciHpP
(Silva et al.. 2006) (rat)
Mono-(3-carboxypropyl) phthalate
MCPP
(Calafat et al.. 2006b; Calafat et al..
2006a) (rat)
Mono-n-octyl phthalate
Mil OP
(Calafat et al., 2006b) (rat)
Phthalic acid
PA
(McKee et al., 2002) (rat)
2.2 Inhalation Route
No controlled human exposure studies or in vivo animal studies are available that evaluate the ADME
properties of DINP for the inhalation route. Therefore, EPA is assuming 100 percent absorption via
inhalation. Similarly, ECHA concluded 75 percent absorption via inhalation for adults and 100 percent
for newborns and infants as a vulnerable subpopulation (EC U \ < l b, « i «1 „oQ3).
2.3 Dermal Route
In vivo and in vitro studies have shown that absorption of phthalates through rat and human skin
decreases as the length of the alkyl chain increases (Mint et al.. 1994; El si si et al.. 1989; Scott et al..
1987). Dermal absorption data specific to DINP are limited. EPA only identified one study directly
Page 21 of 184
-------
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
PUBLIC RELEASE DRAFT
May 2024
related to the dermal absorption of DINP (McKee et ai. 2002; Midwest Research Institu 3). In this
study, neat [14C]DINP at 50 mg/kg-day was applied to the freshly shaven backs (3 cm x 4 cm) of three
groups of male F344 rats as "conditioned skin," "non-conditioned skin," and "occluded" (styrofoam cup
lined with aluminum foil) (McKee et ai. 2002; Midwest Research Institute. 1983). Dermal absorption
was estimated to be 2 to 4 percent over 7 days, with an absorption rate of approximately 0.3 to 0.6
percent per day based on amount of applied dose recovered in urine, feces, and other tissues.
Additionally, radioactivity increased with time on skin: 0.12, 0.26, and 0.27 percent of the applied dose
following exposure of 1, 3, and 7 days, respectively. For all dermal absorption experiments with DINP,
material recovery fell within the Organisation for Economic Co-operation and Development (OECD)
156 (2022) Guidelines of 90 to 1 10 percent for non-volatile chemicals. The metabolic profile of dermal
absorbed DINP was similar to DINP metabolic profile from oral administration.
Although specific data on DINP dermal absorption in humans is lacking, several regulatory agencies
(e.g., Danish EPA, ECHA, NICNAS) recognize that absorption of phthalates would likely be lower in
human skin than through rat skin. This observation is based on data from in vitro migration studies
conducted with DEHP and other phthalates. Notably, other regulatory agencies (e.g., Australia
NICNAS, ECHA) have reached similar conclusions regarding the low dermal absorption of DINP
(ECHA.. b, - lCNAS. :01:).
2.4 Summary
Toxicokinetic data indicates that orally administered DINP is rapidly metabolized in the gut to MINP
and distributed via blood to major tissues, particularly the liver and kidneys. DINP metabolites were
excreted in urine and to a lesser extent in feces. Repeated dosing did not result in accumulation of DINP
and/or its metabolites in blood and tissues but did result in increased formation and elimination of the
monoester oxidation products.
Tissue distribution patterns of DINP revealed that absorption from the GI tract was rapid after both
single and repeated oral dosing. DINP is then primarily hydrolyzed in the GI tract after oral
administration. DINP translocated from the GI tract via the blood rapidly to liver and kidney. The
metabolic profile suggests that DINP is recovered primarily as oxidized products and phthalic acid and
very little as the parent or the metabolite MINP, suggesting that DINP is rapidly metabolized in the GI
tract to the corresponding monoester with a second hydrolysis step in liver to phthalic acid.
DINP is primarily eliminated in urine following oral exposures. Available studies have reported that
more than 90 percent of [14C] DINP was eliminated over 72 hours, with the majority through urine and
to a minor extent through feces(Andcrson et ai. JO I I; ICoch and Angerer. 2007; Silva et ai. 2006;
McKee et ai. 2002). The total radioactivity recovered from the previously identified metabolites
combined was 33 ± 6.4 percent of the labeled DINP in urine over 48 hours. Metabolite half-lives were
estimated to be 4 to 8 hours with over 90 percent excreted in the first 24 hours of urine collection.
In contrast to absorption following oral exposure, dermal absorption of DINP in adult male F344 rats is
low, ranging from 2 to 4 percent of the applied dose when measured 7 days after application (McKee et
ai. 2002). This finding agrees with data from other in vivo and in vitro studies that show absorption of
phthalates through rat and human skin decreases as the length of the alkyl chain increases. The dermally
absorbed fraction is distributed to multiple tissues, including skin, GI tract, muscle, fat, and liver. The
recovery of radioactivity in feces and the GI tract suggests excretion of DINP or its metabolites in the
bile, which in turn suggests that after absorption, DINP undergoes a similar metabolic fate as orally
administered DINP.
Page 22 of 184
-------
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
PUBLIC RELEASE DRAFT
May 2024
3 HAZARD IDENTIFICATION
EPA has developed detailed hazard characterization and mode of action (MOA) analysis for the effects
on fetal testicular testosterone and liver cancer, with an emphasis on liver effects leading to liver tumors.
Effects on fetal testicular testosterone are presented in Section 3.1.2.1. Non-cancer liver effects are
presented in Section 3.2, while liver cancer and EPA's MOA analysis of liver tumors is presented in
EPA's Draft Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP) (U.S. EPA.
2024a). The scientific MOA analysis is presented in accordance with the EPA's Guidelines for
Carcinogen Risk Assessment ( 2005a) and the IPC S Mode of Action Framework (IPCS. 2007)
and includes a description of the state of the science with regards to key events, pathways of toxicity and
weight of evidence following the modified Bradford Hill criteria. Other hazards considered by EPA,
such as kidney, neurotoxicity, cardiovascular health effects, immune system toxicity, and
musculoskeletal toxicity, are presented in Sections 3.3 through 3.7.
3.1 Developmental and Reproductive Toxicity
3.1.1 Summary of Available Epidemiological Studies
EPA reviewed and summarized conclusions from previous assessment conducted by Health Canada
(2018b) and U.S. EPA's IRIS program, including systematic review articles by Radke et al. (2019b;
2018) that investigated the association between DINP exposure and male and female development and
reproductive outcomes. In the Health Canada (2018b) assessment, there were no studies that evaluated
the association between DINP and its metabolites and reproductive outcomes such as altered male
puberty, pregnancy complication and loss, uterine leiomyoma, sexual dysfunction in females, and age at
menopause. There was inadequate evidence for the association between DINP and its metabolites and
reproductive outcomes such as altered female puberty, changes in semen parameters, sexual dysfunction
in males, polycystic ovary syndromes, and sex ratios. There was also no evidence for the association
between DINP and its metabolites and reproductive outcomes such as gynecomastia, endometriosis and
adenomyosis. Overall, Health Canada found that the evidence could not be established for the
association between DINP and its metabolites and any reproductive outcomes, such as altered fertility.
In the conclusions from the IRIS systematic review articles by Radke et al. (2018). examining the
association between DINP male reproductive outcomes the authors found moderate evidence linking
DINP metabolites to lower testosterone levels. However, they could not find clear evidence linking
DINP and male reproductive outcomes such as AGD, time until pregnancy in males, and sperm
parameters due to a combination of low exposure levels {i.e., poor sensitivity) and data availability {i.e.,
fewer accessible studies). In terms of the association between female reproductive and developmental
outcomes and DINP, Radke et al. (2019b) found that the evidence was indeterminate.
EPA identified 11 new epidemiological studies published between 2018 and 2019 that were not
evaluated by Health Canada or either IRIS program systematic reviews. Eight of the available studies
were of medium quality and three were of low quality. Overall, conclusions of the 11 new studies were
consistent with that of Health Canada and the IRIS systematic review articles. EPA preliminarily
concluded that the existing epidemiological studies do not support quantitative dose-response
assessment, but rather provide qualitative support as part of weight of scientific evidence. Further
information on the new studies identified by the EPA can be found in Appendix D.
3.1.2 Summary of Laboratory Animals Studies
The developmental effects of exposure to DINP in experimental animal models have been evaluated as
part of several existing assessments. NTP-CERHR (2003). ECHA (2013b). EFSA (2019). Australia
Page 23 of 184
-------
lie
111
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
PUBLIC RELEASE DRAFT
May 2024
NICNAS (20121 Health Canada ffiC/HC. 2015) and U.S. CPSC (201 I, :0]0) have all consistently
concluded that oral exposure to DINP can cause developmental toxicity in experimental animal models.
Oral exposure to DINP has been shown to cause skeletal and visceral variations, reduced pup body
weight gain, and effects on the developing male reproductive system consistent with a disruption of
androgen action. Effects on the developing male reproductive system and other developmental and
reproductive toxicity are discussed in Sections 3.1.2.1 and 3.1.2.2, respectively.
3.1.2.1 Developing Male Reproductive System
EPA has previously considered the weight of scientific evidence and concluded that oral exposure to
DINP can induce effects on the developing male reproductive system consistent with a disruption of
androgen action (see EPA's Draft Proposed Approach for Cumulative Risk Assessment of High-Priority
and a Manufacturer-RequestedPhthalate under the Toxic Substances Control Act ( '023 a)).
Notably, EPA's conclusion was supported by the Science Advisory Committee on Chemicals (SACC)
( E023b). A summary of available studies evaluating effects on the developing male
reproductive system are provided in Section 3.1.2.1.1, while a brief MO A summary is provided in 0.
Readers are directed to see EPA's Draft Proposed Approach for Cumulative Risk Assessment of High-
Priority and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act (
2023 a) for a more thorough discussion of DINP's effects on the developing male reproductive system
and EPA's MOA analysis. Effects on the developing male reproductive system are considered further
for dose-response assessment in Section 4.
3.1.2.1.1 Summary of Studies Evaluating Effects on the Developing Male
Reproductive System
Available studies (including 13 studies of rats) evaluating the antiandrogenic effects of DINP on the
male reproductive system are summarized below in Table 3-1.
Page 24 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Table 3-1. Summary of DINP Stut
ies Evaluating Effects on the Developing Male Reproductive System
Brief Study Description
NOAEL/ LOAEL
(mg/kg-day)
Effect at LOAEL
Remarks
Pregnant SD rats (8/dose/ timepoint
evaluated) gavaged with 0 (corn oil
vehicle), 50, 250, 750 mg/kg-day DINP
(CASRN 68515-48-0) on GDs 12-19.
Dams sacrificed on GD 19 (2 hours post-
dosing) or GD 20 (24 hours post-dosing)
(Clewell et al. 2013a)
50/ 250
i fetal testicular
testosterone and
testicular
pathology (MNGs)
Maternal Effects
-1 (12%) absolute and relative maternal liver weight (>250 mg/kg-day)
Developmental Effects
- i (50-65%) testicular testosterone on GD 19 (>250 mg/kg-day)
- Testicular pathology on GD 20 (f MNGs [>250 mg/kg-day], Ley dig cell
aggregates [750 mg/kg-day])
Unaffected outcomes
- Maternal body weight gain; terminal maternal body weight; fetal body weight;
male AGD (GD 20); testicular testosterone on GD 20; seminiferous tubule diameter
on GD 20
Pregnant SD rats (20-24 litters/dose) fed
diets containing 0, 760, 3,800, or 11,400
ppm DINP (CASRN 68515-48-0) on GD
12 through PND 14 (equivalent to: 56,
288, 720 mg/kg-day on GD 13-20 and
109, 555, 1,513 mg/kg-day on PND 2-
14). Dams allowed to deliver pups
naturally, and pups sacrificed on PNDs 49
or 50 (Clewell et al. 2013b)
56/ 288
i male pup body
weight on PND 14
and t incidence of
MNGs on PND 2
Maternal Effects
- i body weight on GD 20, PND 2 and 14 (11,400 ppm)
- i (30%) body weight gain on GD 10-20 (11,400 ppm)
-1 food consumption on GD 10-20 (11,400 ppm) and PND 2-14 (>3,800 ppm)
Developmental Effects
- i (10-27%) male pup weight on PND 2 (720 mg/kg-day) and 14 (>288 mg/kg-
day)
- Testicular pathology on PND 2 (f Leydig cell aggregates (720), MNGs (>288
mg/kg-day)
-| AGD on PND 14 (720 mg/kg-day)
-1 (10%) absolute LABC weight on PND 49-50 (720)
Unaffected outcomes
- Live pups/litter; testicular testosterone (PND 49); PPS; AGD (PND 2, 49); NR
(PND 14, 49); absolute testis and epididymis weight (PND 2, 49); gubernacular
cord length (PND 49); male offspring body weight (PND 49); absolute testes,
epididymis, SV, ventral prostate, glans penis, Cowper's Glands weight (PND 49);
reproductive tract malformations (PND 49) (e.g., hypospadias, exposed os penis,
undescended testes, epididymal agenesis); testicular pathology (PND 49)
Pregnant Wistar rats (# of litters per dose
not stated) fed soy-free diets containing 0,
40, 400, 4000, or 20,000 ppm DINP
(CASRN 28553-12-0) from GD 15
through PND 21 and allowed to deliver
pups naturally [received doses, as
estimated bv (EC/HC. 2015): 2. 20. 200.
1000 me/ke-davl (Lee et al.. 2006a)
None/ 2
i male pup AGD,
| pup body
weight, i female
lordosis quotient
Maternal Effects
- Not examined or reported
Developmental Effects
- i male/female body weight on PND 1 (>2 mg/kg-day)
- i male AGD on PND 1 (>2 mg/kg-day)
- i frequency of mounts, intromissions, ejaculations in male rats (PNW 20) (only at
2 mg/kg-day, no dose-response)
- i Lordosis quotient of females in PNW 20 (>2 mg/kg-day)
Unaffected outcomes
- Serum testosterone and estradiol (PND 7); serum testosterone, luteinizing
hormone, follicle stimulating hormone, estradiol (PNW 20)
Page 25 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
NOAEL/ LOAEL
(mg/kg-day)
Effect at LOAEL
Remarks
Pregnant SD rats (5/dose) fed soy-free
diets containing 0, 400, 4,000, 20,000
ppm DINP (CASRN 28553-12-0) on GD
15 through PND 10 (equivalent to: 31,
307, 1,165 mg/kg-day on GD 15-20 and
66, 657, 2,657 mg/kg-day on PND 2-10)
(Masutomi et aL 2003)
66/ 657
i male body
weight on PND 27
Maternal Effects
- i body weight gain and food consumption between GD 15-20 & PND 2-10
(20,000 ppm)
Developmental Effects
-j body weight gain between PND 2-10 (both sexes) (20,000 ppm)
-1 (18-43%) body weight on PND 27 for males (>4,000 ppm) and females (20,000
ppm)
- i Absolute testes weight on PND 27 (20,000 ppm)
- Testicular pathology on PND 77 (20,000 ppm) (i.e., vacuolar degeneration of
Sertoli cells, degeneration of meiotic spermatocytes at stage XIV, scattered cell
debris in ducts of epididymis)
Unaffected outcomes
-Number of live offspring; pup body weight (PND 2); AGD (PND 2); pup body
weight gain (PND 10-21); PPS; vaginal opening; absolute testes weight (PND 77)
Pregnant Wistar rats gavaged with 0 (corn
oil vehicle), 300, 600, 750, 900 mg/kg-
day DINP (CASRN 28553-12-0) on GD 7
through PND 17. Dams sacrificed on GD
21 (subgroup 1) or allowed to give birth
naturally and offspring sacrificed on PND
90 (suburouD 2) (Boberg et aL. 2016.
2011)
300/ 600
t MNGs in fetal
testis and j sperm
motility on PND
90
Maternal Effects
- None
Developmental Effects
- Testis pathology on GD 21 (t incidence of MNGs (>600 mg/kg-day); enlarged
diameter of seminiferous cords (>750); gonocytes with central location in chords
(>750))
- i Testicular testosterone on GD 21 (600, no dose-response)
- i male pup body weight on PND 13 (900)
-1 male pup AGD on PND 1 (900) and t male pup NR on PND 13 (>750)
-1 sperm motility on PND 90 (>600)
Unaffected Outcomes
- Maternal body weight and weight gain; gestation length, post-implantation loss,
litter size, sex ratio, perinatal loss; testicular testosterone production (GD 21);
plasma testosterone and luteinizing hormone (GD 21); fetal birth weight; male and
female body weight (PND 90); absolute reproductive organ weight (PND 90) (e.g.,
testis, prostate LABC, SV, ovary, uterus); AGD or NR (PND 90); testis testosterone
(PND 90); SV, prostate, testis pathology
Pregnant Harlan SD rats (5-9/dose)
gavaged with 0, 500, 750, 1,000, or 1,500
mg/kg-day DINP (CASRNs 28553-12-0
and 68515-48-0 tested) on GDs 14-18.
Dams sacrificed on GD 18, approximately
2 hours oost-dosinu (Hannas et al.. 2011)
None/ 500
i fetal testicular
testosterone
production
Maternal Effects
- None
Developmental Effects
- i (30-69%) ex vivo fetal testicular testosterone production (>500 mg/kg-day, both
CASRNs)
- i expression of StAR and Cyplla mRNA in fetal testes (>1,000 mg/kg-day, both
CASRNs)
Unaffected Outcomes
- Dam mortality; dam body weight gain; litter size
Page 26 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
NOAEL/ LOAEL
(mg/kg-day)
Effect at LOAEL
Remarks
Pregnant Harlan SD rats gavaged with 0,
500, 750, 1,000, or 1,500 mg/kg-day
DINP (CASRNs 28553-12-0 and 68515-
48-0 tested) on GD 14-18. Dams
sacrificed on GD 18, approximately 2
hours oost-dosinu (Hannas et al. 2012)
NOEL/ LOEL:
None/ 500
i steroidogenic
gene expression in
the fetal testes
Maternal Effects
- None
Developmental Effects
-1 mRNA expression of.SV.I/*', Cyplla, Cypllbl, Cypllb2, Hsd3b, Cypl7al,
Scarbl, Insl3, Dhcr7in the fetal testes (>500 mg/kg-day, both CASRNs)
Unaffected Outcomes
- Dam mortality; dam body weight gain; litter size
Pregnant SD rats (5-8/dose) gavaged with
0 (corn oil vehicle), 250, or 750 mg/kg-
day DINP (CASRN not reported) on
embryonic days 13.5-17.5. Dams
sacrificed on embryonic day 19.5
(Adamsson et al.. 2009)
NOEL/ LOEL:
250/ 750
t GATA-4, Insl3,
P450scc mRNA in
the fetal testes
Maternal Effects
- None
Developmental Effects
-1 Testicular mRNA expression of GATA-4, Insl3, P450scc (750 mg/kg-day)
Unaffected Outcomes
- Plasma corticosterone; litter size; sex ratio; fetal body weight; testicular
testosterone; testicular mRNA expression of Star, 3/1-1ISD, SF-1; testicular protein
expression of StAR, P450scc, 3(3-HSD, androgen receptor; testicular pathology
Pregnant SD rats (14-19/dose) gavaged
with 0 (corn oil vehicle) or 750 mg/kg-day
DINP (CASRN 68515-48-0) from GD 14
through PND 3. Dams were allowed to
give birth naturally and mall offspring
were sacrificed between 3 to 7 months of
ase (Gray et al. 2000)
None/ 750
t male pup NR,
reproductive
malformations
Maternal Effects
- i (10%) maternal weight gain to GD 21
Developmental Effects
-1 percent of males with areolas (22.4%) on PND 13
- Reproductive malformations at 3-7 months: permanent nipples in 2/52 males from
2 litters, small and atrophic testes in 1/52 males; flaccid, fluid-filled in 1/52 males;
unilateral epididymal agenesis with hypospermatogenesis in 1/52 males
Unaffected outcomes
- Maternal mortality; maternal weight gain to PND 3; male pup weight at birth;
PPS; absolute reproductive organ weight at 3-7 months (i.e., testes, LABC, SV,
glans penis, ventral prostate, epididymis, cauda epididymis, caput-corpus
epididymis); serum testosterone (3-7 months); male AGD (PND 2); reproductive
malformations at 3-7 months (hypospadias, cleft phallus, vaginal pouch, SV
agenesis, undescended testes, testis absent, abnormal gubernacular cord)
Pregnant Harlan SD rats (3-5/dose)
gavaged with 0 (corn oil vehicle) or 750
mg/kg-day DINP on GDs 14-18. Dams
sacrificed on GD 18, approximately 2
hours post-dosing. Study completed over
several blocks. Block 1 and 5 tested
CASRN 68515-48-0, Block 7 tested
CASRN 28553-12-0 (Fiiit et al. 2014)
None/ 750
i fetal testicular
testosterone
production
Maternal Effects
- None
Developmental Effects
- i (24-50% I across Blocks 1, 5, and 7) ex vivo fetal testicular testosterone
production
Unaffected Outcomes
- Maternal weight gain, fetal viability (all blocks)
Pregnant Wistar rats (8/dose) gavaged
with 0 or 750 mg/kg-day DINP (CASRN
None/ 750
i fetal testicular
testosterone
Maternal Effects
- Not examined or reported
Page 27 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
NOAEL/ LOAEL
(mg/kg-day)
Effect at LOAEL
Remarks
28553-12-0) on GDs 7-21. Dams
sacrificed on GD 21 OBorcli et aL 2004)
content and
production
Developmental Effects
-1 ex vivo fetal testicular testosterone production and testicular testosterone content
(magnitude of effect not reported, only presented graphically
Unaffected Outcomes
- Plasma testosterone and luteinizing hormone
Hershberger assay: Testosterone
propionate-treated (0.4 mg/kg-day)
castrated immature (7 week old) male SD
rats were administered DINP via gavage
at 0, 20, 100, or 500 mg/kg-day for 10
davs (Lee and Koo. 2007)
NA
NA
- i absolute SV (>20 mg/kg-day) (lacked dose-response) and LABC (500) weight
Unaffected Outcomes
- Terminal body weight; absolute liver, kidney, adrenal; ventral prostate, Cowper's
gland; Glans penis weight
Pregnant SD rats (6/dose) gavaged with 0
(corn oil vehicle), 10, 100, 500, 1,000
mg/kg-day DINP (CASRN not provided)
on GD 12-21. Dams were allowed to give
birth naturally and then pups were
sacrificed (Li et aL. 2015)
None/10
i male pup body
weight and fetal
Leydig cell
aggregation
Maternal Effects
- None
Developmental Effects
- i male pup body weight (>10 mg/kg-day) (lacked dose-response)
- i testicular testosterone (1,000)
-1 testis dysgenesis (>100)
-1 incidence of MNGs (>100)
- Fetal Leydig cell aggregation (>10)
-1 testicular gene expression (Insl3 (>10), Lhcgr (>500), Star (>500), Cypllal
(>100), Hsd3bl (>100), Cypl7al (>100), Hsdl7b3 (1,000))
Unaffected outcomes
- Gestation length; number of dams delivering litters; pups per litter; sex ratio; dam
body weight; male AGD
AGD = anogenital distance; GD = gestational day ; MNGs = multinucleated gonocytes; PND = postnatal day; PNW = postnatal week
801
Page 28 of 184
-------
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
PUBLIC RELEASE DRAFT
May 2024
3.1.2.1.2 Mode of Action for Phthalate Syndrome
As shown in Figure 3-1. portions of an MOA for phthalate syndrome have been proposed to explain the
link between gestational or perinatal exposure to DINP and effects on the male reproductive system in
rats. The MOA has been described in greater detail in EPA's Draft Proposed Approach for Cumulative
Risk Assessment of High-Priority Phthalates and a Manufacturer-Re quested Phthalate under the Toxic
Substances Control Act (U.S. EPA. 2023a) and is described briefly below.
Chemical Structure
and Properties
Molecular Initiating
Event
=>
Cellular
Responses
¦=>
Organ
Responses
Adverse Organism
Outcomes
Phthalate
exposure during
critical window of
development
Fetal Male Tissue
-J, AR dependent
mRNA/protein
synthesis
Metabolism to
monoester &
transport to fetal
testes
"=0>
Unknown MIE
(not believed to be
AR or PPARa
mediated)
Key genes involved in the AOP \
for phthalate syndrome
Scarbl
Chcr7
Mvd
Ela3b
StAF
Ebp
Nsdhl
Insl3
Cypllal
Fdos
RGD1S64999 Lhcgr
Cypllbl
Hmqcr
Tm7sf2
Inha
Cypllb2
Hmgcsl
Cyp46ol
NrObl
Cypl 7al
Hsd3b
Ldlr
RhoxlO
CypSl
Fidil
Insigl
Wnt7a
¦=>
Testosterone
synthesis
\1/ Gene
expression
(INSL3, lipid
metabolism,
cholesterol and
androgen synthesis
and transport)
4> INSL3 synthesis
Fetal Leydig cell
Abnormal cell
apoptosis/
proliferation
(Nipple/areolae
retention, .J, AGD,
Disrupted testis
tubules, Leydig cell
clusters, MNGs,
agenesis of
reproductive tissues)
Suppressed
gubernacular cord
development
(inguinoscrotal phase)
J
<=>
4- Androgen-
dependent tissue
weights, testicular
pathology [e.g.,
seminiferous tubule
atrophy),
malformations (e.g.,
hypospadias), <1/
sperm production
Suppressed
gubernacular cord
development
(transabdominal
phase) J
&
<0
A
Impaired
V
fertility
1}
Undescended
testes
Figure 3-1. Hypothesized Phthalate Syndrome Mode of Action Following Gestational Exposure
Figure taken directly from ( J.S. EPA. 2023a) and adapted from (Conlev et al., 2021; Gray et al.. 2021;
Schwartz et aL 202.1; Howdeshell et al.. 2017).
AR = androgen receptor; INSL3 = insulin-like growth factor 3; MNG = multinucleated gonocyte; PPARa =
peroxisome proliferator-activated receptor alpha.
The MOA underlying phthalate syndrome has not been fully established; however, key cellular-, organ-,
and organism-level effects are generally understood (Figure 3-1). The molecular events preceding
cellular changes remain unknown. Although androgen receptor antagonism and peroxisome proliferator-
activated receptor alpha activation have been hypothesized to play a role, studies have generally ruled
out the involvement of these receptors (Foster. 2005; Foster et al.. 2001; Parks et al.. 2000).
Exposure to DINP during the masculinization programming window (i.e., GDs 15.5 to 18.5 for rats;
GDs 14 to 16 for mice; gestational weeks 8 to 14 for humans) in which androgen action drives
development of the male reproductive system can lead to antiandrogenic effects on the male
reproductive system ( lacLeod et al.. 2010; Welsh et al., 2008; Carruthers and Foster. 2005). In vivo
pharmacokinetic studies with rats have demonstrated that monoester metabolites of DINP can cross the
placenta and be delivered to the target tissue, the fetal testes (Clewell et al.. 2013a; Clewell et al.. 2010).
Consistent with the MOA outlined in Figure 3-1, studies of DINP have demonstrated that exposure to
DINP during the masculinization programming window in rats can reduce mRNA levels of insulin-like
Page 29 of 184
-------
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
PUBLIC RELEASE DRAFT
May 2024
growth factor 3 (INSL3), as well as genes involved in steroidogenesis in the fetal testes (Li et ai. 2015;
Hannas et ai. 2011; Adams son et al. 2009). Consistently, studies have also demonstrated that exposure
to DINP during the masculinization programming window can reduce fetal testicular testosterone
content and/or testosterone production (Li et al.. .^ I , Furr et al.. -01 I; i "lewell et al.. 2013a; Sobers et
al.. 2011; Hannas et al.. JO I I; »rch et al.. 2004). Exposure to DINP during the masculinization
programming window can also reduce male pup anogenital distance (AGD) and cause male pup nipple
retention (NR), which are two hallmarks of antiandrogenic substances; however effects on AGD and NR
are less consistently observed following oral exposure to DINP in rats (see Sections 3.1.3.3 and 3.1.3.4
of ( 023a) for additional discussion). In contrast, exposure to DINP generally does not induce
severe reproductive tract malformations such as hypospadias and or cryptorchidism, but has been shown
to cause epididymal agenesis (Gray et al.. 2000). and a spectrum of other effects consistent with
phthalate syndrome, including increased numbers of multinucleated gonocytes (MNGs) (Li et al.. 2015;
Clewell et al.. 2013a; Clewell et al.. 2013b; Sobers et al.. 2011). fetal Leydig cell aggregation (Li et al..
201 \ t iewell et al.. 2013a; Clewell et al.. 2013b). and decrease sperm motility (Sobers ci al.. 201 I).
Based on available data, EPA previously concluded that the weight of scientific evidence demonstrates
that oral exposure to DINP can induce effects on the developing male reproductive system consistent
with a disruption of androgen action and the MOA outlined in Figure 3-1 (see EPA's Draft Proposed
Approach for Cumulative Risk Assessment of High-Priority and a Manufacturer-Requested Phthalate
under the Toxic Substances Control Act (U.S. EPA. 2023 a)). Notably, EPA's conclusion was supported
by the SACC (U.S. EPA. 2023b).
3.1.2.2 Other Developmental and Reproductive Outcomes
EPA has evaluated several oral exposure studies, including two prenatal developmental studies of rats
(Waterman et al.. 1999; Hellwis et al.. 1997). a one-generation study of reproduction of rats (Waterman
et al.. 2000; Exxon Biomedical. 1996a). and a two-generation study of reproduction of rats (Waterman
et al.. 2000; Exxon Biomedical. 1996b). EPA identified several studies published from 2015 to 2019
evaluating estrogenic potential (Sedha et al.. ), reproductive effects (Chiang and Flaws. 2019).
developmental effects (Neier et al.. 2018; Setti Ahmed et al.. 2018). and metabolic effects (Neier et al..
2019) of DINP in mice and rats treated in the perinatal period. No studies of development are available
for the dermal or inhalation exposure routes. Available studies are summarized in Table 3-2 and
discussed further below.
Page 30 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Table 3-2. Summary of DINP Studies Evaluating Ef
'ects on Reproduction and Development
Brief Study Description
NOAEL/
LOAEL
(m«/k«-(lay)
Effect at
LOAEL
Remarks
Pregnant SD rats (23-25/dose) gavaged with
0 (corn oil vehicle), 100, 500, 1,000 mg/kg-
day DINP (CASRN 68515-48-0) on GDs 6-
15. Dams sacrificed on GD 21 (Waterman et
a.L 1999)
100/ 500"
t Skeletal
variations
Maternal Effects
- i (13%) food consumption on GDs 6-9 (1,000 mg/kg-day)
- i body weight gain on GDs 6-9, 6-15 (1,000)
Developmental Effects
-1 incidence of rudimentary lumbar (>500), supernumerary cervical ribs (1,000), renal
pelves (1,000)
Unaffected Outcomes
- Maternal survival, clinical signs, resorptions, post-implantation loss, fetal viability,
fetal body weight, sex ratio, incidence of fetal malformations
Pregnant Wistar rats (10/dose) gavaged with
0 (corn oil vehicle), 40, 200, 1,000 mg/kg-
day DINP-1 (CASRN 68515-48-0) on GDs
6-15. Dams sacrificed on GD 20 (Hellwig et
al. 1997)
200/1000
t Skeletal
variations
Maternal Effects
- i food consumption (1,000 mg/kg-day)
- Clinical signs (vaginal haemorrhage and urine-smeared fur in one dam) (1000)
-1 (13%) relative kidney weight
Developmental Effects
-1 skeletal variations (rudimentary cervical and accessory 14th ribs) (1000)
Unaffected Outcomes
- Survival; maternal body weight; uterus weight; relative liver weight; resorptions; post-
implantation loss; number of live fetuses per dam; fetal weight
Pregnant Wistar rats (10/dose) gavaged with
0 (corn oil vehicle), 40, 200, 1,000 mg/kg-
day DINP-2 (CASRN 28553-12-0) on GDs
6-15. Dams sacrificed on GD 20 (Hellwig et
al. 1997)
200/1000
t Skeletal
variations
Maternal Effects
- Clinical signs (vaginal haemorrhage in one dam) (1,000)
Developmental Effects
-1 skeletal variations (rudimentary cervical and accessory 14th ribs) (1,000)
Unaffected Outcomes
- Survival; food consumption; maternal body weight; uterus weight; relative liver and
kidney weight; resorptions; post-implantation loss; number of live fetuses per dam; fetal
weight
Page 31 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
NOAEL/
LOAEL
(mg/kg-day)
Effect at
LOAEL
Remarks
Pregnant Wistar rats (10/dose) gavaged with
0 (corn oil vehicle), 40, 200, 1,000 mg/kg-
day DINP-3 (CASRN 28553-12-0, resulting
from a different production line than DINP-2)
on GDs 6-15. Dams sacrificed on GD 20
(Hellwie et al. 1997)
200/1000
t incidence
of skeletal,
visceral, and
soft tissue
variations
Maternal Effects
- i food consumption (1000 mg/kg-day)
- i body weight gain from GD 6-15 (,1000)
-1 (11%) relative liver weight
Developmental Effects
-1 skeletal retardations (unossified or incompletely ossified sternebrae) (1,000)
-1 soft tissue variations (hydroureter) (1000
-1 skeletal variations (rudimentary cervical and accessory 14th ribs) (1,000)
Unaffected Outcomes
- Survival; clinical signs; uterus weight; resorptions; post-implantation loss; number of
live fetuses per dam; fetal weight
Male and female SD rats (30/sex/dose) fed
diets containing 0, 0.5, 1.0, 1.5%DINP
(CASRN 68515-48-0) starting 10 weeks prior
to mating, through mating, gestation, and
lactation continuously for one generation.
Received doses in units of mg/kg-day shown
in Table 3-5. (Waterman et al. 2000; Exxon
Biomedical 1996a)
None/ 377
I F1 male
and female
body weight
on PNDs 0,
14,21
Parental (PI) Effects
- i PI body weight (both sexes) (>1.0%)
- i PI food consumption (both sexes) (>1.0%)
-1 absolute and relative liver weight (both sexes) (>0.5%)
-1 absolute and/or relative kidney weight (both sexes) (>0.5%)
-1 absolute testes, right epididymis, and ovary weight (1.5%)
Fertility Effects
- None
OffsDri nu (Fl) Effects
- i live births, j PND 4 survival, j PND 14 survival, j viability at weaning (all at 1.5%)
- i male and female body weights on PND 0, 1, 14, 21 (>0.5%)
Unaffected Outcomes
- Clinical signs (PI); survival (PI); reproductive indices (male mating, male/female
fertility, female fecundity, gestational indices); litter size; number of live/dead offspring
at birth; sex ratio
Male and female SD rats (30/sex/dose) fed
diets containing 0, 0.2, 0.4, 0.8% DINP
(CASRN 68515-48-0) starting 10 weeks prior
to mating, through mating, gestation, and
lactation continuously for two-generations.
Received doses in units of mg/kg-day shown
in Table 3-7. (Waterman et al. 2000; Exxon
Biomedical 1996b)
None/133
I F1 and F2
male and
female body
weight on
PNDs 7 and
21
Parental (PI. P2) Effects
- i PI female body weight on PNDs 14 and 21 (0.8%)
-1 P2 male and female body weight (>0.4%)
- i PI female food consumption during lactational period (0.8%)
-1 P2 male and female food consumption during premating, gestation, and lactational
periods (0.8%)
-1 relative and/or absolute liver weight for PI males and females (>0.4%) & P2 males
and females (0.8%)
-1 absolute kidney weight for PI males (>0.4%) and females (>0.2%) & P2 males
(0.8%)
-1 incidence of minimal to moderate cytoplasmic eosinophilia (both sexes in PI and P2)
(>0.2%)
-1 incidence of minimal to moderate dilation of the renal pelves for P2 males (>0.4%)
Page 32 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
NOAEL/
LOAEL
(mg/kg-day)
Effect at
LOAEL
Remarks
Fertility Effects
- None
OffsDri nu (Fl. F2) Effects
-1 F1 male and female offspring body weight on PND 21 (>0.2%)
- i F2 female offspring body weight on PND 7 (>0.2%)
Unaffected Outcomes
- Clinical signs (PI, P2); survival (PI, P2); reproductive indices (male mating,
male/female fertility, female fecundity, gestational indices) (PI, P2); litter size (Fl, F2);
number of live/dead offspring at birth (Fl, F2); sex ratio (Fl, F2)
Uterotrophic Assay: 20 day old female Wistar
rats (6/group) were gavaged with 0
(untreated), 0 (corn oil vehicle), 276, 1380
mg/kg-day DINP (CASRN 68515-48-0), or
40 |ig/kg-dav diethylstilbesterol for 3 days.
Animals sacrificed 24 hours after dosing
(Sedha et al. 2015)
None/ 276
| body
weight gain
- i body weight gain (>276 mg/kg-day)
- Positive control gave anticipated results
Unaffected Outcomes
- Uterine and pair ovary wet weight
Pubertal Assay: 20 day old female Wistar rats
were gavaged with 0 (untreated), 0 (corn oil
vehicle), 276, 1380 mg/kg-day DINP
(CASRN 68515-48-0), or diethylstilbesterol 6
Hg/kg-day diethylstilbesterol for 20 days
starting on PND 21. Animals were sacrificed
onPND 41 rSedha et al.. 2015)
None/ 276
| body
weight gain
- i body weight gain (>276 mg/kg-day)
- i (10-28%) relative and absolute ovary weight (1380 mg/kg-day)
- Positive control gave anticipated results
Unaffected Outcomes
- Absolute and relative uterine wet weight and vaginal weight; vaginal opening
Pregnant Wistar rats (36/dose) gavaged with
0 (corn oil vehicle) or 380 mg/kg-day DINP
(CASRN 68515-48-0) from GD 8 through
PND 30 (Setti Ahmed et al., 2018)
None/ 380
| pup body
weight gain
Maternal Effects
- i food consumption during gestation (14-39%) and lactation (48-62%)
Developmental Effects
- i pup body weight gain (54-56%) from PND 15 to 30
- i small intestine weight
- Villous atrophy in duodenum, ilium, jejumum (qualitative, no incidence data reported)
Unaffected Outcomes
- Number of live pups per litter
CD-I female mice (4-12/dose) were gavaged
with 0 (corn oil vehicle), 0.02, 0.1, 20, or 200
mg/kg-day DINP (CASRN not provided) for
10 days and then mated with untreated males
immediately after, as well as 3 and 9 months
oost-dosinu (Chiang and Flaws. 2019)
200/ None
NA
Maternal Effects h
- None definitively related to treatment
Developmental Effects h
- None definitively related to treatment
Unaffected Outcomes (all timcDoints. unless otherwise noted)
- Body weight; absolute ovary, uterine, liver weight; time to mating; fertility index;
gestational index; gestation length; litter size; pup weight; pup mortality; estrous
cyclicity (0, 9 months)
Page 33 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
NOAEL/
LOAEL
(mg/kg-day)
Effect at
LOAEL
Remarks
Female yellow agouti mice (resulting in 15-
17 litters/dose) were fed diets of 0 or 75
mg/kg feed DINP (equivalent to 0 or 15
mg/kg-day) from 2 weeks prior to mating
through weaning (PND21) with body and
organ weights were collected on PND21
(Neier et al. 2018)
None/15
t maternal
body weight
gain; f pup
body weight;
t pup
relative liver
weight
Maternal Effects
-1 body weight gains
Developmental Effects (PND21)
-1 pup body weight (both sexes)
-1 pup relative liver weight (females)
Unaffected Outcomes (PND21)
- Number of live pups per litter; maternal body weight; pup hepatic triglycerides; pup
gonadal fat, brain, spleen, and kidney weights; pup liver weight (male); pup Avy DNA
methylation
Female yellow agouti mice (17-21/group)
were fed diets of 0 or 75 mg/kg feed DINP
(equivalent to 0 or 15 mg/kg-day) from 2
weeks prior to mating through weaning
(PND21). 1 male and female pup/litter were
allowed to recover for 10 months (Neier et
al. 2019)
None/15
I birth rates;
t pup liver
masses;
altered pup
body
composition;
| glucose
tolerance
Maternal Effects
- i birth rates
Developmental Effects (PND21)
-1 liver masses (males, p > 0.1)
-1 body fat (females, longitudinal 2-8 months)
- i lean mass percentage (females, longitudinal 2-8 months)
- i glucose tolerance (females, longitudinal 2-8 months)
Unaffected Outcomes (at 2 and 8 months unless noted)
- Pup body weight across life course (PND21-10 months); pup physical activity; pup
food intake; pup energy expenditure; resting metabolic rate, respiratory exchange rate,
fat oxidation rate, glucose oxidation rate; pup plasma adipokines
" Waterman et al. originally identified a developmental NOAEL of 500 mg/kg-day DINP based on increased incidence of skeletal variations. However, a re-analysis of
the data by study sponsors using the generalized estimating equation approach to the linearized model supported a NOAEL of 100 mg/kg-day DINP. Results from the
statistical re-analvsis are reported in (NTP-CERHR 2003).
b The study authors in Chiang (2019) reported several statistically significant findings as related to treatment with DINP; however, EPA considered these differences to
be spurious and incidental to treatment because they were unrelated to dose, transient, and/or not adverse. These significant differences included: differences in estrous
cyclicity at 20 and 100 |ig/kg/day and 200 mg/kg-day DINP and fewer pregnant females at 20 |ig/kg/day at 3 months post-dosing; differences in estrous cyclicity at 100
Hg/kg-day and reduced time to mating at 100 |ig/kg-dav to 200 mg/kg-day DINP and increased percent males in litters at 100 |ig/kg-day and 20 and 200 mg/kg-day DINP
at 9 months post-dosing.
862
Page 34 of 184
-------
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
PUBLIC RELEASE DRAFT
May 2024
In the first study, which adhered to EPA §798.4900 (40 CFR Part 798, 1985), Waterman et al.(1999)
gavaged pregnant SD rats (23 to 25 per dose) with 0, 100, 500, and 1,000 mg/kg-day DINP (CASRN
68515-48-0) on GDs 6 through 15. Maternal toxicity was limited to the high-dose group and included a
reduction in maternal body weight gain on GDs 6 through 9 and 6 through 15 (magnitude of effect not
reported), and a 13 percent decrease in food consumption on GDs 6 through 9. Food consumption and
bodyweight gain significantly increased after cessation of exposure between GDs 18 through 21 and
mean maternal body weight recovered to control levels by GD 21. No treatment-related effects on
maternal survival, clinical signs, resorptions, post-implantation loss, fetal viability, sex ratio, or fetal
body weight were observed. No malformations were observed at any dose. Fetal effects were limited to
treatment-related increases in skeletal and visceral variations, including increased incidence of renal
pelves at 1,000 mg/kg-day, rudimentary lumbar ribs at 500 and 1,000 mg/kg-day, and supernumerary
cervical ribs at 1,000 mg/kg-day (Table 3-3). EPA identified a developmental NOAEL of 100 mg/kg-
day DINP based on increased incidence of skeletal variations at 500 mg/kg-day and above and a
maternal NOAEL of 500 mg/kg-day based on reduced maternal weight gain and food consumption at
1000 mg/kg-day DINP.
Table 3-3. Mean Percent of
'etuses in Litter with Skeletal Variations (Waterman et ai. 1999V
xi b
0
(mg/kg-day)
100
(mg/kg-day)
500
(mg/kg-day)
1,000
(mg/kg-day)
Skeletal variations
16.4
15.0
28.3*
43.4**
Visceral variations
0.5
3.3
3.7
5.8*
Renal pelves
0.0
3.3
3.7
5.3*
Rudimentary lumbar ribs
3.5
4.7
18.1*
34.2**
Supernumerary cervical ribs
1.6
1.5
1.0
5.5*
" Adapted from Tables 5 and 6 in (NTP-CERHR. 2003)
h * indicates P<0.05 and ** indicates p < 0.01. Skeletal variation data was re-analyzed by study sponsors using
the generalized estimating equation (GEE) approach to the linearized model to account for potential litter
effects. The statistical re-anah sis conducted bv studv sponsors is reported in (NTP-CERHR. 2003). Renal
pelves data could not be re-analyzed using the GEE methodology due to the zero incidence in the control. Renal
pelves data was re-analysed using two approaches, including a nested analysis that considered litter effects and
by changing one control fetus to affected and using the GEE approach. Both approaches provided similar
results (significant increase at 1,000 mg/kg-day).
In a second prenatal study, Hell wig et al. (1997) gavaged pregnant Wistar rats (10 per dose) with 0, 40,
200, and 1,000 mg/kg-day DINP on GDs 6 through 15. Three different formulations of DINP were
evaluated, including: DINP-1 (CASRN 68515-48-0, purity >99%), commercially available with the
alcohol moiety consisting of roughly equivalent amounts of 3,4-, 4,6-, 3,6-, 3,5-, 4,5-, and 5,6-
dimethylheptanol-1; DINP-2 (28553-12-0), with at least 95% of the alcohol components as alkyl-
substituted octanol or heptanol derived from //-butene; and DINP-3 (28553-12-0), resulting from a
different production line from DINP-2, with main alcohol components synthesized from //-isobutene,
resulting in >60% alkyl-substituted hexanols. The studies were Good Laboratory Practice (GLP)-
compliant and generally adhered to EPA §798.4900 (40 CFR pat 798, 1992), with the exception that 10
dams, instead of 20 were employed per dose group. For DINP-1, maternal toxicity was limited to the
high-dose group and included reduced food consumption (magnitude of effect not reported), clinical
signs (i.e., vaginal haemorrhage and urine smeared fur in one dam), and a 13 percent increase in relative
kidney (but not liver) weight. No treatment-related effects on maternal body weight, maternal survival,
resorptions, post-implantation loss, number of live fetuses per dam, or fetal weights were observed.
Page 35 of 184
-------
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
PUBLIC RELEASE DRAFT
May 2024
Developmental effects were limited to the high-dose group and included a statistically significant
increase in the percent fetuses per litter with variations (35.3, 41.5, 29.5, and 58.4 percent across dose
groups). Variations showing dose-related increases included rudimentary cervical and accessory 14th
rib(s), and an apparent, non-statistically significant, increase in dilated renal pelves (Table 3-4). For
DINP-2, there was no statistically significant maternal toxicity that was treatment-related. One dam
given 1,000 mg/kg-day DINP-2 had vaginal hemorrhage on GD 14 and 15. No effects on food
consumption, maternal body weight, maternal survival, relative liver or kidney weight, resorptions, post-
implantation loss, number of live fetuses per dam, or fetal weights were observed. Study authors state
that "the only substance-related fetal effect was an increased incidence of a skeletal variation [accessory
14th rib(s)]" in the high-dose group, although the incidence of rudimentary cervical rib(s) also appeared
slightly increased (Table 3-4). Multiple malformations were observed in one high-dose fetus, including
globular-shaped heart, unilobular lung, hydrocephaly, dilation of aortic arch, and anasarca, which were
regarded as spontaneous and not treatment related by study authors. For DINP-3, maternal toxicity was
limited to the high dose group, and included reduced food consumption (magnitude of effect not
reported), decreased body weight gain from GDs 6 to 15, increased (11 percent) relative liver weight,
and a non-statistically significant increase (9 percent) in relative kidney weight. No effects on maternal
survival, resorptions, post-implantation loss, number of live fetuses per dam, or fetal weights were
observed. Developmental effects were limited to the high-dose group and included a statistically
significant increase in the percent fetuses per litter with variations (35.3, 29.6, 39.5, and 60.7 percent
across dose groups), including increased incidences of skeletal retardations (unossified or incompletely
ossified sternebrae), skeletal variations (rudimentary cervical and/or accessory 14th rib[s]) and soft tissue
variations (hydroureter, dilated renal pelvis) (Table 3-4). Additionally, study authors attributed some
soft tissue malformations (predominately affecting the urogenital tract) and skeletal malformations
(shortened and bent humerus and femur in a single fetus) in the high-dose group to be treatment-related.
Overall, similar developmental findings were observed for all three tested formulations of DINP and
support a developmental NOAEL of 200 mg/kg-day based on increased skeletal and visceral variations
at 1,000 mg/kg-day.
Table 3-4. Incidence of Visceral, Skeletal, and Soft Tissue Variations (I
lellwig et al..:
1997)"
DINP
Formulation
Number of Fetuses Evaluated and
Type of Fetal Variation
Control
40
(mg/kg-day)
200
(mg/kg-day)
1,000
(mg/kg-day)
DINP-1
No. fetuses (litters) evaluated
135 (9)
116(9)
111(8)
131 (10)
Rudimentary cervical rib(s)
2(1)
1
11(5)
Accessory 14th rib
2(2)
37 (10)
Dilated renal pelvis
12(7)
11(4)
8(4)
22 (9)
DINP-2
No. fetuses (litters) evaluated
135 (9)
116(9)
135(10)
141 (10)
Rudimentary cervical rib(s)
1
4(2)
10(5)
Accessory 14th rib
1
4(4)
DINP-3
No. fetuses (litters) evaluated
135 (9)
138 (10)
135 (9)
120 (9)
Rudimentary cervical rib(s)
2(1)
12(7)
Accessory 14th rib
9(5)
34 (8)
Sternebrae not ossified
6(3)
1
3(2)
26 (7)
Sternebrae incompletely ossified or
reduced in size
20 (7)
11(7)
16(6)
36(9)
Dilated renal pelvis
12(7)
15(8)
13(9)
20 (9)
Hydroureter
4(3)
5(3)
1
12(8)
"Table adapted from Tables 10, 12, and 14 in Hellwiu et al. (1997).
Page 36 of 184
-------
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
PUBLIC RELEASE DRAFT
May 2024
DINP has also been evaluated in both one- and two-generation studies of reproduction, which were GLP
compliant and conducted in accordance with EPA Test Guidelines for Reproductive and Fertility Effects
(40 CFR Part 798, 1985) (Waterman et ai. 2000; Exxon Biomedical. 1996a. b). In the one generation
study, SD rats (30/sex/dose) were continuously administered dietary concentrations of 0, 0.5, 1.0, and
1.5 percent DINP (CASRN 68515-48-0) starting 10 weeks prior to mating, throughout mating, gestation,
and lactation. Mean received doses in units of mg/kg-day are shown in Table 3-5. PI males were
sacrificed following delivery of the last litter of F1 pups, while PI females were sacrificed at F1
weaning on postnatal day (PND) 21. No treatment-related clinical signs or effects on survival were
reported for PI males or females. Body weight was statistically significantly reduced in mid- and high-
dose males and females during the premating phase, and in mid- (5.3 to 15.3 percent decrease) and high-
dose (10.8 to 23.3 percent decrease) PI females during gestation and lactation. Similarly, food
consumption was significantly reduced in mid- (5.3 to 8.7 percent decrease) and high-dose (5.8 to 10.5
percent decrease) males and females during the premating phase, and in mid- (16.7 to 27.4 percent
decrease) and high-dose (11.6 to 42.2 percent decrease) PI females during gestation and lactation.
Treatment with DINP had no significant effects on any reproductive indices, including male mating,
male/female fertility, female fecundity, or gestational indices. Mean litter size, mean number of live and
dead offspring, and sex ratio were unaffected by treatment with DINP. At the high dose, treatment with
DINP significantly reduced percent live births (95.2 vs. 98.2 percent in controls), PND 4 survival (85.6
vs. 93.1 percent in controls), PND 14 survival (92.7 vs. 98.5 percent in controls), and viability at
weaning (87.2 versus 93.9 percent in controls). Male and female F1 offspring body weight was
significantly reduced in all treatment groups on PNDs 0 (7.9 to 11.5 percent) and continued to be
reduced, although not always statistically significantly, in all treatment groups for both sexes through
PND 21 (Table 3-6). Overall, this study supports a developmental LOAEL of 377 mg/kg-day (no
NOAEL identified), based on reduced F1 offspring body weight throughout the lactational period.
Table 3-5. Mean Measured Doses (mg/kg-day) from the One-Generation Study of DINP in SD
Rats (\XAierm,m ci ,tl. J!000; I won Uums
Dose (%)
Premating - Males
Premating - Females
Gestation
Postpartum
0.5
301-591
363-624
377-395
490-923
1.0
622-1,157
734-1,169
741-765
1,034-1,731
1.5
966-1,676
1114-1,694
1087-1,128
1,274-2,246
"Adapted from Table 12 in Exxon Biomedical (1996a)
Page 37 of 184
-------
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
PUBLIC RELEASE DRAFT
May 2024
Table 3-6. F1 Offspring Postnatal Body Weight (Grams) from the One-Generation Study of
Reproduction in SD Rats (Waterman et *1.. 2000; Ei.1.011 Biomedical l996aV*c
F1 Offspring
Croup
Male
Female
PND 0
PND 1
PND 4
PND 7
PND 14
PND 21
PND 0
PND 1
PND 4
PND 7
PND 14
PND 21
0%
6.98
7.34
9.80
16.02
33.77
54.34
6.68
7.05
9.58
15.60
32.72
52.19
0.2%
6.49**
6.83
9.18
14.52
30.00**
48.94*
6.15**
6.52*
8.81
14.07
29.40**
47.77**
0.4%
6.42**
6.92*
9.12
14.00*
26.23**
39.93**
6.05**
6.49**
8.56*
13.24*
25.04**
38.13**
0.8%
6.27**
6.58**
8.19**
11.04**
20.18**
29.32**
5.91**
6.25**
7.84**
10.71**
19.31**
27.71**
Historical
Control
6.35-
7.02
6.68-
7.46
8.53-
11.43
13.64-
18.74
28.81-
36.73
44.89-
60.77
5.96-
6.74
6.30-
7.16
8.32-
11.05
13.33-
17.69
27.22-
35.74
42.39-
61.19
" Data from Table 4 in Waterman et al. (2000).
4 and '**' indicate the mean is significantly different from the control mean by p < 0.05 and p < 0.01, respectively.
c Historical control data reported to be from the laboratory conducting the study. Further details (e.g., number of studies data
collected from, timespan of studies) regarding the source of historical control data were not provided in (Exxon Biomedical,
1996a).
In the two-generation study, SD rats (30/sex/dose) were continuously administered dietary
concentrations of 0, 0.2, 0.4, and 0.8 percent DINP (CASRN 68515-48-0) starting 10 weeks prior to
mating, throughout mating, gestation, and lactation continuously for two generations (Waterman et at..
2000; Exxon Biomedic; 3b). Mean received doses in units of mg/kg-day are shown in Table 3-7.
For the first parental generation (PI), no treatment-related clinical signs or effects on survival were
reported for PI animals. No significant effects on PI body weight were observed, except for a 6.7 to 7.8
percent decrease in high-dose female body weight on PNDs 14 and 21. Food consumption was
significantly reduced (9 percent) for high-dose females during the postnatal phase of the study but was
not reduced for males or females during other phases of the study. For the second parental generation
(P2), no treatment-related clinical signs or effects on survival were reported. At the start of the
premating period (six weeks after weaning), mean body weights for mid and high dose males and
females were lower than control. Females in the high-dose group had consistently lower body weight
gain compared to the control group during the premating (statistically significant for first 2 weeks),
gestation (not significant), and lactational (significant for PND 4 to 21) phases. Small (less than 8
percent), but statistically significant, decreases in food consumption were observed in high-dose males
and females during the premating period and in high-dose females during gestation (13 to 16 percent
decrease) and lactation (9 percent decrease). No treatment-related effects on any reproductive indices
were observed for either generations, including male mating, male/female fertility, female fecundity, or
gestational indices.
Similarly, gestation length, mean litter size, mean number of live and dead offspring, sex ratio, percent
live births, survival on PNDs 1, 4, 7, 14, and 21, and viability at weaning were unaffected by treatment
with DINP for both the F1 and F2 generations. F1 and F2 offspring body weight was significantly
reduced throughout PNDs 0 to 21 (Table 3-8). For F1 offspring, bodyweight was significantly reduced
6.8 percent for high-dose males on PND 0; 10 to 15 percent for mid- and high-dose males and females
on PNDs 7 and 14; and 8.9 to 19 percent for males and females on PND 21 in all dose groups. For F2
offspring, bodyweight was significantly reduced 14 to 17 percent for mid- and high-dose females on
PND 4; 14 to 19 percent for mid- and high-dose males and 10 to 21 percent for females in all dose
groups on PND 7; 12 to 21 percent for mid- and high-dose males and females on PND 14; and 12 to 22
percent for mid- and high-dose males and females on PND 21. Study authors state that the observed
body weight changes were within historical control ranges from the laboratory conducting the study and
that effects on body weight at 0.2 and 0.4 percent DINP "seem unrelated to treatment." However, no
information regarding the source of the historical control data is provided (e.g., number of studies, years
Page 38 of 184
-------
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
PUBLIC RELEASE DRAFT
May 2024
study conducted, strain/species tested, and diet animals were maintained on were not reported), so it is
unclear if an appropriate historical control dataset was used. Overall, this study suggests a
developmental LOAEL of 0.2 percent DINP (equivalent to approximately 133 mg/kg-day during
gestation) for decrements in F1 and F2 body weight during lactation.
Table 3-7. Mean Measured Doses (mg/kg-day) from the Two-Generation Study of DINP in SD
Rats
Dose
(%)
PI Generation
P2 Generation
Prematinjj-
Malcs
Prematinjj-
Fcmalcs
Gestation
Postpartum
Prematin};-
Males
Prematinjj-
Females
Gestation
Postpartum
0.2
118-212
145-215
139-153
159-350
114-264
140-254
133-153
174-395
0.4
236-126
278-425
274-301
347-731
235-523
271-522
271-307
348-758
0.8
477-852
562-830
543-571
673-1,379
467-1,090
544-1,060
544-577
718-1541
" Adapted from Tables 12 and 32 in Exxon Biomedical C1996b)
Table 3-8. F1 and F2 Offspring Postnatal Body Weight (Grams) from the Two-Generation Study
of Reproduction in SD Rats (Waterman et ai. 2000: Exxon Biomedical. 1996b) ahc
F1 Offspring
Group
Male
Female
PND 0
PND 1
PND 4
PND 7
PND 14
PND 21
PND 0
PND 1
PND 4
PND 7
PND 14
PND 21
0%
6.90
7.49
10.63
17.62
35.01
57.25
6.47
7.11
10.26
16.70
33.52
53.99
0.2%
6.78
7.39
10.26
16.44
33.28
51.40*
6.36
6.96
9.61
15.54
31.89
49.19*
0.4%
6.48
7.03
9.54
15.28**
30.43**
47.95**
6.16
6.67
9.24
14.21**
29.14**
45.63**
0.8%
6.43*
7.05
9.74
15.67*
29.66**
46.52**
6.08
6.70
9.36
15.03*
28.41**
44.68**
Histori-
cal
Control
6.35-
7.02
6.68-
7.46
8.53-
11.43
13.64-
18.74
28.81-
36.73
44.89-
60.77
5.96-
6.74
6.30-
7.16
8.32-
11.05
13.33-
17.69
27.22-
35.74
42.39-
61.19
l '2 iilTsprum
<)"„
"
|(K..
is.us
i" ()')
(¦: m
(.44
"|u
In 4S
1 ~ 4"
'5 X<>
0.2%
6.49
7.12
10.05
16.43
34.80
57.89
6.13
6.75
9.60
15.72*
33.64
55.50
0.4%
6.55
7.08
9.73
15.48**
32.51**
54.82**
6.11
6.59
9.05**
14.56**
31.22**
51.98**
0.8%
6.18
6.64
9.05
14.70**
29.88**
49.12**
5.92
6.41
8.68**
13.76**
28.20**
46.20**
Historic
al
Control
6.35-
7.02
6.68-
7.46
8.53-
11.43
13.64-
18.74
28.81-
36.73
44.89-
60.77
5.96-
6.74
6.30-
7.16
8.32-
11.05
13.33-
17.69
27.22-
35.74
42.39-
61.19
" Data from Tables 8 and 11 in Waterman et al. (2000).
h and '**' indicate the mean is significantly different from the control mean by p < 0.05 and p < 0.01, respectively.
c Historical control data reported to be from the laboratory conducting the study. Further details (e.g., number of studies data
collected from, timesoan of studies) reeardine the source of historical control data were not provided in (Exxon Biomedical.
1996b).
Ahmed et al. (2018) investigated the effects of DINP on development of the small intestine. Pregnant
Wistar rats (36 per dose) were gavaged with 0 (corn oil vehicle) or 380 mg/kg-day DINP from GD 8
through PND 30. Treatment with DINP reduced maternal food consumption 14 to 39 percent during
gestation and 48 to 62 percent during lactation (PNDs 1 to 21), however, it is unclear if reduced food
consumption led to reduced dam body weight, as this outcome was not reported. Pup body weight gain
was significantly reduced (54 to 56 percent) from PND 15 to 30. Study authors report that pup small
intestine weight was significantly reduced 41 percent by treatment with DINP, however, there are
apparent discrepancies between the text and tabular organ weight data (unclear if a statistical analysis as
Page 39 of 184
-------
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
PUBLIC RELEASE DRAFT
May 2024
done on individual organs). Histologically, offspring small intestine (duodenal, jejunal and ileal
samples) showed villous atrophy following exposure to DINP, however, no incidence data is reported
(only representative photomicrographs are provided). Lactase, maltase, sucrase, and ALP activity in the
duodenum, ilium, and jejunum were also reported to be impacted by treatment with DINP on PND7,
PND15, and PND30. Although results from this study suggest that DINP has effects on the developing
small intestine in offspring exposed via maternal exposure during gestation and lactation, these effects
may be related to the substantial decreases in offspring body weight gain which may be secondary to
decreased maternal food consumption during gestation and lactation.
Chiang and Flaws (. ) gavaged adult CD-I female mice (4 to 12 per group) with 0 (corn oil vehicle),
0.02, 0.1, 20, or 200 mg/kg-day DINP (CASRN not provided) for 10 days and then evaluated effects on
organ weight, estrous cyclicity, and mating behavior with untreated male mice immediately after dosing,
as well as 3 and 9 months post-dosing. Treatment with DINP had no effect on body weight, absolute
ovary, uterine or liver weight at any timepoint. Three months post-dosing, females treated with 0.02 and
200 mg/kg-day spent significantly less time in proestrus and more time in metestrus and diestrus.
However, no dose-related effects on estrous cyclicity were observed immediately following dosing or
nine months post-dosing and the effects observed at three months appeared slight (magnitude of effect
not reported) and of uncertain toxicological significance. No adverse, dose-related, effects on time to
mating, fertility index, gestational index, gestation length, the number of females able to produce pups,
litter size, pup weight on PND20, pup mortality, sex ratio were observed at any timepoint. Several
parameters were statistically significantly altered (e.g., fertility index deceased at 0.02 mg/kg-day at 3
months [but not at higher doses or other timepoints], number of females able to produce pups decreased
at 0.02 mg/kg-day at 3 months and 20 mg/kg-day at 9 months [but not at higher doses]), however, these
findings were of uncertain toxicological significance, given the non-monotonic dose relationship and the
lack of mechanistic data from other studies supporting an effect of DINP on these endpoints.
Two perinatal exposure studies of DINP have also been conducted using the viable yellow agouti mouse
model (Neier et al. l , Meier et al. 2018). In in the first study, a/a dams were fed phytoestrogen-free
diets containing 0 of 75 mg/kg DINP (CASRN not reported) (equivalent to approximately 15 mg/kg-day
DINP) starting two weeks prior to mating with A1-7a males and continuing throughout gestation and
lactation until weaning on PND 21 (Neier et al.. 2018). The exact number of mating pairs per treatment
group is not provided in the 2018 study, however, 15 to 17 litters were produced for the control and
DINP treatment groups. Treatment with DINP had no effect on maternal body weight at PND21,
offspring sex ratio, mean pups per litter, pup mortality through PND21, or pup genotype. Body weight
was significantly increased 10 to 20 percent for females (of genotypes a/a and Avy/a) and 15 percent for
males (of genotype Avy/a) on PND21 in the DINP treatment group. Treatment with DINP correlated to
increased relative liver weight for female pups. There was no change in absolute or relative liver weight
(males only), gonadal fat, brain, spleen, or kidney weights in pups. Additionally, no change in pup DNA
methylation was observed. In summary, treatment with DINP showed modest decreases in pup body
weights and increased relative liver weight (females only).
The Neier et al. (2019) study followed the same dosing scheme with viable yellow agouti mouse dams
exposed from 2 weeks prior to mating through PND21 in diet at dosages of 0 and 75 mg/kg feed DINP
(equivalent to 0 and 15 mg/kg-day). A total of 17 control pairs and 21 DINP pairs were dosed to produce
a minimum of 15 litters per treatment group. The largest male and female from each litter (10 per sex
per dose) were fed a phthalate free diet until 10 months old; one male in the 15 mg/kg-day group died
during glucose gavage at 2 months. The DINP treatment group showed a decreased birth rate, a non-
significant increase in liver masses in males at 10 months (9.1 percent control vs. 33 percent treated).
Effects were not reported in dams and pups body weights were not altered. The Neier et al. (2019) study
Page 40 of 184
-------
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
PUBLIC RELEASE DRAFT
May 2024
also evaluated metabolic effects through adulthood in mice exposed to DINP perinatally with
evaluations at 2, 8, and 10 months. The DINP treatment group showed altered body fat, lean mass
percentage in females longitudinally; however, these effects were not significant when accounting for
multiple comparisons. DINP treated females showed a moderate reduction in glucose tolerance
longitudinally driven by decreased glucose tolerance at two months that improved slightly at eight
months. There was no change in pup body weight across life, physical activity, or food intake.
Additionally, there was no alteration in energy expenditure, resting metabolic rate, respiratory exchange
rate, fat oxidation rate, glucose oxidation rate, or plasma adipokines. Overall, treatment with DINP
resulted decreased birth rate, as well as modest alterations to female pup body composition and glucose
tolerance, without corresponding alterations to diet, physical activity, or other markers for metabolic
activity.
Sedha et al. (2015) investigated the estrogenic potential of DINP in a three-day uterotrophic assay and a
20-day pubertal assay. For the uterotrophic assay, 20-day old female Wistar rats (6/dose/group) were
gavaged with 0 (corn oil vehicle), 276, or 1,380 mg/kg-day DINP (CASRN 68515-48-0) for three
consecutive days, while an additional group was treated with diethylstilbesterol (40 |ig/kg-day), which
served as the positive control. Body weight gain was reduced in both DINP treatment groups compared
to the control, however, treatment with DINP had no significant effect on uterine or paired ovary wet
weight, while the positive control increased ovary and uterus wet weight. For the pubertal assay, 20-day
old female Wistar rats were gavaged with 0 (corn oil vehicle), 276, or 1,380 mg/kg-day DINP and
diethylstilbesterol (6 |ig/kg-day) from PND 21 to sacrifice on PND 41. Body weight gain was
significantly reduced in all DINP treatment groups compared to the control. Absolute and relative
uterine wet weight and vaginal weight were unaffected by treatment with DINP, while relative and
absolute ovary weight was significantly reduced 10 to 28 percent by treatment with 1380 mg/kg-day
DINP. Timing of vaginal opening was unaffected by treatment with DINP. Collectively, results from
these assays indicate that DINP lacks estrogenic potential in vivo.
3.1.2.3 Conclusions on Reproductive and Developmental Toxicity
EPA previously proposed a MOA for male reproductive effects in rodents due to antiandrogenic activity
of DINP as part of a proposed approach for cumulative risk assessment of phthalates ( )23a).
which was supported by the SACC (I] S 1T \ 2023b). As outlined in Table 3-1, male reproductive
effects were observed in 13 rat studies with gestational or oral exposures. Collectively, these data
support EPA's conclusion that exposure to of pregnant female rodents to DINP during gestation results
in effects on male offspring consistent with androgen insufficiency.
An additional 12 developmental studies in mice and rats were included in the dataset covering a wide
developmental window. Available studies included a one-generation study of reproduction in rats
(Waterman et al. 2000; Exxon Biomedic; 3a) and two-generation study of reproduction in rats
(Waterman et al. 2000; Exxon Biomedic; 3b), and a uterotrophic assay in rats (Sedha et al. 2015).
along with multiple studies covering the pre-mating, gestation, and lactation periods. All studies were
limited to oral exposures in rodents.
The evidence for effects on the female endocrine system and reproduction is less clear than the evidence
supporting androgen insufficiency. The uterotrophic assay in rats showed decreased body weight gains,
but no change to uterine or paired ovary wet weight (Sedha ). In the pubertal assay, absolute
and relative uterine wet weight and vaginal weight were unaffected by treatment with DINP, while
relative and absolute ovary weight was significantly reduced at the high dose (1,380 mg/kg-day DINP).
Sexual maturation (time to vaginal opening) was unaffected by treatment with DINP. In the study by
Chiang and Flaws (. ) in which adult CD-I female mice were administered DINP via oral gavage and
Page 41 of 184
-------
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
PUBLIC RELEASE DRAFT
May 2024
mated with untreated male mice, there were no adverse effects of treatment on body weight, weights of
the uterus or ovaries, time to mating, fertility index, gestational index, gestation length, the number of
females able to produce pups, litter size, pup weight on PND 20, pup mortality, or sex ratio. Several
parameters were significantly different from controls (e.g., decreases in fertility index and number of
females able to produce pups and differences in estrous cycle; however, these findings were of uncertain
toxicological significance, given the findings were often transient, and the non-monotonic dose
relationship and the lack of mechanistic data from other studies supporting an effect of DINP on these
endpoints. Collectively, results from these assays indicate that DINP lacks estrogenic potential in vivo,
and the results of in vitro receptor-binding assays (Kriieer et ai. 2008; Takeuchi et al. 2005; Roy et al.
2004) are consistent with the lack of effects in the uterotrophic and female pubertal assays in Sedha et
al. (20151
Skeletal variations (Waterman et a ); Hellwig et al.. 1997) and reduced body weights were
observed in rat pups across multiple studies (Setti Ahmed et al.. 2018; Sedha et al. 2015; Waterman et
al.. 2000; Exxon Biomedic 5a). Maternal body weights and food consumption were decreased in
several studies on rats (Setti Ahmed et al.. 2018; Waterman et al.. 1999; Hell wis et a I). The one
generation reproduction study showed decreased live births and postnatal survival (Waterman et al..
2000; Exxon Biomedical lvV)6a). One study also identified gastrointestinal effects, including reduced
small intestine weight and villous atrophy in duodenum, ileum, and jejumum, although these findings
are likely related to decreased offspring body weight gain, and secondary to decreased maternal food
consumption (Setti Ahmed et al.. 2018). Two studies of yellow agouti mice dosed with 15 mg/kg-day
DINP from 2 weeks prior to mating through lactation found increased pup body weights, altered body
compositions, and decreased glucose tolerances (Meier et al.. 2019; Neier et al.. 2018). as well as
decreased birth rates (Neier et al.. ). Although these data show different effects in mice and rats, the
low number of studies in mice make it difficult to confidently determine species sensitivity.
Oral exposure to DINP has consistently been shown to cause developmental effects in animal models as
illustrated by the studies described above and concluded by previous assessments by NTP-CERHR
(2003). ECHA (2013b). EFSA (2019). Australia NICNAS ( ), Health Canada (EC/HC. 2015) and
U.S. CPSC (20 I I, 2010). Therefore, EPA is considering developmental toxicity for dose-response
analysis in Section 4.
3.2 Liver Toxicity
The non-cancer health effects and carcinogenicity of DINP have been evaluated primarily in animal
toxicological studies; no human epidemiologic studies evaluating hepatic effects were identified by
EPA's review of existing assessments (primarily Health Canada (2018a)). Moreover, existing
assessments have consistently identified the liver as one of the most sensitive target organs following
oral exposure to DINP in experimental animal studies (ECCC/HC. 2020; EFSA. 2019; EC/I W _< < i ,
ECHA.. 2013b; NICNAS. 20I 2; I CPSC. 201^. i P \ , U ^ '03; NTP-CERHR. 200 , 1 \
C )
EPA identified twenty-five animal toxicology studies that evaluated non-cancer effects on the liver
following short-term (>1 to 30 days), subchronic (>30 to 90 days), or chronic (>90 days) oral exposure
to DINP. Available studies include: 12 short-term oral studies (6 studies on rats, 5 studies on mice, 1
study on cynomolgus monkeys); 9 subchronic oral exposure studies (6 on rats, 1 on mice, 1 on beagle
dogs, and 1 on marmosets); 4 chronic 2-year oral exposure studies (3 on rats and 1 on mice); and one-
generation and two-generation studies of reproduction of rats that report non-cancer liver effects. More
detailed information on the available studies is provided in Appendix B, including information on
individual study design.
Page 42 of 184
-------
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
PUBLIC RELEASE DRAFT
May 2024
Exposure to DINP resulted in adverse non-cancer effects on the liver across study designs. Adverse non-
cancer effects such as increased absolute and/or relative liver weight consistently coincided with
increased incidences of non-neoplastic lesions or changes in clinical chemistry parameters, indicative of
liver toxicity. Adverse non-cancer effects on the liver were primarily observed in rats and mice of both
sexes, although there was also evidence of hepatotoxicity from one study in beagles. Two studies in non-
human primates with dose ranges comparable to those in the rodent and beagle studies did not provide
evidence of non-cancer or pre-neoplastic effects on the liver following 14- (Push et at.. 2000) and 90-
day oral exposures to DINP (Hall et at.. 1999). Changes in liver weights, histopathology, and clinical
chemistry parameters in rodents coincided with mechanistic endpoints indicative of Peroxisome
proliferator activated receptor alpha (PPARa) activation, which is discussed further in EPA's Draft
Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP) ( 24a).
In general, short term (9 of the 12 studies) and subchronic duration studies (9 of 9) consistently reported
increases in absolute and/or relative liver weight, sometimes in parallel with exposure-related
histopathological effects on the liver (e.g., hepatocellular hypertrophy) or coinciding with increases in
liver enzymes (e.g., ALT, AST, ALP), suggesting impaired liver function. These effects were generally
dose-dependent, observed in both sexes, and in multiple species, including rats, mice, and beagle dogs.
One 13-week study in marmoset monkeys reported non-statistically significant increases in liver weight,
but there was no dose-response, and the authors attribute the lack of statistical significance to high
variability and small sample size (Hall et at.. 1999). More detailed study information for short-term and
subchronic studies is available in Appendix B within TableApx B-l, and TableApx B-2, respectively.
Three chronic 2-year studies in rats (Covance Labs. 1998c; Lington et at.. 1997; Bio/dynamics. 1987)
and one in mice (Covance Labs. 1998b) consistently reported non-cancer liver effects, while all except
the Lington et al. (1997) study reported statistically significant increased incidences of liver tumors (i.e.,
hepatocellular adenomas and/or carcinomas). Non-cancer liver effects that were observed across these
four studies included consistent increases in liver weight that corresponded with histopathological
alterations (e.g., spongiosis hepatis, necrosis) and/or increases in serum enzyme levels or activity in both
sexes. An additional one- and two-generation study in rats by Waterman et al. (2000; Exxon Biomedical.
1996a) found increases in liver weight in the parental generation that coincided with minimal to
moderate cytoplasmic eosinophilia in the liver. More detailed study information for short-term and
subchronic studies is available in Appendix B within Table Apx B-l, and Table Apx B-2.
The NOAEL and LOAEL for non-cancer hepatic effects in F344 rats in Lington et al. (1997) were 15
and 152 mg/kg-day, respectively; based on a statistically significant increase in the incidence of
spongiosis hepatis in mid-dose male rats that was accompanied by increased absolute and relative liver
weights and changes in serum enzyme activities (i.e., increased ALT and AST). These effects are also
the basis for the LOAEL of 359 mg/kg-day (NOAEL of 88 mg/kg-day) in the Covance study (1998c) of
F344 rats. The incidence of spongiosis hepatis was dose-related and significantly increased in male rats
exposed to DINP in both studies. Moreover, a Histopathology Peer Review and Pathology Working
Group (EPL. 1999) independently evaluated the liver slides from rats chronically treated with DINP and
confirmed that the incidence of spongiosis hepatis was increased in male rats in each study.
Bio/dynamics (1987) also reported a significant increase incidence of spongiosis hepatis in male SD rats
of the two highest dose groups, and dose-related trends in both males and females. Detailed information
on lesion incidence is available in Appendix B within Table Apx B-7.
Conclusions on Non-cancer Liver Toxicity
Collectively, short-term, subchronic, and chronic studies of mice, rats, and beagles provide consistent
evidence that oral exposure to DINP can cause liver toxicity. The lowest non-cancer NOAEL identified
Page 43 of 184
-------
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
PUBLIC RELEASE DRAFT
May 2024
by EPA was 15 mg/kg-day based on increased liver weight, increase serum ALT and AST, and
increased incidence of non-neoplastic lesions (e.g., spongiosis hepatis, enlargement, and granular and
pitted rough changes in hepatocytes, central vein dilation, enlarged, discoloured, congestion, oedema,
and narrowing sinusoidal with loose cytoplasm) in 2-year study of F344 rats (Lington etai. 1997). EPA
further considers liver toxicity for dose-response assessment in Section 4.
EPA summarizes the liver cancer associated with exposure to DINP in a separate technical support
document, the Draft Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP) (U.S.
EPA. 2024a).
3.3 Kidney Toxicity
Kidney effects generally occur at higher doses than liver effects and occur inconsistently across study
designs and species (EFSA.. 2019; EC/HC. 2015; EC t P. b, NIC/HAS. 2012; U.S. CPSC. 2010;
EFSA.. 2005; ECB. 2003; NTP-CERHR. 20031
Humans
Although IRIS systematic review process identified five epidemiological studies that investigated the
association between DINP and renal effects, the evidence was deemed inadequate. Three of the five
studies had critical deficiencies in exposure measurement, and the other two studies were of low
confidence and had evidence of selection bias and reverse causality (Radke et al. 2019a).
EPA did not identify any new epidemiologic studies that examine the association between DINP and its
metabolites and/or biomarkers of kidney injury.
Laboratory Animals
Many experimental animal studies have evaluated the kidney toxicity of DINP following oral exposure.
Studies have evaluated the effects on kidney function (i.e., urinalysis parameters, serum BUN levels),
kidney weight, and histopathology. Seventeen studies are available that provide data on
histopathological effects of the kidney, 16 of which also provide data on absolute and/or relative kidney
weights. Six studies report changes in indices of kidney function such as serum BUN levels or urinalysis
parameters. One study was available for the dermal exposure route (Hazleton Laboratories. 1969). No
studies were available for the inhalation exposure route.
Short-Term (>l to 30 Days) Exposure Studies: EPA identified five short-term studies in rodent models
that provide data on the effects of DINP on the kidney (Ma et al.. 2014; Kwack et al.. 2010; Kwack et
al.. 2009; 5; Bio/dynamics. 1982a). An industry-sponsored study by Bio/dynamics (1982a)
exposed male Fischer 344 (F344) rats to 0 or 2 percent (equivalent to 1,700 mg/kg-day) DINP for one
week via feed and evaluated kidney weights and histopathology at study termination. Significant
increases in absolute (7.5 percent increase) and relative (12.2 percent increase) kidney weights were
observed in rats exposed to DINP. No abnormal histopathological findings were observed in the
kidneys. Another study in F344 rats reported similar findings (BIBRA. 1986). BIBRA (1986)
administered 0, 0.6, 1.2, 2.5 percent DINP for 21 days (equivalent to 0, 639, 1,192, 2,195 mg/kg-day
[males]; 0, 607, 1,198, 2,289 mg/kg-day [females]) in the diet to male and female rats and evaluated
kidney weights and histopathology at study termination. Dose-related increases in relative kidney
weights were observed in males and females at all dose levels; the LOAEL was 639 and 607 mg/kg-day
for males and females, respectively. No exposure-related histopathological findings were observed in the
kidneys.
Page 44 of 184
-------
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
PUBLIC RELEASE DRAFT
May 2024
Not all short-term studies reported dose-related changes in kidney weights that coincide with other
effects of the kidney. Two studies in male SD rats reported no change in relative kidney weights and/or
no change in BUN or other urinalysis parameters (Kwack et ai. 2010; Kwack et al. 2009). while
another in B6C3F1 mice reported changes in weights without a consistent dose-related trend (Hazleton
Labs. 1991a). The studies by Kwack et al. exposed male SD rats to 0 or 500 mg/kg-day DINP via
gavage for 14 days (Kwack et al.. 2010; Kwack et al.. 2009). while the Hazleton study (1991a) exposed
mice to 0, 3,000, 6,000, or 12,500 ppm DINP for 4 weeks (equivalent to 0, 635, 1,377, 2,689, or 6,518
mg/kg-day [males]; 0, 780, 1,761, 3,287, or 6,920 mg/kg-day [females]). In the Hazleton study (1991a).
significant increases in relative kidney weight were observed at the highest dose in males (6,518 mg/kg-
day) and females (6,920 mg/kg-day), but significant decreases were observed at lower dose-levels in
both sexes, which was also true for absolute kidney weights. Nevertheless, the increased relative kidney
weights coincided with significant increased serum BUN levels in high-dose males and increased
incidences of tubular nephrosis in all high-dose males and females, supporting an exposure-related effect
on the kidney (Hazleton Labs. 1991a). In a study in which male Kunming mice were exposed to 0.2, 2,
20 or 200 mg/kg-day DINP for 14 days via gavage. Ma et al. (2014) reported significantly increased
incidences in histopathologic lesions of the kidney, including large reduction in tubular space and
extreme edema of epithelial cells in the glomeruli in animals exposed to the highest dose of DINP.
However, this publication only described these findings qualitatively in text and did not include
quantitative data on incidence or severity.
New Literature: EPA identified one new study published from 2015 through 2020 that provided data on
toxicological effects of the kidney following short term exposure to DINP. The developmental exposure
study by Neier et al. (2018) reported no change in absolute or relative kidney weights at PND21 in male
and female yellow agouti (Avy) mice offspring. In that study, dams were administered 0 or 75 ppm
DINP in the diet (equivalent to 15 mg/kg-day) beginning 2-weeks before mating and continuing through
PND21.
Subchronic (>30 to 90 days) Exposure Studies: EPA identified six dietary studies from existing
assessments that provide data on the toxicological effects of DINP on the kidneys following subchronic
oral exposure (Hazleton Labs 1001 h; Hio/dynamics. 1982b. c; Hazleton Labs. 1981; Hazleton
Laboratories. 1971; Hazleton Labs. 1971) and one gavage study in marmoset monkeys (Hall et al..
1999). These studies provided data across a range of species and strains as well as both sexes. Increases
in absolute and/or relative kidney weights and histopathological effects were reported in all of the
studies. (Hazleton Labs * U>, » tunics. 1982b. c; Hazleton Lab*- I'M; Hazleton Laboratories.
1971; Hazleton Labs. 1971). albeit the effects were sometimes attributable to decreased body weight.
Dose-related increases in absolute and/or relative kidney weights sometimes corresponded with
increased incidences of histopathological lesions or altered urine chemistry, but these trends were not
consistent across all studies.
A study by Bio/dynamics labs (1982b) exposed F344 rats to 0, 0.1, 0.3, 0.6, 1.0, or 2.0 percent DINP for
13 weeks via feed (equivalent to 0, 77, 227, 460, 767, 1,554 mg/kg-day). Dose-dependent increases in
kidney weight were noted in males, where doses as low as 227 mg/kg-day DINP resulted in increased
absolute (9.7 percent) and relative (21.9 percent) weights. The increase in kidney weight was
accompanied by a dose-dependent increase in dark brown discoloration in the kidney from 460 mg/kg-
day. A similar study from Bio/dynamics labs (1982c) exposed Sprague Davvley rats to 0.3 or 1.0 percent
DINP in the diet for 13 weeks (equivalent to 201 or 690 mg/kg-day [males]; 251 or 880 mg/kg-day
[females]). The authors reported dose-related increases in absolute and relative kidney weights in males
and females that corresponded with altered clinical chemistry parameters in males, most notably a dose-
Page 45 of 184
-------
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
PUBLIC RELEASE DRAFT
May 2024
dependent decrease in triglycerides and increased calcium in high-dose males. The LOEL was 201 or
251 mg/kg-day for males or females, respectively.
These results were similar to three studies from Hazleton Labs (1991b. 19s I, r" I), each using a
different strain of rats. Hazleton Laboratories (1971) reported increases in absolute (9.3 to 17.6 percent
increases) and relative (14.4 to 25.5 percent increases) kidney weight in male and female albino rats of
the highest dose group (500 mg/kg-day). In that study, animals were exposed to 0, 50, 150, 500 mg/kg-
day DINP for 13 weeks. Hazleton Labs ( ) administered 0, 2,500, 5,000, 10,000, or 20,000 ppm
DINP via diet to CDF (F344)/CrlBr rats for 13 weeks (equivalent to 176, 354, 719, or 1545 mg/kg-day
[males]; 218, 438, 823, or 1,687 mg/kg-day [females]). Dose dependent increases in absolute and
relative kidney weights were observed in both sexes, which coincided with a dose-related increase in
granular casts and regenerative /basophilic tubules in the kidneys, beginning at 354 mg/kg-day in males.
Hazleton Laboratories (1981) administered 0, 1,000, 3,000, or 10,000 ppm DINP to SD rats via feed for
13 weeks (equivalent to 0, 60, 180, and 600 mg/kg-day). A LOAEL of 60 mg/kg-day was identified
based on an increased incidence of kidney lesions (focal mononuclear cell infiltration and
mineralization) in exposed males. Absolute and relative kidney weights were also increased in males
and females exposed to 600 mg/kg-day. Absolute weights increased 20 percent in males and 10.8
percent in females, while relative weight increased 17.7 percent in males and 13.7 percent in females.
Although there is ample evidence that the kidney is a target organ for DINP in rodents, the evidence is
less consistent and less numerous across other species, including dogs, monkeys and rabbits. Increased
kidney weights were observed in high-dose animals in a study of beagle dogs by Hazleton Laboratories
(1971). but were attributed to deceased body weight. In that study, animals were administered 0.125,
0.5, or 2 percent DINP in feed for 13 weeks (equivalent to 37, 160, or 2,000 mg/kg-day). The study also
reported increased incidences of tubular epithelial cell hypertrophy in high-dose (2,000 mg/kg-day)
males and females. Urinalysis parameters were comparable between control and test groups. In contrast,
a study in marmoset monkeys by Hall et al. (1999) did not observe any kidney effects. In that study,
male and female marmoset monkeys were exposed to 0, 100, 500, or 2,500 mg/kg-day DINP via gavage
for 13 weeks. No histological findings were exposure related, and there were no changes in kidney
weights. Similarly, no effects on the kidney were observed in a dermal study of New Zealand White
rabbits exposed to up to 2,500 mg/kg-day DINP for 6 weeks (Hazleton Laboratories. 1969).
New Literature: EPA identified one new study published from 2015 through 2020 that provided data on
toxicological effects of the kidney following subchronic exposure to DINP (Deng et al.. ). Deng et
al. (2019) exposed male C57/BL6 mice to 0, 0.15, 1.5 or 15 mg/kg-day DINP for 6 weeks via gavage.
The authors reported vacuoles and hyaline degeneration in the glomerulus of the kidney, as well as
smaller glomeruli and a thickened glomerular basement membrane, However, the authors do not specify
at which doses the effects were observed.
Chronic (>90 days) Exposure: EPA identified five rodent studies from existing assessments that provide
information on the toxicological effects of DINP on the kidney, including four studies following chronic
oral exposure to DINP (CASRN 685 15-48-0) (Covance Lal-v l 8b, c; Lington et al.. 1997). or DINP
(CASRN 71549-78-5)(Bio/dynamics. 1987). and one study following a one-or two-generation exposure
in SD rats (Waterman et al.. 2000). These studies provide data on absolute and/or relative kidney
weights, histopathology, and urinalysis measures that reflect kidney function {i.e., BUN levels).
Lington et al. (1997) and Covance Labs (1998c) evaluated kidney weights, urinalysis parameters, and
kidney histopathology in F344 rats following exposure to DINP for 2 years. Both studies observed
increases in kidney weights in the mid- and high-dose animals, but reported inconsistent results for
Page 46 of 184
-------
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
PUBLIC RELEASE DRAFT
May 2024
urinalysis parameters and histopathology. Significant increases were observed in relative and absolute
kidney weights in males and females of the mid- and high-dose groups (i.e., 152 and 307 mg/kg-day
[males] or 184 and 375 mg/kg-day [females] at most time points {i.e., 6, 12, 18, and 24 months).
Moreover, relative kidney weight at study termination was increased 10 to 20 percent and 7 to 10
percent in males and females, respectively. In the 2-year study by Covance Labs (1998c). increased
relative kidney weights were observed in rats receiving dietary doses greater than 359 mg/kg-day for
males (over 25 percent increase) and 442 mg/kg-day for females (over 14 percent increase) at study
termination. Kidney weights in the recovery groups were comparable to the same-sex control values at
the end of the 26-week recovery period.
In Lington et al. (1997). there were no exposure-related changes in serum chemistry parameters such as
blood urea nitrogen (BUN). Some of the urine chemistry parameters were affected by DINP exposure in
males. Increased urine volume, potassium, and glucose were observed in high-dose (307 mg/kg-day)
males at most time intervals; potassium and glucose levels were also increased in mid dose males.
Excretion of renal epithelial cells was increased in high-dose males at 6 months, but not at other
timepoints. No urinalysis changes were observed in females. In contrast, Covance Labs (1998c) reported
increases in serum urea (BUN) levels in males and females from the two highest dose groups at multiple
timepoints during the study including study termination {i.e., weeks 26, 52, 78, and 104). BUN was
increased up to 32 percent over controls in the mid-dose (359 mg/kg-day [male] or 442 mg/kg-day
[female]), and 50 percent over controls at the high dose (733 mg/kg-day [male] or 885 mg/kg-day
[female]).
In Covance Labs (1998c). exposure-related increases in the severity of tubule cell pigment occurred in
the kidneys of males exposed to 733 mg/kg-day DINP (Table 3-9). At study termination, a dose-related
increase was observed in the incidence and severity of mineralization of the renal papilla in males at 359
and 733 mg/kg-day DINP as well as in the recovery group. Increased severity of tubule cell pigment was
observed at the two highest dose groups in both sexes (Table 3-9).
Page 47 of 184
-------
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
PUBLIC RELEASE DRAFT
May 2024
Table 3-9. Incidence and Severity of Selected Non-neoplastic Lesions in the Kidneys of Male and
Female F344 Rats Fed DINP for 2 Years (C'ovance Labs. 1998c)
Dose Group
mg/kg-day (ppm)
Control
29 M / 36 F
(500)
88 M /109 F
(1,500)
359 M / 442 F
(6,000)
733 Ml 885 F
(12,000)
Recovery"
637 M / 774 F
(12,000)
Number M/F
examined6
36/37
35/38
39/40
31/33
27/32
29/34
\lincrali/.nlion oI'ivikiI papilla (males)
Minimal
6
11
9
6
2
0
Slight
0
0
0
24
1
2
Moderate
0
0
0
0
22
27
Total
6
11
9
30
25
29
Tubule cell piemen! (males)
Minimal
24
21
18
0
0
0
Slight
10
12
21
23
7
26
Moderate
0
1
0
6
17
3
Moderately
severe
0
1
0
2
3
0
Total
34
35
39
31
27
29
Tubule cell piijmenl (Ivmak-s)
Minimal
22
27
34
4
0
1
Slight
14
10
5
27
21
33
Moderate
0
1
1
1
10
0
Moderately
severe
0
0
0
1
1
0
Total
36
38
40
33
32
34
Source: Table 10D on page 350 of Covance Labs 0998c)
M = Male; F = female
a The 12,000 ppm recovery group received 12,000 ppm DINP in the diet for 78 weeks, followed by a 26-week
recovery period during which the test animals received basal diet alone.
b Number examined at terminal sacrifice; does not include unscheduled deaths.
Bio/dynamics ( 7) also conducted a 2-year chronic dietary study in rats, albeit of a different strain
(SD), and noted significant increases in absolute and relative kidney weights in high-dose males at both
the interim (19 and 25 percent, respectively) and terminal (13 and 12 percent) timepoints. Kidney
weights of mid-dose group males (271 mg/kg-day) were increased by 11 percent, although this was not a
statistically significant change. In high-dose females (672 mg/kg-day), increased relative kidney weights
were observed (20 percent increase) at interim sacrifice as well as terminal sacrifice (14 percent
increase). Increased incidence of medullary mineral deposits in the kidney were observed in high-dose
males (25/70 treated vs. 3/70 controls). However, in females, incidences of renal medullary mineral
deposits at the high dose (15/70) were comparable to controls (14/70). No histopathological evaluation
Page 48 of 184
-------
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
PUBLIC RELEASE DRAFT
May 2024
was conducted on samples from the low- or mid-dose groups, which limits the assessment of dose-
dependency and effect levels.
Waterman et al. (2000) assessed the potential kidney toxicity of DINP in one- and two-generation
studies conducted in SD rats. In the one-generation study, absolute and relative kidney weights in both
sexes were significantly increased at all doses, except in high-dose PI females, and generally in a dose-
related fashion. In the two-generation study, absolute kidney weights of PI males and females were
increased over controls at all DINP treatment levels. Although decreased mean body weights and body
weight gains were also observed in PI males and females for all doses, the changes in kidney weight are
not solely attributable to changes in body weight. Increased incidence of minimal to moderate renal
pelvis dilation was observed in F2 males of the two highest dose groups (0.4 and 0.8 percent, equivalent
to 741-796, 1087-1186 mg/kg-day). No changes were observed in the females; therefore, the authors
attributed the increased incidence of kidney lesions to induction of male rat-specific alpha 2u-globulin
(a2u-globulin).
In contrast to the studies in rats which consistently reported increases in relative and/or absolute kidney
weight, a study in male B6C3F1 mice reported decreased kidney weights (Covance Labs. 1998b). In that
study, male and female mice were exposed to 0, 1,500, 4,000, or 8,000 ppm DINP for 2 years via feed
(equivalent to 0, 276, 742, or 1,560 mg/kg-day). No effects were observed in females. In addition to the
weight changes in males, the authors reported significant increases in urine output, decreases in mean
urine osmolality; and decreased sodium, potassium, and chloride levels in male and female mice from
the 1,560 mg/kg-day dose group at 26, 52, 78, and 104 weeks. The study authors concluded that there
was no DINP-related change in glomerular filtration rate; however, they suggested that this pattern of
urinalysis findings may indicate a compromised ability to concentrate urine in the renal tubule
epithelium, as an increased incidence of chronic progressive nephropathy was observed in high-dose
females (1,888 mg/kg-day). The kidneys of 1,888 mg/kg-day females also had a granular pitted/rough
appearance. The effects of DINP on the kidney, including decreased kidney weights in males, were
partially attenuated in the recovery groups, which were evaluated 26-weeks after the end of exposure.
The reversibility of the kidney effects in the recovery groups was not as pronounced as that for liver
effects (Section 3.1). The incidences of chronic progressive nephropathy in female mice were
comparable to those of the control group upon termination, suggesting that nephropathy is reversible or
that exacerbation of this lesion halted when exposure to DINP was discontinued.
New Literature: EPA did not identify any new studies published from 2015 through 2019 that provided
data on toxicological effects of the kidney following chronic exposure to DINP.
Mechanistic Information
EPA identified two in vivo studies that provide data that may inform mechanisms of action of the
observed nephrotoxic effects of DINP (Ma et al.. 2014; Caldwell et al.. 1999). Mechanisms evaluated
include oxidative stress and male rat-specific a2u-globulin.
Ma et al. (2014) evaluated the contribution of oxidative stress to the aforementioned tissue lesions
observed in the kidneys of male Kunming mice, which were primarily observed at 200 mg/kg-day. In
that study, mice were exposed to 0.2, 2, 20, or 200 mg/kg-day DINP for 14 days via gavage, and
endpoints relevant to oxidative stress were evaluated in renal and hepatic tissue homogenates. Increases
in reactive oxygen species (ROS) and MDA, in parallel with decreases in glutathione (GSH) content,
were observed at 200 mg/kg-day DINP, indicative of oxidative stress. Some indices of oxidative stress
were observed at lower doses than those that resulted in kidney lesions. Indeed, the authors also reported
DNA-protein-crosslinks at 200 mg/kg-day and increases in 8-hydroxydeoxyguanosine (8-OH-dG) at 20
Page 49 of 184
-------
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
PUBLIC RELEASE DRAFT
May 2024
and 200 mg/kg-day, which indicate oxidative damage to DNA. Levels of interleukin (IL)-l and tumor
necrosis factor alpha (TNFa) were also increased at 20 and 200 mg/kg-day, which would be consistent
with enhancement of an inflammatory response. The authors also evaluated the effect of combined
exposure of 200 mg/kg-day DINP and melatonin (50 mg/kg-day). Mice exposed to 200 mg/kg-day
DINP plus 50 mg/kg-day melatonin showed glomerular cell proliferation and milt renal tubule epithelial
cell edema, and attenuated indices of oxidative stress (ROS, GSH, MDA, DNA-protein-crosslinks, and
cytokine levels). These data indicate that melatonin can attenuate the oxidative stress that results from
exposure to DINP in mice, but not fully attenuate damage to renal tissue, and support an MOA where
oxidative stress may contribute to the toxicological effects of DINP on the kidney.
Caldwell et al. (1999) followed up on observations from Lington et al. (1997). that kidney tumors were
observed in male rats, but not female rats. The male-specific nature of the findings led them to evaluate
a mechanism of action involving the male rat-specific a2u-globulin. Tissue sections from male and
female F344 rats at the 12-month interim sacrifice were evaluated. In male rats, a dose-dependent
increase in a2u-globulin accumulation was observed in regions of the kidney where increased cell
proliferation was also observed. In parallel, tubular epithelial hypertrophy and tubular regeneration were
observed. a2u-globulin was not detected in the kidneys of female rats, and renal cell proliferation of
DINP-exposed female rats was comparable to controls. These results are consistent a mechanism where
a2u-globulin accumulation leads to kidney tissue damage, cell proliferation, and subsequent neoplastic
lesions of the kidney in male rats. The two-generation study by Waterman et al. (2000) also attributed
their observations of renal pelvis dilation in the kidney of F2 male rats to induction of a2u-globulin.
However, these effects are not regarded as relevant to humans (Swenberg and Lehm an - Mckeem an.
1999; U.S. EPA. 1991a). Kidney tumors and evidence for an a2u-globulin MOA are further discussed in
EPA's Draft Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP) (U.S. EPA.
2024a).
Conclusions on Kidney Toxicity
Twenty studies in experimental animal models have evaluated toxicologic effects of DINP on the kidney
following short-term, subchronic, developmental, or chronic exposure to DINP. Findings were similar
across study designs, including increased absolute and/or relative kidney weights, and observed in both
sexes, but these data predominantly reflect rat studies, and the toxicological effects of DINP on the
kidney is less certain in other species.
Increases in absolute and/or relative kidney weight have been observed primarily in rat studies across
multiple study designs and often coincide with increased incidences of non-neoplastic lesions of the
kidney or altered urinalysis parameters. Indeed, increased kidney weights were reported in two short-
term studies in F344 rats ( 86; Bio/dynamics. 1982a). five subchronic studies in various
strains of rats (Hazletom Lahv I —! b, r% to namics. 1982b. c; Hazleton Labs. 19\ I, r" I), three
chronic studies in rats (Covance Labs. 1998c; Lington et al. rs° , ^to/dynamics. 1987) and one
developmental study in rats (Waterman et al.. 2000).
In the 2-year study conducted by Lington et al. (1997). increased relative kidney weights of male and
female rats were observed following exposure to dietary levels of 152 and 307 mg/kg-day (males) or
184 and 375 mg/kg-day (females). In the 2-year study reported by Covance Labs (1998c). increased
relative kidney weights occurred in rats receiving dietary doses greater than 359 mg/kg-day for males
and 442 mg/kg-day for females. Urinalysis findings from the chronic studies included significant
increases in urine output and corresponding decreases in electrolyte levels in high-dose males,
suggesting compromised ability to concentrate urine in the renal tubule epithelium. These effects
occurred at the same dosages that produced changes in kidney weights. In the Covance Labs (1998c)
Page 50 of 184
-------
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
PUBLIC RELEASE DRAFT
May 2024
study, serum urea levels (a marker of kidney toxicity) were significantly increased in rats exposed to 359
mg/kg-day and higher during the second half of the study. Increases in urine volume and kidney lesions
were observed in the recovery group exposed to 733 mg/kg-day.
In many of the chronic studies, effects on the kidney generally occurred at doses equivalent to those
where effects on the liver were observed in rats (Covance Labs. 1998c; Lington et ai. 1997) and mice
(Covance Labs. 1998b). Moreover, the LOAELs ranged from 152 to 923 mg/kg-day which reflect
effects on both the liver and kidneys, including increases in absolute and relative kidney weight as well
as histopathologic findings in the kidney in two chronic studies of male rats (Covance Labs. 1998c;
Lington et at.. 1997). The NOAEL in the Lington study was 15 mg/kg-day (males) or 18 mg/kg-day
(females). However, in a third chronic exposure study in rats (Bio/dynamics. 1987). effects on the
kidney were observed, but not at the LOAEL, suggesting that the kidney may be less sensitive than the
liver to the effects of DINP.
The findings of increased kidney weight in rats were inconsistent with one study of mice, which
reported decreased absolute kidney weight in males (LOAEL of 276 mg/kg-day; NOAEL of 90 mg/kg-
day in males) (Covance Labs. 1998b). That study also reported chronic progressive nephropathy in
female mice of the high-dose group (1,888 mg/kg-day) but no effects in males (Covance Labs. 1998b).
The lack of coherence of effects (e.g., organ weight, histopathology data do not coincide in males or
females) is a limitation of this study.
The MOA of kidney toxicity is not currently known, and effects on the kidney are primarily observed in
one species (rats). Furthermore, kidney effects observed in the rat are less sensitive than effects on the
liver and on developmental outcomes. EPA is considering kidney toxicity for dose-response analysis in
Section 4.
3.4 Neurotoxicity
Humans
Health Canada (2018a) evaluated multiple studies that investigated the association between DINP
exposure and several behavioral and neurodevelopmental outcomes, including mental and psychomotor
neurodevelopment, behavioral and cognitive functioning (i.e., autism spectrum disorders, learning
disabilities, attention-deficit disorder, and attention-deficit hyperactivity disorder), neurological
function, and gender-related play behaviors. Across available studies of DINP, Health Canada
determined that the level of evidence for association between DINP and its metabolites and neurological
effects could not be established.
Radke et al. (2020a) evaluated the association between DINP and neurodevelopment and found that
there was no clear association between DINP and neurodevelopment. Three research studies examined
the relationship between DINP and cognition; however, two of the studies found no relationship and one
revealed an inverse relationship. As a result, the evidence supporting the relationship between DINP and
cognition is deemed inconclusive. Because of the limited number of studies examining this relationship,
the evidence linking DINP to motor ability is regarded as weak. The data supporting the link between
boys' behavior and DINP found no increased odds of ADHD with DINP exposure, and the authors
considered the evidence preliminary. Because of the inconsistent reports about the relationship between
DINP and newborn neurobehavior, the evidence was considered indeterminate. The inconsistent nature
of the currently available research renders the evidence for a connection between DINP and
autism/social impairment as unclear.
Page 51 of 184
-------
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
PUBLIC RELEASE DRAFT
May 2024
New Literature: EPA identified eleven new studies (2 high quality and 9 medium quality), that evaluated
the association between urinary DINP and neurological effects. The first high-quality study, by Shin et
al. (2018). examined a subset of the of mother-child pairs from Markers of Autism Risk in Babies
Learning Early Signs (MARBLES) cohort to evaluate the association between exposure to DINP
metabolite (MCOP) and Autism spectrum disorder (ASD) and non-typical development (Non-TD).
Among mothers who did not take prenatal vitamins, prenatal MCOP exposure during mid to late
pregnancy was associated with higher risk of non-TD (vs. typical development) [MCOP RRR =1.86
(95% CI: 1.01, 3.39)]. Among mothers who did take prenatal vitamins, prenatal MCOP exposure during
mid-to-late pregnancy was associated with lower risk of autism spectrum disorder (versus typical
development) [MCOP RRR = 0.49 (95% CI: 0.27, 0.88)]. There was an association in multinominal
logistic regression of MCOP during 2nd trimester and ASD (vs. TD) among mothers who took prenatal
vitamins [RRR = 0.41 (95% CI: 0.21, 0.79)].
Another high quality cross-sectional study, by Jankowska et al. (2019b). conducted from a subset of the
Polish Mother and Child Cohort (REPRO PL), examined the association between Child behavioral and
emotional problems at age 7 years, child cognitive and psychomotor development and DINP exposure.
Negative associations in peer relationship problems were noted for sum DINP metabolites, and lower
Intelligence and Development Scales (IDS) scores were generally positively associated with higher
phthalate concentrations.
The first medium quality prospective analysis, by Balalian et al. (2019). of maternal prenatal and child
age 3, 5 and 7 postnatal DINP metabolite (MCOP) exposures with motor skills at age 11 as assessed by
the short form of the BOT-2 were selected from participants in an ongoing longitudinal birth cohort
study of mothers and newborns conducted by the Columbia Center for Children's Environmental Health
(CCCEH). MCOP measured at age 3 was inversely associated with BOT-2 total, fine motor, and gross
motor composite scores among boys. In linear regression models, a 1 log-unit increase in age 3 MCOP
was associated with lower total [beta: -3.08 995% CI: -5.35, -0.80)], fine motor [beta: -1.64 (95% CI:
-3.16, -0.12)], and gross motor [beta: -1.44 (95% CI: -2.60, -0.28)] composite scores in boys.
Comparisons of the 4th versus 1st quartiles of age 3 MCOP were also associated with all three outcomes
in boys [(Q4 vs. Q1 total composite score [beta: -7.47 (95% CI: -12.60, -2.34)]; fine motor composite
score [beta: -4.18 (95% CI: -7.51, -0.85)]; gross motor composite score [beta: -3.29 (95% CI -6.06,
-0.52)]. No significant associations were found between MCOP at age 3 and outcomes in girls. There
were no significant association for sex differences at age 3. There were also no significant associations
between prenatal MCOP and outcomes in either girls or boys. There were no significant associations
between MCOP measured at ages 5 or 7 and outcomes in either girls or boys.
A medium quality study, by Li et al. ( ), used data from children in the Cincinnati Health Outcomes
and Measures of the Environment (HOME) cohort to analyze associations between DINP metabolites
(MCOP, MCNP) and child cognition measured at ages 5 and 8 years. The pattern of associations for
MCOP and MCNP measures was heterogeneous (p < 0.20 for MCNP), and no adjusted associations
reached significance. Associations between child IQ scores and urinary MCOP measured at different
ages were not statistically significant and were heterogeneous (positive and negative). For exposure at
age 3 years, when associations with several other phthalate metabolites were significantly inverse,
adjusted beta for MCOP = -1.2 (95% CI: -3.2, 0.9)
Another medium quality cohort study, by Tanner et al. (2020). examined mother-child pairs from the
Swedish Environmental Longitudinal Mother and Child, Asthma and Allergy (SELMA) study and the
association between prenatal urinary DINP metabolite (MHiDP, MCNP, MHiNP, MOiNP, MCiOP)
exposure and child IQ at age 7 years. Since this is a mixtures analysis, the DINP metabolites of interest
Page 52 of 184
-------
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
PUBLIC RELEASE DRAFT
May 2024
were not directly analyzed as they were only above the threshold of concern in sensitivity analyses using
positive weights.
A medium quality prospective cohort study, by Jankowska et al. (2019a), evaluated the association
between prenatal and postnatal (age 2 years) OH-MINP and child behavior, cognition, and psychomotor
development at age 7 years. The study included a subset of mother-child pairs from the Polish Mother
and Child Cohort. There were no statistically significant associations between prenatal or postnatal OH-
MINP and any of the study outcomes. There was also no clear pattern of associations with behavioral
outcomes, and associations with cognitive and psychomotor scores were generally weakly negative.
oxo-MINP was measured, but associations with outcomes were not analyzed, as detection rates were
less than 70 percent (56 and 65 percent for pre- and postnatal measures, respectively).
A medium quality cohort study by Hyland et al. (2019) analyzed associations between prenatal DINP
metabolites and neurodevelopment in live singletons in Center for the Health Assessment of Mothers
and Children of Salinas (CHAMACOS), a birth cohort of low-income Mexican American children in
Salinas, California. Associations between IQ scores and MCOP were shown only for combined sexes,
and not significant.
A medium quality longitudinal cohort study, by Jacobson et al. (2021). used data from the NYU
Children's Health and Environment Study, to evaluate urinary DINP metabolites (MCiOP, MINP) levels
in pregnant women and assessed the association with postnatal and postpartum depression following
delivery. There were no significant associations for the Edinburgh Postnatal Depression Scale (EPDS)
score or postpartum depression for sum DINP phthalates.
A medium quality study, by Dzwilewski et al. (2021). used data from a subset of participants in the
Illinois Kids Development Study (IKIDS) to evaluate associations between prenatal exposure to DINP
metabolites (MINP, MCOP, MONP), and infant cognition assessed at 7-8 months of age. The authors
presented results of analyses using the sum of 2 (DINP2) or 3 (DINP3) metabolites, and MONP
individually. Associations varied by infant sex and by the set of images used in testing. DINP2 was
associated with longer processing time for image set 2, and DINP3 with longer processing time among
males viewing set 2. DINP2 and DINP3 had weak negative associations with visual recognition memory
(novelty preference). Urinary EDINP2 metabolites (MINP and MCOP) was associated with significant
increases in average information processing speed (run duration) among infants administered set 2
images. DINP2 was also associated with a non-significant decrease in visual recognition memory
(novelty preference). Urinary EDINP3 metabolites (MINP, MCOP, and MONP) were associated with
significant increases in average information processing speed (run duration) among male infants
administered set 2 images. DINP3 was also associated with a non-significant decrease in visual
recognition memory (novelty preference) overall, while MONP was associated with a non-significant
increase in novelty preference among infants administered set 2 image. DINP3 was associated with a
non-significant decrease in visual attention (time to familiarization) for set 2.
A medium quality case-cohort study, by Kamai et al. (2021). nested in the Norwegian Mother and Child
Cohort (MoBa) analyzed the association between prenatal DINP measured in spot urines at about 17
weeks' gestation and ADHD at age 3 years. DINP was non-linearly associated with increased odds of
preschool ADHD. Results of multivariate logistic regression found an association between increasing
DINP quintile 2 vs. quintile 1, OR = 2.04 (95% CI: 1.2-3.33; includes adjustment for DEHP).
The final medium quality study, a population-based nested case-control study by Engel et al. (2018).
assessed the association of DINP metabolites and ADHD in children of at least 5 years of age of mothers
Page 53 of 184
-------
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
PUBLIC RELEASE DRAFT
May 2024
within the Norwegian Mother and Child Cohort (MoBa). The authors reported no association of ADHD
with sumDINP metabolites. In Bayesian logistic regression models, there was no association [OR =
0.85, (95% CI: 0.61, 1.15) with log sum of DINP and ADHD. Associations with individual DINP
metabolites were also not significant.
Laboratory Animals
A limited number of experimental animal studies have evaluated the neurotoxicity of DINP following
oral exposure. Existing assessments of DINP have not drawn human health hazard conclusions on the
neurotoxicity of DINP, but have evaluated effects on behavior, brain weight, and/or brain histopathology
0 v 3c: ECCC/HC. 201:0:1 i PSC j'lLii -HA. 2013b: NIC/HAS. 2012: ECB. 2003).
Only three rodent studies ((Boberg et ai. m , U , et al , I . Tuyere et a I JO I I)) are
available that are specifically designed to evaluate neurotoxicity. Remaining studies evaluated brain
weight and/or brain histopathology. These included three subchronic exposure duration studies and three
chronic studies, as well as six developmental exposure studies {i.e., one- or two-generation studies of
reproduction, perinatal, postnatal, or peri-and-postnatal exposure studies). No studies are available for
the dermal or inhalation exposure routes.
One developmental study in Wistar rats (Sobers et al.. 1 ) reviewed in existing assessments (.
CPSC. 2014: NICNAS. 2012) provides data on behavior, including an evaluation of learning and
memory following DINP exposure. Boberg et al. (2011) exposed pregnant Wistar rats to 300, 600, 750,
or 900 mg/kg-day DINP via oral gavage daily from GD 7 through PND 17 and evaluated several
neurobehavioral endpoints on male and female offspring at later timepoints. Behavioral examinations
included those of motor activity levels at PNDs 27 through 28, Morris Water Maze (MWM) at 2 to 3
months of age, sweet preference at 4 months, and radial arm maze performance at 5 to 7 months of age.
The MWM test is used to evaluate learning and memory. In this test, animals are placed in a circular
pool of water and required to escape from water onto a hidden platform using spatial memory.
No changes were observed in motor activity levels and radial arm maze performances in male or female
offspring exposed to DINP during development. An increase in saccharin intake in the sweet preference
test was observed in female offspring of the 750 mg/kg-day group; however, this effect was not dose-
dependent, and the study authors concluded that it may be a chance finding. In the MWM test, dose-
dependent improvements in swim length and latency were observed on the first day of memory testing,
with significantly shorter swim length and latency in the 900 mg/kg-day females. The study authors
asserted that performance in the MWM test is sexually dimorphic, and concluded that DINP affected
spatial learning, as female offspring performed better than controls and similarly to control males in the
MWM, indicating masculinization of behavior in DINP exposed females. However, the effects were no
longer apparent on the second day of memory testing or when the platform was moved to a new position
in the maze. Performance was unaffected by exposure to DINP in males. Notably, the male reproductive
parameters were affected at a lower dose than the apparent effects on learning in memory in females,
with: increased MNGs and decreased sperm motility at 600 mg/kg-day and above; increased nipple
retention at 750 mg/kg-day and above; and decreased AGD at 900 mg/kg-day.
Several rodent studies were identified in existing assessments that provide data on absolute and/or
relative brain weight following exposure to DINP. These include three chronic studies (Covance Labs.
1998a. c; Lington et al.. 1997) and two developmental studies (Masutomi et al.. 2003). In general,
changes in absolute and/or relative brain weight were not observed or were only observed at the highest
doses tested in both males and females. No changes in brain index {i.e., relative brain weight) were
observed in male Kunming mice exposed to 1.5, 15, or 150 mg/kg-day DINP for 9 days via gavage
(Peng. 2015). Similarly, no changes were observed in relative and/or absolute brain weight of: B6C3F1.
Page 54 of 184
-------
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
PUBLIC RELEASE DRAFT
May 2024
mice exposed to up to 8,000 ppm DINP in feed for two years (equivalent to 1,600 mg/kg-day) (Covance
Labs. 1998b); F344 rats exposed for 2 years to up to 12,000 ppm (equivalent to 733 mg/kg-day in males;
885 mg/kg-day in females) (Covance Labs. 1998c); or up to 0.6 percent (equivalent to 307 mg/kg-day in
males; 375 mg/kg-day in females) (Lington et al. 1997). In contrast, changes in brain weight were
observed in one perinatal exposure study (Masutomi et al.. 2003). In Masutomi et al. (2003). maternal
SD rats were fed test diets containing 0, 400, 4,000, or 20,000 ppm DINP from GD 15 through PND 10
(equivalent to 31, 307, or 1,164 mg/kg-day during gestation and 66, 657, or 2,657 mg/kg-day during
lactation). Significant decreases in absolute brain weight were observed in male (12.9 percent) and
female (11.1 percent) rat pups from the highest dose group at PND 27, while significant increases in
relative brain weight were observed in males (53.5 percent) and females (46 percent), which likely
reflects decreased terminal body weight at PND 27 in the highest dose group in both males and females.
Body weight gain of male and female pups was decreased as well.
Data from existing assessments on the histopathological effects on the brain following DINP exposure
have been reported. Identified literature includes one short-term exposure duration study (Midwest
Research Institu 1) and three chronic studies (Covance Labs. 1998b. c; Lington et al.. 1997). In
general, there were no exposure-related histopathological findings in the 28-day exposure study by the
Midwest Research Institute (1981) nor in the chronic exposure studies in mice (Covance Labs. 1998b)
and rats (Covance Labs. 1998c; Lington et al.. 1997).
New Literature: Four new studies were identified by EPA that had not been reviewed in existing
assessments (Neief et al.. 2018; Setti Ahmed et al.. 2018; Ma et al. JO I i^'ng. l ), which provide
data on neurobehavioral outcomes, brain weights, and brain histopathology following exposure to DINP.
Results of Ma et al. (2015) and Peng et al. (2015) were not fully evaluated in the 2020 Health Canada
Screening Assessment, (ECCC/HC. 2020). and are therefore considered new literature.
Two short-term exposure duration studies in male Kunming mice (Ma et al.. 201 \ Peng. 2015) are
available that provide data on behavior. Impaired learning and memory following DINP exposure was
observed consistently across the two short-term studies. Peng et al. (2015) and Ma et al. (2015) have
similar study designs. Peng et al. ( ) exposed mice to 1.5, 15, or 150 mg/kg-day DINP daily via oral
gavage for 9 days, while Ma et al. (2015) exposed mice to 0.2, 2, 20, or 200 mg/kg-day DINP daily via
oral gavage for 14 days. In both studies, the authors evaluated the effect of DINP on learning and
memory using the MWM test. In both studies, escape latency {i.e., time it took mice to locate submerged
escape platform) was evaluated throughout the exposure period ("training period"), and memory was
evaluated on the last day of exposure ("probe trial") following one day of no testing (a "forget" period).
Each study also investigated the combined effect of DINP and an antioxidant; these endpoints are
discussed in the mechanistic section. Mice were euthanized 24 h after the last DINP exposure, at which
point brain tissue was harvested for histological examination as well as various non-apical measures of
oxidative stress and inflammation (discussed in Mechanistic Information section).
In both Ma et al. (2015) and Peng et al. (2015) escape latency in the MWM test was reduced in each
exposure group at the end of the training periods compared to the first day. Escape latency was increased
in all groups exposed to DINP compared to controls, indicating impaired learning in DINP groups. Peng
et al. (2015) reported decreased retention time in the target quadrant in the MWM test during the probe
trial, indicative of impaired memory. Similarly, Ma et al. (2015) reported decreased time and number of
entries into the target quadrant in the MWM test during the probe trial, indicative of impaired memory.
In addition to MWM, Ma et al. (2015) conducted an open field test to evaluate locomotor activity.
Decreased time and number of entries into the central area were observed for mice exposed to 200
mg/kg-day DINP, which the authors attributed to anxiety-like behavior.
Page 55 of 184
-------
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
PUBLIC RELEASE DRAFT
May 2024
Four new rodent studies were identified that provide data on absolute and/or relative brain weight
following exposure to DINP, three of which were oral exposure studies. These include one short-term
exposure duration study (Pens. 2015). and two developmental studies (Neier et ai. 2018; Setti Ahmed et
ai. 2018). In general, changes in absolute and/or relative brain weight were not observed, with the
exception of one study weight in yellow agouti (Avy) mice, where biologically significant {i.e., greater
than 10 percent change) changes in brain weight were observed at the highest doses tested in male mice,
which may be exposure-related. No changes in brain index {i.e., relative brain weight) were observed in
male Kunming mice exposed to 1.5, 15, or 150 mg/kg-day DINP for 9 days via gavage (Per ).
Ahmed et al. (2018) observed similar results. In that study, pregnant Wistar rats (36 dams/group) were
exposed to 0 or 380 mg/kg-day DINP via oral gavage beginning on GD 8 and continuing up to PND 30.
Interim sacrifices were conducted on PND 7, PND 15, and PND 21. Brain weight was determined at
interim and terminal timepoints. No changes were observed in absolute brain weights (relative brain
weights not reported) at PND 7, PND 15, or PND 30. Body weight was significantly reduced in pups
exposed to DINP at PND 15 and PND 30. In contrast to the findings of Ahmed et al. (2018). a
developmental study by Neier et al. (2018) reported changes in relative brain weight in yellow agouti
(Avy) mice fed diets containing 5 ppm (equivalent to 15 mg/kg-day) DINP from 2-weeks prior to mating
until weaning. The authors reported absolute and relative brain weights in PND 21 offspring. Decreased
relative brain weights were observed in PND 21 males only, and no changes in absolute weights were
observed. Increased terminal body weights were observed for females, but not males, at PND 21,
indicating that brain weight is decreased in males even when adjusted for body weight. Although it is
likely this observation is exposure-related, uncertainty exists due to the use of the yellow agouti (Avy)
mouse model in the Neier study.
New data on the histopathological effects on the brain following DINP exposure have been reported.
Identified literature includes two short-term exposure duration studies (Ma et al.. 2015; Peng. 2015).
which both reported histopathological alterations in the pyramidal cells of the CAi region of the
hippocampus following short-term exposure to DINP via gavage. Ma et al. (2015) reported damaged
pyramidal neurons in the 20 and 200 mg/kg-day dose groups. Peng et al. ( ) reported that with
increasing DINP exposure, the arrangement of hippocampal cells became more disordered, cells
swelled, and apical dendrites shortened or disappeared. Limitations of the histopathological dataset from
both studies include qualitative presentation of data that lacks incidence or severity information.
Mechanistic Information
EPA identified five in vivo studies and one in vitro study that provide data that may inform mechanisms
of the observed neurological effects of DINP. Three of the in vivo studies investigated mechanisms
involving oxidative stress in mouse models (Duan et al.. 2018; Ma et al.. 1 i 'eng. 2015). The
aforementioned studies by Peng et al. (2015) and Ma et al. (2015) exposed male Kunming mice to DINP
via oral gavage daily for 9 days or 14 days and evaluated several endpoints related to oxidative stress.
Both studies observed increases in ROS, decreases in superoxide dismutase activity, decreases in GSH
content, increases in inflammatory cytokines, and increases in caspase-3 levels, activity, or staining
intensity at the highest dose (200 mg/kg-day) (Ma et al.. 2015) or two highest doses (15 and 150 mg/kg-
day) (Peng. 2015). Ma et al. also reported increases in DNA-protein-crosslinks at 200 mg/kg-day and
increases in 8-OH-dG at 20 and 200 mg/kg-day, indicating oxidative damage to DNA. Although Ma et
al. did not quantify histopathological changes observed in the hippocampus (Section 3.4), they
quantified immunohistochemistry staining of glial fibrillary acidic protein, in addition to caspase-3 in
the hippocampus CAi region and cerebral cortex. Staining intensity of caspase-3 and glial fibrillary
acidic protein was increased at 200 mg/kg-day in both regions of the brain and increased in the cerebral
cortex at the 20 mg/mg-day dose.
Page 56 of 184
-------
1775
1776
Mil
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
PUBLIC RELEASE DRAFT
May 2024
Both studies also evaluated the combined effects of the highest tested dose of DINP in addition to
vitamin E or melatonin {i.e., 150 mg/kg-day + 50 mg/kg-day vitamin E (Pens. 2015); or 200 mg/kg-day
+ 50 mg/kg-day melatonin (Ma et at.. )). Mice exposed to 200 mg/kg-day DINP plus 50 mg/kg-day
melatonin had less caspase-3 and glial fibrillary acidic protein staining than DINP alone, indicating that
melatonin can rescue the increase in caspase-3 and glial fibrillary acidic protein expression that follows
DINP exposure. The addition of melatonin was also sufficient to attenuate the effects consistent with an
oxidative stress response (i.e., increases ROS, DNA-protein-crosslinks, 8-OH-dG, cytokines; decreases
in superoxide dismutase activity and GSH content), implying that DINP induces oxidative stress in the
cerebral cortex which contributes to neuronal damage (Ma et ai. 2015). Similarly, Peng et al (2015)
observed that combined exposure of DINP + vitamin E, which has antioxidant properties, attenuated
effects consistent with an oxidative stress response, implying that the observed effects were consequent
to a pro-oxidant cellular environment in the brain.
In Duan et al (2018). specific pathogen free male Balb/c mice were divided into several groups designed
to evaluate the impact of DINP on an allergic response to an ovalbumin (OVA) antigen. The authors
also investigated the modulatory effect of melatonin, which they state has antioxidant properties, as well
as the role of nuclear factor kappa B (NFkB) signalling and oxidative stress using an inhibitor of NFkB,
Dehydroxymethylepoxyquinomicin (DHMEQ). DINP exposure exacerbated effects consistent with an
oxidative stress response in brain homogenates (i.e., increase in ROS levels and decreases in superoxide
dismutase activity). DINP also increased IL-1B and IL-17 levels in brain homogenates as well as nerve
growth factor (NGF) staining in the prefrontal cortex; all of which were attenuated by the combined
exposure of DINP + metalonin or DINP+ DHMEQ, suggesting that the inflammation is mediated by a
pro-oxidant environment and activation of NFkB signalling. Other endpoints in this study included:
brain histopathology of pyramidal cells in the prefrontal cortex, and immunohistochemistry staining in
the prefrontal cortex for eosinophil cationic proteins, nuclear factor erythroid 2-related factor 2 (Nrf2),
NFkB. Limitations include lack on quantitative results for histopathology.
The other identified study provides a diverse set of data evaluating sexually dimorphic gene expression
in relation to effects on sexual behavior in rodentsU.cc et al.. 2006b). Lee et al. (2006b) investigated the
effects of perinatal exposure to DINP on expression of sex-steroid-regulated genes in the hypothalamus
of offspring and sexual behaviors as adults. Pregnant rats were administered 40, 400, 4,000, or 20,000
ppm DINP in the diet from GD 15 through PND 21. At PND 7, male and female pups were sacrificed,
and the hippocampus was dissected from brains to quantify expression of sexually dimorphic genes such
as granulin (grri) and pi30. After maturation, the authors evaluated and sexual behaviors (e.g., lordosis,
copulatory behavior), reproductive endpoints (e.g., estrus cycles, serum levels of estradiol, LH, and
FSH); these data are discussed in detail in Section 3.1. In male PND 7 pups, there was no change in
hypothalamic grn expression, and a non-monotonic dose response was observed in pi30, but expression
was increased at all dose levels. In females, grn was increased in the 40 and 400 ppm, and 20,000 ppm
exposure groups, and no change was observed in pi30. While the increased pi30 expression in males
coincided with impaired male sexual behavior (i.e., decreased copulatory behavior), serum hormone
levels (i.e., testosterone, FSH, LH) were not changed. The authors suggest that DINP may act on regions
of the hypothalamus that alter sexual behavior, but not gonadotropin secretion, to influence sex-specific
adult behavior.
Conclusions on Neurotoxicity
Fifteen studies in experimental animal models have evaluated neurotoxicological endpoints (i.e.,
behavior, brain weight, or histopathology) following exposure to DINP. However, only three of these
were specifically designed to evaluate behavioral neurotoxicity, which typically may provide insight
Page 57 of 184
-------
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
PUBLIC RELEASE DRAFT
May 2024
into more sensitive effects of DINP and supplement the neurobehavioral data from the epidemiological
database.
Two short-term duration exposure studies with similar designs in male Kunming mice (Ma et ai. 2015;
Pens. 2015) provide consistent evidence for impaired learning and memory following DINP exposure
for 9 or 14 days, with parallel perturbations in the pyramidal cells of the hippocampus at doses up to 200
mg/kg-day. The developmental exposure study by Bob erg et al. (2011) exposed rats to doses up to 900
mg/kg-day from GD7 to PND17 and conducted behavioral examinations at later timepoints. No
evidence of impairment was observed in males or females (2 to 3 months for MWM; radial arm maze
performance at 5 to 7 months). One consideration regarding the study design in Bob erg et al. (2011) is
that a considerable amount of time had elapsed between the cessation of exposure and time of outcome
evaluation, which could make it more difficult to detect an exposure-related effect {i.e., bias towards the
null), and this difference makes a direct comparison to the studies by Ma (2015) and Peng (. )
challenging. However, this design also helps determine the extent to which perinatal exposures influence
behavior later in life. Nevertheless, discordant results across these studies may reflect study design
differences that influence the degree to which the received dose influences the test animals. Moreover,
Ma et al., (2015) and Peng et al., (2015) exposed adult male Kunming mice and measured outcomes in
adults, while Bob erg et al. (2011) exposed pregnant rats and evaluated outcomes in the offspring. In
addition to the inconsistent findings across study designs, a limitation of the behavioral dataset is the
relative lack of studies that consider outcomes in both sexes, especially given the fact that performance
in the MWM test is sexually dimorphic.
Although histopathological alterations were observed in the pyramidal cells of the hippocampus in two
independent short-term exposure duration studies by Ma et al., (2015) and Peng et al., (2015). these
studies were limited by the lack of quantitative data and were inconsistent with findings of the 28-day
exposure study by the Midwest Research Institute ( [) as well as all the chronic exposure studies in
mice (Covance Labs. 1998b) and rats (Covance Labs. 1998c; Lington et al.. 1997). Strengths of the
dataset include coherence with the behavioral datasets from the Ma et al. (2015) and Peng et al. (2015)
studies; pyramidal cells of the hippocampus are involved in learning and memory, and the mechanistic
dataset from these studies provides evidence of biological plausibility via a mechanism involving ROS
damage by DINP to the pyramidal neurons. Limitations of the dataset include lack of quantitative results
for incidence and severity of histopathology effects and lack of chronic exposure studies with
histopathology of neural tissues.
Overall, available laboratory animal studies provide some evidence that DINP may cause behavioral
effects in rodents. Although some uncertainty exists, EPA considered neurotoxicity further for dose-
response analysis in Section 4. Specifically, neurobehavioral endpoints from Ma et al., (2015) and Peng
et al., (2015) were further considered.
3.5 Cardiovascular Health Effects
Humans
Health Canada (2018a) evaluated multiple studies that investigated the association between phthalate
exposure and several cardiovascular outcomes and/or associated risk factors {i.e., cholesterol, diastolic
and systolic blood pressure, HDL-cholesterol, LDL-cholesterol, and blood glucose levels), however only
two studies directly looked at evidence of an association between DINP and/or its metabolites and
cardiovascular effects. A cross-sectional study of good quality by Trasande et al. (2014) looked at
albumin/creatinine ratio (ACR), a biomarker of endothelial dysfunction and increased risk of CVD in
children and adolescents found that there was inadequate evidence for an association between ACR and
MCOP in children and adolescents (Health Canada. 2018a).
Page 58 of 184
-------
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
PUBLIC RELEASE DRAFT
May 2024
New Literature: EPA identified three new medium qualtiy studies that evaluated the association between
urinary DINP levels of metabolite and cardiovascular effects. The first medium quality study, a
prospective birth cohort study, by Heggeseth et al. Q ), used data from the Center for the Health
Assessment of Mothers and Children of Salinas (CHAMACOS) cohort to assess the association between
prenatal urinary DINP measurements and BMI trajectories throughout childhood. The authors did not
report any significant results, however, functional principal components analysis found that MCOP was
an explanatory variable in variation of BMI trajectories among girls.
Another medium quality study, a cross-sectional and longitudinal analysis, by Diaz Santana et al.
(2019). of participants from a nested case-control included using data from the Worn ens Health
Initiative (WHI) evaluated the association between overweight and obesity as well as weight change and
DINP exposure. The study found no significant results in cross-sectional analyses by quartile of
exposure. However, there was significant association across quartiles with MCOP and overweights as
well as obese, with p-trend <0.001 and p-trend = 0.001 respectively.
Finally a medium quality study, a longitudinal cohort study, by Zettergren et al. (2021). examined
associations between DINP metabolites (MHiNP, MOiNP, MCiOP) and obesity measures through age
24y in a subset of participants in the Swedish Abbreviation for Children, Allergy, Milieu, Stockholm,
Epidemiology (BAMSE) cohort. The study found significant associations between increases in DINP
metabolites at age 4y and obesity measures obtained at ages 8 and above. Urinary MHiNP, MOiNP,
MCiOP and DINP measures were significantly associated with an increased odds of overweight at ages
8, 16, and 24 years, and with higher BMI [beta = 1.60 (95% CI: 0.37-2.84) , waist circumference [beta =
4.42 (95% CI: 1.35-7.49)], body fat percent [beta = 2.65 (95% CI: 0.52-4.77)], and trunk fat percent
[beta = 2.70 (0.33-5.07)] at 24 years. The cross-sectional association between DINP metabolites and
obesity at age 4 were not significant.
Laboratory Animals
A limited number of experimental animal studies have evaluated the cardiovascular effects of DINP
following oral exposure. Existing assessments of DINP have not drawn human health hazard
conclusions on the cardiotoxicity of DINP. Nevertheless, data are available on the effects of DINP on
blood pressure, heart rate, other indicators of adverse cardiac events, heart weight and/or heart
histopathology (I c- « ^ \ :023c; Ml ^ V. i PSC. 2010: ECB. 2003). Only one study was
available that was specifically designed to evaluate cardiotoxicity (Deng et al.. 2019). Remaining studies
evaluated heart weight and/or heart histopathology (Kwack et al.. 2009: Lington et al.. 1997:
Bio/dynamics. 1982b: Midwest Research Institm [))• No studies are available for the dermal or
inhalation exposure routes.
Three studies of varying study designs were identified that provide data on the effect of DINP exposure
on heart rate, blood pressure, or other indicators of adverse cardiac events, including levels of total
cholesterol and triglycerides. An subchronic duration study by Deng et al. (2019) investigated the
mechanisms associated with increased blood pressure following exposure to DINP. Groups of C57/BL6
mice were administered 0, 0.15, 1.5 or 15 mg/kg-day DINP via oral gavage daily for 6 weeks. At study
termination, systolic blood pressure, diastolic blood pressure, mean blood pressure, and heart rate were
measured. Additionally, blood samples were collected for measurements of serum nitric oxide levels and
levels of angiotensin converting enzyme (ACE), angiotensin-II type 1 receptor (AT1R), and endothelial
nitric oxide synthase (eNOS), were evaluated via immunohistochemistry staining. Increased systolic,
diastolic, and mean blood pressure was observed in mice of the two highest dose groups (1.5 and 15
mg/kg-day). Immunohistochemistry of the aorta showed increased staining intensity of ACE and AT1R
Page 59 of 184
-------
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
PUBLIC RELEASE DRAFT
May 2024
as well as decreased staining intensity of eNOS and nitric oxide. These latter endpoints are discussed
more in detail in the mechanistic section.
Two additional studies are available that provide data on changes in triglycerides and cholesterol
following short-term duration exposure (Kwack et al. 2009) to DINP. Kwack et al (2009) exposed male
SD rats to 0 or 500 mg/kg-day DINP daily for 4 weeks via oral gavage and evaluated several
cardiovascular outcomes including serum levels of total cholesterol and triglycerides. Serum
triglycerides were significantly increased (50 percent increase compared to controls), while no change
was observed in serum total cholesterol.
Four studies were identified that provide data on the effect of DINP on heart weight, including one
short-term exposure duration study in male SD rats (Kwack et al.. 2009). one short-term study in male
and female F344 (Bio/dynamit 2b), and one chronic study in male and female F344 rats (Lington
et al.. 1997). In general, no statistically or biologically significant {i.e., more than 10 percent change)
exposure-related changes were observed in absolute or relative heart weight across study designs.
Two studies were identified that report histopathology of the heart and/or aorta following exposure to
DINP. The subchronic study in male mice by Deng et al. (2 ) also evaluated histopathology of the
heart and aorta. Lesions were observed in the high-dose group (15 mg/kg-day), including ventricular
wall thickening and cardiomyocyte hypertrophy. In contrast, the study by the Midwest Research
Institute (1981) did not observe discernable lesions in the heart at study termination. In this study, male
and female F344 rats were exposed to 0, 0.2, 0.67, or 2 percent DINP for 28-days via feed (estimated
doses: 0, 150, 500, 1,500 mg/kg-day [males]; 0, 125, 420, 1,300 mg/kg-day [females]). A limitation of
these studies is that histopathology was reported qualitatively.
Table 3-10. Summary of Study Evaluating Cardiovascular Outcomes
Brief Study
Description
(Reference)
NOAEL/
LOAEL
(mg/kg-day)
Effect at LOAEL
Comments
C57/BL6 mice (males
only); oral gavage; 0,
0.15, 1.5, 15 mg/kg-
day; 6 weeks; with or
without induction of
hypertension (Deng et
al. 2019) (Deng et al.,
2019)
0.15/15
t in systolic, diastolic,
and mean blood pressure;
ventricular wall
thickening &
cardiomyocyte
hypertrophy;
immunohistochemistry of
aorta showed |ACE &
AT1R& jeNOS&NO.
15 mg/kg-dav: t Heart Rate and diastolic blood
pressure. Pathological changes in the heart,
aorta, and kidney
Kidnev histopathology (qualitative only): Study
authors also state that "DINP exposure and
DEXA treatment could both induce vacuoles
and hyaline degeneration in the glomerulus as
compared to the saline group. We also found
that DINP exposure resulted in smaller
glomeruli and a thickened glomerular basement
membrane, and that ACEI effectively inhibited
these lesions." Doses at which this occurred are
not stated.
Mechanistic Information
EPA identified one in vivo study (Dene et al.. 2019) that provides data that may inform mechanisms of
the observed cardiovascular effects of DINP. The mouse study by Deng et al. (2019) investigated
mechanisms associated with increased blood pressure following exposure to DINP. Groups of C57/BL6
mice were exposed to 0, 0.15, 1.5, or 15 mg/kg-day DINP daily for 6 weeks via gavage. Parallel groups
Page 60 of 184
-------
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
PUBLIC RELEASE DRAFT
May 2024
of mice also received a subcutaneous injection of 1 mg/kg-day dexamethasone to induce hypertension
and/or 5 mg/kg-day of an ACE inhibitor via gavage in addition to the highest dose of DINP. In addition
to the evaluations of blood pressure described above, the authors measured serum nitric oxide (NO)
levels and determined levels {i.e., staining intensity) of ACE, AT1R, and eNOS in the aorta via
immunohistochemistry staining. The authors observed increased staining intensity of ACE and AT1R as
well as decreased staining intensity of eNOS in the aorta using immunohistochemistry following
exposure to 1.5 or 15 mg/kg-day DINP (AT1R and eNOS) or all doses (ACE). Co-exposure of
15 mg/kg-day DINP and dexamethasone resulted in similar changes in expression of ACE, AT1R, and
eNOS. Co-exposure of dexamethasone +15 mg/kg-day DINP + the ACE-inhibitor did not fully
attenuate the changes. Serum levels of NO were decreased following DINP exposure (all doses) as well
as with co-exposure to dexamethasone and/or the ACE inhibitor. Given the aforementioned increases in
systolic, diastolic, and mean blood pressure, in mice of the two highest dose groups (1.5 and 15 mg/kg-
day), these results provide some evidence to support a mechanism whereby DINP acts through the ACE
pathway to increase blood pressure.
Conclusions on Cardiovascular Health Effects
The database of studies in experimental animals that has evaluated cardiovascular toxicity and
associated risk factors following exposure to DINP is limited and findings were generally inconsistent
across study designs and species. Only one subchronic study was available that was specifically
designed to evaluate cardiotoxicity (Dene et al. ). Limitations of the study included failure to
consider both sexes and reporting deficiencies, including the qualitative reporting of histopathology
data. Nevertheless, the consistency across endpoints within Deng et al. (2019). including increased
blood pressure and histopathological effects in the aorta suggest that DINP may be toxic to the
cardiovascular system. Mechanistic data from the same study suggest the underlying mechanism for
these effects involves the ACE pathway.
Overall, there is limited evidence that DINP can elicit cardiotoxicity in experimental laboratory animals;
only one study in one species of one sex evaluates cardiovascular outcomes. Additionally, the clinical
implications, or relevance to humans, is uncertain for cardiovascular effects of DINP. Due to these
limitations and uncertainty, EPA is not further considering cardiotoxicity for dose-response analysis.
3.6 Immune System Toxicity
Humans
Health Canada (2018a) evaluated multiple studies that investigated the association between urinary
metabolite and immunological outcomes. Across available studies of DINP, Health Canada found that
there was limited or inadequate evidence for association between DINP and its metabolites and
immunological outcomes.
New Literature: EPA identified three new studies (two medium quality studies and one low quality) that
evaluated the association between DINP and its metabolites and immune/allergy outcomes. The first
medium quality study, a prospective birth cohort, by Soomro et al. (2018). of the Etude des
Determinants pre et postnatals du developpement de la sante de l'Enfant (EDEN) study measured
maternal urinary DINP metabolites and their association with eczema diagnosed at ages 1-5 in boys, and
with elevated serum IgE at age 5 years. Results for the main effect association between DINP metabolite
and elevated IgE were described only as not significant for MCOP. There were no significant
associations found with DINP metabolites and elevated serum IgE (>60 IU/mL). However, multivariate
logistic regression of MCOP and odds of diagnosed eczema was only significant for age 5, OR = 1.60
(95% CI: 1.16, 2.23). There was a significant association found in multivariate logistic regression of
MCOP and association with early onset eczema (first 2 years of life), OR = 1.29 (95% CI: 1.04, 1.60), p
Page 61 of 184
-------
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
PUBLIC RELEASE DRAFT
May 2024
< 0.05, and late-onset (age 3-5 years) eczema, OR = 1.63 (95% CI: 1.20, 2.21), p < 0.05. There was also
a significant association in Cox proportional hazard model of MCOP and ever diagnosed with eczema,
HR= 1.09 (95% CI: 0.95, 1.25), p = 0.05.
Another medium quality study, a cross-sectional study, by Ait Bamai et al. (2018). that used data from
Hokkaido study on Environment and Children's Health examined the association between DINP and
eczema within the past 12 months. Logistic regression of DINP (j_ig/g dust) exposure on eczema found
significant gene-environmental interaction with FLG mutation, OR total = 1.17 (95% CI: 0.91, 1.52; p =
0.039). No other significant associations were found between eczema and DINP exposure.
Finally, a low-quality study, a cohort study, by Wan et al. (2021). that used data from the Kingston
Allergy Birth Cohort (KABC) examined the association between skin prick testing and DINP exposure.
The authors did not find any statistically significant results in adjusted logistic regression models for
DINP exposure relation to allergic sensitization.
Laboratory Animals
A limited number of studies are available that have been evaluated for the toxicological effects of DINP
on the immune system. Available studies have provided data on the adjuvant properties of DINP; an
adjuvant is a substance that can enhance immune responsiveness without itself being an antigen. ECB
(2003) summarized the irritation and sensitization data and determined that DINP is a very slight skin
and eye irritant, with effects reversible in short time. The U.S. CPSC ( ) concluded that"in vivo
studies in guinea pigs suggest that DINP is not a skin sensitizer"; however, "in vivo studies in mice show
that DINP or other o-DAP's may augment an antigen mediated IL-4, IgE, and/or IgGl reaction." These
finding suggest that DINP may potentiate allergic and/or asthmatic responses.
The database of studies from existing assessments that evaluate the immune adjuvant effects of DINP is
limited to two studies (Koike et al.. 2010: Iroai et al.. 2006). which investigate the effects of DINP on
atopic dermatitis and skin sensitization.
Koike et al. (2010) investigated the effect of DINP on atopic dermatitis resulting from contact with a
dust mite allergen. Male NC/NgaTndCrlj mice were injected intradermally on the ventral side of their
right ears with saline or extract of the dust mite, Dermatophagoides pteronyssinus (Dp) on study days 0,
3, 5, 8, 10, 12, 15, and 17. On study days 2, 5, 9, and 16, DINP was administered via intraperitoneal (i.p)
injection dose levels: 0, 0.15, 1.5, 15, or 150 mg/kg-day. The authors evaluated several endpoints
including histopathology of the ears, protein expression (from ear homogenates) of Thi-type versus Tin-
type cytokines , as well as chemokines such as eotaxin, eotaxin-2, and thymic stromal lymphopoietin
(TSLP), via ELISA. DINP exposure significantly increased ear thickening and macroscopic features of
the ears from 4 and 6 days after the first injection of Dp. However, no dose-dependent effects of DINP
were observed. Animals exposed to 15 mg/kg-day DINP + Dp had more skin lesions when compared to
animals exposed to Dp or saline (no Dp). Histopathological evaluation of the ears showed that while Dp
had increased infiltration of eosinophils into the skin lesions when compared with saline controls, 15
mg/kg-day DINP + Dp potentiated the infiltration of eosinophils into the skin lesion (compared to Dp)
in parallel with increased mast cell degranulation. Alterations in cytokine levels were observed in the
ears of animals exposed to Dp (compared to saline), including increased IL-4, -5, and -13 and decreased
interferon-y (IFN-y). There was a decrease in expression of IFN-y, eotaxin and eotaxin-2, and increased
expression of TSLP were also observed in the ears of mice exposed to DINP, compared to those exposed
to Dp + vehicle. These data suggest that DINP aggravates allergic dermatitis-like skin lesions caused by
the Dp antigen. To evaluate the adjuvant capacity of DINP for immunoglobulin (Ig) production, the
authors also measured serum levels of anti-DP-IgGi, IgE, as well as histamine release. Intradermal
Page 62 of 184
-------
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
PUBLIC RELEASE DRAFT
May 2024
injection of Dp increased the levels of Dp-specific IgGl, total IgE, and histamine levels in serum
compared to saline alone. Exposure to DINP significantly increased histamine levels in serum compared
to saline alone. However, no significant changes in serum levels of Dp-specific IgGl, total IgE, or
histamine were observed in groups exposed to DINP compared to Dp. Collectively, these data support
that DINP is not an adjuvant in an atopic dermatitis mouse model.
Imai et al. (2006) investigated whether different phthalate esters (including DINP) have adjuvant effects
on skin sensitization using FITC as a sensitizer. Female CD-I (ICR) and BALB/c mice were used for
this skin sensitization study. Experimental groups include having multiple phthalates mixed with
acetone at a 1:1 ratio and the control group with acetone alone. ICR mice were epicutaneously sensitized
with FITC dissolved in an acetone solution containing one of various phthalate esters, including DINP.
The applications on the forelimbs were repeated on day 7 and on day 14; ear thickness and ear swelling
were measured. There were no significant differences in ear thickness/swelling between the DINP
treated group compared to the acetone control group. Similar results with DINP were confirmed using
BALB/c mice. Twenty-four hours following skin sensitization, draining lymph node cells were
examined for FITC fluorescence by means of flow cytometry. Mice sensitized with FITC in acetone
containing DINP did not show consistent ear-swelling response. DINP also showed no significant
increase in the FITC-positive cell number in the draining lymph nodes. These data suggest that DINP
does not act as an adjuvant in a FITC skin sensitization model in mice.
New Literature: EPA identified two new studies that investigated the effects of DINP exposure on
atopic dermatitis (Wu et al.. 2015; Sadakane et al.. 2014).
Wu et al. (2015) investigated the effects of DINP on allergic dermatitis (AD) in a FITC-induced allergic
dermatitis model and the role of oxidative stress and inflammatory factors in skin lesions of the model
mice and characterize the mechanism involved in the DINP. Additionally, uncovering the protective role
of melatonin (MT) on AD and exploring its mechanism as an antioxidant. Forty-nine male Balb/c mice
were divided randomly into seven groups: control, melatonin (30 mg/kg-day) 3 h after saline skin
exposure, 0.5 percent FITC-sensitized group (FITC), 1.4 mg/kg-day) DINP skin exposure+0.5 percent
FITC-sensitized group (FITC + DINP1.4), 14.0 mg/kg-day DINP skin exposure+0.5 percent FITC-
sensitized group (FITC+DINP 14), 140.0 mg/kg-day DINP skin exposure+0.5 percent FITC sensitized
group (FITC+DINP 140), and MT (30 mg/kg-day) 3 h after 140.0 mg/kg-day DINP skin exposure
combined with 0.5 percent FITC sensitized group (FITC+DINP 140.0+MT). The mice were exposed for
40 days, then given saline or FITC on days 41 and 42. Sensitization was terminated on day 47 to
measure ear thickness. This experiment was terminated on day 48 and blood samples were collected to
measure IgE levels and immunohistochemistry were conducted on the sections from the right ear for
TSLP, p-STAT3, p-STAT5, p-STAT6, NF-kB, and p65. Markers of oxidative stress, including ROS,
MDA, GSH, along with cytokines, IL-4 and IFN-y, were evaluated from the ear tissue.
The highest concentration of DINP (140 mg/kg-day) with FITC significantly increased the number of
infiltrating inflammatory cells when compared with the FITC exposed only group. Moreover, the
pathological alterations and the number of infiltrating inflammatory cells were alleviated in the
FITC+DINP 140+MT group as compared with the FITC+DINP 140 group. Ear swelling and bilateral
ear weight were significantly altered in all FITC-immunized groups. Dermal DINP exposure
significantly increased ear swelling and bilateral ear weight when compared to the group exposed to
FITC only, and this adverse effect was potentiated. Also, when MT was added, diminished the DINP-
induced ear swelling and the bilateral ear weight when compared to the same concentration of DINP
without MT. FITC alone and all concentrations of FITC+DINP exposure significantly enhanced serum T
IgE levels, at all concentrations. The highest dose of DINP (140 mg/kg) exposure drastically elevated
serum T-IgE levels compared with the FITC-sensitization only group. Further, T-IgE levels in the FITC
Page 63 of 184
-------
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
PUBLIC RELEASE DRAFT
May 2024
+ DINP 140 group significantly decreased when compared to the FITC+DINP 140+MT group.
Compared with the FITC only group, co-exposure with any concentration of DINP induced a significant
increase in IL-4, IL-5 and a resulting skew in the ratio of IL-4 to IFN-y. These adverse effects
exacerbated by DINP were concentration-dependent. However, MT alleviated the DINP-induced effects,
suggesting that DINP is associated with Th2 cytokine expression by FITC-mediated allergic
inflammation. Their results of histopathological examinations and measurements of ear swelling as well
as immunological and inflammatory biomarkers (total-immunoglobulin IgE and Th cytokines) supported
their conclusion that high doses of DINP may aggravate atopic dermatitis.
Lastly, Sadakane et al. (2014) is another study identified by the EPA that investigated the role of DEHP
and DINP on atopic dermatitis at doses lower than the NOAEL for humans based on chronic liver
toxicity (15 mg/kg-bw-day); however, the DINP-specific effects will be focused on here. Previous
studies have uncovered that DINP in low doses have been shown to cause aggravation of atopic
dermatitis-like skin lesions (ADSLs) in mouse models. In this study, 120 male NC/Nga mice were used
in this experiment, out of which 60 mice each were used to investigate the effect DINP on AD. From the
60 mice used for DINP exposure, they were placed in 5 groups of 12 (1 for saline vehicle control and 4
experimental groups). Animals in the experimental groups were exposed to the allergen,
Dermatophagoidespteronyssinus (Dp), by subcutaneous injection of 5 mg of dissolved in 10 mL of
saline in the ventral side of the right ear for 2 to 3 days a week (a total of 8 times) under anesthesia.
Animals in the experimental DINP groups were exposed to the allergen and treated with 0 (Dp+vehicle),
6.6 (Dp+DINP 6.6), 131.3 (Dp+DINP 131.3), or 2,625 (Dp+DINP 2,625) jig/animal of Dp. In the
experimental groups, mice were orally administered DINP dissolved in O.lmL of olive oil 5 days before
the first injection of the allergen. Control group animals (saline + vehicle and Dp+vehicle groups) were
not exposed to DINP and only given 0.1 mL of olive oil only orally.
Twenty-four hours following Dp injections, skin disease symptomatology and ear thickness were
evaluated and scored for symptom of skin dryness and eruption, edema, crusting and erosion. Also, the
clinical scores of the Dp+DINP 6.6 and Dp+DINP 131.3 groups began increasing when compared with
the Dp+vehicle group from day 16, the Dp+DINP 131.3. The Dp+DINP 131.3 group had a higher (not
significant) wound score compared with the Dp+vehicle group while the Dp+DINP 2,625 did not
change. Statistical tests revealed no significant differences between DINP treated groups and the control
at any doses to contribute to ASDLs. The dorsal skin of the Dp-treated groups with or without DINP
exposure exhibited epidermal and dermal thickening, eosinophil accumulation and mast cell
degranulation. The eosinophil counts of both DP+DINP treatments increased but not significantly.
However, oral exposure to DINP did not increase the eotaxin levels. Exposure to DINP modestly
increased mean total IgE levels. The rank of mean skin scores with specific DINP doses (Dp+DINP
131.34 > Dp+DINP 6.64 > Dp+DINP2,625 > Dp+vehicle) was found to be strongly positively
correlated with the number of eosinophils, the number of severely degranulated mast cells, and
moderately positively correlated with the total number of mast cells. In conclusion, at doses lower than
the NOAEL, DINP increases the allergic response in animal AD models, but the other concentrations of
DINP slightly aggravates allergen-induced ADSL production.
Mechanistic Information
EPA identified seven studies that describe the mechanism of action for the adverse immunological
effects of DINP (Yun-Ho et al.. 2019; Duan et al.. 2018; Kane et al.. 2017; Kane et al.. 2016; Chen et
al.. 201 ^ Koike et al.. 2010; Lee et al.. 2004).
Aforementioned Koike et al. Q ) not only conducted experiments in mice, but also evaluated the
adjuvant effects of DINP on bone-marrow-derived dendritic cells or splenocytes in vitro. Bone-marrow-
Page 64 of 184
-------
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
PUBLIC RELEASE DRAFT
May 2024
derived dendritic cells and splenocytes were exposed to DINP for 24 hours at concentrations of 0
(control), 0.1 [xM, 1 [xM, 10 [xM, and 100 [xM. At 100 [xM, DINP exposure for 24 hours led to
significantly increased the production of Th2 chemokines, TARC/CCL17 and MDC/CCL22, in bone-
marrow-derived dendritic cells when compared with control (0 [xM DINP). However, Thi cytokine IL-
12p40 was not detected in any bone-marrow-derived dendritic cell culture. Moreover, DINP also
significantly increased the expression of the chemokine receptors CCR7, CXCR4, MHC class II, CD80,
and CD86 on bone-marrow-derived dendritic cells compared with controls. DINP exposure for 24 hours
significantly increased IL-4 production from splenocytes compared with controls. After 72-hours of
exposure to DINP in the presence of Dp, there was a significant increase in proliferation of splenocytes
at 0.001 to 1 [xM and decreased proliferation at 10 [xM compared with controls. These results show that
DINP augmented IL-4 production and Dp-stimulated proliferation of splenocytes to suggest that DINP
does aggravate AD-like skin lesions related to Dp through TSLP-related activation of dendritic cells and
by direct or indirect activation of other immune cells.
Kang et al. C ) examined the effects of DINP exposure on the development of allergies and the
underlying mechanisms. Male Balb/c mice were gavaged with 2, 20, or 200 mg/kg-day DINP for 21
days, then sensitized with either saline or 0.5 percent FITC (in 1:1 acetone/DBP) on days 22 and 23 via
dermal application to shaved skin. On day 28, the mice received a 0.5 percent FITC challenge (or saline)
to the right ear, and saline or vehicle (1:1 acetone/DBP) to the left ear and the baseline ear thickness was
measured. On day 29, the study was terminated, and blood samples were collected to determine IgE
levels. Immunohistochemistry staining was performed on the sections from the right ear to visualize the
localization and staining intensity of TSLP, p-STAT3, p-STAT5, p-STAT6, NF-kB, and p65. The
authors also evaluated ROS, MDA, and GSH levels in the ear tissue as well as levels of the cytokines,
IL-4 and IFN-y. In mice administered DINP+FITC, there was an increase in the number of infiltrating
inflammatory immune cells in their ear tissue. Dose-dependent, significant increases in IL-4 and IL-5
were observed in all groups exposed to FITC+DINP. In contrast, there was a dose-dependent decrease in
IFN-y, which increased the IL-4/IFN-y ratio, showing DINP only increases Th2-specific cytokines.
However, no significant pathological changes were observed in the ears of mice exposed to DINP alone,
but the ears of mice from the FITC only group showed inflammatory cell infiltration into the skin.
Additionally, to uncover the pathway of these adverse effects, treatment with FITC+DINP200, and
pyrollidine dithiocarbamate (PDTC), a well-known inhibitor of NF-kB, markedly reduced the ear
swelling when compared to the FITC+DINP200 exposed group. Further, bilateral ear weight decreased
significantly when the FITC+DINP-immunized groups were treated with PDTC. There was an increase
in ROS and MDA levels and a decrease GSH levels were observed in FITC+200 mg/kg-day DINP
exposure groups compared to FITC alone, but PDTC reversed those effects. The adverse pathological
effects observed in higher dose groups were attenuated with PDTC treatment, which suggest that the
adverse effects are facilitated by the NF-kB signalling pathway. Results support that DINP aggravates
FITC-induced allergic contact dermatitis through exacerbating increased MDA and ROS accumulation,
IL-4 and IL-5 production, while also decreasing GSH and IFN-y, which then activates the NF-kB
pathway. Following activation, TSLP expression and activation is increased, causing increased
production of STATs 3, 5, and 6 to ensue.
A subsequent study by Kang et al. (2017) expanded on the previously mentioned underlying
mechanisms of DINP and the role of TRP cation channel, subfamily A, member 1 (TRPA1) on the NF-
kB pathway. In this allergic dermatitis model, male BALB/c mice were gavaged with saline (control) or
DINP (2, 20, 200 mg/(kg-d) from day 1 to 21. On days 22 and 23 mice were smeared with saline or 0.5
percent FITC on their backs to sensitize them, then on day 28, mice are given saline or FITC on their
right ear. Following sensitization, skin lesions showed enhanced levels of IgGl, IL-6, IL-13, and
TRPA1 expression with DINP potentiating these levels. To determine the role of TRPA1 and NF-kB for
Page 65 of 184
-------
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
PUBLIC RELEASE DRAFT
May 2024
allergic dermatitis, on days 22, 23, and 28, mice were injected with HC-030031, a TRPA1 antagonist,
and NF-kB inhibitor, PDTC. Blocking NF-kB inhibited TRPA1 expression; however, TRPA1
antagonism did not have any effect on NF-kB or TSLP expression. These findings suggest that TRPA1
is dependent on NF-kB activation and TSLP expression for DINP aggravated allergic dermatitis.
Similarly, Lee et al. (2004) examined the effects of DINP on IL-4 production in CD4+ T-cells and the
associated mechanisms. BALB/c mice were injected with Keyhole limpet hemocyanin in alum adjuvant
twice at 7-day intervals while being i.p injected with 2 or 5 mg/kg of DINP every other day. Lymph
node cells were harvested and cultured from these mice after 7 days of treatment and used to measure
IL-4 and IFN-y. DINP was shown to enhance IL-4 production in lymph node cells, which originated
from CD4+ T-cells in a concentration dependent manner and increase IgE serum levels in vivo.
Additionally, DINP exposure also increased IL-4 gene promotion activity in Phorbol-12-myristate-13-
acetate stimulated EL4 T-cells. IL-4 gene promoter contains multiple binding sites to nuclear factor of
activated T-cells (NF-AT), and DINP was shown to potentiate IL-4 production via enhancing PI and P4
binding site activity on NF-AT. These study results support that DINP augments the allergic response of
IL-4 production in CD4+T-cells via increased NF-AT binding activity.
Moreover, Chen et al. (2015) investigated how DINP exposure during gestation and lactation affects the
allergic response of pups and the role of the PI3K/Akt pathway. Female Wistar rats are treated with 0, 5,
50, and 500 mg/kg-day from GD 7 to PND 21. On PND 22, 23, and 37, pups were sensitized with
ovalbumin (OVA). Then, protein expression and production of cytokines associated with PI3K/Akt were
measured. In the 50 mg/kg-day DINP group, pups displayed significantly increased lung resistance (RI)
when compared to the controls. Moreover, all DINP-treated groups had significantly increased
eosinophil infiltration into the airways when compared to the control group, as indicated by
immunohistochemistry. Pups exposed to 50 mg/kg-day DINP had increased Akt phosphorylation, NF-
kB translocation, and increased Th2 cytokine (IL-13) expression, while having decreased Thi cytokine
(INF-r) expression, when compared to the vehicle control group. These results suggest DINP aggravates
the OVA-induced response and enhances expression of the PI3K/Akt pathway and NF-kB translocation.
Next, a neuroinflammation mouse asthma model study by Duan et al. (2018) exposed, via i.p injection,
groups of Balb/c mice (8 mice/group): 1) Saline only group (control); 2) Ovalbumin (OVA) only group);
3) OVA and formaldehyde (lmg/m3, 5h/day) exposure (OVA+FA group); 4) OVA and DINP (20
mg/kg-day) exposure (OVA+DINP group); 5) OVA and formaldehyde (lmg/m3, 5h/day) plus DINP (20
mg/kg-day) exposure (OVA+FA+DINP group); 6-9) melatonin (lOmg/kg-day) blocking groups
(OVA+MT group, OVA+FA+MT group, OVA+DINP+MT group, OVA+FA+DINP+MT group); 10-
13) were Dehydroxymethylepoxyquinomicin (DHMEQ; a NF-kB inhibitor) (lOmg/kg-day) NF-kB
blocking groups (OVA+DHMEQ group, OVA+FA+DHMEQ group, OVA+DINP +DHMEQ group,
OVA+FA+DINP+DHMEQ group). Following 18 days of exposure and 7 days of sensitization, allergic
asthma symptoms (eosinophilic catatonic protein) levels and mucus secretion), markers of oxidative
stress (ROS fluorescence, superoxide dismutase, and Nrf2 levels), cytokines (IL-ip and IL-17), and NF-
kB signaling were measured in the brain. Exposure to DINP increased eosinophilic catatonic protein
levels and the number of mucus secreting cells in the airway of the mice with OVA sensitization.
Additionally, DINP exposure increased levels of IL-ip, IL-17, and NGF levels in the brain and
increased NF-kB activation in the pre-frontal cortex. Moreover, DINP exposure increased ROS
fluorescence in the brain, Nrf2, and decreased superoxide dismutase. Results of this study indicate that
DINP promotes neuroinflammation through potentiating oxidative stress and NF-kB signal pathway
activation in this mouse asthma model.
Page 66 of 184
-------
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
PUBLIC RELEASE DRAFT
May 2024
Lastly, another asthma mouse model study identified by EPA is Yun-Ho et al. (2019). They investigate
the role of TLR4 and HMGB1 in the mechanisms of DINP-induced asthma. In this study, female
C57BL/6 mice were i.p injected with 50mg/kg 1 DINP for a week to sensitize them and then challenged
with saline or DINP on days 19, 21, and 23. During the challenge, mice were injected in their tail vein
with either 3 mg/kg 1 TAK-242 (TLR4 inhibitor) or 10 mg/kg 1 anti-HMGBl antibody, respectively, on
each day of the challenge. DINP significantly increased airway hyperresponsiveness, number of
infiltrating cells in bronchoalveolar fluid, numbers of inflammatory cells in blood, pulmonary fibrosis,
mucus production, Th2 cytokine production (IL-4, IL-5, IL-13), and lung cell apoptosis. In contrast,
adding the TLR4 inhibitor or anti-HMGBl antibody following DINP exposure reduces airway
hyperresponsiveness, reduced production of IL-4, IL-5, and IL-13 cytokines, and number of
inflammatory cells in the airway. Therefore, this study supports that HMGB1 and TLR4 signalling
pathways both contribute to DINP-induced asthma and inhibiting them significantly reducing several
biological markers of asthma.
Conclusions on Immune System Toxicity
There are multiple animal toxicity studies that support the adjuvant effects of DINP exposure on the
immune response in dermatitis models and in vitro experiments (Koike et al.. 2010; Iroai et al.. 2006).
Koike et al. (2010) stated that DINP exposure did not aggravate serum levels of IgGl, IgE, and
histamine levels in vivo. Further, Imai et al. (2006) concluded that DINP is not considered a skin
sensitizer based on no significant increase in the FITC-positive cell number in the draining lymph nodes.
Additionally, there were three new studies that all support that DINP aggravates atopic dermatitis via
causing oxidative stress and NF-kB cellular pathway activation (Kane et al.. 2016; Wu et al.. 2015;
Sadakane et al.. 2014). Similarly, EPA identified six mechanistic studies that support DINP enhancing
NF-kB signalling, TSLP transcription, NF-AT, PI3K/Akt, TLR4, and HMGB1 in allergic dermatitis,
atopic dermatitis, and asthma mouse models (Yun-Ho et al.. 2019; Duan et al.. 2018; Kane et al.. 2017;
Kane et al.. 2016; Chen et al.. JO I et al.. 2004). Overall, available studies provide evidence that
DINP augments the inflammatory responses in several sensitization models and the underlying
mechanisms. Specifically, there are several studies that demonstrate DINP's role in potentiating ROS
production, TSLP transcription, PI3K/Akt, TLR4, and NF-kB pathway activation, and Th2 cytokine
production in allergic dermatitis, neuroinflammation, and asthma in animal models.
Although available studies of laboratory animals provide evidence for immune adjuvant effects of DINP
in sensitized animals, EPA is not further considering these effects for dose-response assessment or for
use in extrapolating human risk. Available studies evaluate the adjuvant properties of DINP in
experimental rodent models pre-sensitized by exposure to other compounds (e.g., FITC, ovalbumin).
While these studies may be useful for hazard identification for a specific population (pre-sensitized
individuals), the fact that the outcome evaluated in these studies requires prior exposure to another
chemical precludes its broader applicability.
3.7 Musculoskeletal Toxicity
Humans
Four epidemiologic studies, three cross-sectional and one cohort study examined the association
between DINP urinary levels of metabolites and bone mineral density, Osteoporosis and Vitamin D in
adults, however the evidence was considered inadequate due to inconsistent results (Health Canada.
2018a).
New Literature: EPA considered new studies published since Health Canada's assessment (i.e., studies
published from 2018 to 2019); however, no new studies were identified that evaluated musculoskeletal
injury for DINP and/or its metabolites.
Page 67 of 184
-------
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
PUBLIC RELEASE DRAFT
May 2024
Laboratory Animals
Hwang et al. (2017) was the only study that investigated the relationship between DINP and osteopenia,
which is characterized by bone loss and deterioration of bone structure leading to fractures. DINP (2, 20,
or 200 mg/kg-day) was administered via intraperitoneal injection to 8-week-old female C3H/HeN
ovariectomized (OVX) mice (5 animals/group), including: a sham-operated control group injected with
PBS; a vehicle treated OVX group injected with PBS; and three DINP groups of 2, 20, or 200 mg/kg-
day. The vehicle and DINP were administered for 6 weeks, and the body weights were recorded weekly.
There was significant increase in body weights of OVX mice compared to sham control mice 6 weeks
after OVX surgery. DINP also significantly increased body weight compared to sham control mice.
DINP-treated mice had significantly reduced uterus weight and decreased tibia and femur lengths. Tibia
weights were decreased in OVX mice and in the DINP-treated mice. However, no differences were
noted in femur weights among the groups. DINP treatment of the normal mice increased the inorganic
phosphorus release. Lactate dehydrogenase was unaffected by OVX or DINP treatments.
Further, tartrate-resistant acid phosphatase activity (bone resorption marker) was significantly increased
in both OVX mice and in the mice treated with 200 mg/kg-day DINP at a similar magnitude over
controls. Bone ALP activity was lower than sham controls in the OVX mice and in the DINP mice
treated with 2 and 20 mg/kg-day; however, bone ALP activity in mice treated with 200 mg/kg-day DINP
was comparable to sham controls, indicating that these decreases were not dose-related. Further, the
microarchitecture of the femur and tibia were affected by OVX and DINP. The bone volume, tissue
volume, bone volume/tissue volume ratio, bone surface, bone surface/tissue volume ratio, trabecular
thickness, and trabecular number were all reduced, while the trabecular pattern factor, structure model
index, and trabecular separation were increased in the DINP-treated mice, although these differences
were not as substantial as in the OVX mice compared to sham controls. Similarly, the bone mineral
density of the femur and tibia was dose-dependently decreased in the DINP-treated mice, but not
decreased to the extent noted in the OVX mice, compared to the sham controls. The authors concluded
that these results indicate that DINP contributes to an increased risk of osteopenia via destruction of the
microarchitecture and enhancement of osteoclastic activity, although it is difficult to conclude as the
mechanism of action is currently unknown.
Conclusions on Musculoskeletal Toxicity
Four epidemiological studies and one study in experimental animals have provided data on the
associations between exposure to DINP and musculoskeletal outcomes such as osteoporosis or
osteopenia. The human evidence was considered inadequate due to inconsistent results across study
designs and not further evaluated by EPA. The animal evidence suggests that DINP can reduce bone
mineral density in female mice. Overall, there is limited evidence that DINP can elicit musculoskeletal
toxicity in experimental laboratory animals; only one study in one species of one sex evaluates
musculoskeletal outcomes. Additionally, the clinical implications, or relevance to humans, is uncertain
given the limitations of the epidemiologic database. Due to these limitations and uncertainty, EPA is not
further considering musculoskeletal toxicity for dose-response analysis.
Page 68 of 184
-------
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373
2374
2375
PUBLIC RELEASE DRAFT
May 2024
4 DOSE-REPONSE ASSESSMENT
EPA is considering four non-cancer hazard endpoints related to liver, kidney, neurological and
developmental toxicity for dose-response analysis as described in the following sections. These hazard
endpoints were selected for dose-response analysis because EPA has the highest confidence in these
hazard endpoints for estimating risk to human health in the non-cancer sections. The effects for liver,
kidney, and developmental effects were consistently observed across multiple rodent species and
durations of exposure and occurred in a dose-related manner. EPA considered liver and developmental
effects observed in experimental animal models to be relevant for estimating risk to human health. Other
non-cancer hazard endpoints considered by EPA {i.e., cardiovascular toxicity (Section 3.5), immune
system toxicity (Section 3.6), and musculoskeletal toxicity (Section 3.7) were not considered for dose-
response analysis due to limitations in the number of studies, unknown MOA and uncertainties that
reduce EPA's confidence in using these endpoints for estimating risk to human health.
EPA considered two approaches, including a NOAEL/LOAEL approach, and benchmark dose modeling
for liver effects and benchmark dose modeling of developmental effects performed by NASEM (2017).
EPA considered NOAEL and LOAEL values from oral toxicity studies in experimental animal models.
Acute, intermediate, and chronic non-cancer NOAEL/ LOAEL and BMDL values identified by EPA are
discussed further in Sections 4.1.1, 4.1.2 and 4.1.3, respectively. As described in Appendix F, EPA
converted oral PODs derived from animal studies to human equivalent doses (HEDs) using allometric
body weight scaling to the three-quarters power ( ). In the absence of dermal toxicology
studies, EPA used the oral HED to assesses risks from dermal exposures. Differences in dermal and oral
absorption are corrected for as part of the dermal exposure assessment. In the absence of inhalation
studies, EPA performed route-to-route extrapolation to convert oral HEDs to inhalation human
equivalent concentrations (HECs) (Appendix F).
4.1 Selection of Studies and Endpoints for Non-cancer and Threshold
Cancer Health Effects
EPA considered the suite of oral animal toxicity studies for adverse liver, kidney, neurological and
developmental effects identified during hazard identification (Section 3) when determining non-cancer
PODs for estimating risks for acute, intermediate, and chronic exposure scenarios, as described in
Sections 4.1.1, 4.1.2 and 4.1.3, respectively. EPA assessed relevant non-cancer health effects in these
studies based on the following considerations:
• Exposure duration;
• Dose range;
• Relevance (e.g., what species was the effect in, was the study directly assessing the effect, is the
endpoint the best marker for the toxicological outcome?);
• Uncertainties not captured by the overall quality determination;
• Endpoint/POD sensitivity; and
• Total uncertainty factors (UFs).
The following sections provide comparisons of the above attributes for studies and hazard outcomes
relevant to each of these exposure durations and details related to the studies considered for each
exposure duration scenario.
4.1.1 Non-cancer Oral Points of Departure for Acute Exposures
EPA considered 12 developmental toxicity studies with endpoints relevant to acute exposure duration
(I ), summarized in Table 4-2. The endpoints considered relevant to acute exposure
durations include skeletal and visceral variations, and effects on the developing male reproductive
Page 69 of 184
-------
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
PUBLIC RELEASE DRAFT
May 2024
system consistent with a disruption of androgen action during the critical window of male reproductive
development in rats. These studies were subjected to dose-response analysis to select the study and
endpoint most appropriate to derive the POD for acute hazard. The dose-response array for these studies
is depicted graphically in Figure 4-1. Although these studies entailed exposure durations that exceeded a
single day, EPA considered endpoints from these developmental toxicity studies for which there is
evidence that they can result from a single exposure day during a critical window of development during
gestation. For example, several studies have demonstrated that a single dose of DBP, which is
toxicologically similar to DINP (! ; S 1 T \ 2023a. b), during the critical window of development {i.e.,
GDs 15.5 to 18.5) is sufficient to disrupt fetal testicular testosterone production and steroidogenic gene
expression. Although analogous single dose studies are not available for DINP, studies of DBP support
the conclusion that effects on the developing male reproductive system may occur following acute,
single dose exposures in rodent models (see Appendix C for further justification).
In two prenatal developmental toxicity studies (Waterman et ai. 1999; Hellwie et ai. 1997). an
increased incidence of fetal skeletal variations (e.g., rudimentary/supernumerary cervical or lumbar ribs)
and urogenital variations (Hellwie et; 7) were observed following exposure during GDs 6 to 15.
rudimentary/supernumerary cervical or lumbar ribs) and urogenital variations were observed following
exposure during GDs 6 through 15. However, the doses at which fetal visceral and skeletal variations
occurred (500 and 1,000 mg/kg-day) were higher than doses in other developmental toxicity studies in
which more sensitive effects of androgen insufficiency were observed. Therefore, EPA did not select
these studies and endpoints because they do not provide the most sensitive robust endpoint for an acute
POD.
The remaining 10 developmental toxicity studies considered by EPA resulted in effects on the
developing male reproductive system consistent with a disruption of androgen action during the critical
window of development. EPA identified this hazard in the Draft Proposed Approach for Cumulative
Risk Assessment of High-Priority Phthalates and a Manufacturer-Requested Phthalate under the Toxic
Substances Control Act ( 323a) and concluded that the weight of scientific evidence
indicates that DINP can induce effects on the developing male reproductive system consistent with a
disruption of androgen action and rat phthalate syndrome. Notably, EPA's conclusion was supported by
the SACC ( 2023b). The exposure durations for these 10 studies ranged from initiation of
dosing at implantation through the day prior to expected parturition (i.e., GDs 7 to 21) as employed in
most guideline studies, to more narrow windows of exposure during gestation in which the phthalate-
specific effects on male rodent offspring are known to occur (e.g., GDs 14 to 18) or extended to
encompass the perinatal period (e.g., GDs 14 to PND3). Observed effects included decreased
steroidogenic gene expression in the fetal testes, decreased fetal testicular testosterone, decreased AGD,
increased NR, effects on fetal Ley dig cells, increased incidence of MNGs, and decreased sperm motility.
LOAELs for these effects ranged from 100 to 1,165 mg/kg-day.
Page 70 of 184
-------
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
PUBLIC RELEASE DRAFT
May 2024
I HED LOAEL
A HED NOAEL
• Other Doses Tested
4- fetal testicular testosterone production; GD 14-18; rats; Hannas, 2011,
788239"
t MNGs (GD 21); ^sperm motility (PND 90); GD 7-17; rats; Boberg, 2011,
806135
4- male pup body weight; 1s fetal Leydig cell clusters/aggregates; 4,
testicular mRNA levels of Insl3; GD 12-21; rats; Li, 2015, 2807612°
i" testicular mRNA levels of P450scc, GATA-4, and Insl3; GD 13.5-17.5; rats;
Adamsson, 2009, 679859
4- fetal testicular testosterone content and production; GD 7-21; rats; Borch,
2004, 673587
4- maternal body weight gain; male pup nipples/areola retention; testes
malformations; GD 14 - PND 3; rats; Gray, 2000, 678742
4- Fetal testis testosterone production; GD 14-18; rats; Furr, 2014, 2510906
incidence of rudimentary cervical & accessory lumbar ribs; urogenital &
skeletal variations; GD 6-15; rats; Hellwig, 1997, 674193
1s skeletal variations (total skeletal variations and rudimentary lumbar ribs);
GD 6-15; rats; Waterman, 1999, 680201
4 male pup weight (PND 14), 1" MNGs (PND 2) in the testes; GD 12 - PND
14; rats; Clewell, 2013,1325348
•T" incidence of MNGs, 4' fetal testes testosterone (2 hrs post final dose); GD
12-19; rats; Clewell, 2013,1325350
A
A—
¦ •
10 100
HED (mg/kg-day)
1000
Figure 4-1. Dose-Response Array of Studies Considered for Deriving the Acute Duration Non-
cancer POD
Notes: | = statistically significant increase in response compared to controls; [ = statistically significant decrease
in response compared to controls; M = males; F= females; GD = Gestational Day; PND = Postnatal Day; MNGs =
multinucleated gonocytes; HED = human equivalent dose; NOAEL = No observable adverse effect level; LOAEL
= lowest observable adverse effect level.
11 Study included in NASEM (2017) meta-regression analysis and BMD modeling.
In 2017, NASEM (2017) assessed experimental animal evidence for effects on fetal testicular
testosterone following in utero exposure to DINP using the systematic review methodology developed
by the National Toxicology Program's (NTP) Office of Health Assessment and Translation (OHAT).
Based on results from four studies of rats (Li et al.. 2015; Boberg et al.. 2011; Hannas et al.. 2011;
Adamsson et al.. 20091 NASEM found high confidence in the body of evidence and a high level of
evidence that fetal exposure to DINP is associated with a reduction in fetal testosterone in rats. NASEM
reported that the literature search was conducted on August 15, 2016, so it is not clear why another study
measuring decreased fetal testosterone (Clewell et al.. 2013a) was not included in the analysis. NASEM
further conducted meta-regression analysis and benchmark dose (BMD) modeling on decreased fetal
testicular testosterone production data from two medium-quality prenatal exposure studies of rats (Li et
al.. 2015; Hannas et al.. 2011). although no explanation was provided for the fact that results from the
studies by Adamson et al. (2009) and Li et al. (2015) were not presented in the BMD modeling
supporting the final meta-analysis. NASEM found a statistically significant overall effect and linear
trends in logio(dose) and dose, with an overall large magnitude of effect (greater than 50 percent) in its
meta-analysis for DINP (Table 4-1). Further BMD analysis determined BMDLs and BMDL40 values of
49 and 552 mg/kg-day, the 95 percent lower confidence limit of the BMD associated with a benchmark
response (BMR) of 5 and 40 percent, respectively (Table 4-1). EPA has higher confidence in the
Page 71 of 184
-------
2441
2442
2443
2444
2445
2446
2447
2448
2449
2450
2451
2452
2453
2454
2455
2456
2457
2458
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
PUBLIC RELEASE DRAFT
May 2024
NASEM meta-analysis since it takes into account data from multiples studies. Using allometric body
weight scaling to the three-quarters power, EPA extrapolated an HED of 12 mg/kg-day from the BMDLs
of 49 mg/kg-day. A total UF of 30 was selected for use as the benchmark MOE (based on an
interspecies UF (UFa) of 3 and an intraspecies UF (UFh) of 10).
Table 4-1. Summary of NASEM (2017) Meta-Analysis and BMD Modeling for Effects of DINP in
Fetal Testosterone 11 b
Database
Supporting
Outcome
Confidence
in Evidence
Evidence of
Outcome
Heterogeneity
in Overall
Effect
Model with
Lowest AIC
BMD5 mg/kg-
day (95% CI)
BMD40 mg/kg-
day (95% CI)
4 rat studies
High
High
I2 = 83%
Linear
quadratic
76 (49, 145)
701 (552, 847)
" R code supporting NASEM's meta-regression and BMD analysis of DINP is publicly available through GitHub
(httDs://github.com/wachiuDhd/NASEM-2017-Endocrine-Low-DoseV
b NASEM (20.1.7) calculated BMD40s for this endooint because "previous studies have shown that reproductive-tract
malformations were seen in male rats when fetal testosterone production was reduced by about 40%."
While one of the studies considered in the NASEM meta-analysis (Li et ai. 2015) appears to
demonstrate similar effects on male offspring at lower doses than indicated in many of the other
developmental toxicity studies, EPA did not consider this study further as the sole study on which to
derive the POD because several areas of uncertainty reduced EPA's confidence in the results when
considered independently from the other studies in a meta-analysis. While dose-dependent increases in
testes dysgenesis and decreases in fetal testicular testosterone were noted, this study had limited
statistical power (n = 6). It is also unclear what the study authors considered the broad description of
"testes dysgenesis" to represent, although there is some indication that they are referring to seminiferous
tubule atrophy. Further, effects on male pup body weight were not dose-related, with an essentially flat
dose-response across doses spanning three orders of magnitude. A similar flat dose-response was noted
in the frequency distribution of cluster sizes of fetal Leydig cells, and this endpoint is of uncertain
adversity. Although this study supports EPA's conclusions regarding the endpoint for hazard
identification, there is too much uncertainty in the dose-response in this study to use it quantitatively for
determination of the acute POD.
Two additional developmental toxicity studies not included among the four studies considered in the
meta-analysis by NASEM (Clewell et al. 2013a; Clewell et ai. 2013b; Hamner Institutes for Health
Sciences. 2011) resulted in decreased fetal testosterone production and other effects on the developing
male reproductive system at similar doses (LOAELs from 250 to 307 mg/kg-day and NOAELs from 50
to 56 mg/kg-day) to the BMDLs of 49 mg/kg-day derived from the NASEM meta-analysis. Therefore,
these studies support the selection of the BMDLs of 49 mg/kg-day for the acute POD.
Although several other additional studies were identified for effects on the developing male reproductive
system and specifically for decreased fetal testicular testosterone, they were single doses studies (Furr et
al.. 2014; Borch et al.. 2004; Gray et al.. 2000) with an identified LOAEL of 750 mg/kg-day,
considerably higher than the LOAELs identified in the above studies.
In a dietary study by Lee et al. (2006a). decreased male pup AGD was reported at the lowest dose tested,
40 ppm (estimated to be approximately 2 mg/kg-day). However, several factors reduce EPA's
confidence in this study and its results. First, study authors did not report dam body weight, food intake,
or calculate received doses in units of mg/kg-day, so there is uncertainty related to the achieved doses in
the study. Further, the effect of DINP on male pup AGD normalized to the cube root of bodyweight was
Page 72 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
2481 slight (overall magnitude of effect not reported), and treatment with DBP (a more potent antiandrogen
2482 compared to DINP) at equivalent or higher doses had no effect on male pup AGD once normalized to
2483 the cube root of body weight. This calls into question the significances of the slight change in AGD
2484 observed for DINP. Given these uncertainties, EPA does not consider the study by Lee et al. (2006a)
2485 suitable for use as the acute POD.
2486
2487 EPA selected the BMDLs of 49 mg/kg-day (HED = 12 mg/kg-day) as the acute exposure duration POD
2488 because it is the most sensitive robust endpoint and is based on the NASEM meta-analysis, and it falls
2489 within the narrow range of the NOAELs in two additional developmental toxicity studies, providing
2490 support and confidence in both the effect and the dose at which it occurs.
Page 73 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Table 4-2. Dose-Response Analysis of Selected I
>evelopmental Studies Considered for Deriving the Acute Non-cancer
POD
Study Details
(Species, Duration, Exposure Route/
Method, Doses |mg/kg-dav|)
Study POD/
Type
(mg/kg-day)
Effect
HED
(mg/kg-
day)
HEC
(mg/m3)
[ppm]
Uncertainty
Factors d
Reference
Wislar-Imamichi rats GD 15 to PND 21;
estimated doses (as reported bv (EC/HC,
2015)) 0, 2, 20, 200, 1,000 mg/kg-day;
(28 days)
LOEL= 2
|AGD & AG1, | in hypothalamic
granulin (grn, females) and pl30
(males) mRNA levels; reduced lordosis
quotient in females
0.473
2.57 [0.150J
UFa = 3
UFH= 10
UFl=10
Total UF = 300
(Lee et al.,
2006a)fe
Pregnant SD rats; oral gavage (corn oil);
0, 10, 100, 500, 1,000 mg/kg-day; GD
12-21
NOAEL= 10
i male pup body weight; | fetal Leydig
cell clusters/aggregates; j testicular
mRNA levels for Insl3
2.36
12.9 [0.75]
UFa = 3
UFh= 10
Total UF = 30
(Li et al., 2015)a
Meta-regression and BMD modeling of
fetal testicular testosterone in rats
BMDL5 = 49
i Fetal testicular testosterone
11.6
63.0 [3.68]
UFa = 3
UFh= 10
Total UF = 30
(NASEM. 2017Y
Pregnant SD rats; oral gavage; 0, 50,
250, and 750 mg/kg-day; GDs 12-19
NOAEL = 50
t incidence of MNGs, | fetal testes
testosterone (2 hours post final dose)
11.8
64.3 [3.76]
UFa = 3
UFh= 10
Total UF = 30
(Clewell et al.,
2013 a)
Pregnant SD rats; dietary; 0, 760, 3,800,
11,400 ppm (est. 56, 288, 720 mg/kg-day
on GDs 13-20; 109, 555, 1,513 mg/kg-
day on PNDs 2-14); GD 12-PND 14
NOAEL = 56
i male pup weight (PND 14), | MNGs
(PND 2) in the testes
13.2
72.1 [4.21]
UFa = 3
UFh= 10
Total UF = 30
(Clewell et al.,
2013b)
Pregnant SD rats; oral gavage; 0, 100,
500, and 1,000 mg/kg-day; GDs 6-15
NOAEL =
100
t skeletal variations (total skeletal
variations and rudimentary lumbar ribs)
23.6
129 [7.52]
UFa = 3
UFh= 10
Total UF = 30
(Waterman et al.
bw)
Pregnant Wistar rats; oral gavage; 0, 40,
200, and 1,000 mg/kg-day; GDs 6-15
NOAEL =
200
t incidences of rudimentary cervical
and accessory lumbar ribs; urogenital
and skeletal variations
47.3
257 [15.0]
UFa = 3
UFh= 10
Total UF = 30
(Hellwie et al..
Pregnant Wistar rats; oral gavage (corn
oil); 0, 300, 600, 750, 900 mg/kg-day;
GD 7-17
NOAEL =
300
t MNGs (GD 21); jsperm motility
(PND 90)
70.9
386 [22.6]
UFa = 3
UFh= 10
Total UF = 30
(Sobers et al.,
201 iy
Pregnant Harlan SD rats; Oral gavage
(corn oil); 0, 500, 750, 1,000, 1,500
mg/kg-day; GDs 14-18
LOAEL =
500
I fetal testicular testosterone production
118
643 [37.6]
UFa = 3
UFh=10
UFl = 10
Total UF = 300
(Hannas et al.,
201 iy
Pregnant SD rats; oral gavage (corn oil);
0, 750 mg/kg-day; GDs 14-18
LOAEL =
750
I Fetal testis testosterone production
177
965 [56.4]
UFa = 3
UFh= 10
UFl = 10
Total UF = 300
(Furr et al..
2014)
Page 74 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Study Details
(Species, Duration, Exposure Route/
Method, Doses |mg/kg-day|)
Study POD/
Type
(mg/kg-day)
Effect
HED
(mg/kg-
day)
HEC
(mg/m3)
|ppm|
Uncertainty
Factors''
Reference
Pregnant Wistar rats; oral gavage (peanut
oil); 0, 750 mg/kg-day; GDs 7-21
LOAEL =
750
I fetal testicular testosterone content
and production
177
965 [56.4]
UFa = 3
UFh=10
UFl = 10
Total UF = 300
(Borcli et al.,
2004)
Pregnant SD rats; oral gavage (corn oil);
0, 750 mg/kg-day; GD 14-PND 3
LOAEL =
750
I maternal body weight gain; | male
pup nipples/areola retention; testes
malformations (small, atrophic, flaccid,
fluid-filled, azoospermia, epididymal
agenesis)
177
965 [56.4]
UFa = 3
UFh = 10
UFl=10
Total UF = 300
(Grav et al..
2000)
Pregnant SD rats; oral gavage (corn oil);
0, 250, 750 mg/kg-day; embryonic day
13.5-17.5
NOEL = 250
t testicular mRNA levels of P450scc,
GATA-4, and Ins/3
(Adanisson et al,
2009)fl
" Studv considered as part of NASEM meta-analysis (NASEM, 2017). EPA did not consider this studv (Li et aL, 2015) further as the sole studv on which to
derive the POD because several areas of uncertainty (e.g., low statistical power with n=6, questionable dose-response and uncertain adversity among several
endpoints) reduced EPA's confidence in the results when considered independently from the other studies in a meta-analysis.
h Lee et al. (2006a) was not suitable for use to determine an acute POD due to uncertainties (e.g., reporting deficiencies for dam bodv weight and food
consumption for a dietary exposure study, and others described in the text).
' R code supporting NASEM's meta-regression and BMD analysis of DINP is publicly available through GitHub (httDs://github.com/wachiuDhd/NASEM-2017-
Endocrine-Low-Dose).
'' EPA used allometric bodv weight scaling to the three-auarters power to derive the HED. Consistent with EPA Guidance (U.S. EPA. 201 lb), the interspecies
uncertainty factor (UFa), was reduced from 10 to 3 to account remaining uncertainty associated with interspecies differences in toxicodynamics. EPA used a
default intraspecies (UFh) of 10 to account for variation in sensitivity within human populations due to limited information regarding the degree to which
human variability may impact the disposition of or response to DINP. EPA used a LOAEL-to-NOAEL uncertainty factor (UFl) of 10 to account for the
uncertainty inherent in extrapolating from the LOAEL to the NOAEL.
2492
Page 75 of 184
-------
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
PUBLIC RELEASE DRAFT
May 2024
4.1,2 Non-cancer Oral Points of Departure for Intermediate Exposures
EPA considered 12 short-term (>1 to 30 days) oral exposure studies (6 of rats and 6 of mice) of DINP
for establishing the intermediate duration POD (Table 4-3). Figure 4-2 depicts the dose-response array
for available studies. Ultimately, EPA selected the acute POD (12 mg/kg-day) and benchmark MOE
(total UF of 30) identified in Section 4.1.1 to evaluate risk from intermediate exposures {i.e., ranging
from 1 to 30 days) to DINP.
The acute POD is more sensitive than many of the intermediate HEDs based on liver, kidney, or
developmental toxicity in rodents. As can be seen from Table 4-3 and Figure 4-2, of the 12 short-term
studies under consideration, 7 supported HEDs ranging from 15.6 to 401 (Kwack et al. 2009; Kaufmann
et ai. 2002; Smith et ai. 2000; Hazleton Lab s s ., s 36; Bio/dynamics. 1982a; Midwest
Research Institu j_). These studies are less sensitive than the acute POD (HED of 12 mg/kg-day).
Further, several of these studies are limited by poor dose selection and did not test doses low enough to
support NOAEL identification (Hazleton Lab s \ <, >.' ^ \ s 86; Midwest Research Institute PM)
or only tested a single high dose of DINP (Kwack et al.. 2009; Bio/dynamics. 1982a).
Five short-term studies (Ma et al.. .^ s , < »g. 2015; Ma et al.. 2014; Masutomi et al.. 2003; Smith et
al.. 2000) report HEDs based on NOAELs ranging from 2.0 to 10 mg/kg-day, indicating that they are
more sensitive than the HED that EPA selected for a POD. However, each of these studies had
uncertainties that reduced EPA confidence in their use quantitatively for a POD for intermediate
duration exposure.
Masutomi et al. (2003) supports a developmental NOAEL of 3 1 mg/kg-day (HED of 7.3 mg/kg-day)
based on reduced F1 male offspring body weight on PND 27. However, this study is limited by its small
sample size (n of 5 rats per dose group). Further, the biological significance of the effect on F1 male
body weight is unclear, as F1 male bodyweight was unaffected on PND 2, and no effect on F1 male
bodyweight gain was observed from PND 2 to PND 10 or PND 10 to PND 21, and by PND 77 F1 male
body weight had recovered to control levels. These limitations and uncertainties reduce EPA's
confidence in using the study by Masutomi et al. (2003) for the intermediate POD.
Three studies (Ma et al. JO I \ i^'ng. 1:01 \ Ma et al.. 2014) reported treatment-related effects on
endpoints indicating oxidative stress, but it is unclear if the apparent effects on neurotoxicity (Ma et al..
2015; Pens. 2015) reported in Section 3.4, and the findings in the liver and kidney (Ma et al.. 2014)
reported in Section 3.2 and 3.3 can be directly attributed to the oxidative stress and inflammatory
responses observed in the studies. Although there is some evidence showing protective effects of
antioxidants in mitigating the effects of treatment with DINP, there is not enough data to determine the
link to the apparent effects on neurotoxicity and on the liver and kidneys. This limitation is due, in large
part, to the lack of quantitative data on the incidence or severity of the histopathology findings in the
brain, liver, and kidney. These data were only described qualitatively, with representative micrographs
of control and high dose groups presented as images, which precludes their usefulness to set a POD.
Additional limitations in the two neurotoxicity studies are described below.
In the two neurotoxicity studies (Ma et al.. 2015; Peng. 2015). male Kunming mice were administered
DINP by oral gavage at doses up to 200 mg/kg-day, followed by swim trials in the Morris Water Maze
to determine effects on learning and memory, along with measurements of oxidative stress and
histopathology evaluation of the brain. However, EPA identified several deficiencies in the study
methods and reporting. First, both studies only report mean escape latency of each swimming trial over
the 7-day acquisition phase but provide no measure of variability. Neither study conducted statistical
Page 76 of 184
-------
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
PUBLIC RELEASE DRAFT
May 2024
analysis on escape latency times within a given trial, but instead conducted statistical analysis on the
average escape latency times across the 7 trials. Therefore, EPA is not able to determine whether there
is a significant interaction between treatment and time to determine if the learning curve was steeper in
the controls compared to the mice administered DINP. Second, path length provides another measure of
learning, with path length decreasing over the acquisition phase if learning is occurring. The North
American Free Trade Agreement (NAFTA) Technical Working Group on Pesticides (TWG) -
Developmental Neurotoxicity Study Guidance Document (\ v < < \ < I ) indicates that the mean path
length per trial should be reported, as this outcome is highly correlated with escape latency times. Both
studies (Ma et at.. 2015; Pens. 2015) report use of camera tracking and computer software (ANY-
Maze), which has the capabilities to determine path length. However, neither study reports the path
length numerically for the swimming trials, but instead only depict an image of the swim path for a
representative trial in the high dose and control groups. The lack of quantitative data on swim path
length precludes EPA's ability to discern whether any increase in swim time is due to actual deficits in
learning and memory, or if there is an increase in swim time due to general toxicity (i.e., swimming
more slowly). Neither study included performance controls.
Per the NAFTA guidance document, swim speed and cued-trials are two common performance controls
that can be used to rule out treatment-related visual and motor impairments that can confound
interpretation of cognitive deficits (e.g., longer latency times may be due to slower swim speeds, not
cognitive impairment). Third, for the probe trial, Ma et al. (2015) report both the target quarter retention
time and the number of entries into the target quadrant, which is consistent with the NAFTA guidance
document. There is a clear treatment related effect on target quadrant retention time; however, the
controls spent only -16 seconds in the target quadrant, which is only slightly above chance levels of 25
percent. NAFTA guidance states that controls must show an increase in percent time in the correct
quadrant that exceeds chance levels of 25 percent. For the probe trial by Peng (2015). target quadrant
retention time is reported, and controls spent approximately 25 seconds in the target quadrant, well
above chance levels of 25 percent, but the number of entries into the target quadrant was not reported.
Fourth, both of these studies (Ma et al.. 2015; Pens. ) reported alterations in pyramidal cells in
hippocampus at the high dose (150 and 200 mg/kg-day); however, no quantitative data were provided on
the incidence or severity of the histopathology findings; the data were only described qualitatively, with
representative micrographs of control and high dose groups presented as images. Taken together, these
uncertainties limit the utility of the neurological studies for use in determining an intermediate duration
POD.
Finally, one study (Smith et al.. 2000) provided a HED value for the NOAEL (10 mg/kg-day) in the
same range as the acute HED value (12 mg/kg-day). Smith et al. (2000) report treatment-related
increases in liver weights, hepatic peroxisomal beta oxidation (PBOX), and DNA synthesis,
accompanied by inhibition of gap junctional intercellular communication (GJIC), in male B6C3F1 mice
fed diets containing 6,000 ppm DINP (approximately 900 mg/kg-day) for up to four weeks. This study is
limited in dose selection, with only two treated groups with doses spanning a wide range between the
NOAEL in the low-dose group at 75 mg/kg-day and the LOAEL in the high dose at 900 mg/kg-day.
Therefore, EPA did not consider the dose selection to be refined enough or endpoints examined to be
comprehensive enough to establish a robust POD. However, the fact that the HED value from this study
aligns with the HED from the acute POD adds further support to EPA's selection of the acute POD to be
protective of intermediate exposure durations.
Page 77 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
IHED LOAEL
AHEDNOAEL
• Other Doses Tested
4/ male body weight on PND 27; GD 7-21; rats; Masutomi, 2003,192872
Histopathological alterations in pyramidal cells in hippocampus; 14 days; mice (M); Ma,
2015, 3071020
Histopathological alterations in pyramidal cells in hippocampus; Impaired learning &
memory in MWM; 9 days; mice (M); Peng, 2015, 2919074
"T abs. and rel. liver weight; macroscopic liver observations; sb triglycerides; 7 days; rats
(M); Bio/dynamics, 1982,1987586
'T abs. and rel. liver weight; -f 11- and 12-hydroxylase activity, hypolipidemic effects; 21
days; rats (M/F); BIBRA, 1986,1325463
1" relative liver weight; clinical chemistry AST, ALP & triglycerides); 28 days; rats (M);
Kwack, 2009, 697382
T" abs. 8t rel. liver weight; 1" peroxisomal vol.& enzyme activity; T^hepatocyte proliferation;
4 weeks; mice (M); Kaufmann, 2002, 680011
1" incidence of hepatocytomegaly; enlarged & discolored livers; 4 weeks; mice (M);
Hazleton, 1991,1325464
1s rel. liver wt T" PBOX; Inhibition of GJIC; 2 weeks; rats (M); Smith, 2000, 667301
T1 rel. liver wt T* PBOX; Inhibition of GJIC; 4 weeks; rats (M); Smith, 2000, 667301
1" rel. liver wt "T PBOX; Inhibition of GJIC; 2 weeks; mice (M); Smith, 2000, 667301
T rel. liver wt PBOX; Inhibition of GJIC; 4 weeks; mice (M); Smith, 2000, 667301
Kidney
T* abs. and rel. kidney weight; 7 days; rats (M); Bio/dynamics, 1982,1987586
• •
0.01 0.1 1 10
HED (mg/kg-day)
100
1000
2587
2588 Figure 4-2. Dose-Response Array of Studies Considered for Deriving the Intermediate Duration
2589 Non-cancer POD
2590 Notes: j = statistically significant increase in response compared to controls; j = statistically significant decrease
2591 in response compared to controls
2592 Dev = developmental; Neuro = neurological; M = males; F = females; GD = gestational day; PND = postnatal
2593 day; ALT = alanine aminotransferase; AST= aspartate aminotransferase; ALP = alkaline phosphatase; HED =
2594 human equivalent dose; NOAEL = no-observed-adverse-effect-level; LOAEL = lowest-observed-adverse-effect-
2595 level.
Page 78 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Table 4-3. Dose-Response Analysis of Select
ed Studies Considered for Deriving the Intermediate
Non-ancer POD
Target
Organ/
System
Study Details
(Species, duration, exposure route/
method, doses |mg/kg-day|)
Study POD/
Type (mg/kg-
day)
Effect
HED
(mg/kg)
HEC
(mg/m3)
[ppm ]
Uncertainty
Factors"
Reference
Neurotoxicity
Kunming mice (males only); oral
gavage; 0, 1.5, 15, 150 mg/kg-day; 9
days
NOAEL = 15
i body weight gain; impaired learning
& memory in Morris Water Maze;
oxidative stress & inflammation;
histopathological alterations in
pyramidal cells in hippocampus
1.99
10.9
[0.634]
UFa = 3
UFh=10
Total UF = 30
(Pens. 2015)
Neurotoxicity
Kunming mice (males only); oral
gavage; 0, 0.2, 2, 20, 200 mg/kg-day;
14 days
NOAEL = 20
Histopathological alterations in
pyramidal cells; oxidative stress &
inflammation
2.66
14.5
[0.845]
UFa = 3
UFh=10
Total UF = 30
(Ma et a.L
2015)
Liver and
Kidney
Kunming mice (males only); oral
gavage; 0, 0.2, 2, 20, 200 mg/kg-day;
14 days
NOAEL = 20
Markers of oxidative stress (t ROS,
| GSH, t MDA, t 8-OH-dG) &
inflammation (f IL-1, f TNFa)
2.67
14.5
[0.845]
UFa = 3
UFh = 10
Total UF = 30
(Ma et al.
2014)
Developmental
Pregnant SD rats; dietary; 0, 400,
4000, 20,000 ppm (est. 31-66, 307-
657, 1,165-2,657 mg/kg-day); GD 15
to PND 10
NOAEL = 31
(males);
66 (females)
i male body weight on PND 27
7.33
39.9 [2.33]
UFa = 3
UFh = 10
Total UF = 30
(Masutomi et
al.. 2003)
Liver
B6C3F1 mice (males only); dietary;
0, 500, 6000 ppm (est. 0, 75, 900
mg/kg-day); 2 and 4 weeks
NOEL = 75
Hepatic changes (t liver weight,
t PBOX, t DNA synthesis; Inhibition
of GJIC)
9.97
54.3 [3.17]
UFa = 3
UFh = 10
Total UF = 30
(Smith et al.
2000)
Liver
B6C3F1 mice (both sexes); dietary;
0, 500, 1500, 4000, 8000 ppm (est.
117, 350, 913, 1,860 mg/kg-day
[males]; 0, 167, 546, 1,272, 2,806
mg/kg-day [females]); 1 or 4 weeks
NOAEL=
117 (males)
t absolute and relative liver weight; t
peroxisomal volume, and peroxisomal
enzyme activity; t hepatocyte
proliferation in males
15.6
84.7 [4.95]
UFa = 3
UFh= 10
Total UF = 30
(Kaufmann et
al. 2002)
Liver
F344 rats (males only); dietary; 0,
1000, 12,000 ppm (est. 0, 100, 1200
mg/kg-day); 2 and 4 weeks
NOAEL = 100
Hepatic changes (t liver weight,
t PBOX, t DNA synthesis; Inhibition
of GJIC)
23.6
129 [7.52]
UFa = 3
UFh = 10
Total UF = 30
(Smith et al.
2000)
Liver &
Kidney
F344 rats (both sexes); dietary; 0, 0.2,
0.67, 2% (est. 150, 500, 1,500 mg/kg-
day [males]; 0, 125, 420, 1,300
mg/kg-day [females]); 28 days
LOEL=
125 (females)
t hepatic catalase and carnitine
acetyltransferase activity
29.6
161 [9.39]
UFa = 3
UFh= 10
UFl = 10
Total UF =
300
(Midwest
Research
Institute. 1981)
Page 79 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Target
Orjjan/
System
Study Details
(Species, duration, exposure route/
method, doses |mjj/kjj-day|)
Study POD/
Type (m«/k«-
day)
Effect
HED
(ms/k$i)
HEC
(mj*/mJ)
[ppm]
Uncertainty
Factors"
Reference
Liver
B6C3F1 mice (both sexes); dietary;
0, 3000, 6000, 12,500 ppm (est. 635,
1,377, 2,689, 6,518 mg/kg-day
[males]; 780, 1761, 3,287, 6,920
mg/kg-day [females]); 4 weeks
LOAEL=
635 (males)
Enlarged and discolored livers;
t incidence of hepatocytomegaly
84.4
460 [26.8]
UFa = 3
UFh= 10
UFl = 10
Total UF =
300
(Hazleton Labs,
1991a)
Liver
SD rats (males only); oral gavage; 0,
500 mg/kg-day; 28 days
LOAEL = 500
i body weight gain; f relative liver
weight; clinical chemistry (f AST,
ALP & triglycerides)
118
643 [37.6]
UFa = 3
UFh= 10
UFl = 10
Total UF =
300
(Kwack et al..
2009)
Liver
F344 rats (both sexes); diet; 0, 0.6,
1.2, 2.5% (est. 639, 1192, 2,195
mg/kg-day [males]; 607, 1,198, 2,289
mg/kg-day [females]); 21 days
LOAEL=
607 (females)
t absolute and relative liver weight;
|11- and 12-hydroxylase activity,
hypolipidemic effects
144
781 [45.6]
UFa = 3
UFh= 10
UFl = 10
Total UF =
300
(BIBRA. 1986)
Liver and
Kidney
F344 rats (males only); dietary; 0, 2%
(est. 1,700 mg/kg-day); 7 days
LOAEL=
1,700
t absolute and relative liver and kidney
weight, macroscopic liver
observations, changes in clinical
chemistry
402
2,187
[128]
UFa = 3
UFh= 10
UFl = 10
Total UF =
300
(Bio/dvnamics.
1982a)
"EPA used allometric bodv weieht scaline to the three-auarters power to derive the HED. Consistent with EPA Guidance (U.S. EPA. 201 lb), the interspecies
uncertainty factor (UFA), was reduced from 10 to 3 to account remaining uncertainty associated with interspecies differences in toxicodynamics. EPA used a default
intraspecies (UFH) of 10 to account for variation in sensitivity within human populations due to limited information regarding the degree to which human variability may
impact the disposition of or response to DINP. EPA used a LOAEL-to-NOAEL uncertainty factor (UFL) of 10 to account for the uncertainty inherent in extrapolating
from the LOAEL to the NOAEL.
2597
Page 80 of 184
-------
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
2615
2616
2617
2618
2619
2620
2621
2622
2623
2624
2625
2626
2627
2628
2629
2630
2631
2632
2633
2634
2635
2636
2637
2638
2639
2640
2641
2642
2643
2644
2645
PUBLIC RELEASE DRAFT
May 2024
4,1.3 Non-cancer Oral Points of Departure for Chronic Exposures
EPA considered four 2-year chronic dietary studies (3 of rats, 1 of mice), six 13-week subchronic dietary
studies (4 of rats, and 1 each of mice and beagles), a one-generation study of reproduction of rats, and a
two-generation study of reproduction of rats for establishing the chronic POD (Table 4-5). Across one-
and two-generation studies of reproduction, reduced offspring bodyweight was the most sensitive effect,
while liver and kidney toxicity were the most sensitive effects observed across chronic and subchronic
studies, and these effects were considered for establishing the chronic POD. Figure 4-3 depicts the dose-
response array for available studies.
Across the one- and two-generation studies of reproduction (Waterman et ai. 2000; Exxon Biomedical.
1996a. b), both of which were GLP-compliant and adhered to available guidelines (40 CFR Part 798, §
798.4700), LOAELs for developmental effects were 377 mg/kg-day in the one-generation study based
on reduced male and female F1 offspring body weight on PNDs 0, 14, and 21; and 133 mg/kg-day in the
two generation study based on reduced F1 and F2 offspring body weight on PNDs 7 and 21. Neither
study tested sufficiently low doses to establish a developmental NOAEL. Further, there is some
uncertainty associated with the LOAEL from the two-generation study, as F1 offspring bodyweight
(both sexes) was reduced on PND21, while F2 offspring body weight was reduced only on PND 7 for
females (Table 3-8). More consistent effects on F1 and F2 offspring body weight were observed in the
mid-dose group. These sources of uncertainty reduce EPA's confidence in using the LOAEL of 133
mg/kg-day from the two-generation study as a chronic POD. Further, EPA identified more sensitive
PODs based on liver toxicity from subchronic and chronic studies that tested lower doses of DINP and
allowed for the identification of a NOAEL.
Across the six available subchronic studies, the lowest LOAELs for each of the tested species were 160
mg/kg-day in beagles (NOAEL = 37 mg/kg-day; HED = 23) based on increased absolute and relative
liver weight and increase serum ALT (Hazleton Laboratory [); 972 mg/kg-day in mice (NOAEL =
365; HED = 49 mg/kg-day) based on increased absolute and relative liver weight and histopathological
findings (e.g., necrosis) (Hazleton Labs JiHj2); and 60 mg/kg-day in SD rats (no NOAEL identified;
HED = 14 mg/kg-day) based on increased incidence of histopathological lesions in the kidney of male
rats (i.e., focal mononuclear cell infiltration and mineralization) (Hazleton Labs. 1981). LOAELs based
on liver and kidney toxicity from the remaining three subchronic studies of rats were less sensitive and
ranged from 176 to 227 mg/kg-day (Hazleton Lab s U>, < namics. 1982b. c). The study of
beagles was conducted prior to the establishment of GLP principles and OECD test guidelines, and
additionally only included four dogs per sex in each treatment group, so no statistical analysis was
performed due to the small sample size (Hazleton Laboratories. 1971). These limitations reduced EPA's
confidence in using the study to establish a chronic POD, and importantly, other subchronic and chronic
studies of rats provide more sensitive and health protective candidate PODs. Similarly, the one
subchronic study of mice (Hazleton Labs. 1992) provides a less sensitive candidate POD compared to
studies of rats. The lowest subchronic LOAEL of 60 mg/kg-day in rats comes from a study conducted
prior to the establishment of GLP principles and OECD test guidelines (Hazleton Labs. 1981). and did
not test sufficiently low doses to establish a NOAEL. Furthermore, EPA did not consider this study
sufficient for selection of a POD because it only reported effects on kidney in male rats which may be
related to a2u-globulin and not relevant for human health.
Across the four available 2-year dietary studies of rats and mice, the lowest LOAEL is 152 mg/kg-day
(NOAEL = 15 mg/kg-day; HED = 3.5 mg/kg-day) from a 2-year dietary study of F344 rats (Lineton et
ai. 1997; Bio/dynamics. 1986). The study by Lington et al. is GLP-compliant and received a high
overall study quality determination. Although the study does not explicitly state compliance with any
Page 81 of 184
-------
2646
2647
2648
2649
2650
2651
2652
2653
2654
2655
2656
2657
2658
2659
2660
2661
2662
2663
2664
2665
2666
2667
2668
2669
2670
2671
2672
2673
2674
2675
2676
2677
2678
2679
2680
2681
2682
2683
2684
2685
2686
2687
PUBLIC RELEASE DRAFT
May 2024
testing guidelines, it generally follows the guidelines outlined by OECD Test Number 453 (Combined
Chronic Toxicity/Carcinogenicity Studies). At the LOAEL, a spectrum of dose-related effects consistent
with liver toxicity was observed in male and female rats, including treatment related increases in relative
liver weight, serum ALT, AST, and ALP, and histopathological findings {i.e., spongiosis hepatis,
sinusoid ectasia, hepatopathy associated with leukemia). One source of uncertainty associated with the
findings of Lington et al. results from spongiosis hepatis. The MOA underlying spongiosis hepatis is
unknown but is not believed to be related to peroxisome proliferation. Further, as discussed by ECHA
(2 ), spongiosis hepatis has been observed in the livers of some strains of rats and certain species of
fish {e.g., medaka), but is less common in mice, has not been observed in non-human primates or dogs,
and with the exception of two case reports, has not been described in humans. These findings raise some
uncertainty as to the human relevance of spongiosis hepatis (Karbe and Kerlin. 2002). However,
spongiosis hepatis co-occurred with other hepatic effects that are more clearly adverse and relevant for
use in human health risk assessment {e.g., increase liver weight, serum ALT, AST, ALP, focal necrosis).
Further supporting use of the LOAEL reported by Lington et al., similar hepatic effects {e.g., increased
relative liver weight, serum ALT, AST, and ALP, spongiosis hepatis, necrosis) have consistently been
reported in two other chronic dietary studies of DINP with F344 (Covance Labs. 1998c) and SD rats
(Bio/dynamics. 1987). albeit at slightly higher doses of DINP (Table 4-5).
Given the broad dose spacing between the NOAEL of 15 mg/kg-day and LOAEL of 152 mg/kg-day
identified in Lington et al. (1997). EPA attempted to refine the POD by conducting BMD modeling in
accordance with EPA's Benchmark Dose Technical Guidance ( ). Endpoints modeled
included relative liver weight at terminal sacrifice (both sexes); serum ALT at 6-and 18-month sacrifices
(males only); incidence of focal necrosis in the liver (both sexes); incidence of spongiosis hepatis (males
only); and incidence of sinusoid ectasia (males only). For each endpoint, multiple BMRs were modeled.
BMD modeling results are presented in Appendix E, and results for representative BMRs are presented
in Table 4-4. For dichotomous endpoints, BMDLio values ranged from 8.6 mg/kg-day for spongiosis
hepatis to 125 mg/kg-day for focal necrosis in male rats. BMDLio values for spongiosis (8.6 mg/kg-day)
in the liver and sinusoid ectasia in the liver (14 mg/kg-day) were less than the study NOAEL of 15
mg/kg-day, however, BMD/BMDL ratios were greater than 3 (ranging from 3.7 to 8.9), indicating
model uncertainty. For continuous endpoints, the BMDLio was 85 mg/kg-day for increased relative liver
weights for males, while no models adequately fit relative liver weight data for female rats. For increase
in serum ALT at 6 and 18 months, BMDLioo values were 87 and 134 mg/kg-day, respectively. A BMR
of 100 percent was selected for this endpoint since 2 to 3 fold changes in ALT are generally considered
biologically significant and outside the range of normal variation (Hall et al.. JO I J; 1, c. < i1 \ 2002a).
However, there is some uncertainty related to the BMR selection, so EPA also presents BMDLisd values
in Table 4-4, which is consistent with EPA's Benchmark Dose Technical Guidance ( ).
BMDLisd values for increased serum ALT at 6 and 18 months were 16 and 33 mg/kg-day, respectively.
Overall, calculated BMDLs shown in Table 4-4 ranged from 8.6 to 134 mg/kg-day, which is similar to
the study NOAEL and LOAEL values of 15 and 152 mg/kg-day. The wide variability in BMDLs and
uncertainty in several modelled outcomes {i.e., BMD/BMDL ratios >3) reduce EPA's confidence in
using the BMD modeling results for establishing a POD.
Page 82 of 184
-------
2688
2689
2690
2691
2692
2693
2694
2695
2696
2697
2698
2699
2700
2701
PUBLIC RELEASE DRAFT
May 2024
Table 4-4. Summary of B
MD Model Results from Lingt
oil et al. (1997)
Endpoint
Sex
Selected Model
BMDisd /
BMDLisd
(mg/kg-day)
BMDio/
BMDLio
(mg/kg-day)
BMDioo/
BMDLioo
(mg/kg-day)
Dicholomous endpoints
Focal necrosis in the liver
Male
Logistic
-
159/125
-
Focal necrosis in the liver
Female
Log-Probit
-
222/34
-
Spongiosis hepatis in the
liver
Male
Log-Probit
-
32/8.6
-
Sinusoid ectasia in the liver
Male
Log-Probit
-
125/14
-
( onlinuous aid points
Relative Liver weight at
terminal sacrifice
Male
Linear, CV
242/196
106/85
-
Relative Liver weight at
terminal sacrifice
Female
None selected;
LOAEL (184 mg/kg-
day) was used
"
"
"
Serum ALT at 6-month
sacrifice
Male
Linear
23/16
-
125/87
Serum ALT at 18-month
sacrifice
Male
Power
63/33
-
179/134
Overall, EPA selected the NOAEL of 15 mg/kg-day (HED = 3.5 mg/kg-day) based on liver toxicity
observed in a 2-year dietary study of F344 rats (Lington et ai. 199 , «'t<> dynamics. 1986) as the chronic
POD for use in estimating non-cancer risk from exposure to DINP in the draft DINP risk evaluation.
This POD represents the most sensitive POD identified by EPA. Furthermore, the NOAEL of 15 mg/kg-
day supports the suite of effects occuring at 152 mg/kg-day in Lington et al. (1997). Consistently, other
regulatory bodies have selected the same chronic POD for use in quantifying risk from exposures to
DINP (ECCC/HC. 2020; 1 U'SC^M i) (U v \ , LCI \ . M !.). A total UF of 30 was
selected for use as the benchmark MOE (based on an interspecies UF (UFa) of 3 and an intraspecies UF
(UFh) of 10). Consistent with EPA guidance (2022. 2002b. 1993). EPA reduced the UFa from a value of
10 to 3 because allometric body weight scaling to the three-quarter power was used to adjust the POD to
obtain a HED (Appendix F).
Page 83 of 184
-------
0)
>
>
<
<
10 100 1000
HED (mg/kg-day)
10000
Figure 4-3. Dose-Response Array of Studies Considered for Considered for Deriving the Chronic
Non-cancer POD
Notes: | = statistically significant increase in response compared to controls; | = statistically significant decrease
in response compared to controls; M = males; F= females; PI = parental generation; PND = postnatal day; ALT =
alanine aminotransferase; AST aspartate aminotransferase; ALP = alkaline phosphatase; HED = human
equivalent dose; NOAEL = no-observed-adverse-effect-level; LOAEL = lowest-observed-adverse-effect-level.
Page 84 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Table 4-5. Dose-Response Analysis of Seleci
ted Studies Considered for Deriving the C
ironic >
on-cancer POD
Target Organ/
System
Study Details
(Species, Duration, Exposure
Route/ Method, Doses |mg/kg-
day])
Study POD/
Type
(mg/kg-day)
Effect
HEP
(mg/kg)
HEC
(mg/m3)
[ppm]
Uneertainty
Factors "b
Rcfcrcncc(s)
Liver and
Kidney
F344 rals (bolli sexes); dietary; 0,
0.03, 0.3, 0.6% (est. 15, 152, 307
mg/kg-day [males]; 18, 184, 375
mg/kg-day [females]); 2 years
NOAF.I ,=
15 (males)
18 (females)
t absolute and relative liver and
kidney weight; t in serum ALT and
AST; histopathological alterations
(e.g., spongiosis hepatis, focal
necrosis)
3.55
19.3 [1.13]
UFa = 3
UFh = 10
Total UF =
30
(Lington et al. 1997;
Bio/dvnamics, 1986)
Liver
SD rats (both sexes); dietary; 0, 500,
5000, 10,000 ppm (est. 27, 271, 553
mg/kg-day [males]; 33, 331, 672
mg/kg-day [females]); 2 years
NOAF.I. = 27
t serum ALT, AST, ALP (males);
histopathological findings in the
liver (i.e., minimal-to-slight focal
necrosis, spongiosis hepatis)
6.38
34.7 [2.03]
UFa = 3
UFl = 10
Total UF =
30
(Bio/dvnamics, 1987)
Liver and
Kidney
F344 rats (both sexes); dietary; 0,
500, 1500, 6000, 12,000 ppm (est.
29, 88, 359, 733 mg/kg-day [males];
36, 109, 442, 885 mg/kg-day
[females]); 2 years
NOAEL =
88 (males)
109 (females)
t absolute and relative liver and
kidney weight; t in serum ALT,
AST, BUN; histopathological
findings in liver (e.g., spongiosis
hepatis) and kidney (e.g.,
mineralization of renal papilla,
pigment in tubule cells)
20.8
113 [6.61]
UFa = 3
UFh = 10
Total UF =
30
(Covance Labs.
1998c)
Liver and
Kidney
B6C3F1 mice (both sexes); dietary;
0, 500, 1500, 4000, 8000 ppm (est.
90, 276, 742, 1,560 mg/kg-day
[males]; 112,336,910, 1,888
mg/kg-day [females]); 2 years
NOAEL=
90 (males)
112 (females)
t absolute and relative liver weight,
histopathological changes in the
liver (EXAMPLES); j body weight
gain (females); t incidence of liver
masses and j absolute kidney
weight (males)
12.0
65.1 [3.80]
UFa = 3
UFh = 10
Total UF =
30
(Covance Labs.
1998b)
Developmental
Two-eeneration studv: SD rats
LOAEL = 133
| F1 and F2 offspring body weight
onPNDs7 and 21
31.4
171 [10.0]
UFa = 3
UFh = 10
UFl = 10
Total UF =
300
(Waterman et al.
(30/group) administered 0, 0.2, 0.4,
0.8% DINP in the diet continuously
starting 10 weeks prior to mating,
throughout mating, gestation and
lactation for two generations
2000; Exxon
Biomedical, 1996b)
Developmental
One generation studv: SD rats
LOAEL = 377
i male and female offspring body
weight on PND 0, 14, and 21
89.1
485 [28.3]
UFa = 3
UFh = 10
UFL=10
(Waterman et al.
(30/group); administered 0, 0.5, 1.0,
1.5% DINP in diet continuously
starting 10 weeks prior to mating
2000; Exxon
Biomedical 1996a)
Page 85 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Target Orjjan/
System
Study Details
(Species, Duration, Exposure
Route/ Method, Doses |mjj/kjj-
day|)
Study POD/
Type
(mjj/kjj-day)
Effect
HED
(mjj/kjO
HEC
(mjj/m3)
[ppm]
Uncertainty
Factors "b
Refcrcncc(s)
and throughout mating, gestation
and lactation for one generation.
Total UF =
300
Liver
Beagle dogs (both sexes); dietary; 0,
0.125, 0.5, 2% (est. 37, 160, 2,000
mg/kg-day); 13 weeks
NOAEL = 37
t absolute and relative liver weight;
t serum ALT
23.0
125 [7.32]
UFa = 3
UFh = 10
Total UF =
30b
(Hazleton
Laboratories. 1971)
Liver
B6C3F1 mice (both sexes); dietary;
0, 1500, 4000, 10,000, 20,000 ppm
(est: 365, 972, 2,600, 5,770 mg/kg-
day); 13 weeks (Hazleton 1992)
NOAEL = 365
t absolute and relative liver weight;
liver histopathology (e.g., necrosis,
degeneration, hepatocyte
enlargement)
48.5
264 [15.4]
UFa = 3
UFh = 10
UFS= 10
Total UF =
300
(Hazleton Labs, 1992)
Liver and
Kidney
F344 rats (both sexes); dietary; 0,
0.1, 0.3, 0.6, 1.0, 2.0% (est. 0, 77,
227, 460, 767, 1,554 mg/kg-day); 13
weeks
NOAEL = 77
t absolute and relative liver and
kidney weight; j cholesterol level
(females)
18.2
99.1 [5.79]
UFa = 3
UFh = 10
UFS= 10
Total UF =
300
(Bio/dvnamics.
1982b)
Liver &
Kidney
F344 rats (both sexes); dietary; 0,
2500, 5000, 10,000, 20,000 ppm
(est. 176, 354, 719, 1545 mg/kg-day
[males]; 218, 438, 823, 1,687
mg/kg-day [females]); 13 weeks
LOAEL =
176 (males)
218 (females)
t kidney and liver weights
41.6
226 [13.2]
UFa = 3
UFh= 10
UFS= 10
UFl = 10
Total UF =
3000
(Hazleton Labs.
1991b)
Liver &
Kidney
SD rats (both sexes); dietary; 0, 0.3,
1.0% (est. 201, 690 mg/kg-day
[males]; 251, 880 mg/kg-day
[females]); 13 weeks
LOAEL=
201 (males)
251 (females)
t absolute and relative liver &
kidney weight accompanied by j in
triglycerides and altered urine
chemistry
47.5
259 [15.1]
UFa = 3
UFh= 10
UFS= 10
UFl = 10
Total UF =
3000
(B io/dv nam ics, 1982c)
Kidney
SD rats (both sexes); dietary; 0,
1000, 3000, 10,000 ppm (estimated:
0, 60, 180, 600 mg/kg-day); 13
LOAEL = 60
(males)
t incidence of histopathology
lesions in the kidney [i.e., focal
14.2
77.2 [4.51]
UFa = 3
UFh= 10
(Hazleton Labs. 1981)
Page 86 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Target Organ/
System
Study Details
(Species, Duration, Exposure
Route/ Method, Doses |mg/kg-
day|)
Study POD/
Type
(mg/kg-day)
Effect
HED
(nig/kg)
HEC
(mg/m3)
[ppm]
Uncertainty
Factors "b
Refcrcncc(s)
weeks
mononuclear cell infiltration and
mineralization]; males only
UFS= 10
UFl = 10
Total UF =
3000
"EPA used allomctric bodv weieht scaline to the three-auarters power to derive the HED. Consistent with EPA Guidance (U.S. EPA. 201 lb), the interspecies
uncertainty factor (UFA), was reduced from 10 to 3 to account remaining uncertainty associated with interspecies differences in toxicodynamics. EPA used a default
intraspecies (UFH) of 10 to account for variation in sensitivity within human populations due to limited information regarding the degree to which human variability
may impact the disposition of or response to DINP. EPA used a LOAEL-to-NOAEL uncertainty factor (UFL) of 10 to account for the uncertainty inherent in
extrapolating from the LOAEL to the NOAEL.
b EPA considered applying a subchronic-to-chronic (UFS) of 10 for the intermediate (13-week) dog study under consideration for deriving a chronic POD. However,
retrospective analyses of 13-week and 1-year dog studies have shown that dog studies beyond 13-weeks do not have a significant impact on the derivation of chronic
PODs (Bishop et al, 2023; Dellarco et al, 2010; Box and Spielmann, 2005). Therefore, this a UFs was not used.
2710
Page 87 of 184
-------
2711
2712
2713
2714
2715
2716
2717
2718
2719
2720
2721
2722
2723
2724
2725
2726
2727
2728
2729
2730
2731
2732
2733
2734
2735
2736
2737
2738
2739
2740
2741
2742
2743
2744
2745
2746
2747
2748
2749
2750
2751
PUBLIC RELEASE DRAFT
May 2024
4.2 Weight of Scientific Evidence
4,2,1 POD for Acute and Intermediate Durations
EPA has preliminarily concluded that the HED of 12 mg/kg-day (BMDLs of 49 mg/kg-day) from the
NASEM (2017) meta-regression of reduced fetal testicular testosterone in rats is appropriate for
calculation of risks for acute and intermediate exposure durations. A total UF of 30 was selected for use
as the benchmark MOE (based on an interspecies UF (UFa) of 3 and an intraspecies UF (UFh) of 10).
Consistent with EPA guidance (2022. 2002b. 1993). EPA reduced the UFa from a value of 10 to 3
because allometric body weight scaling to the three-quarter power was used to adjust the POD to obtain
a HED (Appendix F). EPA has robust overall confidence in the selected POD based on the following
weight of scientific evidence:
• DINP exposure resulted in treatment-related effects on the developing male reproductive system
consistent with a disruption of androgen action during the critical window of development in 13
studies of rats (Section 3.1.2.1). Observed effects included: reduced mRNA expression of INSL3
and genes involved in steroidogenesis in the fetal testes; reduced fetal testes testosterone content
and/or production; reduced male pup anogenital distance; increased male offspring nipple
retention; increased incidence of MNGs and fetal Ley dig cell aggregation; and decreased sperm
motility in adult rats exposed perinatally to DINP.
• EPA has previously considered the weight of scientific evidence and concluded that oral
exposure to DINP can induce effects on the developing male reproductive system consistent with
a disruption of androgen action (see EP A's Draft Proposed Approach for Cumulative Risk
Assessment of High-Priority and a Manufacturer-Requested Phthalate under the Toxic
Substances Control Act ( 023 a)). Notably, EPA's conclusion was supported by the
SACC (U.S. EPA. 2023b).
• The selected POD is based on meta-regression analysis of fetal testosterone data from two
studies of rats (Li et ai. 2015: Hannas et ai. ).
• Two additional developmental toxicity studies (Clewell et ai. 2013a: Clewell et ai. )
resulted in decreased fetal testosterone production and other effects on the developing male
reproductive system at similar doses (LOAELs from 250 to 307 mg/kg-day and NOAELs from
50 to 56 mg/kg-day) to the BMDLs of 49 mg/kg-day derived from the NASEM meta-analysis.
These studies support the selection of the BMDLs of 49 mg/kg-day for the acute and
intermediate duration PODs.
There are no studies conducted via the dermal and inhalation route relevant for extrapolating human
health risk. Therefore, EPA is using the oral HED of 12 mg/kg-day to extrapolate to the dermal route.
Differences in absorption will accounted for in dermal exposure estimates in the draft risk evaluation for
DINP.
EPA is also using the oral HED of 12 mg/kg-day to extrapolate to the inhalation route. EPA assumes
similar absorption for the oral and inhalation routes, and no adjustment was made when extrapolating to
the inhalation route. For the inhalation route, EPA extrapolated the daily oral HEDs to inhalation HECs
using a human body weight and breathing rate relevant to a continuous exposure of an individual at rest.
Appendix F provides further information on extrapolation of inhalation HECs from oral HEDs.
Page 88 of 184
-------
2752
2753
2754
2755
2756
2757
2758
2759
2760
2761
2762
2763
2764
2765
2766
2767
2768
2769
2770
2771
2772
2773
2774
2775
2776
2777
2778
2779
2780
2781
2782
2783
2784
2785
2786
2787
2788
2789
2790
2791
2792
2793
2794
2795
PUBLIC RELEASE DRAFT
May 2024
4.2,2 POD for Chronic Durations
EPA has preliminarily concluded that the HED of 3.5 mg/kg-day (NOAEL of 15 mg/kg-day) from the 2-
year dietary study of F344 rats based on liver toxicity (Lington et a I _ I' »• }7; <1t< < < l\ namit1 l - 5) is
appropriate for calculation of risk for chronic exposure durations. A total UF of 30 was selected for use
as the benchmark MOE (based on an interspecies UF (UFa) of 3 and an intraspecies UF (UFh) of 10).
Consistent with EPA guidance (2022. 2002b. 1993). EPA reduced the UFa from a value of 10 to 3
because allometric body weight scaling to the three-quarter power was used to adjust the POD to obtain
a HED (Appendix F). EPA has robust overall confidence in the selected POD based on the following
weight of scientific evidence:
• The NOAEL of 15 mg/kg-day (HED = 3.5 mg/kg-day) from the 2-year dietary study of F344 rats
(Lington etai. 1997; Bio/dynamics. 1986) represents the most sensitive POD identified by EPA
across the 12 relevant studies subjected to dose-response analysis, including four 2-year chronic
dietary studies (3 of rats, 1 of mice), six 13-week subchronic dietary studies (4 of rats, and 1 each
of mice and beagles), a one-generation study of reproduction of rats, and a two-generation study
of reproduction of rats.
• This study received a high overall study quality determination and is GLP-compliant.
• At the LOAEL, a spectrum of dose-related effects consistent with liver toxicity was observed in
male and female rats, including treatment related increases in relative liver weight, serum ALT,
AST, and ALP, and histopathological findings (i.e., spongiosis hepatis, focal necrosis, sinusoid
ectasia, hepatopathy associated with leukemia).
• Given the relatively broad dose-spacing between the NOAEL (15 mg/kg-day) and the LOAEL
(152 mg/kg-day) in the principal study, EPA attempted to refine the POD by conducting BMD
modeling of relevant dose-related findings showing a substantial increase in magnitude over
controls, including: relative liver weight at terminal sacrifice (both sexes); serum ALT at 6-and
18-month sacrifices (males only); incidence of focal necrosis in the liver (both sexes); incidence
of spongiosis hepatis (males only); and incidence of sinusoid ectasia (males only). Calculated
BMDLs ranged from 8.6 to 125 mg/kg-day, which is similar to the study NOAEL and LOAEL
values of 15 and 152 mg/kg-day. The wide variability in BMDLs and uncertainty in several
modelled outcomes (i.e., BMD/BMDL ratios greater than 3) reduce EPA's confidence in using
the BMD modeling results for establishing a POD, and further affirm the use of the NOAEL for
establishing the POD.
• The NOAEL of 15 mg/kg/day in Lington et al. (1997) also aligns with the BMD05 of 12
mg/kg/day for one of the more sensitive endpoints in this study, spongiosis hepatis, determined
by CPSC (2010). However, EPA considers it more appropriate to use the NOAEL of 15 mg/kg-
day instead of the BMD05 of 12 mg/kg-day because the NOAEL supports the suite of effects on
the liver occuring at 152 mg/kg-day instead of being based on the single effect of spongiosis
hepatis with its associated uncertainty regarding human relevance.
• The endpoints indicative of liver toxicity on which the POD is based were robust in that they
were observed across species and durations.
o The remaining three chronic studies in rodents (Covance Labs. 1998b. c; Bio/dynamics.
1987) reported similar findings of liver toxicity (e.g., increased liver weights; clinical
chemistry changes such as increased ALT, AST, ALP; and histopathology findings such
as liver necrosis and spongiosis hepatis), with similar but less sensitive NOAELs ranging
from 27 to 112 mg/kg-day.
Page 89 of 184
-------
2796
2797
2798
2799
2800
2801
2802
2803
2804
2805
2806
2807
2808
2809
2810
2811
2812
2813
2814
2815
2816
2817
2818
PUBLIC RELEASE DRAFT
May 2024
o Similar findings indicative of liver toxicity were observed in the subchronic studies,
although at higher doses than observed in the chronic study by Lington et al. (1997). In
these subchronic studies, the lowest LOAELs for each of the tested species were: 160
mg/kg-day in beagles (NOAEL = 37 mg/kg-day; HED = 23) based on increased absolute
and relative liver weight and increase serum ALT (Hazleton Laboratories. 1971) and 972
mg/kg-day in mice (NOAEL = 365; HED = 49 mg/kg-day) based on increased absolute
and relative liver weight and histopathological findings (e.g., necrosis) (Hazleton Labs.
1992). LOAELs based on liver toxicity from the remaining three subchronic studies of
rats were less sensitive and ranged from 176 to 227 mg/kg-day (Hazleton Labs. 1991b;
Bio/dynamics. 1982b. c).
• Consistently, other regulatory bodies have selected the same chronic POD (NOAEL 15 mg/kg-
day) for use in quantify risk from exposures to DINP (ECCC/HC. 2020; 1 c. t PSC. 2014)
(EFSA. 2019; ECHA.: ).
There are no studies conducted via the dermal and inhalation route relevant for extrapolating human
health risk. Therefore, EPA is using the oral HED of 3.5 mg/kg-day to extrapolate to the dermal route.
Differences in absorption will accounted for in dermal exposure estimates in the draft risk evaluation for
DINP.
EPA is also using the oral HED of 3.5 mg/kg-day to extrapolate to the inhalation route. EPA assumes
similar absorption for the oral and inhalation routes, and no adjustment was made when extrapolating to
the inhalation route. For the inhalation route, EPA extrapolated the daily oral HEDs to inhalation HECs
using a human body weight and breathing rate relevant to a continuous exposure of an individual at rest.
Appendix F provides further information on extrapolation of inhalation HECs from oral HEDs.
Page 90 of 184
-------
2819
2820
2821
2822
2823
2824
2825
2826
2827
2828
2829
2830
2831
2832
2833
2834
2835
2836
2837
2838
2839
2840
2841
2842
2843
2844
2845
2846
2847
2848
2849
2850
2851
2852
2853
2854
2855
2856
2857
2858
2859
2860
2861
2862
PUBLIC RELEASE DRAFT
May 2024
5 CONSIDERATION OF PESS AND AGGEGRATE EXPOSURE
5.1 Hazard Considerations for Aggregate Exposure
For use in the risk evaluation and assessing risks from other exposure routes, EPA conducted route-to-
route extrapolation of the toxicity values from the oral studies for use in the dermal and inhalation
exposure routes and scenarios. Health outcomes that serve as the basis for acute, intermediate and
chronic hazard values are systemic and assumed to be consistent across routes of exposure. EPA
therefore concludes that for consideration of aggregate exposures, it is reasonable to assume that
exposures and risks across oral, dermal, and inhalation routes may be additive for the selected PODs in
Section 6.
5.2 PESS Based on Greater Susceptibility
In this section, EPA addresses subpopulations expected to be more susceptible to DINP exposure than
other populations. Table 5-1 presents the data sources that were used in the potentially exposed or
susceptible subpopulations (PESS) analysis evaluating susceptible subpopulations and identifies whether
and how the subpopulation was addressed quantitatively in the draft risk evaluation of DINP. EPA
identified a range of factors that may have the potential to increase biological susceptibility to DINP,
including lifestage, chronic liver or kidney disease, pre-existing diseases, physical activity, diet, stress,
and co-exposures to other environmental stressors that contribute to related health outcomes.
Regarding lifestage, exposure to DINP during the masculinization programming window {i.e., GDs 15.5
to 18.5 for rats; GDs 14 to 16 for mice; gestational weeks 8 to 14 for humans) can lead to antiandrogenic
effects on the male reproductive system (MacLeod et at.. 2010; Welsh et at.. 2008; Carruthers and
Foster. 2005). Animal studies demonstrating effects of DINP on male reproductive development and
other developmental outcomes provide direct evidence that gestation is a particularly sensitive lifestage.
EPA considered the sensitivity of this lifestage in its derivation of the POD for acute and intermediate
exposure duration based on reduced fetal testicular testosterone in rats after evaluation of the weight of
scientific evidence that DINP resulted in treatment-related effects on the developing male reproductive
system consistent with a disruption of androgen action during the critical window of development in 13
studies of rats. In humans, there is moderate evidence for the association between DINP and testosterone
and semen parameters, based on studies that found decreasing testosterone levels with increasing DINP
exposure (Radke et at.. 2018). Based on this evidence from animal and human studies, EPA has
identified two groups that may be more susceptible to DINP exposure due to lifestages:
• Pregnant women/women of reproductive age, and
• Male infants, male toddlers, and male children.
Animal evidence also demonstrates that the liver, kidneys, nervous system, cardiovascular system,
immune system, may be sensitive target organs. EPA is quantifying risks based on liver and
developmental toxicity in the draft DINP risk evaluation, and determining risk based these endpoints is
protective of the other hazards that occur at higher doses.
Regarding the factor of co-exposure, studies have demonstrated that co-exposure to DINP and other
toxicologically similar phthalates {e.g., DEHP, DBP, BBP) and other classes of antiandrogenic
chemicals {e.g., certain pesticides and pharmaceuticals that are discussed more in ( 323a))
can induce effects on the developing male reproductive system in a dose-additive manner. EPA details
how it intends to evaluate risk to above-identified PESS from co-exposure to DINP and several other
toxicologically similar phthalates in its Draft Proposed Approach for Cumulative Risk Assessment of
Page 91 of 184
-------
2863
2864
2865
2866
2867
2868
2869
2870
2871
2872
2873
2874
2875
2876
2877
PUBLIC RELEASE DRAFT
May 2024
High-Priority Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control
Act ( 2023a).
The effect of other factors on susceptibility to health effects of DINP is not known; therefore, EPA is
uncertain about the magnitude of any possible increased risk from effects associated with DINP
exposure for subpopulations that may be relevant to other factors.
For non-cancer endpoints, EPA used a default value of 10 for human variability (UFh) to account for
increased susceptibility when quantifying risks from exposure to DINP. The Risk Assessment Forum, in
A Review of the Reference Dose and Reference Concentration Processes ( 32b). discusses
some of the evidence for choosing the default factor of 10 when data are lacking and describe the types
of populations that may be more susceptible, including different lifestages (e.g., of children and elderly).
U.S. EPA (2002b). however, did not discuss all the factors presented in Table 5-1. Thus, uncertainty
remains whether additional susceptibility factors would be covered by the default UFh value of 10
chosen for use in the draft DINP risk evaluation.
Page 92 of 184
-------
2878 Table 5-1. P
PUBLIC RELEASE DRAFT
May 2024
CSS Evidence Crosswalk for Biological Susceptibility Considerations
Susceptibility
Category
Examples of
Specific
Factors
Direct Evidence this Factor
Modifies Susceptibility to DINP
Description of Interaction
Kcv Citations
Indirect Evidence of Interaction with Target
Organs or Biological Pathways Relevant to
DINP
Description of
Interaction
Key Citation(s)
Susceptibility Addressed in
Risk Evaluation?
Lifestage
Embryos/
fetuses/infants
Direct quantitative animal
evidence for developmental
toxicity (e.g., increased skeletal
and visceral variations,
decreased live births, decreased
offspring body weight gain, and
decreased offspring survival
with increased severity in the
second generation).
There is direct quantitative
animal evidence for effects on
the developing male
reproductive system consistent
with a disruption of androgen
action.
Heltwig et aL
997)
Waterman et al..
999)
Waterman et al..
000)
U.S. EPA,
023a)
U.S. EPA,
2023b)
Pregnancy/
lactating status
Rodent dams not particularly
susceptible during pregnancy
and lactation, except for effects
related to reduced maternal
weight gain, food consumption,
and increased organ weight
(liver and kidney), which
occurred at doses higher than
those that caused developmental
toxicity.
(Heltwig et aL,
.1.997)
(Waterman et aL.
.1.999)
Acute and intermediate duration
PODs for developmental
endpoints protective of effects
in offspring
Acute and intermediate duration
PODs for developmental
endpoints protective of effects
in dams
Page 93 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Susceptibility
Category
Examples of
Specific
Factors
Direct Evidence this Factor
Modifies Susceptibility to DINP
Indirect Evidence of Interaction with Target
Organs or Biological Pathways Relevant to
DINP
Susceptibility Addressed in
Risk Evaluation?
Description of Interaction
Key Citations
Description of
Interaction
Key Citation(s)
Lifestage
Males of
reproductive
age
Increased testes, right
epididymis, liver, and kidney
weights. There was also
decreased food consumption.
(Waterman et al.
2000; Exxon
Biomedical
1996a)
Use of default lOx UFH
Children
Reduced rodent offspring
bodyweight gain between PNDs
1 to 21 was observed in one and
two-generation studies of
reproduction.
(Waterman et al..
2000; Exxon
Biomedical
1996a. b)
Acute and intermediate duration
PODs for developmental
endpoints protective of effects
of offspring bodyweight gain
Use of default lOx UFH
Elderly
No direct evidence identified
Use of default lOx UFH
Pre-existing
disease or
disorder
Health
outcome/
target organs
No direct evidence identified
Several preexisting
conditions may contribute
to adverse developmental
outcomes (e.g., diabetes,
high blood pressure,
certain viruses).
Individuals with chronic
liver and kidney disease
may be more susceptible
to effects on these target
organs
Viruses such as viral
hepatitis can cause liver
damage.
CDC (2023e)
CDC (2023 g)
Use of default lOx UFH
Page 94 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Susceptibility
Category
Examples of
Specific
Factors
Direct Evidence this Factor
Modifies Susceptibility to DINP
Indirect Evidence of Interaction with Target
Organs or Biological Pathways Relevant to
DINP
Susceptibility Addressed in
Risk Evaluation?
Description of Interaction
Key Citations
Description of
Interaction
Key Citation(s)
Pre-existing
disease or
disorder
Toxicokinetics
No direct evidence identified
Chronic liver and kidney
disease are associated with
impaired metabolism and
clearance (altered
expression of phase 1 and
phase 2 enzymes,
impaired clearance),
which may enhance
exposure duration and
concentration of DINP.
Use of default lOx UFH
Lifestyle
activities
Smoking
No direct evidence identified
Smoking during
pregnancy may increase
susceptibility for
developmental outcomes
(e.g., early delivery and
stillbirths).
CDC (2023f)
Qualitative discussion in
Section 5.2 and this table
Alcohol
consumption
No direct evidence identified
Alcohol use during
pregnancy can cause
developmental outcomes
(e.g., fetal alcohol
spectrum disorders).
Heavy alcohol use may
affect susceptibility to
liver disease.
CDC (2023d)
CDC (2023a)
Qualitative discussion in
Section 5.2 and this table
Physical
activity
No direct evidence identified
Insufficient activity may
increase susceptibility to
multiple health outcomes.
Overly strenuous activity
may also increase
susceptibility.
CDC (2022)
Qualitative discussion in
Section 5.2 and this table
Page 95 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Susceptibility
Category
Examples of
Specific
Direct Evidence this Factor
Modifies Susceptibility to DINP
Indirect Evidence of Interaction with Target
Organs or Biological Pathways Relevant to
DINP
Susceptibility Addressed in
Risk Evaluation?
Factors
Description of Interaction
Key Citations
Description of
Interaction
Key Citation(s)
Sociodemo-
Race/ethnicity
No direct evidence identified
(e.g., no information on
polymorphisms in DINP
metabolic pathways or diseases
associated race/ethnicity that
would lead to increased
susceptibility to effects of DINP
by any individual group).
Qualitative discussion in
Section 5.2 and this table
graphic status
Socioeconomic
status
No direct evidence identified
Individuals with lower
incomes may have worse
health outcomes due to
social needs that are not
met, environmental
concerns, and barriers to
health care access.
ODPHP (2023b)
Sex/gender
No direct evidence identified
Use of default lOx UFH
Nutrition
Diet
No direct evidence identified
Poor diets can lead to
chronic illnesses such as
heart disease, type 2
diabetes, and obesity,
which may contribute to
adverse developmental
outcomes. Additionally,
diet can be a risk factor for
fatty liver, which could be
a pre-existing condition to
enhance susceptibility to
DINP-induced liver
toxicity.
CDC (2023e)
CDC (2023b)
Qualitative discussion in
Section 5.2 and this table
Page 96 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Susceptibility
Category
Examples of
Specific
Factors
Direct Evidence this Factor
Modifies Susceptibility to DINP
Indirect Evidence of Interaction with Target
Organs or Biological Pathways Relevant to
DINP
Susceptibility Addressed in
Risk Evaluation?
Description of Interaction
Key Citations
Description of
Interaction
Key Citation(s)
Nutrition
Malnutrition
No direct evidence identified
Micronutrient malnutrition
can lead to multiple
conditions that include
birth defects, maternal and
infant deaths, preterm
birth, low birth weight,
poor fetal growth,
childhood blindness,
undeveloped cognitive
ability.
Thus, malnutrition may
increase susceptibility to
some developmental
outcomes associated with
DINP.
CDC (2021)
CDC (2023b)
Qualitative discussion in
Section 5.2 and this table
Genetics/
epigenetics
Target organs
No direct evidence identified
Polymorphisms in genes
may increase
susceptibility to liver,
kidney, or developmental
toxicity.
Use of default lOx UFH
Toxicokinetics
No direct evidence identified
Polymorphisms in genes
encoding enzymes (e.g.,
esterases) involved in
metabolism of DINP may
influence metabolism and
excretion of DINP.
Use of default lOx UFH
Page 97 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Susceptibility
Category
Examples of
Specific
Direct Evidence this Factor
Modifies Susceptibility to DINP
Indirect Evidence of Interaction with Target
Organs or Biological Pathways Relevant to
DINP
Susceptibility Addressed in
Risk Evaluation?
Factors
Description of Interaction
Key Citations
Description of
Interaction
Key Citation(s)
Built
environment
No direct evidence identified
Poor-quality housing is
associated with a variety
of negative health
outcomes.
ODPHP (2023a)
Qualitative discussion in
Section 5.2 and this table
Other
Social
environment
No direct evidence identified
Social isolation and other
social determinants (e.g.,
decreased social capital,
stress) can lead to negative
health outcomes.
CDC (2023c)
ODPHP (2023c)
Qualitative discussion in
Section 5.2 and this table
chemical and
nonchemical
stressors
Chemical co-
exposures
Studies have demonstrated that
co-exposure to DINP and other
toxicologically similar
phthalates (e.g., DEHP, DBP,
BBP) and other classes of
antiandrogenic chemicals (e.g.,
certain pesticides and
pharmaceuticals - discussed
more in (U.S. EPA, 2023a")") can
induce effects on the developing
male reproductive system in a
dose-additive manner.
See fU.S. EPA.
2023a) and (U.S.
EPA. 2023b")
Qualitative discussion in
Section 5.2 and this table and
will be quantitatively addressed
as part of the phthalate
cumulative risk assessment.
2879
Page 98 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
2880 6 POINTS OF DEPARTURE USED TO ESTIMATE RISKS FROM
2881 DINP EXPOSURE
2882 After considering hazard identification and evidence integration, dose-response evaluation, and weight
2883 of scientific evidence of POD candidates, EPA chose two non-cancer endpoints for the risk evaluation—
2884 one for acute and intermediate exposure scenarios and a second one for chronic scenarios (Table 6-1).
2885 HECs are based on daily continuous (24-hour) exposure, and HEDs are daily values.
Page 99 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
2886 Table 6-1. Non-cancer HECs and HEDs Used to Estimate Risks
Exposure
Scenario
Target
Organ
System
Species
Duration
POD
(mg/kg-
day)
Effect
HEC
(mg/mJ) [ppm]
HED
(mg/kg-day)
Benchmark
MOE
Reference
Acute and
Intermediate
Development
Rat
5 to 14 days
throughout
gestation
BMDL5 =
49 a
i fetal testicular
testosterone
63
[3.7]
12
UFa= 3
ufh=io
Total UF=30
(NASEM. 2017)
Chronic
Liver
Rat
2 years
NOAEL
= 15
t liver weight, |
serum chemistry,
histopathology b
19
[1.1]
3.5
UFa= 3
ufh=io
Total UF=30
(Lington et al.,
jOO";
Bio/dvn amies.
t«>So)
" The BMDL5 was derived by NASEM (2017) through meta-regression and BMD modeling of fetal testicular testosterone data from two studies of DINP with rats
(Bobere et al. 2011: Kaunas et al. 2011). R code suroortins NASEM's meta-reeression and BMD analysis of DINP is Diibliclv available throueh GitHub
(httDs://gi thub.com/wachiuDhd/NASEM-2017-Endocrine-Low-Dose).
h Liver toxicity included increased relative liver weight, increased serum chemistry (i.e., AST, ALT, ALP), and histopathologic findings (e.g., focal necrosis, spongiosis
heratis)) in F344 rats following 2 vears of dietary exposure to DINP (Lington et al. 1997; Bio/dynamics. 1986).
2887
Page 100 of 184
-------
2888
2889
2890
2891
2892
2893
2894
2895
2896
2897
2898
2899
2900
2901
2902
2903
2904
2905
2906
2907
2908
2909
2910
2911
2912
2913
2914
2915
2916
2917
2918
2919
2920
2921
2922
2923
2924
2925
2926
2927
2928
2929
2930
2931
2932
2933
2934
2935
PUBLIC RELEASE DRAFT
May 2024
REFERENCES
:Si'S(2019). Manufacturer Request for Risk Evaluation Di-isononyl Phthalate (DINP).
(730R19001). American Chemistry Council High Phthalates Panel :: ACC HPP
https://nepis.epa.gov/exe/ZvPIJRL.cgi?Dockev=Pl 00YEGF.txt
Adamssoii \ c.alonen. \ l\tranko. J; Toppari. J. (2009). Effects of maternal exposure to di-
isononylphthalate (DINP) and l,l-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) on
steroidogenesis in the fetal rat testis and adrenal gland. Reprod Toxicol 28: 66-74.
http://dx.doi.ore .reprotox.2009.03.002
Ait Bam a i \ \ul i \ 'x omura. T; Kawai. T; Tsuboi. T; Kobayashi. S: Miyashita. C; Takeda. M;
Shimizu. H; Kishi. R. (2018). Association of filaggrin gene mutations and childhood eczema and
wheeze with phthalates and phosphorus flame retardants in house dust: The Hokkaido study on
Environment and Children's Health. Environ Int 121: 102-110.
http://dx.doi.ore .envint.2018.08.046
Anderson \\ \ t jstle. L; Hird. S: J effort, . i, hotter. MI. (2011). A twenty-volunteer study using
deuterium labelling to determine the kinetics and fractional excretion of primary and secondary
urinary metabolites of di-2-ethylhexylphthalate and di-iso-nonylphthalate. Food Chem Toxicol
49: 2022-2029. http://dx.doi.oiv 10 101 /jufci .01 I 0- 01 '<
Aylw Hays. SM; Zidek. A. (2016). Variation in urinary spot sample, 24 h samples, and longer-
term average urinary concentrations of short-lived environmental chemicals: implications for
exposure assessment and reverse dosimetry. J Expo Sci Environ Epidemiol 27: 582-590.
http://dx.doi.ore 10 IP'S ies.201 I
Balalian. AA; Whyatt. RM; Liu. X; In set. iN ^ uih. 1 \ i lerbstman. J; Factor-Litvak. 1,(2019).
Prenatal and childhood exposure to phthalates and motor skills at age 11 years. Environ Res 171:
416-427. http://dx.doi.cnv 10 101 5/i.envres.2QI" 01 0 1
^ (1987). [Study of the oral toxicity of palatinol N in rats. Administration in the diet over 3
months], (Project No 31S0513/85103).
Berger. K; Eskenazi «' Uogut. K; Parra. K; Lustig. RH; Greenspan 1 Holland. N: Calafat. AM; Ye.
X; Harlev. KG. (2018). Association of Prenatal Urinary Concentrations of Phthalates and
Bisphenol A and Pubertal Timing in Boys and Girls. Environ Health Perspect 126: 97004.
http://dx.doi. org/10.1289/EHP3424
(1986). A 21-day feeding study of di-isononyl phthalate to rats: Effects on the liver and liver
lipids [TSCA Submission], (3.0495.6. 0495/6/85. OTS0509544. 40+8626208. 42005 Gl-23.
TSCATS/201730). Chemical Manufacturers Association.
https://ntrl.ntis.gov/.NTRL/dashboard/searchResults.xhtml?searchQuery=OTS0509544
Bio/dynamics. (1982a). One week prechronic oral feeding study. Test materials: MRD 8240, MRD 8241
[unpublished laboratory report submitted to Exxon Biomedical Sciences, Inc.] [TSCA
Submission], (878210917). Exxon Biomedical Sciences, Inc.
https://ntrl.ntis.gov/.NTRL/dashboard/searchResults.xhtml?searchQuery=OTS0206292
Bio/dynamics. (1982b). Thirteen week pre-chronic oral feeding study in Fischer 344 rats: Test material:
MRD-82-41 [TSCA Submission], (V04154-P. OTS0206327. 878213562. TSCATS/020176).
Houston, TX: Exxon Chemical Americas.
https://ntrl.ntis.gov/NTRL/dashboard/searchResiilts/titleDetail/OTS0206327.xhtml
Bio/dynamics. (1982c). Thirteen week pre-chronic oral feeding study in Sprague-Dawley rats: Test
material: MRD-82-41 [TSCA Submission], (EPA/OTS Doc #878213561). Houston, TX: Exxon
Chemical Americas.
https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchOuery=OTS02Q6327
Bio/dynamics. (1986). Chronic toxicity/oncogenicity study in F-344 rats (final report) with cover letter
dated 042386 [TSCA Submission], (EPA/OTS Doc #868600062). Houston, TX: Exxon
Page 101 of 184
-------
2936
2937
2938
2939
2940
2941
2942
2943
2944
2945
2946
2947
2948
2949
2950
2951
2952
2953
2954
2955
2956
2957
2958
2959
2960
2961
2962
2963
2964
2965
2966
2967
2968
2969
2970
2971
2972
2973
2974
2975
2976
2977
2978
2979
2980
2981
2982
2983
2984
PUBLIC RELEASE DRAFT
May 2024
Chemical Americas.
https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuerv=QTS0510211
Bio/dynamics. (1987). A chronic toxicity carcinogenicity feeding study in rats with Santicizer 900 with
cover letter dated 06/05/87 [TSCA Submission], (EPA/OTS Doc #86870000362). St. Louis,
MO: Monsanto Company.
https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OT xhtml
Bishop. PL; Dellarco. VL; Woh 1 * (2023). Is the 90-day dog study necessary for pesticide toxicity
testing? [Review], CritRev Toxicol 53: 207-228.
http://dx.doi.orE 30/10408444.2023.2221987
Bobe hristiansen. S; Axelstad. M; Kledal. TS; Vinggaard. A gaard. M; Nellemann. C; Hass.
U. (2011). Reproductive and behavioral effects of diisononyl phthalate (DINP) in perinatally
exposed rats. Reprod Toxicol 31: 200-209. http://dx.doi.ore/10.1016/i .reprotox.2010 I I 001
Sobers. J; Christiansen. S; Axelstad. M; Kledal. TS; Vingg gaard. M; Nellemann. C; Hass.
U. (2016). Corrigendum to "Reproductive and behavioral effects of diisononyl phthalate (DINP)
in perinatally exposed rats" [Reprod. Toxicol. 31 (2) (2011) 200-209] [Erratum], Reprod Toxicol
63: 183-184. http://dx.doi.org/10.1016/i .reprotox.201 0 001
Borch. J; Ladefoged. O; Hass. U; Vinggaard. AM. (2004). Steroidogenesis in fetal male rats is reduced
by DEHP and DINP, but endocrine effects of DEHP are not modulated by DEHA in fetal,
prepubertal and adult male rats. Reprod Toxicol 18: 53-61.
http://dx.doi.org/10.1016/i .reprotox.200 < 10 01 I
B elmann. H. (2005). Use of the dog as non-rodent test species in the safety testing schedule
associated with the registration of crop and plant protection products (pesticides): present status.
Arch Toxicol 79: 615-626. http://dx.doi.org/ 0204-005-0678-0
Butala. JH; David. RM; Gans. G; McKee. RH; Guo. TL; Peachee. VL; White. KL. Jr. (2004). Phthalate
treatment does not influence levels of IgE or Th2 cytokines in B6C3F1 mice. Toxicology 201:
77-85. hj!|: tSv.doi.org 10 101 i.tox.2004.04.004
Calat'n Wl: Brock. JW; Silva. Mi u.\ U h < \ <\,u feedham. LL. (2006a). Urinary
and amniotic fluid levels of phthalate monoesters in rats after the oral administration of di(2-
ethylhexyl) phthalate and di-n-butyl phthalate. Toxicology 217: 22-30.
http://dx.doi.org 10 101 i.tox.2005.QS 01 '<
Calat'n \ \ L Longnecker. MP; Koch. HM; Swan. SH; Hauser. " idman. LR; Lanphear. BP; Rudel.
RA; En gel. SM; Teitelbaum. SL; Whyatt. RM; Wolff. MS. (2015). Optimal exposure biomarkers
for nonpersistent chemicals in environmental epidemiology. Environ Health Perspect 123: A166-
A168. http://dx.doi.org/10.1289/e'
Calat'n WL Silva. Ml; Reidv t \
-------
2985
2986
2987
2988
2989
2990
2991
2992
2993
2994
2995
2996
2997
2998
2999
3000
3001
3002
3003
3004
3005
3006
3007
3008
3009
3010
3011
3012
3013
3014
3015
3016
3017
3018
3019
3020
3021
3022
3023
3024
3025
3026
3027
3028
3029
3030
3031
3032
PUBLIC RELEASE DRAFT
May 2024
CDC. (2023a). Alcohol and Public Health: Alcohol use and your health [Website],
https://www.cdc.eov/alcohol/fact-sheets/alcohol-use.htm
CDC. (2023b). CDC Health Topics A-Z: Nutrition [Website], https://www.cdc.eov/nutrition/index.html
CDC. (2023c). CDC Health Topics A-Z: Stress at work [Website],
https://www.cdc.eov/niosh/topics/stress/
CDC. (2023d). Fetal Alcohol Spectrum Disorders (FASDs): Alcohol use during pregnancy [Website],
https://www.cdc.eov/ncbddd/fasd/alcohol-use.html
CDC. (2023e). Pregnancy: During pregnancy [Website], https://www.cdc.gov/pregnancv/during.html
CDC. (2023f). Smoking & Tobacco Use: Smoking during pregnancy - Health effects of smoking and
secondhand smoke on pregnancies [Website],
https://www.cdc.eov/tobacco/basic information/health effects/ pregn an cv/i n dex. htm
CDC. (2023g). Viral Hepatitis: What is viral hepatitis? [Website],
http s ://www. cdc. eov/h epatiti s/abc/index.htm
Chang. WH; Tsai. YS: Warn < \ t lion U* N jne. WH; Lee. CC. (2019). Sex hormones and oxidative
stress mediated phthalate-induced effects in prostatic enlargement. Environ Int 126: 184-192.
http://dx.doi.ore 10 101 |.envint.2019.02.006
Chen. L; Chen. J; Xie. CM; Zhao. Y; Wane. X; Zhang. YH. (2015). Maternal disononyl phthalate
exposure activates allergic airway inflammation via stimulating the phosphoinositide 3-
kinase/Akt pathway in rat pups. Biomed Environ Sci 28: 190-198.
http://dx.doi.ore/10.3967/bes2 5
Chiang. C; Flaw (2019). Sub-Chronic Exposure to Di(2-ethylhexyl) Phthalate and Diisononyl
Phthalate During Adulthood Has Immediate and Long-Term Reproductive Consequences in
Female Mice. Toxicol Sci 168: 620-63 1. http://dx.doi.ore/10.1093/toxsci/kfzQl3
Clewell. RA; Campbell. JL; Ross. SM; Gaido. KW: Cle ndersen. ME. (2010). Assessing
the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response.
Toxicol In Vitro 24: 327-334. http://dx.doi.o /i.tiv.2009.08.003
Clewell. RA: Sochaski. M; Edwards. K; Creav \ 1 * Vt; Willson. G; Andersen. ME. (2013a). Disposition
of diiosononyl phthalate and its effects on sexual development of the male fetus following
repeated dosing in pregnant rats. Reprod Toxicol 35: 56-69.
http://dx.doi.ore/10.1016/i .reprotox.2012.07.001
Clewell.. ipmas. A: Willson. G; Creasy. DM: Andersen. ME. (2013b). A dose response study to
assess effects after dietary administration of diisononyl phthalate (DINP) in gestation and
lactation on male rat sexual development. Reprod Toxicol 35: 70-80.
http://dx.doi.ore/10.1016/i .reprotox.2012.07.008
Conlev. JM; Lambright. CS; Evans. N: Cardon. M; Medlock-Kakalev. E; Wilson. VS: Gray. LE. (2021).
A mixture of 15 phthalates and pesticides below individual chemical no observed adverse effect
levels (NOAELs) produces reproductive tract malformations in the male rat. Environ Int 156:
106615. http://dx.doi.ore/10 101 /j.envint.20. l h1 615
Corton. JC; Peters. JM: Klaunie. IE. (2018). The PPARa-dependent rodent liver tumor response is not
relevant to humans: addressing misconceptions [Review], Arch Toxicol 92: 83-119.
http://dx.doi.ore/10.1007/s0020 I 01 :094-7
Covance Labs. (1998a). Oncogenicity study in mice with di(isononyl)phthalate including ancillary
hepatocellular proliferation & biochemical analyses: Part 1 of 2, volumes 1-3. (OTS0556283-3).
Philadelphia, PA: Aristech Chemical Corp.
Covance Labs. (1998b). Support: oncogenicity study in mice with di(isononyl)phthalate including
ancillary hepatocellular proliferation and biochemical analyses with cover letter dated
11/18/1998 [2598-105] [TSCA Submission], (2598-105). Philadelphia, PA: Aristech Chem
Corp. https://ntrl.ntis.gOv/NTRL/dashboard/searchResults/titleDetail/OTS05562833.xhtml
Page 103 of 184
-------
3033
3034
3035
3036
3037
3038
3039
3040
3041
3042
3043
3044
3045
3046
3047
3048
3049
3050
3051
3052
3053
3054
3055
3056
3057
3058
3059
3060
3061
3062
3063
3064
3065
3066
3067
3068
3069
3070
3071
3072
3073
3074
3075
3076
3077
3078
3079
3080
PUBLIC RELEASE DRAFT
May 2024
Covance Labs. (1998c). Support: Oncogenicity study in rats with di(isononyl) phthalate including
ancillary hepatocellular proliferation & biochemical analyses with cover [TSCA Submission],
(EPA/OTS Doc #89980000308). Philadelphia, PA: Aristech Chemical Corp.
https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS05562832.xhtml
Dellarco. VL; Rowland. J; Ma~ (2010). A retrospective analysis of toxicity studies in dogs and
impact on the chronic reference dose for conventional pesticide chemicals. Crit Rev Toxicol 40:
16-23. hi .doi.org/10.3109/10408440903401529
Dene. T; Xie. X; Duan. J; Chen. M. (2019). Exposure to diisononyl phthalate induced an increase in
blood pressure through activation of the ACE/ AT1R axis and inhibition of NO production.
Toxicol Lett 309: 42-50. http://dx.doi.ore/10.1016/i.toxlet.lO I" 0 '<011
Diaz Santana. MY; Hankinson. SE; Bigelow. C; Sturgeon. SR; Zoeller. RT; Tinker. L; Man son
Calal;n \M: Meliker. JR; Reeves. KW. (2019). Urinary concentrations of phthalate biomarkers
and weight change among postmenopausal women: a prospective cohort study. Environ Health
18: 20. him .tvdoi.org/10. i 186/sl2940~019~0458~6
Downs. £ ck. N. (1998). The feasibility of creating a checklist for the assessment of the
methodological quality both of randomised and non-randomised studies of health care
interventions. J Epidemiol Community Health 52: 377-384.
http://dx.doi.ore ech.52.6.377
Duan. J: Kam i \\ « 1 u> U U r 'hi W: Gong. S: Yang. X: Chen. M. (2018V
Exposure to formaldehyde and diisononyl phthalate exacerbate neuroinflammation through NF-
kB activation in a mouse asthma model. Ecotoxicol Environ Saf 163: 356-364.
http://dx.doi.ore 10 101 i.ecoenv.201 \ 0 089
Durmaz. E; Erkekogtu. P; Asci \ Mccurin. S: Bircan. I; Kocer-Gumusel. B. (2018). Urinary phthalate
metabolite concentrations in girls with premature thelarche. Environ Toxicol Pharmacol 59: 172-
181. http://dx.doi.ore/10.1016/i.etap.201 \ 0 '<.010
Dzwilewski. KLC: Woodbury. ML; Aguiar. A: Shoaff. J: Merced-Nieves. F: Korrick. SA: Schg ^
(2021). Associations of prenatal exposure to phthalates with measures of cognition in 7.5-month-
old infants. 84:84-95.
https://heronet.epa.gov/heronet/index.cfm/reference/download/reference id/7978460
EC/HC. (2015). State of the science report: Phthalate substance grouping 1,2-Benzenedicarboxylic acid,
diisononyl ester; 1,2-Benzenedicarboxylic acid, di-C8-10-branched alkyl esters, C9-rich
(Diisononyl Phthalate; DINP). Chemical Abstracts Service Registry Numbers: 28553-12-0 and
68515-48-0. Gatineau, Quebec, https://www.ec.ec.ca/ese~
ees/default.asp?lane=En&n=47F58AA5~l
ECB. (2003). European union risk assessment report: DINP. European Commission.
http://publications.irc.ec.europa.eu/repositorv/handle/JRC25827
ECCC/HC. (2020). Screening assessment - Phthalate substance grouping. (En 14-393/2019E-PDF).
Environment and Climate Change Canada, Health Canada.
https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-
substances/screening-assessment-phthalate-substance-grouping.html
ECHA. (2013a). Committee for Risk Assessment (RAC) Opinion on the ECHA's draft review report on
"Evaluation of new scientific evidence concerning DINP and DIDP in relation to entry 52 of
Annex XVII to Regulation (EC) No 1907/2006 (REACH)" ECHA/RAC/A77-0-0000001412-86-
10/F. https://echa.europa.eu/documents/10162/13579/rac opinion dinp didp en.pdf/f54e95e0-
F680e3ebc6
ECHA. (2013b). Evaluation of new scientific evidence concerning DINP and DIDP in relation to entry
52 of Annex XVII to REACH Regulation (EC) No 1907/2006. Helsinki, Finland.
http ://echa. europa. eu/docum en iv 101 . '
-------
3081
3082
3083
3084
3085
3086
3087
3088
3089
3090
3091
3092
3093
3094
3095
3096
3097
3098
3099
3100
3101
3102
3103
3104
3105
3106
3107
3108
3109
3110
3111
3112
3113
3114
3115
3116
3117
3118
3119
3120
3121
3122
3123
3124
3125
3126
3127
3128
PUBLIC RELEASE DRAFT
May 2024
ECH.A. (2018). Committee for Risk Assessment (RAC) Opinion proposing harmonised classification
and labelling at EU level of 1,2-Benzenedicarboxylic acid, di-C8-10-branched alkylesters, C9-
rich; [1] di-"isononyl" phthalate; [2] [DINP]. (CLH-0-0000001412-86-201/F). Helsinki,
Finland, https://echa.eiiropa.eii/documents/10162/56980740-fcb6-6755-d7bb-bfe797c36ee7
EFSA. (2005). Opinion of the scientific panel on food additives, flavourings, processing aids and
materials in contact with food (AFC) on a request from the commission related to di-
isononylphthalate (DINP) for use in food contact materials. Question N° EFSA-q-2003-194 (pp.
1-18). http://dx.doi.Org/10.2903/i.efsa.2005.244
EFSA. (2019). Update of the risk assessment of di-butyl phthalate (DBP), butyl-benzyl-phthalate (BBP),
bis(2-ethylhexyl)phthalate (DEHP), di-isononylphthalate (DINP) and di-isodecylphthalate
(DIDP) for use in food contact materials. EFSA J 17: ee05838.
http://dx.doi. ore/10,2903/i. efsa. 2 019.5838
El si si. AE; Carter. DE; Sip (1989). Dermal absorption of phthalate diesters in rats. Fundatn Appl
Toxicol 12: 70-77. http://dx.doi.oi '0272-0590(89190063-8
Engel. SM; Villanger. GD; Netherv. R€; Thorn sen. C; Saktn U 1 Hover. SSM; Hoppin ^mer. P;
Knudsen. GP; Reichborn-Kienner iierring. AH; Aase. H. (2018). Prenatal phthalates,
maternal thyroid function, and risk of attention-deficit hyperactivity disorder in the Norwegian
mother and child cohort. Environ Health Perspect 126: 057004.
http://dx.doi.ore 39/EHP2358
EPL. (1999). Histopathology Peer Review and Pathology Working Group. Review of selected lesions of
the liver and spleen in male and female F344 rats exposed to di(isononyl)phthalate. (WIL-
354002). Research Triangle Park, NC: Experimental Pathology Laboratories Inc.
Exxon Biomedical. (1996a). Reproduction toxicity study in rats with diisononyl phthalate (DINP; MRD-
92-455) (sanitized). (Project No. 145535). Houston, TX: ExxonMobil Chemical Company.
Exxon Biomedical. (1996b). Two generation reproduction toxicity study in rats with diisononyl
phthalate (DINP; MRD-92-455) [unpublished] (sanitized). (Project No. 145535A). Houston, TX:
Exxon Chemical Company.
Foster. P (2005). Mode of action: Impaired fetal Leydig cell function - Effects on male reproductive
development produced by certain phthalate esters [Review], Crit Rev Toxicol 35: 713-719.
http://dx.doi.orE 30/10408440591007395
Foster. PMD; Mvlchreest. E; Gaido. KW; Sar. M. (2001). Effects of phthalate esters on the developing
reproductive tract of male rats [Review], Hum Reprod Update 7: 231-235.
http://dx.doi.ore ?3/humupd/7.3.231
Furr. JR.; Lambright. CS; Wilson. VS; Foster. PM; Gray. LE. Jr. (2014). A short-term in vivo screen
using fetal testosterone production, a key event in the phthalate adverse outcome pathway, to
predict disruption of sexual differentiation. Toxicol Sci 140: 403-424.
http://dx.doi.ore )3/toxsci/kfu081
Gray. LE. Jr.; Lambright. CS; Conlev. JM; Evans. N; Furr. JR; Hannas. BR; Wilson. VS; Sampson. H;
Foster. P (2021). Genomic and Hormonal Biomarkers of Phthalate-Induced Male Rat
Reproductive Developmental Toxicity Part II: A Targeted RT-qPCR Array Approach That
Defines a Unique Adverse Outcome Pathway. Toxicol Sci 182: 195-214.
http://dx.doi.ore oxsci/kfab053
Gray. LE. Jr.; Ostb\ J t tin < l\t >•' M; Veeramachaneni. DNR; Parks. L. (2000). Perinatal exposure to
the phthalates DEHP, BBP, and DNIP, but not DEP, DMP, or DOTP, alters sexual
differentiation of the male rat. Toxicol Sci 58: 350-365. http://dx.doi.c ^/toxsci/58.2.350
Hall. AP; Elcombe. CR; Foster. JR; Harada. T; Kaufmann. W; Knippe sr. K; Malarke
Maronpot. RR; Nishikawa. A; Nolte. T; Schuiu' \ c.uauss \ \»
-------
3129
3130
3131
3132
3133
3134
3135
3136
3137
3138
3139
3140
3141
3142
3143
3144
3145
3146
3147
3148
3149
3150
3151
3152
3153
3154
3155
3156
3157
3158
3159
3160
3161
3162
3163
3164
3165
3166
3167
3168
3169
3170
3171
3172
3173
3174
3175
3176
3177
PUBLIC RELEASE DRAFT
May 2024
3rd International ESTP Expert Workshop [Review], Toxicol Pathol 40: 971-994.
http://dx.doi.org/10.1177/0192 3935.
Hall. M; Matthe irling. R. (1999). Effects of di-isononyl phthalate (DINP) on
peroxisomal markers in the marmoset - DINP is not a peroxisome proliferator. J Toxicol Sci 24:
237-244. http://dx.doi.Org/10.2131/its.24.3 237
Hamner Institutes for Health Sciences. (2011). A dose response study of the effects on male rat sexual
development after administration of diisononyl phthalate to the pregnant and lactating dam
(sanitized). (The Hamner Protocol #10003). Irving, TX: ExxonMobil Chemical Company.
Hannas. BR; Lambright. CS; Furr. J; Evan*- x I <"->er. PMD; Gray. EL; Wilson. VS. (2012). Genomic
biomarkers of phthalate-induced male reproductive developmental toxicity: A targeted RT-PCR
array approach for defining relative potency. Toxicol Sci 125: 544-557.
http://dx.doi.org 10 10° '< toxsci/kli '< I
Hann.r ^k 1 ,irobright. O iuu < U^wdeshell. KL; Wilson. VS; Gray. LE. (2011). Dose-response
assessment of fetal testosterone production and gene expression levels in rat testes following in
utero exposure to diethylhexyl phthalate, diisobutyl phthalate, diisoheptyl phthalate, and
diisononyl phthalate. Toxicol Sci 123: 206-216. http://dx.doi.org/10.1093/toxsci/kfrl46
Hazleton Laboratories. (1969). Repeated dermal application - Rabbits. MRD-69-4. Linden, NJ: Esso
Research and Engineering Company.
Hazleton Laboratories. (1971). Thirteen week dietary administration - dogs: MRD-70-45, MRD-70-46
(diisononyl phthalate), Final report (sanitized). Linden, NJ: Esso Research and Engineering
Company.
Hazleton Labs. (1971). Three-month dietary administration - Rats [MRD-70-46 (diisononyl phthalate)]
(sanitized). (Project No. 145-475). Linden, NJ: Esso Research and Engineering Company.
Hazleton Labs. (1981). Thirteen-week toxicity study in rats: DINP (unpublished). (Project No. 2096-
104). Tokyo, Japan: Nissan Chemical Industries.
Hazleton Labs. (1991a). A subchronic (4-week) dietary oral toxicity study of di(isonony 1 )phthalate in
B6C3F1 mice (final report) with cover sheet dated 052991 [TSCA Submission], (HWA Study
No. 2598-100. OTS0529425. 86-910000793. TSCATS/415527). Vienna, VA: Aristech Chemical
Corporation.
https://ntrl.ntis. gov/NTRL/dashboard/searchResults.xhtml?searchOuery=OTSQ529425
Hazleton Labs. (1991b). A subchronic (13-week) dietary oral toxicity study of di(isonony 1 )phthalate in
fischer 344 rats with attachments and cover letter dated 082291. (EPA/OTS Doc #86-
910000969). Pittsburgh, PA: Aristech Chemical Corporation.
https://ntrl.ntis. gov/NTRL/dashboard/searchResults.xhtml?searchOuery=OTSQ53Q645
Hazleton Labs. (1992). A 13-week subchronic dietary oral toxicity study in mice with
di(isononyl)phthalate including ancillary hepatocellular proliferation and biochemical analyses.
(HWA 2598-103). Aristech Chemical Corporation.
Health Canada. (2015). Supporting documentation: Carcinogenicity of phthalates - mode of action and
human relevance. In Supporting documentation for Phthalate Substance Grouping. Ottawa, ON.
Health Canada. (2018a). Supporting documentation: Evaluation of epidemiologic studies on phthalate
compounds and their metabolites for effects on behaviour and neurodevelopment, allergies,
cardiovascular function, oxidative stress, breast cancer, obesity, and metabolic disorders. Ottawa,
ON.
Health Canada. (2018b). Supporting documentation: Evaluation of epidemiologic studies on phthalate
compounds and their metabolites for hormonal effects, growth and development and
reproductive parameters. Ottawa, ON.
Heggesel Holland. N; Eskenazi. B; Kogut. K; Harley. KG. (2019). Heterogeneity in childhood
body mass trajectories in relation to prenatal phthalate exposure. Environ Res 175: 22-33.
http://dx.doi.org 10 101 | .envres. JO I'1 0 i 036
Page 106 of 184
-------
3178
3179
3180
3181
3182
3183
3184
3185
3186
3187
3188
3189
3190
3191
3192
3193
3194
3195
3196
3197
3198
3199
3200
3201
3202
3203
3204
3205
3206
3207
3208
3209
3210
3211
3212
3213
3214
3215
3216
3217
3218
3219
3220
3221
3222
3223
3224
3225
PUBLIC RELEASE DRAFT
May 2024
Hellv denberger. H; Jackh. R (1997). Differential prenatal toxicity of branched phthalate
esters in rats. Food Chem Toxicol 35: 501-512. http://dx.doi.oi ?S0278~6915(97)00008-
2
Henrotin. hi I oigerlova. Ev; Rob-n i \ nirla. M; Burgart. M; Lambert-Xolin. AM; Jean del. F;
Wervha. G. (2020). Decrease in serum testosterone levels after short-term occupational exposure
to diisononyl phthalate in male workers. 77: 214-222.
https://heronet.epa.gov/heronet/index.cfm/reference/download/reference id/7978431
Howdeshell. KL; Hotchkiss. AK; Gra (2017). Cumulative effects of antiandrogenic chemical
mixtures and their relevance to human health risk assessment [Review], Int J Hyg Environ
Health 220: 179-188. http://dx.doi.on 10 101 i.ijheh.20 \ I I 00
Hills AG. (1992). A 14-days oral toxicity study with three different types of di-isononylphthalates in
female Fischer 344 rats; final report SA-92/0062. Enzyme activities in liver fractions from
female Fischer-344 rats treated with three isomeric di-isononyl phthalates (14-day oral gavage
study): Final report BT-92/0062. Dodecanoic acid 12-hydroxylase activity in liver microsomes
from female Fischer-344 rats treated with three isomeric di-isononyl phthalates (14-day oral
gavage study) - results of individual animals and statistical evaluation; final report BT-92/0062-
1.
Hwang. YH; Son. YJ; Paik. MI; Yee. ST. (2017). Effects of diisononyl phthalate on osteopenia in intact
mice. Toxicol Appl Pharmacol 334: 120-128. http://dx.doi.org/10 101 | taap.2017.0'
Hvland. C; Mora. AM; Kogut. K; Calafat. AM; Hartey. K; Deardorff. J; Holland. N; Eskem jiagiv.
SK. (2019). Prenatal exposure to phthalates and neurodevelopment in the CHAMACOS cohort.
Environ Health Perspect 127. http://dx.doi. org/10.1289/EH
Iroai. Y; Kondo. A; lizuka. H; Maruvama. T; Kurohane. K. (2006). Effects of phthalate esters on the
sensitization phase of contact hypersensitivity induced by fluorescein isothiocyanate. Clin Exp
Allergy 36: 1462-1468. http://dx.doij )~2222.2006.02574.x
IPCS. (2007). Harmonization project document no. 4: Part 1: IPCS framework for analysing the
relevance of a cancer mode of action for humans and case-studies: Part 2: IPCS framework for
analysing the relevance of a non-cancer mode of action for humans. Geneva, Switzerland: World
Health Organization.
http://www.who.int/ipcs/methods/harmonization/areas/cancer mode.pdf?ua=l
Jacob son. MH; Stein. CR; Liu. M; Ackermar kemore. IK; Long. SE; Pinna. G; Romav-Tallon.
R; Kannan. K; Zhu. H; Trasande. L. (2021). Prenatal Exposure to Bisphenols and Phthalates and
Postpartum Depression: The Role of Neurosteroid Hormone Disruption. 106: 1887-1899.
https://heronet.epa.gov/heronet/index.cfm/reference/download/reference id/7978436
Jankowska. A; Pol ah ska. K; Hanke. W; Wesolowska. E; Ligoc t¥ aszkowska. M; Stahczak. A;
Tartaglione. AM; Mirabelh i:'. (' hian nn t s.d. M; Calamandrei. G. (2019a). Prenatal and
early postnatal phthalate exposure and child neurodevelopment at age of 7 years - Polish Mother
and Child Cohort. Environ Res 177: 108626. http://dx.doi.cnv 10 101 5/i.envres.2Q I" 108626
jankowska. A; Pol an ska. K; Koch. HM; Palmke. C; Waszkowska. M; Stahczak. A; Wesolowska. E;
Hanke. W; Bose-O'Reilly. S; Calamai (2019b). Phthalate exposure and
neurodevelopmental outcomes in early school age children from Poland. Environ Res 179:
108829. http://dx.doi.org/10 101 /j.envres.20 I" I OS829
Johnson. :ger. NE; Boekelheide. K. (2012). Of mice and men (and rats): phthalate-induced fetal
testis endocrine disruption is species-dependent [Review], Toxicol Sci 129: 235-248.
http://dx.doi.ore )3/toxsci/kfs206
Johnson. KJ; McDowell EN; Vlereck. MP; Xia. JO. (2011). Species-specific dibutyl phthalate fetal
testis endocrine disruption correlates with inhibition of SREBP2-dependent gene expression
pathways. Toxicol Sci 120: 460-474. http://dx.doi.org/10.1093/toxsci/kfr020
Page 107 of 184
-------
3226
3227
3228
3229
3230
3231
3232
3233
3234
3235
3236
3237
3238
3239
3240
3241
3242
3243
3244
3245
3246
3247
3248
3249
3250
3251
3252
3253
3254
3255
3256
3257
3258
3259
3260
3261
3262
3263
3264
3265
3266
3267
3268
3269
3270
3271
3272
PUBLIC RELEASE DRAFT
May 2024
Karri ai. EM; Villam etherv. RC: Thorn sen. C; Sakhi. AK; Drover. SSM; Hoppin. J A; Knudsen.
GP; Reichborn-Kjennerud. T; Zeiner. P; Overgaard. K; Herring. AH; Aase. H; En gel. SM.
(2021). Gestational phthalate exposure and preschool attention deficit hyperactivity disorder in
Norway. Environmental Epidemiology 5: el61.
http://dx.doi.org 10 1097/EE9.00000000000001 I
Kang > Utin \ It Tn 1 iu. H; Yang. X; Chen. M. (2017). TRPA1 mediated aggravation of allergic
contact dermatitis induced by DINP and regulated by NF-kB activation. Sci Rep 7: 43586.
http://dx.doi.ore rep43586
Kang. J; Song. J; Shen. S; 1 >. X; Chen. M. (2016). Diisononyl phthalate aggravates allergic
dermatitis by activation of NF-kB. Onct 7: 85472-85482.
http://dx.doi.ore 532/oncotarget. 13403
Karbi ;rlin. RL. (2002). Cystic degeneration/spongiosis hepatis in rats. Toxicol Pathol 30: 216-
227. http://dx.doi.org/10.1080/01926230:
Kaufmann. W; Deckardt K; McKee. RH; Butala. J.H; Bahnemann. R (2002). Tumor induction in mouse
liver: Di-isononyl phthalate acts via peroxisome proliferation. Regul Toxicol Pharmacol 36: 175-
183. http://dx.doi.org/10.10Q6/rtph.2C
Koch. HM; Angerer. J. (2007). Di-iso-nonylphthalate (DINP) metabolites in human urine after a single
oral dose of deuterium-labelled DINP. Int J Hyg Environ Health 210: 9-19.
http://dx.doi.Org/10.1016/i.iiheh.2006.l 1.008
Koch. HM; Halln \ \\ i i ott'rlein c.K»rk. J; Briining. T. (2012). Phthalate exposure during
cold plastisol application - A human biomonitoring study. Toxicol Lett 213: 100-106.
http://dx.doi.ore 10 101 i.toxlet.l01 I 0 010
Koike. E; Yanagisawa. R; Sadakane. K; Inoue. K; Ichinose. ano. H. (2010). Effects of diisononyl
phthalate on atopic dermatitis in vivo and immunologic responses in vitro. Environ Health
Perspect 118: 472-478. http://dx.doi.org/ Vehp.0901255
Kriigi ong. M; Bonefeld-Jgrgensen. EC. (2008). Plastic components affect the activation of the
aryl hydrocarbon and the androgen receptor. Toxicology 246: 112-123.
http://dx.doi.ore 10 101 i .tox.200 IJ 028
Kwack. S; Kim. K; Kin (2009). Comparative toxicological evaluation of phthalate diesters
and metabolites in Sprague-Dawley male rats for risk assessment. J Toxicol Environ Health A
72: 1446-1454. http://dx.doi.org/10.1080/152873909Q3212923
Kwack. SI; Han. EY; Park. IS; Ba*' i \ 1 im. SK; Kim. DH; Jang. DE; Choi. L; Lim. HI; Kim.
TH; Patra. N; Park. K.L; Kim. HS; Lee. BM. (2010). Comparison of the short term toxicity of
phthalate diesters and monoesters in Sprague-Dawley male rats. Toxicological Research 26: 75-
82. http://dx.doi.ore B7/TR.2010.26.1.075
Lapinska*- P< r%mwn. S; Leesniton 1
-------
3273
3274
3275
3276
3277
3278
3279
3280
3281
3282
3283
3284
3285
3286
3287
3288
3289
3290
3291
3292
3293
3294
3295
3296
3297
3298
3299
3300
3301
3302
3303
3304
3305
3306
3307
3308
3309
3310
3311
3312
3313
3314
3315
3316
3317
3318
3319
3320
PUBLIC RELEASE DRAFT
May 2024
Lee. H.C; Yamanouchi. K; Nishihara. M. (2006b). Effects of perinatal exposure to phthalate/adipate
esters on hypothalamic gene expression and sexual behavior in rats. J Reprod Dev 52: 343-352.
http://dx.doi.ore 52/ird. 17096
Lee. MH; Pai I < 1 -hung. SW; Kam r%\ t im. SH; Kim. TS. (2004). Enhancement of interleukin-4
production in activated CD4+ T cells by diphthalate plasticizers via increased NF-AT binding
activity. Int Arch Allergy Immunol 134: 213-222. http://dx.doi.ors 100078768
lil, Hu. T; Su. H: Chen. Z: Liang. Y: Zham hu. D; Sha» \ \ U i Uu < >an. Q;
Ge. RS. (2015). In utero exposure to diisononyl phthalate caused testicular dysgenesis of rat fetal
testis. Toxicol Lett 232: 466-474. http://dx.doi.oi ^ 10 101 /j .toxlei JO I I I I 0J I
1 i N. Papandonatos. GD; Calafat. AM \ t'hon. i 1 anpheai r%P 1 jion \ .un. IM. (2019).
Identifying periods of susceptibility to the impact of phthalates on children's cognitive abilities.
Environ Res 172: 604-614. http://dx.doi.org/10 J 016/i .envres.201'" 0 '< 009
Liao. KW: Kuo. PL; Huang. HB; Chang. JW; Chiang. HC: Huang. PC. (2018). Increased risk of
phthalates exposure for recurrent pregnancy loss in reproductive-aged women. Environ Pollut
241: 969-977. http://dx.doi.on .envpol.2018.06.022
Lington. AW; Bird. MG; Plutnick. RT; Stubblefl a. RA. (1997). Chronic toxicity and
carcinogenic evaluation of diisononyl phthalate in rats. Fundam Appl Toxicol 36: 79-89.
http://dx.doi.ore oxsci/36.1.79
Ma. P; Ln> \ < \
-------
3321
3322
3323
3324
3325
3326
3327
3328
3329
3330
3331
3332
3333
3334
3335
3336
3337
3338
3339
3340
3341
3342
3343
3344
3345
3346
3347
3348
3349
3350
3351
3352
3353
3354
3355
3356
3357
3358
3359
3360
3361
3362
3363
3364
3365
3366
3367
3368
PUBLIC RELEASE DRAFT
May 2024
Miura. T; Suemizu. t i < go. M; Sakai. N: Iwata. H; Shimizu. M, \ nmazaki. H. (2018). Human urinary
concentrations of monoisononyl phthalate estimated using physiologically based
pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally
administered with diisononyl phthalate. Xenobiotica 49: 1-8.
http://dx.doi.ore 10 1080/00498254.20IN II I m
MoreiiTi Fernandez. MA; Card-' il < 1 arneiro. MM; Andre 1 (* (2019). Study of possible association
between endometriosis and phthalate and bisphenol A by biomarkers analysis. J Pharm Biomed
Anal 172: 238-242. http://dx.doi.oi^ 10 101 j/i.jpba.-O I" 0 I 0 W
Mustieles. V; Mtnguez-Alarcon. L; Christou. iihiI JH. 1 Hiiiitriadis. I; Hauser. R; Souter. I;
Messerlian. C. (2019). Placental weight in relation to maternal and paternal preconception and
prenatal urinary phthalate metabolite concentrations among subfertile couples. Environ Res 169:
272-279. http://dx.doi.Hv 10 101 5/i.envres.2Q I s II 0.2
NASEM. (2017). Application of systematic review methods in an overall strategy for evaluating low-
dose toxicity from endocrine active chemicals. In Consensus Study Report. Washington, D.C.:
The National Academies Press, http://dx.doi. *26/24758
Neier. K; Cheatham idrosian. LP; Dolinov. DC. (2018). Perinatal exposures to phthalates and
phthalate mixtures result in sex-specific effects on body weight, organ weights and intracisternal
A-particle (LAP) DNA methylation in weanling mice. J Dev Orig Health Dis 10: 1-12.
http://dx.doi.ore 10 101 S2040I i 11 \Q00430
Neier. K; Cheatham. D; Bedrosian. LP; Gregg. BE; Sons. PXK; Dolinov. DC. (2019). Longitudinal
metabolic impacts of perinatal exposure to phthalates and phthalate mixtures in mice.
Endocrinology 160: 1613-1630. http://dx.doi.org/10.12 10/en.2019-00287
NICNAS. (2012). Priority existing chemical assessment report no. 35: Diisononyl phthalate. (PEC35).
Sydney, Australia: Australian Government Department of Health and Ageing.
https://www.indiistrialchemicals.gov.aii/sites/defaiilt/files/PEC35-Piisononyl-phthalate-
NICNAS. (2015). Priority existing chemical draft assessment report: Diisodecyl Phthalate & Di-n-octyl
Phthalate. Sydney, Australia: Australian Department of Health and Ageing, National Industrial
Chemicals Notification and Assessment Scheme.
https://www.indiistrialchemicals.gov.aii/sites/defaiilt/files/PEC39-Diisodecyl-phthalate-DIPP-
Pi-n-octyl-phthalate-PnOP.pdf
N (2003). NTP-CERHR monograph on the potential human reproductive and
developmental effects of di-isononyl phthalate (DINP) (pp. i-III90). (NIH Publication No. 03-
4484). Research Triangle Park, NC: National Toxicology Program Center for the Evaluation of
Risks to Human Reproduction.
http://ntp.niehs.nih.gov/ntp/ohat/phthalates/dinp/dinp monograph final.pdf
ODPHP. (2023a). Healthy People 2030 - Social determinants of health literature summaries:
Neighborhood and built environment [Website], https://health.gov/healthvpeople/prioritv-
areas/social-determinants-health/literature-summaries#neighborhood
OPPHP. (2023b). Healthy People 2030 - Social determinants of health literature summaries: Poverty
[Website], https://health.gov/healthvpeople/prioritv-areas/social-deterrninants-health/literature-
summ aries/povertv
OPPHP. (2023c). Healthy People 2030 - Social determinants of health literature summaries: Social and
community context [Website], https://health.gov/healthvpeople/prioritv-areas/social-
determinants-health/literature-summaries#social
OECP. (2022). Series on Testing & Assessment, No. 156: Guidance notes on dermal absorption studies
(Second edition). (ENV/LM/MONO(2011)36/REV1). Paris, France: Organisation for Economic
Co-operation and Pevelopment (OECP).
Page 110 of 184
-------
3369
3370
3371
3372
3373
3374
3375
3376
3377
3378
3379
3380
3381
3382
3383
3384
3385
3386
3387
3388
3389
3390
3391
3392
3393
3394
3395
3396
3397
3398
3399
3400
3401
3402
3403
3404
3405
3406
3407
3408
3409
3410
3411
3412
3413
3414
3415
3416
3417
PUBLIC RELEASE DRAFT
May 2024
https://www.oecd.ore/otTicialdociiments/piiblicdisplaydociimentpdf/7cote ;
MQNQC 5%20&doclanguage=en
Parks < Ostbv. IS; Lambrieht. CR: Abbott iv. LE. Jr. (2000).
The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone
synthesis during sexual differentiation in the male rat. Toxicol Sci 58: 339-349.
http://dx.doi.ore oxsci/58.2.339
Pens. L. (2015). Mice brain tissue injury induced by diisononyl phthalate exposure and the protective
application of vitamin e. J Biochem Mol Toxicol 29: 311-320.
http://dx.doi. ore/10.1002/i bt. 21700
Philippat. C; Heude. B; Botton < Ufaidy. N: Calafat. AM; Slama. R; Group. EMCCS. (2019). Prenatal
Exposure to Select Phthalates and Phenols and Associations with Fetal and Placental Weight
among Male Births in the EDEN Cohort (France). Environ Health Perspect 127: 17002.
http://dx.doi.ore 39/EHP3523
Push. G; Isenbere. J; Kamendulis. L; Ackley. D; Clare 1 . Urown. R; Lineton \ v mith. J; Klaunig. J.
(2000). Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus
monkeys. Toxicol Sci 56: 181-188. http://dx.doi.ore 10 10°'< ioxsci/56.1.1S1
Radk i am. JM; Meekei H * per. GS. (2018). Phthalate exposure and male reproductive
outcomes: A systematic review of the human epidemiological evidence [Review], Environ Int
121: 764-793. http://dx.doi.ore .envint.2018.07.029
Radk Lin. JM; Nachman. KM; Cooper. GS. (2020a). Phthalate exposure and
neurodevelopment: A systematic review and meta-analysis of human epidemiological evidence
[Review], Environ Int 137: 105408. http://dx.doi.ore/10.1016/i.envint.2019.105408
Radke. EG; Galizia. A; Thayer. KA; Cooper. GS. (2019a). Phthalate exposure and metabolic effects: A
systematic review of the human epidemiological evidence [Review], Environ Int 132: 104768.
http://dx.doi.ore 10 101 |.envint.-0 I • > 0 i 0 SO
Radke. EG; Glenn. BS; Braun. JM; Coop (2019b). Phthalate exposure and female reproductive
and developmental outcomes: A systematic review of the human epidemiological evidence
[Review], Environ Int 130: 104580. http://dx.doi.ore/10.1016/i .envint.2019.02.003
Radke. EG; Yost. EE; Roth. N; Sathyanaravana. S; Whaley. P. (2020b). Application of US EPA IRIS
systematic review methods to the health effects of phthalates: Lessons learned and path forward
[Editorial], Environ Int 145: 105820. http://dx.doi.o /i.envint.2020.105820
Roy. P; Salminen. H; Koskimies. P; SimoLt < * metiv \ Saukko. P; Huhtaniemi. IT. (2004). Screening
of some anti-androgenic endocrine disruptors using a recombinant cell-based in vitro bioassay. J
Steroid Biochem Mol Biol 88: 157-166. http://dx.doi.ore/10.1016/i jsbmb.200 '< I I 00
Sadakane. K; Ichinose. T; Takano. H; Yanaeisawa. R; Koike. E. (2014). Effects of oral administration of
di-(2-ethylhexyl) and diisononyl phthalates on atopic dermatitis in NC/Nga mice.
Immunopharmacol Immunotoxicol 36: 61-69. http://dx.doi.ore/10.3109/08923973.2013.866678
Schw\in 1 < Christiansen. S; Ha 1 ^ o thgi. L; Axelstad. M; Lobl. NM; Svineen. T. (2021). On the
use and interpretation of areola/nipple retention as a biomarker for anti-androgenic effects in rat
toxicity studies [Review], Front Toxicol 3: 730752.
https://heronet.epa.eov/heronet/index.cfm/reference/download/reference id/10492323
Scott. 'ueard. PH; Ramsey. JD; Rhodes. C. (1987). In vitro absorption of some o-phthalate diesters
through human and rat skin. Environ Health Perspect 74: 223-227.
http://dx.doi.ore/10-23(
Sedha. S; Gautam. AK; Verm a imad. R; Kumar. S. (2015). Determination of in vivo estrogenic
potential of Di-isobutyl phthalate (DIBP) and Di-isononyl phthalate (DINP) in rats. Environ Sci
Pollut Res Int 22: 18197-18202. http://dx.doi.on 10 100 v I I > m 01 ¦> -0. I
Setti Ahmed. K; Kharoubi. O; Aoues. AEK; Bouchekara. M; Khal; (2018). Effect of
gestational and lactational exposure to dehp, dinp, and dep on intestinal morphology,
Page 111 of 184
-------
3418
3419
3420
3421
3422
3423
3424
3425
3426
3427
3428
3429
3430
3431
3432
3433
3434
3435
3436
3437
3438
3439
3440
3441
3442
3443
3444
3445
3446
3447
3448
3449
3450
3451
3452
3453
3454
3455
3456
3457
3458
3459
3460
3461
3462
3463
3464
PUBLIC RELEASE DRAFT
May 2024
disaccharidases, and alkaline phosphatase in rats during postnatal development. Am J Perinatol
35: 1251-1259. http://dx.doi.org/10.1055/s-0038-1642Q27
Shin. HM; Bennett r%arkov i i < \ o \ t jlafat. AM; Tancredi O, Hertz-Picci otto. I. (2019).
Variability of urinary concentrations of phthalate metabolites during pregnancy in first morning
voids and pooled samples. Environ Int 122: 222-230.
http://dx.doi.ore 10 101 i.envint..^ I * I n' I _
Shin. HM; Sebum it M < qncr-'ili I* r^irkoski. J; Ozonoff. S; Bennett. PH.; Hertz-Picciotto. I. (2018).
Prenatal exposure to phthalates and autism spectrum disorder in the MARBLES study. Environ
Health 17: 85. http://dx.doi.ors 86/s 12940-018-0428-4
Silva. MI; R ti. JL. Jr.; Needham. LL; Calafat. AM. (2006). Oxidative metabolites of
diisononyl phthalate as biomarkers for human exposure assessment. Environ Health Perspect
114: 1158-1161. http://dx.doij 9/ehp.8865
Smith. JH; Isenberg. IS; Ptigh. G. Jr.; Kamendulis. LM; Acklev. D; Lington. A.W; Klaunig. JE. (2000).
Comparative in vivo hepatic effects of Di-isononyl phthalate (DINP) and related C7-C11 dialkyl
phthalates on gap junctional intercellular communication (GJIC), peroxisomal beta-oxidation
(PBOX), and DNA synthesis in rat and mouse liver. Toxicol Sci 54: 312-321.
http://dx.doi.ore B/toxsci/54.2.312
Soomro. MH; Baiz. N; Philipp let. C; Siroux. V; Nichole Maesano. C; Sanyal. S; Slama. R;
Bomehag. CG; Annesi-Maesano. I. (2018). Prenatal exposure to phthalates and the development
of eczema phenotypes in male children: results from the EDEN mother-child cohort study.
Environ Health Perspect 126: 027002. http://dx.doi.org/10 I-N9/EH*11S J9
Suzuki \ \ phliina^i J. Mizumoto. Y; Serizawa. S; Shiraishi. H. (2012). Foetal exposure to phthalate
esters and anogenital distance in male newborns. Int J Androl 35: 236-244.
http://dx.doi.ore 10 I I I I j I '< : J 0: .01 I 01 rO \
Swenber; nan-Mckeeman. LP. (1999). Alpha 2-urinary globulin-associated nephropathy as a
mechanism of renal tubule cell carcinogenesis in male rats [Review], In CC Capen; E Dybing;
JM Rice; JD Wilbourn (Eds.), IARC Scientific Publications (pp. 95-118). Lyon, France:
International Agency for Research on Cancer.
http://apps.who.int/bookorders/anglais/detartl ¦jsp?sesslan=l&codlan=l&codcol=73&codcch=14
7
Takeuchi. S; Iida. M; Kobavashi. S; Jin. K; Matsuda. T; Koiima. H. (2005). Differential effects of
phthalate esters on transcriptional activities via human estrogen receptors a and P, and androgen
receptor. Toxicology 210: 223-233. http://dx.doi.org/10.1016/i.tox.2005.02.002
Tanner. EM; Hallerback. Mil; Wikstrom. S; Lindh. C; Kiviranta. H; Penning ornehag. CG.
(2020). Early prenatal exposure to suspected endocrine disruptor mixtures is associated with
lower IQ at age seven. Environ Int 134: 105185. http://dx.doi.org/10 J 016/i .envint.201'" ! 0 ^ i s
Thompson. CI; Ross. SM; Her I \ 1 * >u. K; Heinze. Si N >nmg. SS; Gaido. KW. (2005). Differential
steroidogenic gene expression in the fetal adrenal gland versus the testis and rapid and dynamic
response of the fetal testis to di(n-butyl) phthalate. Biol Reprod 73: 908-917.
http://dx.doi.org/10.1095/biolreprod. 105.042382
Trasande. L; Sathyanaravana. S; Traehtman. H. (2014). Dietary phthalates and low-grade albuminuria in
US children and adolescents. Clin J Am Soc Nephrol 9: 100-109.
http://dx.doi. org/10.2215/C JN. 045 70413
>€. (2001). Report to the U.S. Consumer Product Safety Commission by the Chronic Hazard
Advisory Panel on diisononyl phthalate (DINP). Bethesda, MD.
>€. (2010). Toxicity review of Diisononyl Phthalate (DINP). Bethesda, MD.
http://www.cpsc.gov/PageFiles/126539/toxicityDI.MP.pdf
Page 112 of 184
-------
3465
3466
3467
3468
3469
3470
3471
3472
3473
3474
3475
3476
3477
3478
3479
3480
3481
3482
3483
3484
3485
3486
3487
3488
3489
3490
3491
3492
3493
3494
3495
3496
3497
3498
3499
3500
3501
3502
3503
3504
3505
3506
3507
3508
3509
3510
3511
3512
PUBLIC RELEASE DRAFT
May 2024
>€. (2014). Chronic Hazard Advisory Panel on Phthalates and Phthalate Alternatives (with
appendices). Bethesda, MD: U.S. Consumer Product Safety Commission, Directorate for Health
Sciences. https://www.cpsc.eov/s3fs-piiblic/CHAP-REPORT-With-Appendices.pdf
(1991a). Alpha-2u-globulin: Association with chemically induced renal toxicity and
neoplasia in the male rat [EPA Report], (EPA625391019F. PB92143668). Washington, DC: U.S.
Environmental Protection Agency, National Center for Environmental Assessment.
https://ntrl.ntis. eov/NTRL/dashboard/searchResults.xhtml?searchQuerv= 58
1 \ (1991b). Guidelines for developmental toxicity risk assessment. Fed Reg 56: 63798-63826.
(1993). Reference Dose (RfD): description and use in health risk assessments background
document 1A, March 15, 1993. Washington, DC: U.S. Environmental Protection Agency,
Integrated Risk Information System, https://www.epa.gov/iris/reference-dose-rfd-description-
and-use-health-risk-assessments
(1994). Methods for derivation of inhalation reference concentrations and application of
inhalation dosimetry [EPA Report], (EPA600890066F). Research Triangle Park, NC.
https://cfpub.epa.gov/ncea/risk/fecofdisplay.cfm?deid=?1993«S 829&CFTOKEN=2
U.S. EPA. (2002a). Hepatocellular hypertrophy. HED guidance document #G2002.01 [EPA Report],
Washington, DC.
(2002b). A review of the reference dose and reference concentration processes.
(EPA630P02002F). Washington, DC. https://www.epa.gov/sites/production/files/2014-
)cum ents/ ifd-f in al. p df
U.S. EPA. (2005a). Guidelines for carcinogen risk assessment [EPA Report], (EPA630P0300IF).
Washington, DC. https://www.epa.gov/sites/production/files/2013-
09/documents/cancer guidelines final 3-25-05.pdf
U.S. EPA. (2005b). Revised technical review of diisononyl phthalate. Office of Environmental
Information, Environmental Analysis Division, Analytical Support Branch.
https://www.regiilations.gov/dociiment/EPA-HQ-TRI-2005-0004-0003
U.S. EPA. (201 la). Exposure factors handbook: 201 1 edition [EPA Report], (EPA/600/R-090/052F).
Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development,
National Center for Environmental Assessment.
https://nepis.epa. gov/Exe/ZyPURL.cgi?Dockey=P 100F2QS.txt
U.S. EPA. (201 lb). Recommended use of body weight 3/4 as the default method in derivation of the
oral reference dose. (EPA100R110001). Washington, DC.
https://www.epa.gov/sites/production/files/2013-09/documents/recommended-use-of-bw34.pdf
U.S. EPA. (2012). Benchmark dose technical guidance [EPA Report], (EPA 100R12001). Washington,
DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
https://www.epa.gov/risk/benchmark-dose-technical-guidance
U.S. EPA. (2016). Developmental neurotoxicity study (DNT) guidance document. NAFTA Technical
Working Group on Pesticides (TWG). https://www.epa.gov/pesticide-science-and-assessing-
pesticide-risks/developmental-neurotoxicity-study-guidance
U.S. EPA. (2020). Draft scope of the risk evaluation for di-isononyl phthalate (CASRNs 28553-12-0 and
68515-48-0) [EPA Report], (EPA Document No. EPA-740-D-20-033). Research Triangle Park,
NC: Office of Pollution Prevention and Toxics; U.S. Environmental Protection Agency.
U.S. EPA. (202 la). Draft systematic review protocol supporting TSCA risk evaluations for chemical
substances, Version 1.0: A generic TSCA systematic review protocol with chemical-specific
methodologies. (EPA Document #EPA-D-20-031). Washington, DC: Office of Chemical Safety
and Pollution Prevention. https://www.regiilations.gov/dociiment/EPA-HQ-OPPT-2'
0005
Page 113 of 184
-------
3513
3514
3515
3516
3517
3518
3519
3520
3521
3522
3523
3524
3525
3526
3527
3528
3529
3530
3531
3532
3533
3534
3535
3536
3537
3538
3539
3540
3541
3542
3543
3544
3545
3546
3547
3548
3549
3550
3551
3552
3553
3554
3555
3556
3557
3558
3559
3560
PUBLIC RELEASE DRAFT
May 2024
U.S. EPA. (202 lb). Final scope of the risk evaluation for di-isononyl phthalate (DINP) (1,2-benzene-
dicarboxylic acid, 1,2-diisononyl ester, and 1,2-benzenedicarboxylic acid, di-C8-10-branched
alkyl esters, C9-rich); CASRNs 28553-12-0 and 68515-48-0 [EPA Report], (EPA-740-R-21-
002). Washington, DC: Office of Chemical Safety and Pollution Prevention.
https://www.epa.eov/system/files/documents/2021-08/casrn-2l di-isononyl-phthalate-
final~scope.pdf
U.S. EPA. (2022). ORD staff handbook for developing IRIS assessments [EPA Report], (EPA 600/R-
22/268). Washington, DC: U.S. Environmental Protection Agency, Office of Research and
Development, Center for Public Health and Environmental Assessment.
https://cfpub.epa.eov/ncea/iris drafts/recordisplay.cfm?deid=356370
U.S. EPA. (2023a). Draft Proposed Approach for Cumulative Risk Assessment of High-Priority
Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act.
(EPA-740-P-23-002). Washington, DC: U.S. Environmental Protection Agency, Office of
Chemical Safety and Pollution Prevention. https://www.reeulations.eov/document/EPA-HQ-
QPPT-2022-0918-0009
U.S. EPA. (2023b). Science Advisory Committee on Chemicals meeting minutes and final report. No.
2023-01 - A set of scientific issues being considered by the Environmental Protection Agency
regarding: Draft Proposed Principles of Cumulative Risk Assessment (CRA) under the Toxic
Substances Control Act and a Draft Proposed Approach for CRA of High-Priority Phthalates and
a Manufacturer-Requested Phthalate. (EPA-HQ-OPPT-2022-0918). Washington, DC: U.S.
Environmental Protection Agency, Office of Chemical Safety and Pollution Prevention.
https://www.reeiilations.eov/dociiment/EPA-HQ-OPPT-2022-0918-0067
U.S. EPA. (2023c). Technical review of diisononyl phthalate (Final assessment). Washington, DC:
Office Pollution Prevention and Toxics, Data Gathering and Analysis Division and Existing
Chemicals Risk Assessment Division.
U.S. EPA. (2024a). Draft Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP).
Washington, DC: Office of Pollution Prevention and Toxics.
(2024b). Draft Risk Evaluation for Diisononyl Phthalate (DINP) - Systematic Review
Protocol. Washington, DC: Office of Pollution Prevention and Toxics.
(2024c). Draft Risk Evaluation for Diisononyl Phthalate (DINP) - Systematic Review
Supplemental File: Data Quality Evaluation Information for Human Health Hazard Animal
Toxicology. Washington, DC: Office of Pollution Prevention and Toxics.
U.S. EPA. (2024d). Draft Risk Evaluation for Diisononyl Phthalate (DINP) - Systematic Review
Supplemental File: Data Quality Evaluation Information for Human Health Hazard
Epidemiology. Washington, DC: Office of Pollution Prevention and Toxics.
Valle^ i i juehtei \K Tnmn. CS; Cannelle. S: Swanson. CL; Cattlev. RC: Corton. JC. (2003). Role
of the peroxisome proliferator-activated receptor alpha in responses to diisononyl phthalate.
Toxicology 191: 211 -225. http://dx.doi.o /S0300-483X(03)00260-9
Wan. Y; North. ML; Navaranian. G: Ellis. AK; Siee .mond. ML. (2021). Indoor exposure to
phthalates and polycyclic aromatic hydrocarbons (PAHs) to Canadian children: the Kingston
allergy birth cohort.
https://heronet.epa.eov/heronet/index.cfm/reference/download/reference
Waterman. SI: Ambroso. JL; Kelb'i I u < iimmer. GW; Nlkiforov. Al; Harris. SB. (1999).
Developmental toxicity of di-isodecyl and di-isononyl phthalates in rats. Reprod Toxicol 13:
131-136. http://dx.doi.c 5/S0890-6238(99)00002-7
Waterman. SJ: Kethn 1 U < iimmer. GW; Freeman, < < 'x ildfoic U Harris. SB; Nicolich. MI;
McKee. RH. (2000). Two-generation reproduction study in rats given di-isononyl phthalate in
the diet. Reprod Toxicol 14: 21-36. http://dx.doi.ore/10.1016/50890-6238(99)00067-2
Page 114 of 184
-------
3561
3562
3563
3564
3565
3566
3567
3568
3569
3570
3571
3572
3573
3574
3575
3576
3577
PUBLIC RELEASE DRAFT
May 2024
Welsh. M; Saunders. PTK; Fisken. M; Scott. HM; Hutchison. GR: Smith. LB; Sharpe. R.M. (2008).
Identification in rats of a programming window for reproductive tract masculinization, disruption
of which leads to hypospadias and cryptorchidism. J Clin Invest 118: 1479-1490.
http://dx.doi.ore ci34241
in 1 i ( \L. P 1 i
-------
PUBLIC RELEASE DRAFT
May 2024
3578 Appendix A EXISTING ASSESSMENTS FROM OTHER REGULATORY AGENCIES OF
3579 DINP
3580 The available existing assessments of DINP are summarized in TableApx A-l, which includes details regarding external peer-review, public
3581 consultation, and systematic review protocols that were used.
3582
3583 Table Apx A-l. Summary of Peer Review, Public Comments, and Systematic Review for Existing Assessments of DINP
Agency
Asscssmcnt(s) (Reference)
External
Peer-
Review?
Public
Consultation?
Systematic
Review Protocol
Employed?
Remarks
U.S. EPA (IRIS
Program)
Phthalate exposure and male reproductive
outcomes: A systematic review of the
human epidemiological evidence (Hadke et
a.L 2018)
Phthalate exposure and female
reproductive and developmental outcomes:
A systematic review of the human
epidemiological evidence dladke et aL
2019b)
Phthalate exposure and metabolic effects:
A systematic review of the human
epidemiological evidence dladke et aL,
2019a)
Phthalate exposure and neurodevelopment:
A systematic review and meta-analysis of
human epidemiological evidence (Hadke et
al.. 2020a).
No
No
Yes
- Publications were subjected to peer-review prior to
being published in a special issue of Environment
International
- Publications employed a systematic review
process that included literature search and
screening, study evaluation, data extraction, and
evidence synthesis. The full systematic review
protocol is available as a supplemental file
associated with each publication.
U.S. EPA
Technical review of diisononyl phthalate
(Final assessment) (U.S. EPA, 2023c)
No
Yes
No
- Technical review of DINP was reviewed by two
internal EPA reviewers, but was not subjected to
external peer-review
- Draft technical review of DINP was subjected to a
public review period. Public comments available
here: httos://www.reeulations.eov/docket/EPA-HO-
TRI-2022-0262/comments
U.S. CPSC
Toxicity review of Diisononyl Phthalate
(DINP) (U.S. CPSC. 2010)
Yes
Yes
No
- Peer-reviewed by panel of four experts. Peer-
review report available at:
Page 116 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
A^cncv
Asscssmcnt(s) (Reference)
External
Peer-
Review?
Public
Consultation?
Systematic
Review Protocol
Employed?
Remarks
Chronic Hazard Advisory Panel on
Phthalates andPhthalate Alternatives
(IIS. CPSC. 20141
httDs://www.CDSC.gov/s3ts-Dubiic/Peer-Review-
Reno rt-Co m me nts.odf
-Public comments available at:
httDs://www.cDsc. eov/chao
- No formal systematic review protocol employed.
- Details regarding CPSC's strategy for identifying
new information and literature are provided on page
12 of (U.S. CPSC, 2014)
NASEM
Application of systematic review methods
in an overall strategy for evaluating low-
dose toxicity from endocrine active
chemicals fNASEM. 2017)
Yes
No
Yes
- Draft report was reviewed by individuals chosen
for their diverse perspectives and technical expertise
in accordances with the National Academies peer-
review process. See Acknowledgements section of
(NASEM, 2017) for more details.
- Employed NTP's Office of Heath Assessment and
Translation (OHAT) systematic review method
Health Canada
State of the science report: Phthalate
substance grouping 1,2-
Benzenedicarboxylic acid, diisononyl ester;
1,2-Benzenedicarboxylic acid, di-C8-10-
branched alkyl esters, C9-rich (Diisononyl
Phthalate; DINP). Chemical Abstracts
Service Registry Numbers: 28553-12-0 and
68515-48-0 fEC/HC. 2015)
Supporting Documentation:
Carcinogenicity of Phthalates - Mode of
Action and Human Relevance (Health
Canada. 2015)
Supporting documentation: Evaluation of
epidemiologic studies on phthalate
compounds and their metabolites for
hormonal effects, growth and development
and reproductive parameters (Health
Canada. 2018b")
Yes
Yes
No (Animal
studies)
Yes
(Epidemiologic
studies)
- Ecological and human health portions of the
screening assessment report (ECCC/HC, 2020) were
subject to external review and/or consultation. See
uase 2 of (ECCC/HC, 2020) for additional details.
- State of the science rcDort (EC/HC, 2015) and
draft screening assessment report for the phthalate
substance group subjected to 60-day public
comment periods. Summaries of received public
comments available at:
httDs://www.canada.ca/en/health-
canada/services/chemical-substances/substance-
grouDings-initiative/Dhthalate.html#al
- No formal systematic review protocol employed to
identify or evaluate experimental animal toxicology
studies.
- Details regarding Health Canada's strategy for
identifying new information and literature are
orovided in Section 1 of (EC/HC, 2015) and
(ECCC/HC. 2020)
Page 117 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
A^cncv
Asscssmcnt(s) (Reference)
External
Peer-
Review?
Public
Consultation?
Systematic
Review Protocol
Employed?
Remarks
Supporting documentation: Evaluation of
epidemiologic studies on phthalate
compounds and their metabolites for
effects on behaviour and
neurodevelopment, allergies,
cardiovascular function, oxidative stress,
breast cancer, obesity, and metabolic
disorders (Health Canada, 2018a)
- Human epidemiologic studies evaluated using
Downs and Black Method (Health Canada. 2018a.
b)
Screening Assessment - Phthalate
Substance Grouping (ECCC/HC, 2020)
NICNAS
Priority existing chemical assessment
report no. 35: Diisononyl phthalate
(NICNAS. 2012)
No
Yes
No
- NICNAS (2012) states "The report has been
subjected to internal peer review by NICNAS
during all stages of preparation." However, a formal
external peer-review was not conducted.
- NICNAS (2012) states "Applicants for assessment
are given a draft copy of the report and 28 days to
advise the Director of any errors. Following the
correction of any errors, the Director provides
applicants and other interested parties with a copy
of the draft assessment report for consideration.
This is a period of public comment lasting for 28
days during which requests for variation of the
report mav be made." See Preface of (NICNAS.
2012) for more details.
- No formal systematic review protocol employed.
- Details regarding NICNAS's strategy for
identifying new information and literature are
provided in Section 1.3 of (NICNAS, 2012)
ECHA
Evaluation of New Scientific Evidence
Concerning DINP and DIDP in Relation to
Entry 52 of AnnexXVII to REACH
Regulation (EC) No 1907/2006 (ECHA.
2013b)
Yes
Yes
No
- Peer-reviewed by ECHA's Committee for Risk
Assessment (ECHA, 2013a)
- Subject to 12-week public consultation
- No formal systematic review protocol employed..
Page 118 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
A^cncv
Asscssmcnt(s) (Reference)
External
Peer-
Review?
Public
Consultation?
Systematic
Review Protocol
Employed?
Remarks
- Details regarding ECHA's strategy for identifying
new information and literature are provided on
raees 14-15 of (ECHA. 2013b)
EFSA
Update of the Risk Assessment ofDi-
butylphthalate (DBF), Butyl-benzyl-
phthalate (BBP), Bis(2-
ethylhexyl)phthalate (DEHP), Di-
isononylphthalate (DINP) and Di-
isodecylphthalate (DIDP) for Use in Food
Contact Materials (EFSA, 2019)
No
Yes
No
- Draft report subject to public consultation. Public
comments and EFSA's response to comments are
available at:
httDs://doi.ore/10.2903/so.efsa.2019.EN-1747
- No formal systematic review protocol employed.
- Details regarding EFSA's strategy for identifying
new information and literature are provided on page
18 and Aroendix B of (EFSA. 2019)
NTP-CERHR
NTP-CERHR monograph on the potential
human reproductive and developmental
effects of di-isononyl phthalate (DINP)
^NTP-CERHR. 2003)
No
Yes
No
- Report prepared by NTP-CERHHR Phthalates
Expert Panel and was reviewed by CERHR Core
Committee (made up of representatives of NTP-
participating agencies, CERHR staff scientists,
member of phthalates expert panel)
- Public comments summarized in Appendix III of
(NTP-CERHR. 2003)
- No formal systematic review protocol employed.
3584
Page 119 of 184
-------
3585
3586
3587
3588
3589
3590
3591
3592
3593
3594
3595
3596
3597
3598
3599
3600
3601
3602
3603
3604
3605
3606
3607
3608
3609
3610
3611
3612
3613
3614
3615
3616
3617
3618
3619
3620
3621
3622
3623
3624
3625
3626
3627
3628
3629
3630
3631
3632
3633
PUBLIC RELEASE DRAFT
May 2024
Appendix B SUMMARY OF LIVER TOXICITY STUDIES
This Appendix contains more detailed information on the available studies described in the liver toxicity
hazard identification (Section 3.2), including information on individual study design.
Humans
No epidemiologic studies were identified by Health Canada (2018a) or by IRIS assessment that
examined the association between DINP and/or its metabolites and biomarkers of liver injury.
New Literature: EPA considered new studies published since Health Canada's assessment (Health
Canada. 2018a) {i.e., studies published from 2018 to 2019); however, no studies were identified that fall
within this date range and evaluated liver injury for DINP and/or its metabolites.
Laboratory Animals
Existing assessments have consistently identified the liver as one of the most sensitive target organs
following oral exposure to DINP in experimental animal studies (ECCC/HC. 2020; EFSA. 2019;
EC/HC. 2015; ECHA. b, - VTNAS. 2012; U.S. CPSC. 20 h'. { P \ N U'
CERHR. 200 , "i v i PSC. 2001). Short-term (>1 to 30 days), subchronic (>30 to 90 days) and chronic
(>90 days) exposure studies have reported significant liver effects. Available studies include: 11 short-
term oral studies (six studies on rats, four studies on mice, 1 study on cynomolgus monkeys); nine
subchronic oral exposure studies (six on rats, one on mice, one on beagle dogs, and one on marmosets)
and five chronic oral exposure studies (four on rats and one on mice) Available studies are summarized
in TableApx B-l, TableApx B-2,and TableApx B-7, and are discussed further below.
Considerations for Interpretation of Hepatic Effects: Consistent with previous guidances (Hall et at..
201 J; 1 c. i i1 \ . K)2a), EPA considered hepatocellular hypertrophy and corresponding increases in
liver size and weight to be adaptive non-adverse responses, unless accompanied by exposure-related,
biologically significant changes in clinical markers of liver toxicity {i.e., decreased albumin; or
increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), gamma glutamyltransferase, bilirubin, cholesterol) and/or histopathology indicative of an
adverse response {e.g., hyperplasia, degeneration, necrosis, inflammation). Further, phthalates, including
DINP, can induce peroxisome proliferation in the livers of mice and rats (Gorton et at.. 2018; Lapinskas
et at.. 2005; Valles et at.. 2003). and EPA considered evidence supporting a role for PPARa activation in
peroxisome-induced hepatic effects of DINP. For purposes of identifying study NOAEL and LOAEL
values, effects consistent with peroxisome proliferation and PPARa activation were also considered
relevant for setting the LOAEL.
Short-Term (>l to 30 Days) Exposure Studies: EPA evaluated 12 short-term exposure animal studies
from existing assessments that evaluated liver effects following oral exposure to DINP (Ma et at.. 2014;
Kwack et at.. 2010; Kwack et at.. 2009; Valles et at.. 2003; Kaufmaim et at.. 2002; Push et at.. 2000;
Smith et at.. 2000; Hilts AG. 1992; Hazleton Labv t'U*k \ Ps86; Bio/dynamics. 1982a;
Midwest Research Institute. 1981). The database includes six studies in various strains of rat, three
studies in mice, and one study in monkeys. One short-term dermal exposure study in female B6C3F1
mice was identified (Butala et at.. 2004). These studies provide data on relative/and/or absolute liver
weights, histopathology, hepatic enzyme levels and/or activity {e.g., AST, ALT, and ALP), and other
parameters useful to determining the effects of DINP on the liver. These studies are summarized in
Table Apx B-l.
Eight of the available short-term studies reported increases in absolute and/or relative liver weights or
incidences of hepatocyte proliferation or other nonneoplastic lesions following oral exposure to DINP
Page 120 of 184
-------
3634
3635
3636
3637
3638
3639
3640
3641
3642
3643
3644
3645
3646
3647
3648
3649
3650
3651
3652
3653
3654
3655
3656
3657
3658
3659
3660
3661
3662
3663
3664
3665
3666
3667
3668
3669
3670
3671
3672
3673
3674
3675
3676
3677
3678
3679
3680
3681
3682
PUBLIC RELEASE DRAFT
May 2024
(Ma et al.. 2014; Kwack et al.. 2009; Valles et ai. 2003; Kaufmann et ai. 2002; Smith et al.. 2000; Hills
\ ^ rs°2; Hazleton Lahv l Li, \ l 986; Bio/dynamics. 1982a). These observations sometimes
coincided with increases in peroxisomal volume, peroxisomal beta oxidation, and activity of enzymes
such as palmitoyl-CoA oxidase, indicative of PPARa activation, which is discussed in further detail in
the mechanistic section.
The BIBRA (1986) study evaluated the ability of DINP to induce peroxisome proliferation in male and
female F344 rats fed 0, 0.6, 1.2, or 2.5 percent DINP in the diet for 21 days (equivalent to 0, 639, 1,192,
or 2,195 mg/kg-day [males] and 0, 607, 1,193, or 2,289 mg/kg-day [females]). Body weights were
significantly reduced in males (6 to 12 percent decrease) and in females (6 to 14 percent decrease) in a
time- and dose-dependent manner. Food intake was also significantly reduced (19 to 49 percent) in
males and females. Significant dose-dependent increases in absolute and relative liver weight were
observed in males and females beginning in animals from the low dose group (639 mg/kg-day in males;
607 mg/kg-day females). The effects observed on liver weight were considered exposure-related even
though terminal body weights were significantly reduced in males and in females in a dose-dependent
manner, and body weight gain was reduced in animals at the highest dose level. In parallel with the
increases in liver weights, the authors reported dose-dependent increases in cyanide-insensitive
palmitoyl-CoA oxidation levels in males and females of the mid- and high-dose groups, dose-dependent
increases in microsomal protein levels of males and females (all dose levels) and increases in lauric acid
11- and 12-hydroxylase activities in males of the low-dose group (639 mg/kg-day in males).
Hydroxylase activities were increased in high-dose females. The authors also reported decreases in total
cholesterol in males (9 to 24 percent) and females (14 to 24 percent), as well as dose-dependent
decreases in serum triglycerides in males (24 to 48 percent). However, dose-dependent increases in
serum triglycerides (24 to 26 percent) were observed in females. The inconsistency of effects between
sexes is source of uncertainty in the dataset. The authors also examined liver tissue via electron
microscopy and observed increases in peroxisome proliferation in males and females from the highest
exposure groups. However, these effects were not further quantitatively described, which is another
limitation of the dataset.
Data from BIBRA (1986) were consistent with Kwack et al. (2009). In the Kwack study, male SD rats
were administered 0 or 500 mg/kg-day DINP daily via gavage for 4 weeks. Increased relative liver
weight (45 percent) was observed, which coincided with perturbations in several clinical chemistry
parameters. Increases were observed in the serum levels of AST (32 percent), ALP (260 percent), and
triglycerides (53 percent). The observed effects were considered adverse because the liver weight
changes were accompanied by clinical chemistry markers of hepatoxicity. Interestingly, these results
were not wholly consistent with a study by the same authors with a shorter exposure duration (Kwack et
al.. 2010). In that study, male SD rats were again administered to 0 or 500 mg/kg-day DINP daily via
gavage for 2 weeks. Increases in AST levels (31 percent) and ALP (159 percent) were observed as well
as increases in serum triglycerides. There was no change in ALT levels and no significant change in
relative liver weight.
Several other studies reported increases in relative and/or absolute liver weight with concomitant
changes in other hepatic endpoints in B6C3F1 mice (Valles et al.. 2003; Kaufmann et al.. 2002; Smith et
al.. 2000; Hazleton Labs. 1991a) and/or F344 rats (Smith et al.. 2000; Hub \ ^
-------
3683
3684
3685
3686
3687
3688
3689
3690
3691
3692
3693
3694
3695
3696
3697
3698
3699
3700
3701
3702
3703
3704
3705
3706
3707
3708
3709
3710
3711
3712
3713
3714
3715
3716
3717
3718
3719
3720
3721
3722
3723
3724
3725
3726
3727
3728
3729
3730
3731
PUBLIC RELEASE DRAFT
May 2024
weeks exposure to 6,000 ppm DINP (equivalent to 900 mg/kg-day). The LOEL in each species was the
high-dose of DINP (1,200 mg/kg-day for rats, 900 mg/kg-day in mice). Valles et al. (2003) reported
similar findings in male and female B6C3F1 mice fed diets containing 0, 150, 1,500, 4,000, or 8,000
ppm of DINP (CASRN 68515-48-0) for 2 weeks. Relative liver weight was significantly increased in
both sexes at the two highest dose groups and in females at the mid dose-group. The percent change in
relative liver weight for the high dose group was 37 percent in males and over 50 percent in females.
The other statistically significant increases in females were less than 10 percent over controls, while
relative liver weight in males of the 4,000 ppm increased by almost 17 percent.
Two other studies (Kaufmann et al. 2002; Hazleton Lai ) reported similar findings at lower
doses after similar exposure durations {i.e., 4 weeks). In Kaufmann et al. (2002). male and female
B6C3F1 mice were exposed to 0, 500, 1500, 4000, or 8000 ppm DINP in the diet for 4 weeks
(equivalent to 0, 117, 350, 913, 1860 mg/kg-day [males]; or 0, 167, 546, 1272, or 2806 mg/kg-day
[females]). Significant increases in absolute and relative liver weight were observed in males and
females, which corresponded with increased peroxisomal volume and peroxisomal enzyme activity
(cyanide-insensitive palmitoyl-CoA) at doses as low as 350 mg/kg-day in males or 546 mg/kg-day in
females. The LOEL/NOEL was 350/117 mg/kg-day in males and 546/167 mg/kg-day in females.
Hazleton Labs (1991a) reported similar LOEL values for liver effects in males (635 mg/kg-day) and
females (780 mg/kg-day). That study exposed male and female B6C3F1 mice to 0, 3000, 6000, or
12,500 ppm DINP in the diet for 4 weeks (equivalent to 0, 635, 1,377, 2,689, or 6,518 mg/kg-day
[males]; 0, 780, 1761, 3,287, or 6,920 mg/kg-day [females]) and evaluated liver weights, histopathology,
and serum liver enzymes at study termination. Increases in absolute and relative liver weights were
observed in all male and female exposure groups except the low dose, and increased ALT activity was
observed in males and females from the high dose only. Additional findings included enlarged and
discolored livers, increased incidence of hepatocytomegaly (all male dose groups; all female dose
groups except low dose), and increased incidence of coagulative necrosis and/or separate chronic
inflammatory foci in high-dose males (6,518 mg/kg-day) and females (6,920 mg/kg-day) as well as
females of the 3,287 mg/kg-day group. Similar findings were reported in a study by Ma et al. (2014).
which administered 0.2, 2, 20 or 200 mg/kg-day DINP to male Kunming mice via oral gavage daily for
14 days. This study established a NOAEL at 20 mg/kg-day and a LOAEL at 200 mg/kg-day based on
significantly increased incidences of histopathologic lesions of the liver, including central vein dilation,
congestion, and narrowing of the sinusoid with loose cytoplasm in animals exposed to the highest dose
of DINP.
The findings that support liver toxicity in mice and the rat study by Smith et al. (2000) were consistent
with two additional rat studies. A study by the Midwest Research Institute (1981) fed male and female
F344 rats 0, 0.2, 0.67, or 2 percent DINP in the diet for 28 days (estimated doses: 0, 150, 500, 1,500
mg/kg-day [males]; 0, 125, 420, 1,300 mg/kg-day [females]). Increases in hepatic catalase and carnitine
acetyltransferase activity were observed in low dose males (150 mg/kg-day) and females (125 mg/kg-
day). Increases in absolute and relative liver weight were also observed in the mid dose males (500
mg/kg-day) and females (420 mg/kg-day) with no corresponding change in body weight. Additionally,
Bio/dynamics ( la) administered 0 or 1,700 mg/kg-day DINP in the diet to male rats for 1 week and
then evaluated liver weight, general appearance (i.e., macroscopic observation), and clinical chemistry
parameters, including serum ALP at study termination. At study termination, the treated animals had
increased absolute and relative liver weight, as well as increased body weight, and the authors noted
slight congestion in all lobes of the liver in animals exposed to DINP. No statistically or biologically
significant changes were observed for serum ALP levels. A 14-day study by Hiils AG (1992) exposed
female F344 rats to 0, 25, 75, 150, or 1,500 mg/kg-day and then evaluated liver weights, clinical
chemistry parameters, and histopathology at study termination, as well as activities of several
Page 122 of 184
-------
3732
3733
3734
3735
3736
3737
3738
3739
3740
3741
3742
3743
3744
3745
3746
3747
3748
3749
3750
3751
3752
3753
3754
PUBLIC RELEASE DRAFT
May 2024
microsomal enzymes. In general, effects were observed at the highest dose, including increases in
absolute and relative liver weight, and increases in EROD. A dose-dependent increase was observed in
lauric acid hydroxylase, beginning at 25 mg/kg-day. Of note, this study was not reasonable available to
EPA, and data reported on this study reflect those reported by Health Canada's Hazard Assessment
(EC/HC. 2Q15Y
Not all studies identified in existing assessments reported hepatic effects consistent with peroxisomal
beta-oxidation and/or PPARa activation. Indeed, one study in cynomolgus monkeys (Push et at.. 2000)
reported no effect on relative liver weights, histopathology, or serum chemistry parameters in monkeys
administered 0 or 500 mg/kg-day DINP daily via oral gavage for 14 days.
New Literature: EPA identified one new study published between 2015 and 2020 that provided data on
toxicological effects of the liver following short term exposure to DINP ('Meier et at.. 2018). The
developmental exposure study by Neier et al. (2018) evaluated absolute and relative liver weights as
well as hepatic triglyceride levels in PND21 male and female yellow agouti (Avy) mice. Dams were
administered 0 or 75 ppm DINP in the diet (equivalent to 15 mg/kg-day) beginning 2-weeks before
mating and lasting through PND21. Increased absolute (27.6 percent) and relative (15.5 percent) liver
weights were observed in exposed female offspring at PND21. No significant changes were observed in
males. No significant changes were observed in hepatic triglyceride levels, suggesting that differences in
liver weight were not attributed to increases in lipid accumulation in the liver in this study.
TableApx B-l. Summary of Liver Effects Reported in Animal Toxicological Studies Following
Short-Term Exposure to DI
NP
Brief Study Description
(Reference)
NOAEL/
LOAEL
(m«/k«-day)
Effect at LOAEL
Remarks
Kunming mice (males only);
gavage; 0, 0.2, 2, 20, 200
me/ke-dav: 14 davs (Ma et al.
2014)
20/200
Markers of oxidative
stress (t ROS, j GSH,
|MDA, t 8-OH-dG) &
inflammation (|IL-1, f
TNFa) at > 20 mg/kg-
day
Other liver effects:
Liver histopathology: t incidences of
edema (20 mg/kg-day); central vein
dilation, congestion, edema, &
narrowing sinusoidal with extremely
loose cytoplasm (200 mg/kg-day).
Considerations: BW not reported.
Limitations: Historatholoev
qualitative only (no incidence data or
statistical analysis); organ weight and
clinical chemistry not evaluated
F344 rats (females only);
gavage; 0, 25, 75, 150, 1,500
me/ke-dav: 14 davs (Hills AG.
1992)
25 (LOEL)
t lauric acid hydroxylase
(dose-dependent
beginning at 25 mg/kg-
day)
Other liver effects: t absolute and
relative liver weight at 1,500 mg/kg-
day; t liver microsomal enzyme
activities (pentoxyresorufin O-
desalkylase (PROD) and lauryl-CoA
oxidase) at 1,500 mg/kg-day
F344 rats (both sexes); dietary;
0, 0.2, 0.67, 2% (est. 150, 500,
1,500 mg/kg-day [males]; 0,
125, 420, 1,300 mg/kg-day
Ifcmalcsl): 28 davs (Midwest
Research Institute. 1981)
ND/125
(females)
ND/ 150
(males) (LOEL)
t in hepatic catalase and
carnitine
acetyltransferase activity
Other liver effects: t absolute and
relative liver weight (500 mg/kg-day
[males]; 420 mg/kg-day [females])
Page 123 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
(Reference)
NOAEL/
LOAEL
(mg/kg-day)
Effect at LOAEL
Remarks
B6C3F1 mice (both sexes);
dietary; 0, 500, 1500, 4000,
8000 ppm (est. 117,350,913,
1,860 mg/kg-day [males]; 0,
167, 546, 1,272, 2,806 mg/kg-
day [females]); 1 or 4 weeks
(Kaufmann et aL 2002)
117/350
(males)
167/546
(female)
t abs. and rel. liver
weight; t peroxisomal
volume, and
peroxisomal enzyme
activity; t hepatocyte
proliferation in males
Other liver effects:
Liver histopathology: t hepatocyte
proliferation in females at >1272
mg/kg-day.
Considerations: Multiple zones of the
liver examined for quantitative
measurement of hepatocyte
proliferation; BW not reported.
SD rats (males only); oral
gavage; 0, 500 mg/kg-day; 28
davs (Kwack et aL 2009)
ND/500
i body weight gain; f
relative liver weight;
clinical chemistry (f
AST, ALP &
triglycerides)
Considerations: J. bodv weisht sain
(-10%) in DINP exposed mice
F344 rats (both sexes); diet; 0,
0.6, 1.2, 2.5% (est. 639, 1192,
2,195 mg/kg-day [males]; 607,
1,198, 2,289 mg/kg-day
ffemalesl): 21 davs (BIBRA.
1986)
ND/639
(males)
ND/607
(females)
t absolute and relative
liver weight (abs.
increase in males: 136,
150, and 165%; rel.
increase in males: 136,
173, 232%; abs. increase
in females: 124, 164,
and 198%; rel. liver
weights in females: 131,
175,231%)
t 11-and 12-
hydroxylase activity,
hypolipidemic effects
Considerations: Bodv weishts and
food intake were significantly reduced
in males (6 to 12%) and in females (6
to 14% decrease). Food intake was
also significantly reduced (19 to 49%)
in males and females.
B6C3F1 mice (both sexes);
dietary; 0, 3000, 6000, 12,500
ppm (est. 635, 1,377, 2,689,
6,518 mg/kg-day [males]; 780,
1761, 3,287, 6,920 mg/kg-day
1 Females 1): 4 weeks (Hazleton
Labs. 1991a)
ND/635 (males)
ND/780
(females)
(LOEL)
Enlarged and discolored
livers; t incidence of
hepatocytomegaly
Other liver effects:
t incidence of coagulative necrosis
and/or separate chronic inflammatory
foci.
B6C3F1 mice (males only);
dietary; 0, 500, 6000 ppm (est.
0, 75, 900 mg/kg-day); 2 or 4
weeks (Smith et aL 2000)°
75 (NOEL)/
900 (LOEL)
t in relative liver weight
at 4 weeks
Other liver effects: t PBOX. t DNA
synthesis; inhibition of GJIC
Limitations: BW not rcDortcd
F344 rats (males only); dietary;
0, 1000, 12,000 ppm (est. 0, 100,
1200 mg/kg-day); 2 or 4 weeks
(Smith et aL. 2000)°
100
(NOEL)/ 1200
(LOEL)
t in relative liver weight
at 4 weeks
Other liver effects: t PBOX. t DNA
synthesis; inhibition of GJIC
Considerations: significant increases
in relative liver weight observed at 4-
week but not 2-week timepoint.
Limitations: onlv males were
evaluated.
F344 rats (males only); dietary;
0, 2% (est. 1,700 mg/kg-day); 7
davs (Bio/dvnamics, 1982a)
ND/1,700
t abs. and rel. liver
weight; macroscopic
liver observations;
changes in clinical
chemistry (J,
triglycerides)
Page 124 of 184
-------
3755
3756
3757
3758
3759
3760
3761
3762
3763
3764
3765
3766
3767
3768
3769
3770
3771
3772
3773
3774
3775
3776
3777
3778
3779
3780
3781
3782
3783
3784
3785
3786
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
(Reference)
NOAEL/
LOAEL
(m«/k«-day)
Effect at LOAEL
Remarks
Cynomolgus monkeys (males
only); 0, 500 mg/kg-day; oral
eavaee: 14 davs (Push et al.
2000)
500/ND
No statistically or biologically
significant effects were observed
SD rats (male and female); 0 or
500 mg/kg-day; gavage; 14 days
(Kwack et al. 2010)
ND/500
t AST activity (31%), t
ALP (159%); | serum
triglycerides
Other liver effects: liver weishts.
serum biochemistry, and urinalysis
Considerations: No chanee in serum
ALT
" Dose equivalent calculated from 75 mg DINP/kg chow/day based on the assumption that pregnant and nursing female
mice weigh approximately 25g and eat approximately 5 g chow/day.
b Data for the Huls AG studv (1992) were not reasonably available to EPA; Data here reflect those reported bv Health
Canada's Hazard Assessment (EC/HC. 2015).
c Smith et al. (2000) evaluated two isomers of DINP: DINP-1 [CAS 68515-48-0] and DINP-A [CAS 71549-78-5], The
DINP-A isomer is outside the scope of the hazard evaluation; all results herein refer to the DINP-1 isomer.
Sub-chronic (>30 to 90 Days) Exposure Studies: EPA identified nine studies from existing assessments
that provide data on the toxicological effects of DINP on the liver following subchronic duration oral
exposure, including six studies in rats (Hazleton Laty l lb, ^ V t l \ , «11<> dynamics. 1982b. c;
Hazleton Lai 1_, 1971). one in mice (Hazleton Labs. 1992). one study in dogs (Hazleton
Laboratories. 1971). and one study in marmoset monkeys (Hall et at.. 1999). The available studies are
summarized in Table Apx B-2 and discussed further below. One dermal exposure study in New Zealand
white rabbits was also available (Hazleton Laboratories. 1969).
The lowest achieved dose across these rodent studies was 50 mg/kg-day and the highest was 5,770
mg/kg-day (Table_Apx B-2). All studies reported increases in absolute and/or relative liver weight,
sometimes in parallel with exposure-related histopathological effects on the liver (e.g., hepatocytic
hypertrophy), and sometimes coinciding with increases in liver enzymes (i.e., ALT, ALP), suggesting
impaired liver function. These data suggest that the liver is a target organ for DINP, which is consistent
with conclusions from previous assessments by regulatory agencies.
Hazleton Laboratories ( ) reported increased absolute and relative liver weights in both sexes at 500
mg/kg-day as well as exposure-related changes in liver histopathology in males (hepatocytic
hypertrophy throughout the panlobular section). In that study, albino rats were exposed to 0, 50, 150, or
500 mg/kg-day DINP for 13 weeks via diet. Two additional dietary exposure studies in rats by Hazleton
Labs (1991b. 1981) reported increased liver weights, and increased incidences of histopathological
lesions or altered clinical chemistry parameters that suggest liver toxicity. Consistent with the earlier
Hazleton study ( ), Hazleton Labs ( ) found evidence to suggest liver toxicity in F344 rats
exposed to 0, 2500, 5,000, 10,000 or 20,000 ppm DINP for 13 weeks via feed (equivalent to 0, 176, 354,
719, or 1,545 mg/kg-day [males]; 0, 218, 438, 823, or 1,687 mg/kg-day [females]). Increases in absolute
and relative liver weight were accompanied by hepatocellular enlargement in the highest treatment
group. The LOEL was 176 mg/kg-day in males and 218 mg/kg-day in females based on increased liver
weights.
Another study from Hazleton Labs (1981) administered 0, 1,000, 3,000, or 10,000 ppm DINP to male
and female albino rats for 13 weeks in feed (equivalent to 0, 60, 180, or 600 mg/kg-day). Exposure
related increases in absolute and relative liver weights were observed in males and females from the
Page 125 of 184
-------
3787
3788
3789
3790
3791
3792
3793
3794
3795
3796
3797
3798
3799
3800
3801
3802
3803
3804
3805
3806
3807
3808
3809
3810
3811
3812
3813
3814
3815
3816
3817
3818
3819
3820
3821
3822
3823
3824
3825
3826
3827
3828
3829
3830
3831
3832
3833
3834
PUBLIC RELEASE DRAFT
May 2024
high dose groups (absolute weights: 33 percent increase in males, 23.3 percent increase in females;
relative liver weights: 30.2 percent increase in males; 33.3 percent in females). Unlike the other
Hazleton rat studies (1991b. 1971). exposure-related nonneoplastic lesions in the liver were not
observed, although hepatocellular degeneration was noted in two individual high-dose (600 mg/kg-day)
males. Moreover, the authors note that exposure-related changes in histopathology were limited to the
kidneys of high dose males. Dose-related decreases in several clinical chemistry parameters were
observed in both sexes, including total protein, globulin, and total bilirubin, apart from total bilirubin
from males of the mid-dose group (180 mg/kg-day). The decrease in globulin levels reached statistical
significance in mid- (180 mg/kg-day) and high-dose (600 mg/kg-day) females. Decreased bilirubin
reached statistical significance in high-dose males.
Two similarly designed studies in rats from Bio/dynamics (1982b. c) also reported increased absolute
and/or relative liver weight at similar doses in parallel with changes in clinical chemistry parameters. In
the first Bio/Dynamics study, male and female F344 rats were administered 0, 0.1, 0.3, 0.6, 1.0, or 2.0
percent DINP in diet for 13 weeks (equivalent to 0, 77, 227, 460, 767, or 1,554 mg/kg-day)
(Bio/dynami 2b). In the second study, male and female SD rats were administered 0.3 or 1.0
percent DINP in diet for 13 weeks (equivalent to 0, 201 or 690 mg/kg-day [males]; 0, 251 or 880 mg/kg-
day [females]) (Bio/dynamics. 1982c). In the first study, increased absolute and relative liver weights
and decreased cholesterol were observed in females exposed to 227 mg/kg-day (LOAEL)
(Bio/dynami 2b). Other effects included increases in ALT in the two highest doses in males (767
or 1,554 mg/kg-day) and highest dose in females. In the second study, increased relative liver weight
and decreased serum triglyceride levels were observed in males exposed to doses as low as 201 mg/kg-
day and females exposed to 251 mg/kg-day (LOEL), as well as at higher doses. These changes were
accompanied by a 49 or 53 percent increase in ALP (in males or females, respectively) and 31 percent
increase in ALT (males) in rats from the high dose groups. In both studies, terminal body weight was
decreased by at least 10 percent in high-dose males and females. In the SD rat study, terminal body
weight was also reduced in the low dose animals by 24 percent (males; 201 mg/kg-day) or over 15
percent (females; 25 1 mg/kg-day) (Bio/dynamics. 1982c).
An additional study from BASF ( 7) reported effects on clinical chemistry and other hepatic changes
related to hepatotoxicity with similar LOAELs to the Bio/dynamics studies. In that study, male and
female Wistar rats were fed 0, 3000, 10,000, or 30,000 ppm DINP in the diet for 13 weeks (equivalent to
0, 152, 512, 1,543 mg/kg-day [males]; 0, 200, 666, 2,049 mg/kg-day [females]). Decreased triglyceride
levels and peripheral fat deposits in hepatocytes were reported in low-dose male (152 mg-kg-day) and
female (200 mg/kg-day) rats. Increased absolute and relative liver weights were observed at 1,101
mg/kg-day [males] and 1214 mg/kg-day [females]), which are doses much higher than those in which
increased liver weights were observed in the two Bio/dynamics studies (1982b. c). The BASF study
(1987) was not reasonably available to EPA in English; it was identified from Health Canada's Hazard
Assessment (EC/HC. 2015) and therefore is not further considered.
One sub chronic duration study in mice provided evidence that the liver is a target of DINP (Hazleton
Labs. 1992). In that study, male and female B6C3F1 mice were administered 1500, 4000, 10,000, or
20,000 ppm DINP (equivalent to 365, 972, 2,600, or 5,770 mg/kg-day) in the diet for 13 weeks.
Increases in absolute and relative liver weight, as well as histopathologic effects such as hepatocyte
enlargement, liver degeneration, necrosis, and pigment in Kupffer cells as well as in the bile canaliculi
were observed in the 972 mg/kg-day group (LOAEL). One limitation of this study was the small sample
size, which results in limited statistical power to detect differences between treated groups and controls.
Page 126 of 184
-------
3835
3836
3837
3838
3839
3840
3841
3842
3843
3844
3845
3846
3847
3848
3849
3850
3851
3852
3853
3854
3855
3856
3857
3858
3859
3860
3861
3862
3863
3864
PUBLIC RELEASE DRAFT
May 2024
Not all studies have consistently demonstrated the liver toxicity of DINP. Indeed, studies in non-rodent
species, including one study in beagle dogs (Hazleton Laboratories. 1971) and one study in marmoset
monkeys (Hall et al. 1999). have reported contrasting findings. In a study by Hazleton Laboratories
(1971). 0, 0.125, 0.5, 2 percent DINP was administered to beagles in the diet for 13 weeks (equivalent to
0, 37, 160, or 2,000 mg/kg-day). Increases in absolute and relative liver weights were observed at 160
mg/kg-day in males and 2,000 mg/kg-day in both sexes. Histopathologic changes were also observed,
including hepatocyte hypertrophy associated with decreased prominence of hepatic sinusoids at 2,000
mg/kg-day in both sexes. Serum ALT levels increased by 37 percent in males and 48 percent in females
from week 4 at 160 and 2,000 mg/kg-day. Dose-responsive increases in ALT levels were observed in
males (47, 32 and 60 percent increase) and females (48, 74, and 107 percent increase) at study
termination. Limitations of this study include the small sample size and lack of statistical analysis,
which increase uncertainty in the data from this study. Nevertheless, existing assessments of DINP have
supported NOAEL and LOAEL values of 37 and 160 mg/kg-day based on increased absolute and
relative liver weights accompanied with histopathological changes at the highest dose (2,000 mg/kg-
day) tested (EC/HC. 2015). or a LOAEL of 37 mg/kg-day with no NOAEL based on increase liver
weight and serum ALT (ECHA. 2013b; ECB. 2003). Additional limitations of this study include
reporting deficiencies, including the lack of statistical analyses and inconsistencies between text and
tables. These limitations increase uncertainty in the data from this study.
In contrast, a study in marmoset monkeys by Hall et al. (1999) did not observe any statistically
significant liver effects. In that study, male and female marmoset monkeys were administered 0, 100,
500, or 2,500 mg/kg-day DINP daily via oral gavage for 13 weeks. Exposure to DINP increased liver
weight in males, but the effect was not dose-dependent nor statistically significant at any dose, which the
authors attribute to low sample size and high variability.
New Literature: EPA did not identify any new studies published from 2015 through 2020 that provided
data on toxicological effects of liver following chronic exposure to DINP.
TableApx B-2. Summary of Liver Effects Reported in Animal Toxicological Studies Following
Subchronic Exposure to DINP
Brief Study Description
(Reference)
NOAEL/LOAEL
(mg/kg-day)
Effect at LOAEL
Comments
Beagle dogs (both sexes);
dietary; 0, 0.125, 0.5, 2% (est.
37, 160, 2,000 mg/kg-day); 13
weeks (Hazleton Laboratories.
1971)
37/160
t abs. and rel. liver wt.;
t ALT activity
Other liver effects:
Hepatocytic hypertrophy associated
with decreased prominence of
hepatic sinusoids at 2000 mg/kg-day.
Hepatocytic cytoplasm varied from
fine granular to vacuolated
appearance.
Considerations: No NOAEL
established due to absence of
statistical analysis and some
inconsistencies in data reporting (i.e.,
text and tables in the study).
F344 rats (both sexes); dietary;
0,0.1,0.3,0.6, 1.0, 2.0% (est.
0, 77, 227, 460, 767, 1,554
mg/kg-day); 13 weeks
(B io/dvnamics. 1982b)
77/ 227
t abs. and rel. liver wt.;
i cholesterol (females)
Other liver effects: t ALT (males of
767 and 1,554 mg/kg-day males;
1,554 mg/kg-day females); j
cholesterol (227, 460, 767, and 1,554
mg/kg-day females)
Page 127 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
(Reference)
NOAEL/LOAEL
(mg/kg-day)
Effect at LOAEL
Comments
Considerations:
i BW gains in the 767 mg/kg-day
males, j terminal BW (> 10%) at
1554 mg/kg-day in both sexes.
Wistar rats (both sexes);
dietary; 0, 3000, 10,000,
30,000 ppm (est. 0, 152, 512,
1,543 mg/kg-day [males]; 0,
200, 666, 2,049 mg/kg-day
Ifcmalcsl): 13 weeks ((BASF.
1987) as cited by Health
Canada (EC/HC. 2015V)3
ND/152 (males)
ND/ 200
(females)
Clinical chemistry and
liver changes related to
hepatotoxicity
(J, triglyceride level and
i peripheral fat deposits
in hepatocytes)
Considerations:
I BW in males at 152 and 1543
mg/kg-day. Insufficient information
to discern if reported BW was
terminal or B W change.
F344 rats (both sexes); dietary;
0, 2500, 5000, 10,000, 20,000
ppm (est. 0, 176, 354, 719,
1545 mg/kg-day [males]; 0,
218, 438,
823, 1,687 mg/kg-day
Ifcmalcsl): 13 weeks (Hazleton
Labs. 1991b)
ND/176 (males)
ND/218 (females)
t liver weights
Other liver effects:
Hepatocellular enlargement at the
highest dose.
Considerations:
i BW gain at 1545 mg/kg-day in
males and females. j terminal BW
> 10%. (Body weight gains were
decreased in both sexes at 1545
mg/kg-day, along with decreases in
terminal body weight >10% relative
to controls).
SD rats (both sexes); dietary; 0,
1000, 3000, 10,000 ppm (est. 0,
60, 180, 600 mg/kg-day); 13
weeks
LOEL = 180
i total protein and
globulin levels (males)
Other liver effects: t liver weishts
(high dose (both sexes); j total
protein, and total bilirubin
Considerations: historatholoeical
findings limited to the kidney
SD rats (both sexes); dietary; 0,
0.3, 1.0% (est. 201, 690 mg/kg-
day [males]; 251, 880 mg/kg-
day [females]); 13 weeks
(B io/dvnaniics, 1982c)
ND/201 (males;
LOEL)
ND/251 (females;
LOEL)
I terminal body
weights in both sexes; t
abs. and rel. liver wt.
accompanied by j in
triglycerides.
Other liver effects: t ALP (males &
females) and t ALT (males) from the
high dose groups
Considerations:
I Terminal B W by 24% and 28% in
201 mg/kg-day and 690 mg/kg-day
males, respectively. j Terminal BW
by >15% and 31% in 25 lmg/kg-day
and 880 mg/kg-day females,
respectively.
Albino rats (both sexes);
dietary; 0, 50, 150, 500 mg/kg-
dav: 3 months (Hazleton Labs.
1971)
150 (NOEL)/500
(LOEL)
t abs. and rel. liver wt.
and t hepatocyte
hypertrophy
Considerations:
Slight non-significant j BW gain in
500 mg/kg-day males. BW gain
similar across all female groups.
Terminal BW within 10% of controls
for all male and female exposed
groups.
B6C3F1 mice (both sexes);
dietary; 0, 1500, 4000, 10,000,
20,000 ppm (est: 0, 365, 972,
2,600, 5,770 mg/kg-day); 13
weeks (Hazleton Labs. 1992)
365/972
t abs. and rel. liver wt;
hepatocyte
enlargement; other
histopathology in liver
[i.e., pigments in
Kupffer cells and bile
Considerations: J. BW sain and J.
terminal BW of males and females at
5770 mg/kg-day.
Page 128 of 184
-------
3865
3866
3867
3868
3869
3870
3871
3872
3873
3874
3875
3876
3877
3878
3879
3880
3881
3882
3883
3884
3885
3886
3887
3888
3889
3890
3891
3892
3893
3894
3895
3896
3897
3898
3899
3900
3901
3902
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
(Reference)
NOAEL/LOAEL
(mg/kg-day)
Effect at LOAEL
Comments
canaliculi, liver
degeneration/ necrosis]
Marmoset (both sexes); 0, 100,
500, 2,500 mg/kg-day; oral
savase; 13 weeks (Hall et al.
1999)
500/ND
i body weight and
body weight gain
Considerations: J. relative liver
weight (males) but not dose-
dependent & did not reach statistical
significance
" The BASF studv (1987) was only available in German; EPA reports its use bv Health Canada's Hazard Assessment
(EC/HC. 2015).
Chronic (>90 days) Exposure: EPA identified five studies from existing assessments that provide
information on the toxicological effects of DINP on the liver, including two oral exposure studies
conducted in F344 rats (Covance Labs. 1998c; Lington et ai. 1997). one oral study in SD rats
(Bio/dynami 7), one oral exposure study conducted in B6C3F1 mice (Covance Labs. 1998b). and
a combined one and two generation study in SD rats (Waterman et at.. 2000; Exxon Biomedical. 1996a.
b). No chronic exposure data on DINP are available for humans or other primates. Available studies are
summarized in TableApx B-7.
Two studies in F344 rats reported similar findings, most notably of nonneoplastic lesions of the liver
including spongiosis hepatis (Covance Labs. 1998c; Lington et at.. 1997). Lington et al. (1997)
administered 0, 300, 3,000, or 6,000 ppm DINP to F344 rats in the diet for up to 24 months,
corresponding to mean daily intakes of 0, 15, 152, or 307 mg/kg-day in males and 0, 18, 184, or 375
mg/kg-day in females, respectively. Male and female rats in the mid- and high-dose groups had
statistically significant increases in absolute and relative liver weights throughout the exposure period
and study termination, where relative weight increased 19 to 31 percent in males and 16 to 29 percent in
females. Increases in liver weight corresponded with increases in liver enzyme levels. In males, dose-
related increases of 1.5- to 3-fold were observed in ALP, AST, and ALT activities of mid- and high-dose
groups throughout the study. No significant differences were observed in females. Increased incidences
of several non-neoplastic histopathological lesions were observed in the liver at 18 months, including
minimal to slight centrilobular to midzonal hepatocellular enlargement in high-dose males (incidence:
9/10 vs. 0/10 in controls) and females (10/10 vs 0/10 in controls). At study termination {i.e., 24 months),
dose-related increases were observed in the incidence of focal necrosis, spongiosis hepatis, sinusoid
ectasia, hepatocellular enlargement, and hepatopathy associated with leukemia (Table Apx B-3). The
study authors did not report statistical significance for any of the observed lesions. EPA conducted an
independent review of the incidences of spongiosis hepatis and hepatopathy associated with leukemia
and determined that these histopathology findings were significantly increased in mid- (152 mg/kg-day)
and high-dose (307 mg/kg-day) male rats (Table Apx B-3). Additionally at the high dose in the males,
the incidences of sinusoid ectasia, hepatocellular enlargement, and focal necrosis were significantly
increased over controls. In females, dose-related increases in the incidence of focal necrosis,
hepatopathy associated with leukemia, and hepatocellular enlargement were noted at study termination.
The independent statistical analysis determined that the incidences of hepatocellular enlargement and
hepatopathy associated with leukemia were significantly increased in high-dose females. The NOAEL
and LOAEL for non-cancer hepatic effects in this study were 15 and 152 mg/kg-day, respectively; both
are based on a statistically significant increase in the incidence of spongiosis hepatis in mid-dose male
rats that was accompanied by increased absolute and relative liver weights and changes in serum
enzyme activities.
Page 129 of 184
-------
3903
3904
3905
3906
3907
3908
3909
3910
3911
3912
3913
3914
3915
3916
3917
3918
3919
3920
PUBLIC RELEASE DRAFT
May 2024
TableApx B-3. Incidence of Selected Non-neoplastic Hepatic Lesions in F344 Rats Exposed to
DINP for 24 Months (Liiigton et ai. 1997)
Lesion
Dose Group
mg/kg-day (ppm)
Control
15 M/18 F
(300)
152 M/184
(3,000)
307 M/375
(6,000)
Males"
Spongiosis hepatis
24/81
(29.6%)
24/80
(30%)
51/80*
(63.8%)
62/80*
(77.5%)
Hepatopathy
associated
with leukemia
22/81
(27.2%)
17/80
(21.3%)
34/80*
(42.5%)
33/80*
(41.3%)
Sinusoid ectasia
16/81
(19.8%)
16/80
(20.0%)
24/80
(30.0%)
33/80*
(41.3%)
Hepatocellular
enlargement
1/81
(1.2%)
1/80
(1.3%)
1/80
(1.3%)
9/80*
(11.3%)
Focal necrosis
10/81
(12.3%)
9/80
(11.2%)
16/80
(20.0%)
26/80*
(32.5%)
1 vi miles
l ocal necrosis
13/81
(16.0%)
11/81
(13.6%)
19/80
(23.8%)
21/80
(26.3%)
Spongiosis hepatis
4/81
(4.9%)
1/81
(1.2%)
3/80
(3.8%)
4/80
(5.0%)
Sinusoid ectasia
9/81
(11.1%)
4/81
(4.9%)
6/80
(7.5%)
10/80
(12.5%)
Hepatocellular
enlargement
1/81
(1.2%)
0/81
(0%)
0/80
(0%)
11/80*
(13.8%)
Source: Table 7 in Lington et al. (1997)
M = male; F = female
"Number of animals with lesion/total number of animals examined. Percent lesion incidence in parentheses.
* Statistically significant at p < 0.05 when compared to the control incidence using Fischer's Exact test;
statistical analysis performed by EPA.
Another 2-year study in F344 rats with comparable dose levels to Lington et al. (1997) provided data to
support the liver toxicity of DINP (Covar s. 1998c). In that study, DINP was administered to rats
at dietary concentrations of 500, 1,500, 6,000 or 12,000 ppm (equivalent to average daily doses of 29,
88, 359, or 733 mg/kg-day in males, and 36, 109, 442, or 885 mg/kg-day in females for 104 weeks.
Additional groups of male and female rats were given 12,000 ppm (637 and 774 mg/kg-day,
respectively) for 78 weeks and received basal diet only for the remainder of the study (26 weeks) to
evaluate the reversibility of DINP toxicity (recovery group). Increased absolute and relative liver
weights were observed in the two highest dose groups in males and females at multiple timepoints
throughout the study as well study termination. Relative liver weights were increased 35 to 61 percent in
males and 26 to 71 percent in females. There were no significant changes in absolute liver weights in the
recovery group at the end of the 26-week recovery period, suggesting a reversibility of liver
enlargement. Significant increases in activities of serum enzymes (AST and ALT) were also observed in
both sexes at the two highest doses at weeks 52, 78, and study termination. Serum liver enzyme
activities were also increased in the recovery group. Increases in palmitoyl-CoA oxidase activity were
observed in high dose male and female rats, which is further discussed in the mechanistic section below.
Page 130 of 184
-------
3921
3922
3923
3924
3925
3926
3927
3928
3929
3930
3931
3932
PUBLIC RELEASE DRAFT
May 2024
Histological evidence of liver toxicity was observed in parallel with increases in liver weight and
alterations in serum enzyme activity. Incidences of select non-neoplastic lesions from the Covance study
are summarized in TableApx B-4. A dose-responsive increase in the incidence of spongiosis hepatis
was observed at doses as low as 359 mg/kg-day in males. Other lesions observed in males, such as
cytoplasmic eosinophilia, diffuse hepatocellular enlargement, pigment, and individual cell degeneration
or necrosis were generally observed at higher doses, suggesting spongiosis hepatis was the most
sensitive histopathological response to DINP. EPA's independent review determined that diffuse
hepatocellular enlargement was significantly increased in high-dose males and females at study
termination.
Table Apx B-4. Incidence of Selected Hepatic Lesions in F344 Rats Exposed to DINP in the Diet
for 2 Years (C ovan- < 1 'Us. 1998c)
Dose Group mg/kg-day (ppm)
Lesion
29 Ml
88 Ml
359 M/
733 Ml
Recovery" 637
Control
36 F
109 F
442 F
885 F
M/ 774 F
(500)
(1,500)
(6,000)
(12,000)
(12,000)
\la
OS
Spongiosis
5/55b
5/50
2/50
13/55*
21/55*
9/50
hepatis
(9.1%)
(10.0%)
(4.0%)
(23.6%)
(38.2%)
(18.0%)
Cytoplasmic
0/55
0/50
0/50
0/55
31/55*
0/50
eosinophilia
(0%)
(0%)
(0%)
(0%)
(56.4%)
(0%)
Diffuse
0/55
0/50
0/50
0/55
17/55*
0/50
hepatocellular
(0%)
(0%)
(0%)
(0%)
(30.9%)
(0%)
enlargement
Increased
1/55
0/50
1/50
0/55
7/55*
9/50
pigment
(1.8%)
(0%)
(2.0%)
(0%)
(12.7%)
(18.0%)
Individual cell
0/55
0/50
0/50
1/55
5/55*
0/50
degeneration/
(0%)
(0%)
(0%)
(1.8%)
(9.1%)
(0%)
necrosis
Ivimik-s
Spongiosis
0/55
0/50
0/50
1/55
2/55
0/50
hepatis
(0%)
(0%)
(0%)
(1.8%)
(3.6%)
(0%)
Cytoplasmic
0/55
0/50
0/50
0/55
35/55*
0/50
eosinophilia
(0%)
(0%)
(0%)
(0%)
(63.6%)
(0%)
Diffuse
0/55
0/50
0/50
0/55
33/55*
0/50
hepatocellular
(0%)
(0%)
(0%)
(0%)
(60.0%)
(0%)
enlargement
Increased
7/55
8/50
9/50
5/55
16/55*
10/50
pigment
(12.7%)
(16.0%)
(18.0%)
(9.1%)
(29.1%)
(20.0%)
Individual cell
0/55
0/50
0/50
0/55
0/55
0/50
degeneration/
(0%)
(0%)
(0%)
(0%)
(0%)
(0%)
necrosis
Page 131 of 184
-------
3933
3934
3935
3936
3937
3938
3939
3940
3941
3942
3943
3944
3945
3946
3947
3948
3949
3950
3951
3952
3953
3954
3955
3956
3957
3958
3959
3960
3961
3962
3963
3964
3965
3966
3967
3968
3969
3970
PUBLIC RELEASE DRAFT
May 2024
Dose Group mg/kg-day (ppm)
Lesion
29 M/
88 Ml
359 M/
733 Ml
Recovery" 637
Control
36 F
109 F
442 F
885 F
Ml 174F
(500)
(1,500)
(6,000)
(12,000)
(12,000)
Source: Tables 10A and 10C in Covance Labs (1998c)
M = male; F = female
* = significantly different from control (p < 0.05) by Fisher's Exact test as performed by EPA.
a The 12,000 ppm recovery group received 12,000 ppm DINP in the diet for 78 weeks, followed by a 26-
week recovery period during which the test animals received basal diet alone.
h Number of animals with lesion/number of animals with livers examined; percentage is given in parentheses.
Incidence is sum of lesions observed in unscheduled deaths and at terminal sacrifice.
A third study in rats by Bio/dynamics (1987) provided data on liver weights, histopathology, and effects
on clinical chemistry parameters following chronic exposure to DINP. In that study, male and female
SD rats were administered 0, 500, 5,000, or 10,000 ppm DINP in the diet for up to 2-years (equivalent to
0, 27, 271, or 553 mg/kg-day in males and 0, 33, 331, or 672 mg/kg-day in females). Increased absolute
and relative liver weights were observed in high-dose males and females at the 12-month interim
sacrifice and study termination; all increases were between 14 and 34 percent. In the mid-dose females,
there were non-significant increases in absolute (14 percent) and relative (11 percent) liver weight at
interim sacrifice and absolute liver weight (15 percent) at terminal sacrifice, and a significant increase in
relative liver weight (16 percent) at terminal sacrifice. In mid-dose males, a nonsignificant increase of
11 percent was seen in the mid-dose group at interim sacrifice. Histopathological findings were
observed at lower doses than changes in liver weights. Increased incidences of spongiosis hepatis and
minimal-to-slight hepatic focal necrosis were observed in males from the mid-dose group (271 mg/kg-
day). The increases in liver weights and incidences of nonneoplastic lesions were attributed to the
administration of DINP. Incidences of select non-neoplastic lesions from the Bio/dynamics (1987) study
are summarized in Table Apx B-5.
In parallel with increases in liver weight and histopathological findings, changes in clinical chemistry
parameters were observed. Serum ALT was significantly increased in high-dose males at interim
sacrifices on months 6, 12, and 18 by 292, 203, and 232 percent, respectively. A non-statistically
significant increase of 218 percent was observed in males at study termination (24 months). Serum ALP
was significantly increased at months 6 and 12 in high-dose males by 88 and 76 percent, respectively.
Non-significant increases in AST were observed in males from the mid and high dose groups. In
females, non-significant increases in AST (63 percent) and ALT (89 percent) were observed at 6
months. Serum ALP was significantly increased in females of the high-dose group by 81 percent at 18
months, while a non-significant increase of 38 percent was observed at study termination. No exposure-
related changes in serum ALP were observed at earlier timepoints in this group or in females of the low-
or mid-dose groups. The increased serum AST, ALT, and ALP in treated males were for the most part
not statistically significant; however, these findings were considered treatment-related due to the
consistency with which they were noted in the treated males at most timepoints. The increased ALP in
females of the high-dose group at month 18 and month 24 is considered treatment-related and adverse.
However, the increased AST and ALT values in females of the high-dose group at month 6 were not
considered treatment-related due to their isolated occurrence in only one animal at only one timepoint.
Moreover, data from this animal were considered to be statistical outliers via the Grubb's outlier test.
Overall, the Bio/dynamics study (1987) supports a NOAEL of 27 mg/kg-day in male rats based on
treatment related increases in histopathologic lesions {i.e., spongiosis hepatis, focal necrosis) and
increases in serum ALT, AST, and ALP at the LOAEL of 271 mg/kg-day.
Page 132 of 184
-------
3971
3972
3973
3974
3975
3976
3977
3978
3979
3980
3981
3982
3983
3984
3985
3986
3987
3988
3989
3990
3991
3992
3993
3994
3995
PUBLIC RELEASE DRAFT
May 2024
TableApx B-5. Overall Incidence of Selected Tumors in Male and Female Sprague Dawley Rats Exposed
to DINP for 2 Years (Bio/dvnamics. 1987)
Lesion
Dose Group
mg/kg-day (ppm)"
Control
27 MI 33 F
(500 ppm)
271 Ml 331F
(5,000 ppm)
553 M/ 672 F
(10,000 ppm)
Males
nb
70 (57)c
69 (57)
69 (59)
70 (59)
Hepatocellular carcinoma^
2
2
6
4
Neoplastic nodulefs)
5
lemales
6
5
n
70 (59)
70 (56)
70 (60)
70 (59)
Hepatocellular carcinoma
ot
0
5
7*
Neoplastic nodule(s)
1
1
5
2
Source: Aroendix K. Fieure 1. dd. 11 (uu. 426 of the studv rcDort PDF) (Bio/dvnamics. 1987).
Statistical significance for an exposed group indicates a significant pairwise test. Statistical significance for the vehicle
control group indicates a significant trend test.
M = males; F = females; ppm = parts per million
* Statistically significant (p < 0.05) from the control group by a two-tailed Fisher's exact test
t Statistically significant trend (p < 0.05) based on a Chi-square contingency trend test calculated for this review.
" Equivalent doses in mg/kg-day, administered doses in ppm
h Number of animals with tissue examined microscopically; includes all animals throughout the study; i.e., including the
interim sacrifice, the terminal sacrifice, and unscheduled deaths.
c Sample size excluding animals that died or were sacrificed early, which was used for performing statistical analysis for
hepatocellular carcinoma.
d Number of animals with lesion. Percent lesion incidence in parentheses.
One chronic study in mice by Covance Labs (1998b) was identified from existing assessments. Covance
Labs exposed male and female B6C3F1 mice to 500, 1,500, 4,000, or 8,000 ppm DINP for at least 104
weeks. These concentrations corresponded to average daily doses of 0, 90, 276, 742, and 1,560 mg/kg-
day in males and 0, 112, 336, 910, and 1,888 mg/kg-day in females. Evidence of liver toxicity was
observed in treated animals of both sexes. At interim sacrifice, significant increases were observed in
relative liver weights in mid-dose males (742 mg/kg-day) and females (910 mg/kg-day) and in high-dose
males (1,560 mg/kg-day). At study termination, significant increases were observed in absolute (13 to
33 percent increase) and relative (25 to 60 percent increase) liver weights in males exposed to 742 or
1,560 mg/kg-day DINP. Relative liver weight was also significantly increased 32 percent in the recovery
group. In females, increases in absolute liver weight (18 to 34 percent increase) and relative liver weight
(24 to 39 percent) were observed in females exposed to 910 or 1,888 mg/kg-day DINP, as well as in the
recovery groups. However, the responses were not statistically significant.
Exposure-related changes in serum chemistry profiles were also observed and supported the liver as a
target organ. AST and ALT activities were increased in high-dose males (1,560 mg/kg-day) and
recovery group males and females. Exposure-related increases in the serum levels of total protein,
albumin, and globulin were also observed in high-dose males. Increases in albumin and globulin were
also observed in recovery males.
Gross findings, including liver masses, occurred with greatest frequency at the 910 and 1,560 mg/kg-day
dose groups, as well as the recovery group. These masses corresponded to hepatocellular neoplasms or
involvement by lymphoma or histiocytic sarcoma and are discussed further in ( 024a).
Page 133 of 184
-------
3996
3997
3998
3999
4000
4001
4002
4003
4004
4005
4006
4007
4008
4009
4010
4011
4012
4013
4014
PUBLIC RELEASE DRAFT
May 2024
Increased incidences of several nonneoplastic lesions were observed in the livers of high-dose males and
females, including cytoplasmic eosinophilia, diffuse slight to moderate hepatocellular enlargement, and
slight to moderate pigment (TableApx B-6). These changes were also observed in the recovery group,
but generally at lower incidences than in the high-dose groups. No other statistically significant or dose-
related nonneoplastic lesions of the liver were observed in the Covance study (1998b). Liver weights in
recovery group animals were comparable to those of controls, and histological evidence of liver
enlargement was not observed in the male or female recovery groups. The incidences of non-neoplastic
lesions in the recovery groups were decreased at study termination relative to the high-dose groups, but
in most cases were significantly greater than the control values. These data suggest that DINP-induced
liver toxicity was partially reversed in the recovery groups.
EPA identified a LOAEL value from the Covance study (1998b) of 742 mg/kg-day in males and 910
mg/kg-day in females based on increased incidence of liver masses in males, and increased absolute and
relative liver weights, and decreased absolute and relative kidney weights (Section 3.3). ANOAEL of
276 mg/kg-day in males or 336 mg/kg-day in females was identified based on non-cancer and cancer
effects.
Table Apx B-6. Incidence of Selected Non-neoplastic Lesions in B6C3F1 Mice Exposed to DINP in
the Diet for 2 Years (Covance Labs. 1998b)
Dose Group
mg/kg-day (ppm)
Lesion
Control
90 M
112 F
(500)
276 M
336 F
(1,500)
742 M
910 F
(4,000)
1,560 M
1,888 F
(8,000)
Recovery''
1,560 M
1,888 F
(8,000)
NhiL-s
Diffuse hepatocellular
enlargement
0/55fl
(0%)
1/50
(2.0%)
1/50
(2.0%)
2/50
(4.0%)
45/55*
(81.8%)
10/50*
(20.0%)
Increased cytoplasmic
eosinophilia
0/55
(0%)
0/50
(0%)
0/50
(0%)
0/50
(0%)
52/55*
(94.5%)
10/50*
(20.0%)
Pigment
0/55
(0%)
0/50
(0%)
0/50
(0%)
0/50
(0%)
49/55*
(89.1%)
6/50*
(12.0%)
Ivnuk-s
Diffuse hepatocellular
enlargement
0,55
(0%)
0.51
(0%)
0,50
(0%)
1.50
(2.0%)
52/55*
(94.5%)
6,50*
(12.0%)
Increased cytoplasmic
eosinophilia
0/55
(0%)
0/51
(0%)
0/50
(0%)
0/50
(0%)
53/55*
(81.8%)
6/50*
(12.0%)
Pigment
1/55
(1.8%)
1/51
(2.0%)
2/50
(4.0%)
2/50
(4.0%)
41/55*
(74.5%)
3/50
(6.0%)
Source: Tables 11A and 11C in Covance Labs (1998b).
M = male; F = female
* = significantly different from control (p < 0.05) by Fisher's Exact test performed by Syracuse Research
Corporation.
" Number of animals with lesion/total number of animals examined; percent incidence of lesion in parentheses.
Incidences are sum of unscheduled deaths and lesions observed at terminal sacrifice.
b The 8,000 ppm recovery group received 8,000 ppm for 78 weeks, followed by a 26-week recovery period during
which the test animals received basal diet alone.
Page 134 of 184
-------
4015
4016
4017
4018
4019
4020
4021
4022
4023
4024
4025
4026
4027
4028
4029
4030
4031
4032
PUBLIC RELEASE DRAFT
May 2024
Waterman et al. (2000) assessed the potential toxicity of DINP in one- and two-generation studies
conducted in SD rats. In the one-generation study, male and female animals were administered 0.5, 1.0,
or 1.5 percent DINP in the diet for 10 weeks prior to mating and lasting throughout the mating period.
The females were subsequently exposed throughout gestation and lactation until PND 21. Mean received
doses in units of mg/kg-day are shown in Table 3-5. Parental body weight gain was significantly
reduced at the 1.0 and 1.5 percent dose groups in both sexes during the premating phase and in females
during gestation and lactation. Absolute liver weights in both sexes were significantly increased at all
doses, except in PI females at the 1.5 percent level.
For the two-generation study, male and female SD rats were fed DINP at dietary concentrations of 0.0,
0.2, 0.4, or 0.8 percent for 10 weeks before mating and for an additional 7 weeks, through mating,
gestation, and lactation continuously for two-generations. Mean received doses in units of mg/kg-day
are shown in Table 3-7. Absolute liver weights of PI males and females were increased over controls at
all DINP treatment levels. Minimal to moderate increases in cytoplasmic eosinophilia were observed in
all males and females from all dose groups of parents in both generations.
TableApx B-7. Summary of Liver Effects Reported in Animal Toxicological Studies Following
Chronic Exposure to DINP
Brief Study Description
(Reference)
NOAEL/ LOAEL
(mjj/kjj-day)
Effect at LOAEL
Remarks
F344 rats (both sexes); dietary; 0,
0.03, 0.3, 0.6% (est. 0, 15, 152, 307
mg/kg-day [males]; 0, 18, 184, 375
mg/kg-day [females]); 2 years
(Lington et al, 1997)
15/152
(males)
18/184
(females)
t abs. and rel. liver
weight; t in serum
ALT, AST; | non-
neoplastic lesions
(e.g., focal necrosis,
spongiosis hepatis)
SD rats (both sexes); dietary; 0, 500,
5000, 10,000 ppm (est. 0, 27, 271,
553 mg/kg-day [males]; 0, 33, 331,
672 mg/kg-day [females]); 2 years
(B io/dvnamics, 1987)
27/271 (males)
t serum ALT, AST,
ALP (males); t
spongiosis hepatis; t
hepatic focal necrosis
Other liver effects: t absolute and
relative liver weight (both sexes); t
serum ALP (females); t incidence
of hepatocyte necrosis at low- and
high-doses (males)
GLP-compliant study, non-guideline
Considerations: J. BW sains in
females (672 mg/kg-day); no
change in terminal B W in males; t
food consumption for females at
multiple timepoints during study
(672 mg/kg-day)
Male and female SD rats
(30/sex/dose) fed diets containing 0,
0.5, 1.0, 1.5% DINP (CASRN
68515-48-0) starting 10 weeks prior
to mating, through mating, gestation,
and lactation continuously for one
generation (received doses in units of
mg/kg-day shown in Table 3-5)
(Waterman et al., 2000; Exxon
Biomedical 1996a).
ND/ LOEL = 301
t absolute and
relative liver weight
for PI and P2 males
and females; |
incidence of minimal
to moderate
cytoplasmic
eosinophilia
Male and female SD rats
(30/sex/dose) fed diets containing 0,
0.2, 0.4, 0.8% DINP (CASRN
68515-48-0) starting 10 weeks prior
to mating, through mating, gestation,
Page 135 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Brief Study Description
(Reference)
NOAEL/ LOAEL
(mg/kg-day)
Effect at LOAEL
Remarks
and lactation continuously for two-
generations. Received doses in units
of mg/kg-day shown in Table 3-7.
(Waterman et aL 2000; Exxon
Biomedical 19965).
B6C3F1 mice (both sexes); dietary;
0, 500, 1500, 4000, 8000 ppm (est. 0,
90, 276, 742, 1,560 mg/kg-day
[males]; 0, 112,336,910, 1,888
mg/kg-day [females]); 2 years
Recovery study; 0, 1,377 [males]; 0,
1,581 [females]); diet; 78 weeks,
followed by 26 weeks recovery.
(Covance Labs. 1998b)
GLP-compliant and adhere to EPA
guidelines (40 CFR Part 798.330)
276/742
(males)
336/910
(females)
t abs. liver weight,
histopathological
changes in the liver
and i body weight
gain) (females); (t
incidence of liver
masses (males)
Significant neoplastic findinss: t
hepatocellular carcinoma; t
incidence of total liver neoplasms
(combined carcinomas and
adenomas)
Considerations:
i mean body weights in males
(>742 mg/kg-day) and females
(>336 mg/kg-day)
F344 rats (both sexes); dietary; 0,
500, 1500, 6000, 12,000 ppm (est. 0,
29, 88, 359, 733 mg/kg-day [males];
0, 36, 109, 442, 885 mg/kg-day
[females]); 2 years
Recovery study: 0, 637 mg/kg-day
[males]; 0, 774 mg/kg-day
[females]); diet; 78-week exposure,
followed by 26 week recovery period
(Covance Labs. 1998c)
GLP-compliant and adhere to EPA
guidelines (40 CFR Part 798.330)
88/359
(males)
109/442
(females)
t abs. and rel. liver
wt.; t in serum ALT
and AST;
histopathological
findings in liver.
Significant neoplastic findinss
t incidence of mononuclear cell
leukemia; t in hepatocellular
carcinoma; t in combined
hepatocellular carcinoma and
adenoma (See (U.S. EPA. 2024a)
for further discussion)
Limitations:
Did not report results for statistical
analyses of lesion incidence data
4033
Page 136 of 184
-------
4034
4035
4036
4037
4038
4039
4040
4041
4042
4043
4044
4045
4046
4047
4048
4049
4050
4051
4052
4053
4054
4055
4056
4057
4058
4059
4060
4061
PUBLIC RELEASE DRAFT
May 2024
Appendix C FETAL TESTICULAR TESTOSTERONE AS AN
ACUTE EFFECT
No studies of experimental animal models are available that investigate the antiandrogenic effects of
DINP following single dose, acute exposures. However, there are studies of dibutyl phthalate (DBP)
available that indicate a single acute exposure during the critical window of development {i.e., GD14-
19) can reduce fetal testicular testosterone production and disrupt testicular steroidogenic gene
expression. Two studies were identified that demonstrate single doses of 500 mg/kg DBP can reduce
fetal testicular testosterone and steroidogenic gene expression. Johnson et al. (2012; ) gavaged
pregnant SD rats with a single dose of 500 mg/kg DBP on GD 19 and observed reductions in
steroidogenic gene expression in the fetal testes three (Cypl7al) to six {Cypllal, StAR) hours post-
exposure, while fetal testicular testosterone was reduced starting 18 hours post-exposure. Similarly,
Thompson et al. (2005) reported a 50 percent reduction in fetal testicular testosterone 1-hour after
pregnant SD rats were gavaged with a single dose of 500 mg/kg DBP on GD 19, while changes in
steroidogenic gene expression occurred 3 (StAR) to 6 {Cypllal, Cypl7al, Scarbl) hours post-exposure,
and protein levels of these genes were reduced 6 to 12 hours post-exposure. Additionally, studies by
Carruthers et al. (2005) further demonstrate that exposure to as few as two oral doses of 500 mg/kg DBP
on successive days between GDs 15 to 20 can reduce male pup AGD, cause permanent nipple retention,
and increase the frequency of reproductive tract malformations and testicular pathology in adult rats that
received two doses of DBP during the critical window.
In summary, studies of DBP provide evidence to support use of effects on fetal testosterone as an acute
effect. However, the database is limited to just a few studies of DBP that test relatively high (500 mg/kg)
single doses of DBP. Although there are no single dose studies of DINP that evaluate anti androgenic
effects on the developing male reproductive system, there are four studies that have evaluated effects on
fetal testicular testosterone production and steroidogenic gene expression following daily gavage doses
of 500 to 1,500 mg/kg-day DINP on GDs 14 to 18 (5 total doses) (Gray et al.. 2021; Furr et al.. JO I I;
Hannas et al.. 2012; Hannas et al.. 2011)—all of which consistently report anti androgenic effects at the
lowest dose tested (500 mg/kg-day).
Page 137 of 184
-------
4062
4063
4064
4065
4066
4067
4068
4069
4070
4071
4072
4073
4074
4075
4076
4077
4078
4079
4080
4081
4082
4083
4084
4085
4086
4087
4088
4089
4090
4091
4092
4093
4094
4095
4096
4097
4098
4099
4100
4101
4102
4103
4104
4105
4106
4107
4108
4109
PUBLIC RELEASE DRAFT
May 2024
Appendix D SUMMARY OF EPIDEMIOLOGY STUDIES ON
REPRODUCTIVE OUTCOMES
Radke et al. (2018) report the results of a systematic review that evaluated the association between
DINP and male reproductive outcomes. In examining the relationship between DINP exposure and
AGD, the authors found that there is little evidence linking DINP to AGD. The combination of low
exposure levels {i.e., poor sensitivity) and data availability {i.e., fewer accessible studies) may account
for the weaker evidence of an association between AGD and DINP. When evaluating the relationship
between DINP exposure and sperm parameters, the author determined that the association was moderate
due to the morphology's consistency across studies. In examining the association between DINP and the
time until pregnancy in males, the authors did not report a relationship for DINP and the evidence was
deemed inconclusive due to the small number of studies and narrow range of exposure. Finally, when
examining the relationship between DINP metabolite (MINP or MCiOP) exposure and testosterone, the
authors found that there is moderate evidence linking DINP metabolites to lower testosterone levels.
Another systematic review by Radke et al. (2019b) evaluated the association between DINP and female
reproductive and developmental outcomes and also found no clear evidence of association due to
inadequate sensitivity in the available data. When examining the relationship between DINP exposure
and pubertal development the authors found that there was no association linking DINP and pubertal
development and the strength of the evidence was deemed indeterminate. Study evaluations of the
relationship between DINP and a woman's time to pregnancy found that the evidence of an association
between fecundity and exposure to DINP was deemed indeterminate due to lack of the evidence of
relationship for the key fecundity outcomes. The authors also found that in studies that measured the
relationship between DINP and spontaneous abortion, there was no association between early loss and
total loss. Thus, the evidence for an association between DINP and spontaneous abortion was deemed
indeterminate. Finally, when evaluating the association between DINP and gestational duration, the
authors found slight evidence for the association between DINP exposure and preterm birth, however
while there was modest increase in the odds of preterm birth with higher DINP exposure the association
was not statistically significant. In summary there was indeterminate evidence linking DINP and female
reproductive and developmental outcomes.
EPA identified 11 new studies (8 medium quality and 3 low quality) that evaluated the association
between DINP metabolites and developmental and reproductive outcomes. The first medium quality
study, a longitudinal cohort study, by Berger et al. (2018). using data from Center for Health Assessment
of Mothers and Children of Salinas (CHAMACOS) cohort examined prenatal urinary DINP levels and
the association with timing of puberty milestones (thelarche, menarche, pubarche, gonadarche) in
children. The authors found an association between pubarche and menarche age increased in "normal"
weight girls per log2 increase in MCOP. The authors also found gonadarche and pubarche age decreased
in all obese boys. There was not significant a significant association between thelarche age increased in
all girls per log2 increase in MCOP.
A medium quality birth cohort study, by Philipat et al. (2019). Etude des Determinants pre et postnatals
du developpement et de la sante de l'Enfant (EDEN) cohort, evaluated associations between DINP
metabolites (MCOP, MCNP) and a set of outcomes measured at birth (birth weight, placental weight,
placental-to-birth weight ratio). MCNP and MCOP were both associated with lower placental-to-birth
weight ratio; MCNP was additionally associated with lower placental weight. MCOP was associated
with lower placental-to-birth weight ratio (PFR) in multipollutant elastic net penalized regression
models. MCOP was not associated with birth weight or placental weight based on elastic net regression
models.
Page 138 of 184
-------
4110
4111
4112
4113
4114
4115
4116
4117
4118
4119
4120
4121
4122
4123
4124
4125
4126
4127
4128
4129
4130
4131
4132
4133
4134
4135
4136
4137
4138
4139
4140
4141
4142
4143
4144
4145
4146
4147
4148
4149
4150
4151
4152
4153
4154
4155
4156
4157
4158
PUBLIC RELEASE DRAFT
May 2024
A medium quality cross-sectional pilot study, by Zota et al. (2019). included a racially diverse
population of premenopausal women within the Fibroids Observational Research on Genes and the
Environment (FORGE) study presenting to a university gynecology clinic and undergoing either
hysterectomy or myomectomy for symptomatic uterine fibroids to examine the potential associations
between urinary DINP biomarkers and two measures of fibroid burden (uterine volume and fibroid size).
Higher urinary concentrations of MCOP and MCNP were significantly associated with odds of greater
uterine volume. In multivariate logistic regression analyses, each log-unit increase in MCOP was
significantly associated with 2.1 (95% CI: 1.2-3.5) times increased odds of greater uterine volume, and
each log-unit increase in MCNP was associated with 2.8 (95% CI: 1.2-3.5) times increased odds of
greater uterine volume, p < 0.05. Results from additional multivariate linear regression analyses of
urinary phthalate exposure on percent increase in uterine volume were positive but not significant.
Results from multivariate logistic regression analysis of urinary DINP exposure on odds of fibroid size
increase for MCOP were non-significant. Results from additional multivariate linear regression analyses
of urinary MCOP phthalate exposure on percent increase in fibroid size (cm) were also non-significant.
A medium quality cross-sectional study, by Chang et al. (2019). evaluated the association between sex
hormone levels (luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex hormone binding
globulin (SHBG), inhibin B, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-
S), androstenedione (AD), estrone (El), estradiol (E2), total testosterone (TT), free testosterone (FT),
dihydrotestosterone (DHT), dihydrotestosterone/total testosterone ratio, estradiol/total testosterone ratio,
estradiol/estrone ratio), Oxidative stress/Inflammation [(malondialdehyde (MDA), inducible nitric oxide
synthetase (iNOS), 8-hydroxy-2'-deoxyguanosine (8-OHdG)] and benign prostatic hyperplasia (prostate
specific antigen (PSA), prostate volume) and DINP exposure. There were significant positive
associations between the outcomes, FSH, Inhibin B, DHEA, iNOS and MINP with regression
coefficients of 0.91 (95% CI: 0.85, 0.98), 0.90 (95% CI: 0.83, 0.97), 1.58 (95% CI: 1.40, 1.79) and 1.61
(95%) CI: 1.29, 2.03) respectively, p < 0.05. Multivariate regression coefficients showed significant
results for FHS, Inhibin B, iNOS and DHEA, but showed nonsignificant results for LH, SHBG, DHEA-
s, AD, El, E2, TT, FT, DHT, MDA, 8-OHdG, PSA, and prostate volume.
A medium quality study, by Mustieles et al. ( ), used data from a small cohort of subfertile couples
in the Environment and Reproductive Health (EARTH) study to analyze the association between
paternal and maternal preconception urinary DINP metabolites (MCOP), as well as maternal prenatal
DINP metabolites, and measures of placental weight. The authors did not find any significant
association between paternal and maternal preconception urinary phthalates, as well as maternal prenatal
phthalates, and measures of placental weight and MCOP.
A medium quality cohort, by Machtinger et al. (2018). examined the association between urinary
concentrations of DINP with intermediate and clinical in vitro fertilization (IVF) outcomes. There was
an association (adjusted means) between urinary MCOP concentration and intermediate outcomes of
assisted reproduction (total oocytes and mature oocytes) [total oocytes T2 = 10.2 (95% CI: 9.3, 11.2), T2
vs. T1 < 0.05; mature oocytes T2 = 8.4 (95% CI: 7.6, 9.3) T2 vs. T1 < 0.05], However, there was no
significant association (adjusted means) between urinary MCOP concentration and intermediate
outcomes of assisted reproduction (fertilized oocytes, top quality embryos). While there was an
association (adjusted means) between urinary MINP concentration and intermediate outcomes of
assisted reproduction (total oocytes) [total oocytes T2 = 9.2 (95% CI: 8.2, 10.2), T2 vs. T1 < 0.05]; there
was not an association (adjusted means) between urinary MINP concentration and intermediate
outcomes of assisted reproduction (mature oocytes, fertilized oocytes, top quality embryos).
Associations between MOiNP or MONP and intermediate outcomes of assisted reproduction (total
oocytes, mature oocytes, fertilized oocytes, top quality embryos) and live birth following assisted
Page 139 of 184
-------
4159
4160
4161
4162
4163
4164
4165
4166
4167
4168
4169
4170
4171
4172
4173
4174
4175
4176
4177
4178
4179
4180
4181
4182
4183
4184
4185
4186
4187
4188
4189
4190
4191
4192
4193
4194
4195
4196
4197
4198
4199
4200
4201
4202
PUBLIC RELEASE DRAFT
May 2024
reproduction were all non-significant for T2, T3 versus T1 intermediate outcomes and for p-trend of live
birth.
A medium quality case-control study, by Lee et al. (2020). assessed the relationship between uterine
fibroids and DINP metabolite concentrations. The authors did not find any statistically significant
associations between uterine fibroids and DINP metabolite concentrations. The authors did find
associations between cases and controls for OH-MINP concentrations (p-value: 0.042) as mono(4-
methyl-7-hydroxyoctyl) phthalate (OH-MINP) concentrations were significantly higher in the cases than
controls, but it was not statistically significant.
A medium quality occupational short longitudinal study, by Henrotin et al. (2020), observed the three-
day changes in levels of total and free testosterone and oxidized MINP exposure in male factory
workers. A significant inverse association was found between the decrease in serum total testosterone
(TT) concentrations between T1 and T2 and an increase in urinary OXO-MINP. There was no
significant associations observed for total testosterone and models for OH-MINP, or CX-MINP. No
significant associations were noted for free testosterone and oxo-MINP, OH-MINP, or CX-MINP.
Bivariate analyses of sexual health scales (IIEF-5 and ADAM) between DINP exposed and non-exposed
groups: No association was observed between the level of urinary oxo-MINP concentrations and FSH,
LH, index of aromatase activity (ratio of total testosterone to estradiol (TT/E2). No association was
observed between the level of urinary OXO-MINP concentrations and bone turnover biomarkers (P1NP,
CTX).
The first low qualtiy study, a case control study, by Durmaz et al. (2018), examined the association
between DINP metabolites (MINP, MHiNP, MOiNP, MCiOP) and serum luteinizing hormone (LH),
plasma follicle stimulating hormone (FSH) and serum estradiol in non-obese girls aged 4 to 8 years with
premature thelarche. DINP metabolites (MINP, MHiNP, MOiNP, MCiOP and their sum) measured in
spot urine samples were compared among cases and controls. Spearman correlations with uterine
volumes, ovarian volume and pubic hair growth varied but were largely weak, negative and/or not
significant, with some significant positive correlation for the association between MCiOP, MINP and
pubic hair growth, rho = 0.440, p = 0.002 and rho = 0.480, p = 0.000, respectively. Thyroid hormone
levels had largely negative Spearman correlations with DINP metabolites, however MCiOP had a
significant negative correlation with fT4 (rho = -0.335, p = 0.041). Spearman correlations between
DINP metabolites (MCiOP, MiNP, MHiNP, MOiNP, SumDiNP) and BMI and weight were positive and
significant.
A low quality case-control study, by Moreira Fernandez et al. (2019). of women in Brazil evaluated the
association between one DINP metabolite (MINP) and endometriosis. The authors found that there was
a positive but non-significant association for the relationship between MINP and endometriosis (OR=2.5
[95% CI: 0.46, 13.78]).
A final low quality study, a case-control study, by Liao et al. (2018). examined associations between
exposure to one DINP metabolite (MINP) measured in urine samples and recurrent pregnancy loss
among women in Taiwan. The MINP samples was below the limit of detection. The highest sample was
70.4 ng/mL in controls (detection rate 2.6 percent) and 1.43 ng/mL in cases (detection rate 2.9 percent).
Page 140 of 184
-------
4203
4204
4205
4206
4207
4208
4209
4210
4211
4212
4213
4214
4215
4216
4217
4218
4219
4220
4221
4222
4223
4224
4225
4226
4227
4228
4229
4230
4231
4232
4233
4234
4235
4236
4237
4238
4239
4240
4241
4242
4243
4244
4245
PUBLIC RELEASE DRAFT
May 2024
Appendix E BENCHMARK DOSE ANALYSIS OF LINGTON ET AL.
(1997)
E.l Background
OCSPP requested that CPHEA run benchmark dose (BMD) models that are available in EPA's
Benchmark Dose Software version 3.3.2 (BMDS 3.3.2), to estimate risk from DINP for select endpoints
from a chronic exposure study (Lington et al. s , ^ >vnamics. 1986) using specified benchmark
response (BMR) levels. The specific endpoints and BMRs provided by OCSPP for analysis are:
1. Liver weight relative to bodyweight at terminal sacrifice (males and females)
o BMR: 1 control SD, 5%, 10%, 25%
2. Serum ALT at 6- and 18-month sacrifices (males only)
o BMR: 1 control SD, 10%, 20%, 100% {i.e., 2x)
3. Incidence of focal necrosis in the liver (males and females)
o BMR: 5%, 10%
4. Incidence of spongiosis hepatis in the liver (males only)
o BMR: 5%, 10%
5. Incidence of sinusoid ectasia in the liver (males only)
o BMR: 5%, 10%
While BMD and BMDL values are provided for all of the BMRs, this report provides detailed model run
outputs for only the models that were run using the standard BMRs generally recommended by EPA for
these endpoints, 10 percent relative deviation from the control mean (10 percent RD) for the
dichotomous endpoints and organ weight change and 1 standard deviation change from the control mean
(1 SD). Detailed modeling results for all standard noncancer models are provided for all six endpoints
using all of the BMRs requested by OCSPP in separately delivered BMDS Excel output files.
E.2 Summary of BMD Modeling Approach
All standard BMDS 3.3.2 dichotomous and continuous models that use maximum likelihood (MLE)
optimization and profile likelihood-based confidence intervals were used in this analysis. Standard
forms of these models (defined below) were run so that auto-generated model selection
recommendations accurately reflect current EPA model selection procedures EPA's benchmark Dose
Technical Guidance ( ). BMDS 3.3.2 models that use Bayesian fitting procedures and
Bayesian model averaging were not applied in this work.
Standard BMDS 3.3.2 Models Applied to Continuous Endpoints:
• Exponential 3-restricted (exp3-r)
• Exponential 5-restricted (exp5-r)
• Hill-restricted (hil-r)
• Polynomial Degree 3-restricted (ply3-r
• Polynomial Degree 2-restricted (ply2-r)
• Power-restricted (pow-r)
• Linear-unrestricted (lin-ur)
Standard BMDS 3.3.2 Models Applied to Dichotomous Endpoints:
• Gamma-restricted (gam-r)
• Log-Logistic-restricted (lnl-r)
• Weibull-restricted (wei-r)
Page 141 of 184
-------
4246
4247
4248
4249
4250
4251
4252
4253
4254
4255
4256
4257
4258
4259
4260
4261
4262
4263
4264
4265
4266
4267
4268
4269
4270
4271
4272
4273
4274
4275
4276
PUBLIC RELEASE DRAFT
May 2024
• Dichotomous Hill-unrestricted (dhl-ur)
• Logistic (log)
• Log-Probit-unrestricted (lnp-ur)
• Probit (pro)
General Model Options Used for Individual Endpoint Analyses:
• Risk Type: Extra Risk
• Preferred Continuous Endpoint BMRs
o Relative Liver Weight: 0.1 (10%)
o Serum ALT: 1 Standard Deviation (1 SD)
• Preferred Dichotomous Endpoint BMR: 0.1 (10%)
• Confidence Level: 0.95
• Background response: Estimated
• Model Restrictions: Restrictions for BMDS 3.3.2 models are defined in the BMDS 3.3.2 User
Guide and are applied in accordance with EPA BMD Technical Guidance (U.S. EPA. 2012).
Model Selection:
The preferred model for the BMD derivations was chosen from the standard set of dichotomous and
continuous models listed above. The modeling restrictions and the model selection criteria facilitated in
BMDS 3.3.2, and defined in the BMDS User Guide, were applied in accordance with EPA BMD
Technical Guidance ( ) for noncancer endpoints.
With respect to the continuous endpoints, responses were first assumed to be normally distributed with
constant variance across dose groups. If no model achieved adequate fit to response means (BMDS Test
4 p > 0.1) and response variances (BMDS Test 2 p > 0.05) under that assumption, models that assume
normal distribution with non-constant variance, variance modeled as a power function of the dose group
mean ( ), were considered. If no model achieved adequate fit to response means and
variances (BMDS Test 2 p > 0.05) under that assumption, a BMD/BMDL was not derived, and a
LOAEL was selected as POD for the endpoint.
E.3 Summary of BMD Modeling Results
TableApx E-l. Summary of Benchmark Dose Modeling Results from Selected Endpoints in Male
Section
Endpoint
Sex
Selected
Model"
BMDio
(mg/kg-d)
BMDLio
(mg/kg-d)
E.4
Continuous endpoints
E.4.1.1
Relative Liver weight at terminal sacrifice
Male
Linear, CV
106
85.0
E.4.1.2
Relative Liver weight at terminal sacrifice
Female
LOAEL (184 mg/kg-day)
E.4.2.1
Serum ALT at 6-month sacrifice
Male
Linear, NCV
12.5
8.68
E.4.2.2
Serum ALT at 18-month sacrifice
Male
Power, NCV
37.2
17.4
i: ?
Didiolomous 1 indpoinls
E.5.1.1
Focal necrosis in the liver
Male
Logistic
159
125
Page 142 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Section
Endpoint
Sex
Selected
Model"
BMDio
(mg/kg-d)
BMDLio
(mg/kg-d)
E.5.1.2
Focal necrosis in the liver
Female
Log-Probit
222
34.3
E.5.2
Spongiosis hepatis in the liver
Male
Log-Probit
31.9
8.57
E.5.3
Sinusoid ectasia in the liver
Male
Log-Probit
125
14.4
" As described in Section 2, BMDs for noncancer endpoints were derived from the standard set of models as defined in
the EPA BMD technical guidance and as identified in BMDS 3.3.2 as defaults. Since the standard approach gave
adequate results for all endpoints, non-standard models were not considered for BMD derivations.
CV = constant variance model; NCV = non-constant variance model
4277 E.4 Continuous Endpoints
4278 E.4.1 Relative Liver Weight - Terminal Sacrifice
4279 E.4.1.1 Male F344 Rats
4280
4281 Table Apx E-2. Dose-Response Modeling Data for Relative Liver Weight at Terminal Sacrifice in
Male F344 Rats Following 2-Year Exposure to D
NP (Lington et al., 1997)
Dose (mg/kg-dav)
Number per Group
Mean
Standard Deviation
0
61
0.032
0.006
15
54
0.034
0.008
152
50
0.038
0.008
307
51
0.042
0.008
4283
Page 143 of 184
-------
4284
4285
PUBLIC RELEASE DRAFT
May 2024
TableApx E-3. Summary of Benchmark Dose Modeling Results for Relative Liver Weight at Terminal Sacrifice in Male F344 Rats
Models "
Restriction''
I5MR = 10%
1' Value
AIC
I5MDS
Recommends
HMDS Recommendation
Notes
I5MR = 5%
I5MR = 1 SI)
I5MR = 25%
15M1)
I5MDL
HMD
I5MDL
I5MI)
I5MDL
I5MI)
I5MDL
Exponential 3
Restricted
116.26
95.59
0.3786
-1497.4
98773
Viable -
Alternate
Modeled control response
std. dev. >1.5 actual
response std. dev.
59.51
48.93
248.94
206.95
272.19
223.80
Exponential 5
Restricted
79.84
36.41
0.3253
-1496.4
71899
Viable -
Alternate
37.70
16.38
218.32
131.93
248.11
147.52
Hill
Restricted
154.16
151.00
NA
-1488.6
14597
Questionable
Residual at control > 2
d.f.=0, saturated model
(Goodness of fit test cannot
be calculated)
85.09
83.34
303.22
296.39
340.22
333.23
Polynomial
Degree 3
Restricted
36.76
10.37
NA
-1495.3
18631
Questionable
BMD/BMDL ratio > 3
d.f.=0, saturated model
(Goodness of fit test cannot
be calculated)
16.01
4.92
272.09
29.48
283.55
31.16
Polynomial
Degree 2
Restricted
88.20
49.76
0.3087
-1496.4
03289
Viable -
Alternate
42.54
23.75
225.74
141.55
254.52
155.99
Power
Restricted
106.22
85.08
0.4626
-1497.8
97726
Viable -
Allemale
53.11
42.54
241.06
195.89
265.55
212.69
1.incur
1 nrc>lrielcd
HNi.44
X4.%
M.4(.2~
I4T.X
25
\ inlilc
Recommended
1 OHC-I \l<
50.59
42.54
241.50
195.75
266.10
211.11
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = benchmark dose lower limit; NA = not applicable.
" Selected Model (bolded and shaded gray); residuals for doses 0, 15, 152, and 307 mg/kg-day were -0.8549, 0.7132, 0.4739, and -0.2682, respectively.
b Restrictions defined in the BMDS 3.3 User Guide.
Page 144 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4287
Model Summary with BMR of 0.1 Rel. Dev. for the BMD and 0.95
Lower Confidence Limit for the BMDL
0 0455334
U.U4J J JJt
H 041^334
¦
0.0375334
0.0335334
n rm ^^a
U.Uj 1 j j
0.0295334
-43 7 57 107 157 207 257 307
MG/KG-DAY
Frequentist Exponential Degree 3 Estimated Probability Frequentist Exponential Degree 5 Estimated Probability
Frequentist Hill Estimated Probability Frequentist Polynomial Degree 3 Estimated Probability
Frequentist Polynomial Degree 2 Estimated Probability Frequentist Power Estimated Probability
Frequentist Linear Estimated Probability • Data
Page 145 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4288
Selected Frequentist Linear Model with BMR of 0.1 Added Risk for
the BMD and 0.95 Lower Confidence Limit for the BMDL
f) 044SQQ7
U.UttJ J J /
0 049SQQ7
U.Uft ujj/
U.U4UJ33 /
U.UjOj /
Ct n2CCQQ7
(
>
n 034^007
n n^?qqQ7
<
U.UjZ jjj /
C
n n^n^qQ7
~
U.UjU J" J /
n mcic;QQ7
0.0265997
-43 7 57 107 157 207 257 307
MG/KG-DAY
Estimated Probability Response at BMD • Data BMD BMDL
4289
Page 146 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - Linear, CV (Unrestricted) - Rel. Dev., BMR = 0.1
User Input
Model Results
Benchmark Ddse
BMD
105.440033
BMDL
34.95359659
BMD'J
139.9032525
AIC
-1497.897925
Test 4 P-value
0.452657772
D.O.F.
2
Model Parameters
# of Parameters
3
Variable
Estimate
£
0.032S14937
beta
3.08295E-05
alpha
5.54312E-05
Goodness of Fit
Dose
Size
Estimated
Median
Cale'd
Median
Observed
Mean
Estimated
5D
Calcd
SD
Observed
5D
Scaled
Residual
0
61
0.032814937
0.032
0.032
0.00744522
O.OD6
0.006
-0.854892965
15
54
0.0332773S
0.034
0.034
0.00744522
O.OOS
O.OOS
0.713230418
152
50
0.037501021
0.038
0.038
0.00744522
0.008
O.OOS
0.47390353
307
51
0.042279594
0.042
0.042
0.00744522
O.OOS
0.008
-0.268185348
Likelihoods of Interest
Model
Log Likelihood*
# of Parameters
AIC
A1
752.7197303
5
-1495.43946
A2
755.9925165
8
-1495.98503
A3
752.7197303
5
-1495.43946
fitted
751.9489626
3
-1497.S9793
R
726.8720033
2
-1449.74401
Tests of Interest
Test
-2*LoEUikelihocd Ratio)
Test ^
p-value
1
58.24102629
6
<0.0001
2
6.545572396
3
0.0878S246
3
6.545572396
3
0.0S788246
4
1.541535303
2
0.46265777
4290
Page 147 of 184
-------
4291
4292
4293
4294
4295
PUBLIC RELEASE DRAFT
May 2024
E.4.1.2 Female F344 Rats
Table Apx E-4. Dose-Response Modeling Data for Relative Liver Weight at
Terminal Sacrifice in Female F344 Rats Following 2-Year Exposure to DINP
Dose
(mg/kg-day)
Number per
Group
Mean
Standard Deviation
0
65
0.031
0.005
18
57
0.032
0.007
184
48
0.036
0.008
375
53
0.04
0.007
4296
Page 148 of 184
-------
4297
4298
PUBLIC RELEASE DRAFT
May 2024
TableApx E-5. Summary of Benchmark Dose Modeling Results for Relative Liver Weight at Terminal Sacrifice in Female F344
StiiiHliml Models "
Restriction''
I5MR = 10%
1' Virtue
AIC
HMDS Recommends
HMDS Recommendation
Notes
HMR = 5%
I5MR = 1 SI)
I5MR = 25%
I5MI)
ISM 1)1 y
15M1)
HMDL
15M1)
HMDL
15M1)
HMDL
Exponential 3
Restricted
143.27
118.57
0.2610
-1596.49
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
Modeled control response
std. dev. >1.5 actual
response std. dev.
73.34
60.66
268.59
219.51
335.42
277.61
Exponential 5
Restricted
86.77
35.03
0.3336
-1596.24
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
39.99
15.51
199.97
114.18
309.91
167.83
Hill
Restricted
135.95
99.63
NA
-1592.96
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
d.f.=0, saturated model
(Goodness of fit test
cannot be calculated)
69.29
48.44
263.02
194.84
338.00
256.96
Polynomial Degree 3
Restricted
72.04
14.45
NA
-1594.31
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
BMD/BMDL ratio > 3
d.f.=0, saturated model
(Goodness of fit test
cannot be calculated)
31.23
6.76
207.53
28.21
350.14
44.06
Polynomial Degree 2
Restricted
91.72
58.72
0.3068
-1596.13
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
44.59
27.86
204.48
123.24
308.82
189.00
Power
Restricted
131.94
106.23
0.3428
-1597.04
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
65.97
53.08
257.01
205.66
329.86
265.74
Linear
Unrestricted
128.47
105.83
0.3429
-1597.04
Questionable
Non-constant variance test
failed (Test 3 p-value <
0.05)
62.63
53.11
256.89
204.62
329.42
264.54
AIC = Akaike information criterion; BMD = benchmark dose; BMDL =benchmark dose lower limit; NA = not applicable.
" No selected model due to inadequate fit of constant or non-constant variance models.
b Restrictions defined in the BMDS 3.3 User Guide.
Page 149 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4300
Model Summary with BMR of 0.1 Rel. Dev. for the BMD and 0.95
Lower Confidence Limit for the BMDL
n HAA1 7A3
n f)4?1743
U.Utt l/tJ
n D401743
u.utui / to
n 03R1743
U.UJOl / to
n A3C1 "7/ia
n H3/11 ~7A 3
0.0321743
D 0301743
u.uoui / to
n mai 7A3
5 25 75 125 175 225 275 325 375
MG/KG-DAY
Frequentist Exponential Degree 3 Estimated Probability Frequentist Exponential Degree 5 Estimated Probability
Frequentist Hill Estimated Probability Frequentist Polynomial Degree 3 Estimated Probability
Frequentist Polynomial Degree 2 Estimated Probability Frequentist Power Estimated Probability
Frequentist Linear Estimated Probability • Data
Page 150 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4301 E.4.2 Serum ALT - Male F344 Rats
4302 E.4.2.1 6-Month Sacrifice
4303
4304 Table Apx E-6. Dose-Response Modeling Data for Serum ALT Levels in Male F344
Rats Following 6-Month Exposure to DIN
P (Lineton et aL. 1997)
Dose (mg/kg-dav)
Number per Group
Mean
Standard Deviation
0
10
37
8
15
10
38
7
152
10
81
52
307
10
128
145
4306
Page 151 of 184
-------
4307
4308
PUBLIC RELEASE DRAFT
May 2024
TableApx E-7. Summary of Benchmark Dose Modeling Results for Serum ALT Levels in Male F344 Rats Following 6-Month
Models "
Restriction 6
15MR = 10%
1> Value
AIC
HMDS Recommends
HMDS
Recommendation
Notes
HMR= 1 SI)
HMR = 20%
HMR = 100%
HMD
HMDL
HMD
HMDL
HMD
HMDL
HMD
HMDL
Exponential 3
Restricted
20.05
15.84
0.0692
382.00
Questionable
Goodness of fit p-
value <0.1
Modeled control
response std. dev.
>1.5 actual response
std. dev.
40.15
28.50
38.35
30.29
CF
CF
Exponential 5
Restricted
CF
CF
CF
CF
Unusable
BMD computation
failed
124.58
27.19
CF
CF
CF
CF
Hill
Restricted
19.94
9.12
NA
382.16
Questionable
d.f.=0, saturated
model (Goodness of
fit test cannot be
calculated)
34.15
16.39
CF
CF
123.97
90.11
Polynomial Degree 3
Restricted
40.68
11.16
NA
380.67
Questionable
BMD/BMDL ratio >
3 d.f.=0, saturated
model (Goodness of
fit test cannot be
calculated)
55.33
20.32
56.49
22.31
134.04
98.56
Polynomial Degree 2
Restricted
13.99
0
0.1351
380.89
Unusable
BMD computation
failed; lower limit
includes zero
BMDL not estimated
26.33
14.94
27.79
16.84
132.49
87.19
Power
Restricted
18.76
9.26
0.2143
380.20
Viable - Alternate
32.59
16.63
33.74
18.51
131.87
91.22
1 iiu;ii
1 nre-lricled
12.52
S.(.S
0.3050
3~').03
\ ialile Recommended
1 i m e»l VIC
23.42
15.50
25.04
17.37
125.20
86.83
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = benchmark dose lower limit; NA = not applicable; CF = computation failed
" Selected model (bolded and shaded gray); residuals for doses 0, 15, 152, and 307 were 0.5396, -0.7686, 0.1084, 0.0955, respectively.
1 Restrictions defined in the BMDS 3.3 User Guide.
4309
Page 152 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Model Summary with BMR of 0.1 Rel. Dev. for the BMD and 0.95
Lower Confidence Limit for the BMDL
1 39 9fiQQR
IjZ.ZDjjO
119 9fiQQR
11Z.ZD330
Q9 9P1QQR9
79 9P1QQR9
J,
CO OCOOQO
32.269982
-43 7 57 107 157 207 257 307
MG/KG-DAY
— Frequentist Exponential Degree 3 Estimated Probability Frequentist Hill Estimated Probability
Frequentist Polynomial Degree 3 Estimated Probability Frequentist Polynomial Degree 2 Estimated Probability
Frequentist Power Estimated Probability Frequentist Linear Estimated Probability
• Data
4310
Page 153 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Frequentist Linear Model with BMR of 0.1 Added Risk for the
BMD and 0.95 Lower Confidence Limit for the BMDL
193 opi7f;Q
¦
¦
O
J.Z j.OO/ UI7
103.86769
Q2 QC7CQC
OJ.OO / UOD
UJ.OU / uou
/I3 QC7CQC t
^O.OD/OOD
Z j.Ou / uou
J.OO / OOJ j
43
-16.13231
57 107 157 207 257 30
MG/KG-DAY
Estimated Probability Response at BMD • Data BMD BMDL
4311
Page 154 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - Linear, NCV (Unrestricted) - Rel. Dev., BMR = 0.1
User Input
Model
Data
Dependent
Variable
mg/kg-day
Independe
nt
Variable
Total # of
Observatio
n
4
Info
Model
Frequentist Linear,
NCV
Dataset
Name
Male F344 Rats
Serum ALT 6mon
Formula
M[dose] = g + bl
*dose
Var[i] = alpha
*meanfil A rho
Options
Risk
Type
Rel. Dev.
BMR
0.1
Confiden
ce Level
0.95
Distributi
on
Normal
Variance
Non-Constant
Model Results
Benchmark Dose
BMD
12.51986155
BMDL
8.683091255
BMDU
12.77902268
AIC
379.0287425
Test 4 P-value
0.304955816
D.O.F.
2
Model Parameters
# of Parameters
4
Variable
Estimate
8
35.85553524
beta
0.286389228
rho
4.902699939
alpha
1.07545E-06
Goodness of Fit
Dose
Size
Estimated
Median
Calc'd
Median
Observed
Mean
Estimated
SD
Calc'd
SD
Observed
SD
Scaled
Residual
0
10
35.85553524
37
37
6.7074289
8
8
0.539568203
15
10
40.15137365
38
38
8.85168002
7
7
-0.768581876
152
10
79.38669783
81
81
47.0696879
52
52
0.108386302
307
10
123.7770281
128
128
139.825984
145
145
0.095505923
Likelihoods of Interest
Model
Log Likelihood*
# of Parameters
AIC
A1
-228.508524
5
467.017048
A2
-184.1836225
8
384.367245
A3
-184.3267829
6
380.653566
fitted
-185.5143713
4
379.028743
Page 155 of 184
-------
4313
4314
4315
4316
PUBLIC RELEASE DRAFT
May 2024
E.4.2.2 18-Month Sacrifice
TableApx E-8. Dose-Response Modeling Data for Serum ALT Levels in Male F344
Dose (mg/kg-dav)
Number per Group
Mean
Standard Deviation
0
9
42
10
15
10
39
7
152
10
69
39
307
10
128
126
4317
Page 156 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4318 TableApx E-9. Summary of Benchmark Dose Modeling Results for Serum ALT Levels in Male F344 Rats Following 18-Month
Exposure to DI>
P (Non-constant Variance) (Line!
ton et al., 1997)
Models "
Restriction 6
BMR = 10%
1> Value
AIC
BMDS Recommends
BMDS
Recommendation
Notes
BMR = 1 SI)
BMR = 20%
BMR = 100%
HMD
BMDL
BMD
BMDL
BMD
BMDL
BMD
BMDL
Exponential 3
Restricted
28.31
19.66
0.0433
371.30
Questionable
Goodness of fit p-value
<0.1
Modeled control
response std. dev. >1.5
actual response std. dev.
56.70
37.76
52.87
37.61
191.28
143.00
Exponential 5
Restricted
103.76
21.91
NA
370.80
Questionable
BMD/BMDL ratio > 3;
d.f.=0, saturated model
(Goodness of fit test
cannot be calculated)
113.99
40.10
113.67
39.87
154.96
134.70
Hill
Restricted
61.57
28.62
NA
371.00
Questionable
d.f.=0, saturated model
(Goodness of fit test
cannot be calculated)
CF
CF
82.15
46.68
182.90
133.66
Polynomial Degree 3
Restricted
63.43
20.61
NA
370.94
Questionable
BMD/BMDL ratio > 3
d.f.=0, saturated model
(Goodness of fit test
cannot be calculated)
85.51
40.83
84.98
40.09
200.71
131.37
Polynomial Degree 2
Restricted
29.49
14.27
0.0428
371.32
Questionable
Goodness of fit p-value
<0.1
56.99
28.32
55.73
28.45
210.39
132.17
1'inwr'
Reminded
r. 4?
0.0')25
3~0.04
(Jiieolhinnlile
( ilMldlK'NN 0|* Ml |)-
\:ilur 0.1
62.51
33.36
59.71
33.45
179.20
134.31
Linear
Unrestricted
20.06
12.52
0.0655
370.67
Questionable
Goodness of fit p-value
<0.1
40.61
24.79
40.11
25.04
200.56
125.22
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = benchmark dose lower limit; NA = not applicable
a Selected Model is bolded and shaded gray; residuals for doses 0, 15, 152, and 307 were 0.7610,-0.6609, -0.2070, and 0.0131, respectively.
b Restrictions defined in the BMDS 3.3 User Guide.
c Despite p < 0.1, the Power model fit would pass at p > 0.05, the variance model passed p > 0.05, and visual fit of model to data is still adequate for BMD calculation.
4320
Page 157 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Model Summary with BMR of 0.1 Rel. Dev. for the BMD and 0.95
Lower Confidence Limit for the BMDL
-43
130
110
107 157
MG/KG-DAY
307
Frequentist Exponential Degree 3 Estimated Probability
Frequentist Hill Estimated Probability
Frequentist Polynomial Degree 2 Estimated Probability
¦Frequentist Linear Estimated Probability
Frequentist Exponential Degree 5 Estimated Probability
Frequentist Polynomial Degree 3 Estimated Probability
Frequentist Power Estimated Probability
O Data
4321
Page 158 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4322
Frequentist Power Model with BMR of 0.1 Added Risk for the
BMD and 0.95 Lower Confidence Limit for the BMDL
Estimated Probability Response at BMD • Data BMD BMDL
Page 159 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - Power, NCV (Restricted) - Rel. Dev., BMR = 0.1
User Input
Model
Data
Dependent
Variable
mg/kg-day
Independe
nt
Variable
Total # of
Observatio
n
4
Info
Model
Frequentist Power,
NCV
Dataset
Name
MaleF344Rats_S eru
m ALT 18mon
Formula
M[dose] = g + v *
dose A n
Var[i] = alpha *
mean[il A rho
Options
Risk
Type
Rel. Dev.
BMR
0.1
Confiden
ce Level
0.95
Distributi
on
Normal
Variance
Non-Constant
Model Results
Benchmark Dose
BMD
37.19126348
BMDL
17.45080887
BMDU
37.96112263
AIC
370.0444752
Test 4 P-value
0.092488008
D.O.F.
1
Model Parameters
# of Parameters
5
Variable
Estimate
8
39.8382544
V
0.019980069
n
1.464367921
rho
4.643124981
alpha
2.69559E-06
Goodness of Fit
Dose
Size
Estimated
Median
Calc'd
Median
Observed
Mean
Estimated
SD
Calc'd
SD
Observed
SD
Scaled
Residual
0
9
39.8382544
42
42
8.5216504
10
10
0.761030608
15
10
40.89222207
39
39
9.05422294
7
7
-0.66087743
152
10
71.14361683
69
69
32.7473294
39
39
-0.207000441
307
10
127.4742711
128
128
126.82257
126
126
0.013108871
Likelihoods of Interest
Model
Log Likelihood*
# of Parameters
AIC
A1
-217.2980126
5
444.596025
A2
-178.4089743
8
372.817949
A3
-178.6069741
6
369.213948
fitted
-180.0222376
5
370.044475
4324
Page 160 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4325 E.5 Dichotomous Endpoints
4326 E.5.1 Focal Necrosis in the liver
4327 E.5.1.1 Male F344 Rats
4328
4329 Table Apx E-10. Dose-Response Modeling Data for Focal Necrosis of the Liver in Male
4330 F344 Rats Following 2-Year Exposure to DINP (? ^ A )
Dose (mg/kg-dav)
Number per Group
Incidence
0
81
10
15
80
9
152
80
16
307
80
26
4331
Page 161 of 184
-------
4332
4333
PUBLIC RELEASE DRAFT
May 2024
TableApx E-ll. Summary of Benchmark Dose Modeling Results for Focal Necrosis of the Liver in Male F344 Rats Following 2-Year
Models "
Restriction ''
HMR = 10%
P Value
AIC
HMDS Recommends
HMDS Recommendation
Notes
HMR = 5%
HMD
liMDL
HMD
BMDL
Dichotomous Hill
Restricted
154.87
48.90
NA
305.83
Questionable
BMD/BMDL ratio > 3
d.f.=0, saturated model
(Goodness of fit test cannot be
calculated)
132.94
18.97
Gamma
Restricted
161.40
85.98
0.7925
303.85
Viable - Alternate
100.26
41.86
Log-Logistic
Restricted
160.91
78.23
0.7930
303.85
Viable - Alternate
100.39
37.06
Multistage Degree 3
Restricted
162.13
85.74
0.7420
303.89
Viable - Alternate
94.76
41.74
Multistage Degree 2
Restricted
162.13
85.74
0.7420
303.89
Viable - Alternate
94.76
41.74
Multistage Degree 1
Restricted
126.33
84.11
0.8212
302.17
Viable - Alternate
61.50
40.94
Weibull
Restricted
161.48
85.94
0.7832
303.86
Viable - Alternate
98.74
41.84
1 ."ni-lir
1 nreNlriiled
I5S.52
124.50
O.'MI"
30l.')0
\ iiilile Recommended
l.owe-l \l(
88.34
69.47
Log-Probit
Unrestricted
159.84
46.47
0.8230
303.83
Viable - Alternate
BMD/BMDL ratio > 3
104.60
12.63
Probit
Unrestricted
153.31
118.45
0.9368
301.91
Viable - Alternate
83.82
64.96
Quantal Linear
Unrestricted
126.33
84.11
0.8212
302.17
Viable - Alternate
61.50
40.95
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = benchmark dose lower limit; NA = not applicable
"Selected Model is bolded and shaded gray; residuals for doses 0, 15, 152 and 307 were 0.2347, -0.2546, 0.0189 and 0.0007, respectively.
bRestrictions defined in the BMDS 3.3 User Guide.
4334
Page 162 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Model Summary with BMR of 10% Extra Risk for the BMD and 0.95
Lower Confidence Limit for the BMDL
CD
U
£
CD
¦g
u
£
0.5
0.45
n a
\J. *T
0.35
n 3 i
n 9^:
U.Zj
0.15
0.05
-43
57
107 157
mg/kg-day
207
257
307
Frequentist Dichotomous Hill
Estimated Probability
Frequentist Gamma Estimated
Probability
Frequentist Log-Logistic Estimated
Probability
• Frequentist Multistage Degree 3
Estimated Probability
Frequentist Multistage Degree 2
Estimated Probability
¦ Frequentist Multistage Degree 1
Estimated Probability
¦ Frequentist Weibull Estimated
Probability
¦ Frequentist Logistic Estimated
Probability
¦ Frequentist Log-Probit Estimated
Probability
¦ Frequentist Probit Estimated
Probability
4335
Page 163 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Frequentist Logistic Model with BMR of 10% Extra Risk for the
BMD and 0.95 Lower Confidence Limit for the BMDL
i
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
^^Estimated Probability
Response at BMD
O Data
BMD
BMDL
57
107 157
mg/kg-day
207
257
307
Page 164 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - Logistic (Unrestricted) - Extra Risk, BMR = 0.1
User Input
Info
Model
Logistic
Dataset Name
Male F344 Rats-
Formula
P[dose] =
l/[l+exp(-a-b*de
Options
Risk Type
Extra Risk
Model Data
BMR
0.1
Dependent Variable
mg/kg-day
Confidence
Level
0.95
Independent Variable
Incidence
Total # of Observation
4
Background
Estimated
Model Results
Benchmark Dose
BMD
158.52
BMDL
124.56
BMDU
239.50
AIC
301.50
P-value
0.94
D.O.F.
2.00
Chi3
0.12
Slope Factor
158.52
Model Parameters
# of Parameters
2
Variable
Estimate
a
-2.0393
b
0.00426
Goodness of Fit
Dose
Estimated
Probability
Expected
Observed
Size
Seated
Residual
0
0.115134137
9.32586507
ID
81
0.2347
15
0.121808403
9.744672223
9
80
-0.2546
152
0.199154436
15.932354SS
16
80
0.0189
307
0.324963347
25.99710772
26
80
0.0007
Analysis of Deviance
Model
Log Likelihood
# of Parameters
Deviance
Test dX
P Value
Full Model
-14S.SS97738
4
-
NA
Fitted Model
-148.950072
2
0.12059642
2
0.9414837
Reduced Model
-156.0920707
1
14.4045939
3
0.0024031
4337
Page 165 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
User Input
Info
Model
Logistic
Dataset Name
Male F344 Rats-
Formula
P[dose] =
l/[l+exp(-a-b"dc
Options
Risk Type
Extra Risk
Model Data
BMR
0.1
Dependent Variable
mg/kg-day
Confidence
Level
0.95
Independent Variable
Incidence
Total it of Observation
4
Background
Estimated
Model Results
Benchmark Dose
BMD
158.52
BMDL
124.56
BMDU
239.50
AIC
301:90
P-value
0.94
D.O.F.
2.00
Chi3
0.12
Slope Factor
158.52
Model Parameters
# of Parameters
2
Variable
Estimate
a
-2.0393
b
0.00426
Goodness of Fit
Dose
Estimated
Probability
Expected
Observed
Size
Scaled
Residual
0
0.115134137
9.32586507
10
81
0.2347
15
0.121808403
9.744672223
9
SO
-0.2546
152
0..199154436
15.93235483
16
SO
0.0189
307
0.324963S47
25.99710772
26
80
0.0007
Analysis of Deviance
Model
Log Likelihood
# of Parameters
Deviance
Test cJX.
P Value
Full Model
-14S.S897738
4
-
NA
Fitted Model
-148.950072
2
0.12059642
2
0.9414837
Reduced Model
-156.0920707
1
14.4045939
3
0.0024031
4339
4340
4341
4342
4343
4344
4345
Page 166 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4346 E.5.1.2 Female F344 Rats
4347
4348 Table Apx E-12. Dose-Response Modeling Data for Focal Necrosis of the Liver in
Female F344 Rats Following 2-Year Exposure to
DINP (Liiigtoi! et al, 1997)
Dose (mg/kg-dav)
Number per Group
Incidence
0
81
13
18
81
11
184
80
19
375
80
21
4350
Page 167 of 184
-------
4351
4352
PUBLIC RELEASE DRAFT
May 2024
TableApx E-13. Summary of Benchmark Dose Modeling Results for Focal Necrosis of the Liver in Female F344 Rats Following 2-
Models "
Restriction b
BMR = 10%
P
Value
AIC
BMDS Recommends
BMDS Recommendation Notes
BMR = 5%
BMD
BMDL
BMD
BMDL
Dichotomous Hill
Restricted
179.57
19.90
NA
323.73
Questionable
BMD/BMDL ratio > 3
d.f.=0, saturated model (Goodness of
fit test cannot be calculated)
148.09
7.87
Gamma
Restricted
247.12
136.68
0.7185
320.19
Viable - Alternate
120.31
66.54
Log-Logistic
Restricted
239.78
125.46
0.7335
320.15
Viable - Alternate
113.58
59.43
Multistage Degree 3
Restricted
247.12
136.68
0.7185
320.19
Viable - Alternate
120.31
66.53
Multistage Degree 2
Restricted
247.12
136.68
0.7185
320.19
Viable - Alternate
120.31
66.54
Multistage Degree 1
Restricted
247.12
136.68
0.7185
320.19
Viable - Alternate
120.31
66.54
Weibull
Restricted
247.12
136.68
0.7185
320.19
Viable - Alternate
120.31
66.54
I .ogistic
Unrestricted
275.16
179.48
0.6509
320.39
Viable - Alternate
148.92
98.02
l.iiSi-Pnihil
I nreslriiled
222.0N
34.30
0.4N0')
322.03
Viable - Recommended
Limes 1 BMDL
BMD/BMDL ralio>3
96.76
0.90
Probit
Unrestricted
271.03
173.31
0.6617
320.36
Viable - Alternate
144.53
93.23
Quantal Linear
Unrestricted
247.12
136.68
0.7185
320.19
Viable - Alternate
120.31
66.54
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = benchmark dose lower limit; NA = not applicable.
" Selected Model is bolded and shaded gray; residuals for doses 0, 18, 184 and 375 were 0.3259, -0.4779, 0.3508 and -0.1977, respectively.
h Restrictions defined in the BMDS 3.3 User Guide.
4353
Page 168 of 184
-------
4354
0.4
0.35
0.3
0.1
0.05
PUBLIC RELEASE DRAFT
May 2024
Model Summary with BMR of 10% Extra Risk for the BMD and 0.95
Lower Confidence Limit for the BMDL
Frequentist Dichotomous Hill
Estimated Probability
Frequentist Gamma Estimated
Probability
Frequentist Log-Logistic Estimated
Probability
¦ Frequentist Multistage Degree 3
Estimated Probability
Frequentist Multistage Degree 2
Estimated Probability
¦ Frequentist Multistage Degree 1
Estimated Probability
¦ Frequentist Weibull Estimated
Probability
¦ Frequentist Logistic Estimated
Probability
¦ Frequentist Log-Probit Estimated
Probability
¦ Frequentist Probit Estimated
Probability
0
-25 25 75 125 175 225 275 325 375
mg/kg-day
4355
Page 169 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4356
Female F344 Relative Liver Weight vs mg/kg-day; LogProbit model
with BMR of 10% Extra Risk for the BMD and 0.95 Lower Confidence
Limit for the BMDL
0.35
0.1
0.05
0
-25 25 75 125 175 225 275 325 375
mg/kg-day
Estimated Probability
Response at BMD
O Data
BMD
BMDL
Page 170 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - ^4)gPyqbi^ (Unrestricted) - Extra Risk, BMR = 0.1
User Input
Info
Model
Log-Pro bit
Dataset
Name
Female F344 Rats - focal necrosis
Formula
Pfdose] =
g+(l-E) * KmMDOT[atb*LDSfDose))
Options
Risk Type
Extra Risk
BMR
0.1
Confidence
Level
0.95
Background
Estimated
Model Data
Dependent Variable
mg/kg-day
Independent Variable
Incidence
Total # of Observation
4
Model Results
Benchmark Dose
BMD
222.0606266
BMDL
34.3001408
BMDU
Infinity
AIC
322.0-314517
P-value
0.48 QUI 731
D.O.F.
1
Chi2
0.496782444
Model Parameters
# of Parameters
3
Variable
Estimate
Background (g)
0.147649782
a
-3.644150287
b
0.437272073
Goodness of Fit
Dose
Estimated
Probability
Expected
Observed
Size
Scaled
Residual
0
0.147649782
11.95963234
13
81
0.3258509
18
0.155022564
12.55682771
11
81
-0.477945
184
0.221220007
17.69760055
19
80
0.3508162
375
0.2723415S
21.7873264
21
80
-0.197738
Analysis of Deviance
Model
Log Likelihood
# of Parameters
Deviance
Test .it
P Value
Full Modell
-157.7653174
4
-
NA
Fitted Model
-158.0157259
3
0.50081701
1
0.4791414
Reduced Model
-160.5735074
1
5.61638012
3
0.1318411
4357
4358
Page 171 of 184
-------
4359
PUBLIC RELEASE DRAFT
May 2024
4360
4361
4362
4363
E.5.2 Spongiosis hepatis in the liver - Male F344 Rats
Table Apx E-14. Dose-Response Modeling Data for Spongiosis Hepatis of the Liver
Dose (mg/kg-dav)
Number per Group
Incidence
0
81
24
15
80
24
152
80
51
307
80
62
4364
Page 172 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4365 TableApx E-15. Summary of Benchmark Dose Modeling Results for Spongiosis Hepatis of the Liver in Male F344 Rats Following 2-
4366 Year Exposure to DINP (Lington et ai. 1997)
Models"
Restriction*
BMR = 10%
P Value
AIC
BMDS Recommends
BMDS Recommendation Notes
BMR = 5%
BMD
BMDL
BMD
BMDL
Dichotomous Hill
Restricted
53.05
9.92
1
394.27
Viable - Alternate
BMD/BMDL ratio > 3
37.76
4.81
Gamma
Restricted
26.33
20.77
0.8496
390.93
Viable - Alternate
12.82
10.11
Log-Logistic
Restricted
30.45
11.96
0.7322
392.47
Viable - Alternate
17.20
5.67
Mutlistage Degree 3
Restricted
26.33
20.77
1
-9999
Unusable
AIC not estimated
12.82
10.11
Mutlistage Degree 2
Restricted
26.33
20.77
1
-9999
Unusable
AIC not estimated
12.82
10.11
Mutlistage Degree 1
Restricted
26.33
20.77
0.8496
390.93
Viable - Alternate
12.82
10.11
Weibull
Restricted
26.33
20.77
0.8496
390.93
Viable - Alternate
12.82
10.11
Logistic
Unrestricted
42.42
35.87
0.6349
392.50
Viable - Alternate
21.74
18.35
Lo^-Prohil
I nresl riiied
3I.NN
8.57
O.NI37
3')2.37
Viable - Recommended
Limes i BMDL; BMD/BMDL ralio >3
20.08
4.03
Probit
Unrestricted
42.55
36.41
0.6037
392.70
21.70
18.55
Quantal Linear
Unrestricted
26.33
20.77
0.8496
390.93
12.82
10.11
AIC = Akaike information criterion; BMD = benchmark dose; BMDL = benchmark dose lower limit
" Selected Model is bolded; residuals for doses 0,15, 152, and 307 were 0.1279, -0.1656, 0.0941, and -0.0539, respectively.
4 Restrictions defined in the BMDS 3.3 User Guide.
4367
Page 173 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Model Summary with BMR of 10% Extra Risk for the BMD and
0.95 Lower Confidence Limit for the BMDL
—1—
n q
U.J
n £
U.o
n 7
u. /
n F>
¦
u.o
n c:
n A
n 5
U.3
n i
n 1
U. -L
0
-43 7 57 107 157 207 257 307
MG/KG-DAY
Frequentist Dichotomous Hill Estimated Probability Frequentist Gamma Estimated Probability
Frequentist Log-Logistic Estimated Probability Frequentist Multistage Degree 3 Estimated Probability
Frequentist Multistage Degree 2 Estimated Probability Frequentist Multistage Degree 1 Estimated Probability
Frequentist Weibull Estimated Probability Frequentist Logistic Estimated Probability
Frequentist Log-Probit Estimated Probability Frequentist Probit Estimated Probability
Frequentist Quantal Linear Estimated Probability • Data
4368
Page 174 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4369
Frequentist Log-Probit Model with BMR of 10% Extra Risk for the
BMD and 0.95 Lower Confidence Limit for the BMDL
1
n q
0.8
0.7
0.6
rt c
n A -r- T ^0^0000"^
0.3 i—
n ? -L
r
n 1
U. -L
0
-43 7 57 107 157 207 257 307
MG/KG-DAY
Estimated Probability Response at BMD • Data BMD BMDL
4370
Page 175 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - LogProbit (Unrestricted) - Extra Risk, BMR = 0.1
Model
Info
Options
Data
Model
Log-Probit
Risk
Dependent
Dataset
Name
Male F344
Type
Extra Risk
Variable
mg/kg-day
Rats spongiosis
BMR
0.1
Independe
hepatis
Confiden
nt
P[dose] = g+(l-g) *
ce Level
0.95
Variable
Incidence
Formula
CumNorm(a+b*Log(
Dose))
Backgrou
nd
Estimated
Total # of
Observatio
n
4
Vlodel Results
Benchmark Dose
BMD
31.87966632
BMDL
8.566931336
BMDU
77.63938389
AIC
392.3657526
P-value
0.813651618
D.O.F.
1
Chi2
0.055562904
Model Parameters
# of Parameters
3
Variable
Estimate
Background (g)
0.288658724
a
-4.003497521
b
0.786242291
Goodness of Fit
Dose
Estimated
Probability
Expected
Observed
Size
Scaled
Residual
0
0.288658724
23.38135661
24
81
0.1279398
15
0.310314502
24.82516015
24
80
0.1656122
152
0.629151263
50.33210107
51
80
0.094143
307
0.780322211
62.4257769
62
80
-0.053889
Analysis of Deviance
Log
#of
Test
Model
Likelihood
Parameters
Deviance
d.f.
P Value
Full Model
-193.1328632
4
-
-
NA
Fitted Model
-193.1828763
3
0.10002618
1
0.7517982
Reduced Model
-222.4986873
1
58.6316221
3
0.7517982
4371
Page 176 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4372 E.5.3 Sinusoid Ectasia in the Liver Male F344 Rats
4373
4374 Table Apx E-16. Dose-Response Modeling Data for Sinusoid Ectasia of the Liver
4375 in Male F344 Rats Following 2-Year Exposure to DINP (? ^ ^ A )
Dose (mg/kg-dav)
Number per Group
Incidence
0
81
16
15
80
16
152
80
24
307
80
33
4376
Page 177 of 184
-------
4377
4378
PUBLIC RELEASE DRAFT
May 2024
TableApx E-17. Summary of Benchmark Dose Modeling Results for Sinusoid Ectasia of the Liver in Male F344 Rats Following 2-
Models "
Restriction b
BMR = 10%
P
Value
AIC
BMDS Recommends
BMDS Recommendation
Notes
BMR=5%
BMD
BMDL
BMD
BMDL
Dichotomous Hill
Restricted
126.62
19.59
NA
374.75
Questionable
BMD/BMDL ratio > 3
d.f.=0, saturated model
(Goodness of fit test cannot
be calculated)
79.29
7.58
Gamma
Restricted
121.73
68.52
0.9441
372.76
Viable - Alternate
66.95
33.36
Log-Logistic
Restricted
122.39
58.96
0.9572
372.75
Viable - Alternate
69.06
27.93
Multistage Degree 3
Restricted
118.39
68.47
0.9930
370.77
Viable - Alternate
60.57
33.33
Multistage Degree 2
Restricted
118.39
68.47
0.9930
370.77
Viable - Alternate
60.57
33.33
Multistage Degree 1
Restricted
104.19
68.30
0.9746
370.80
Viable - Alternate
50.72
33.25
Weibull
Restricted
121.20
68.51
0.9372
372.76
Viable - Alternate
65.82
33.35
Logistic
Unrestricted
128.86
97.30
0.9836
370.78
Viable - Alternate
68.24
51.73
l.iiSi-Pnihil
I nreslriiled
125.23
14.42
O.'WI 1
372.75
Viable - Recommended
Limesi BMDI.
BMD/BMDI. ralio >3
76.52
2.40
Probit
Unrestricted
125.62
93.71
0.9883
370.77
Viable - Alternate
65.79
49.29
Quantal Linear
Unrestricted
104.19
68.30
0.9746
370.80
Viable - Alternate
50.72
33.25
AIC = Akaike information criterion; BMD = benchmark dose; BMDL =benchmark dose lower limit; NA = not applicable.
" Selected Model is bolded; residuals for doses 0,15, 152 and 307 were -0.0075, 0.0082, -0.0013 and 0.0007, respectively.
4 Restrictions defined in the BMDS 3.3 User Guide.
4379
Page 178 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
4380
4381
Model Summary with BMR of 10% Extra Risk for the BMD and 0.95
Lower Confidence Limit for the BMDL
0.5
0
-43 7 57 107 157 207 257 307
mg/kg-day
^^—Frequentist Dichotomous Hill
Estimated Probability
Frequentist Gamma Estimated
Probability
Frequentist Log-Logistic Estimated
Probability
^^—Frequentist Multistage Degree 3
Estimated Probability
^^—Frequentist Multistage Degree 2
Estimated Probability
^^—Frequentist Multistage Degree 1
Estimated Probability
^^—Frequentist Weibull Estimated
Probability
^^—Frequentist Logistic Estimated
Probability
^^—Frequentist Log-Probit Estimated
Probability
^^—Frequentist Probit Estimated
Probability
Page 179 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Male F344 Relative Liver Weight vs mg/kg-day; LogProbit model
with BMR of 10% Extra Risk for the BMD and 0.95 Lower Confidence
Limit for the BMDL
Page 180 of 184
-------
PUBLIC RELEASE DRAFT
May 2024
Results for Selected Model - LogProbit (Unrestricted) - Extra Risk, BMR = 0.1
wwWvavwwvvvw-
User Input
Options
Info
Risk Type
Extra Risk
Model Data
Model
Log-Probit
BMR
0.1
Dependent Variable
rng/kg-day
Dataset Name
Sinusoid Ectasia -
Confidence
Level
0.95
Independent Variable
Incidence
Formula
Pjdose] = g+(l-g)
Total # of Observation
4
Background
Estimated
Model Results
Benchmark Dose
BMD
125.23
BMDL
14.42
BMDU
247.62
AIC
372.75
P-value
0.99
D.O.F.
1.00
Chi2
0.00
Model Parameters
# of Parameters
Variable
Estimate
g
0.197861854
a
-4.343490179
b
0.73743943
Goodness of Fit
Dose
Estimated
Probability
Expected
Observed
Size
Scaled
Residual
0
0.197861854
16.02681018
16
SI
-0.0075
15
0.199634872
15.97073978
16
SO
0.00S2
152
0.300063561
24.00543434
24
SO
-0.0013
307
0.412461541
32.99692324
33
SO
0.0007
Analysis of Deviance
Model
Log Likelihood
of Parameters
Deviance
Test slX.
P Value
Full Model
Full Model
-133.3755714
4
-
Fitted Model
Fitted Model
-183.3756339
3
0.00012493
1
Reduced Model
Reduced Model
-139.500S934
1
12.2506439
3
Page 181 of 184
-------
4384
4385
4386
4387
4388
4389
4390
4391
4392
4393
4394
4395
4396
4397
4398
4399
4400
4401
4402
4403
4404
4405
4406
4407
4408
4409
4410
4411
4412
4413
4414
4415
4416
4417
4418
4419
4420
4421
4422
4423
4424
4425
4426
4427
4428
PUBLIC RELEASE DRAFT
May 2024
Appendix F CALCULATING DAILY ORAL HUMAN
EQUIVALENT DOSES AND HUMAN EQUIVALENT
CONCENTRATIONS
For DINP, all data considered for PODs are obtained from oral animal toxicity studies in rats, mice, or
beagles. Because toxicity values for DINP are from oral animal studies, EPA must use an extrapolation
method to estimate HEDs. The preferred method would be to use chemical-specific information for such
an extrapolation. EPA identified one study reporting a physiologically based pharmacokinetic model for
DINP based on humanized liver mice (Miura et ai. 2018). Since the study made use of genetically
modified animals and has not been validated by the Agency, it was not considered fit-for-purpose or
used to calculate HEDs. EPA did not locate other DINP information to conduct a chemical-specific
quantitative extrapolation. In the absence of such data, EPA relied on the guidance from U.S. EPA
(2 ), which recommends scaling allometrically across species using the three-quarter power of body
weight (BW3/4) for oral data. Allometric scaling accounts for differences in physiological and
biochemical processes, mostly related to kinetics.
For application of allometric scaling in risk evaluations, EPA uses dosimetric adjustment factors
(DAFs), which can be calculated using EquationApx F-l.
EquationApx F-l. Dosimetric Adjustment Factor
U.S. EPA (2 ), presents DAFs for extrapolation to humans from several species. However, because
those DAFs used a human body weight of 70 kg, EPA has updated the DAFs using a human body
weight of 80 kg for the DINP risk evaluation ( |). EPA used the body weights of 0.025,
0.25, and 12 kg for mice, rats and dogs, respectively, as presented in U.S. EPA (2 ). The resulting
DAFs for mice, rats, and dogs are 0.133, 0.236, and 0.622, respectively.
Use of allometric scaling for oral animal toxicity data to account for differences among species allows
EPA to decrease the default intraspecies UF (UFa) used to set the benchmark MOE; the default value of
10 can be decreased to 3, which accounts for any toxicodynamic differences that are not covered by use
of BW3 4 Using the appropriate DAF from Equation Apx F-l, EPA adjusts the POD to obtain the HED
using Equation Apx F-2:
Equation Apx F-2. Daily Oral Human Equivalent Dose
Where:
DAF
BWa
BWh
Dosimetric adjustment factor (unitless)
Body weight of species used in toxicity study (kg)
Body weight of adult human (kg)
HEDDaily — PODDauy X DAF
Where:
HEDnaily
P ODDaily
DAF
Human equivalent dose assuming daily doses (mg/kg-day)
Oral POD assuming daily doses (mg/kg-day)
Dosimetric adjustment factor (unitless)
Page 182 of 184
-------
4429
4430
4431
4432
4433
4434
4435
4436
4437
4438
4439
4440
4441
4442
4443
4444
4445
4446
4447
4448
4449
4450
4451
4452
4453
4454
4455
4456
4457
4458
4459
4460
4461
4462
4463
4464
4465
4466
4467
4468
4469
4470
4471
4472
PUBLIC RELEASE DRAFT
May 2024
For this draft risk evaluation, EPA assumes similar absorption for the oral and inhalation routes, and no
adjustment was made when extrapolating to the inhalation route. For the inhalation route, EPA
extrapolated the daily oral HEDs to inhalation HECs using a human body weight and breathing rate
relevant to a continuous exposure of an individual at rest, as follows:
EquationApx F-3. Extrapolating from Oral HED to Inhalation HEC
wrrn r BWh
HECDaily, continuous ~ H E D Daily X ( )
in^ * EiU£
Where:
HECoaily continuous = Inhalation HEC based on continuous daily exposure (mg/m3)
HEDoaiiy = Oral HED based on daily exposure (mg/kg-day)
BWh = Body weight of adult humans (kg) = 80
IRr = Inhalation rate for an individual at rest (m3/hr) = 0.6125
EDc = Exposure duration for a continuous exposure (hr/day) = 24
Based on information from U.S. EPA (201 la). EPA assumes an at rest breathing rate of 0.6125 nrVhr.
Adjustments for different breathing rates required for individual exposure scenarios are made in the
exposure calculations, as needed.
It is often necessary to convert between ppm and mg/m3 due to variation in concentration reporting in
studies and the default units for different OPPT models. Therefore, EPA presents all PODs in
equivalents of both units to avoid confusion and errors. Equation Apx F-4 presents the conversion of the
HEC from mg/m3 to ppm.
Equation Apx F-4. Converting Units for HECs (mg/m3 to ppm)
mg 24.45
X ppm = Y —5- x
m3 MW
Where:
24.45 = Molar volume of a gas at standard temperature and pressure (L/mol), default
MW = Molecular weight of the chemical (MW of DINP = 418.62 g/mol)
F.l DINP Non-cancer HED and HEC Calculations for Acute and
Intermediate Duration Exposures
The acute and intermediate duration non-cancer POD is based on a BMDLs of 49 mg/kg-day, and the
critical effect is decreased fetal testicular testosterone. The BMDLs was derived by NASEM (2017)
through meta-regression and BMD modeling of fetal testicular testosterone data from two studies of
DINP with rats (Bobere et al. JO I I; liannas et al. 2011). R code supporting NASEM's meta-regression
and BMD analysis of DINP is publicly available through GitHub). This non-cancer POD is considered
protective of effects observed following acute and intermediate duration exposures to DINP. EPA used
Equation Apx F-l to determine a DAF specific to rats (0.236), which was in turn used in the following
calculation of the daily HED using Equation Apx F-2:
mq mq
11.6 — = 49- — X 0.236
kg — day kg — day
Page 183 of 184
-------
4473
4474
4475
4476
4477
4478
4479
4480
4481
4482
4483
4484
4485
4486
4487
4488
4489
4490
4491
4492
4493
4494
4495
4496
4497
4498
PUBLIC RELEASE DRAFT
May 2024
EPA then calculated the continuous HEC for an individual at rest using EquationApx F-3:
mq mq 80 kq
63-0 —j = 11.6- x( ^ )
m kg day 0.6125 * 24 hr
hr
Equation Apx F-4 was used to convert the HEC from mg/m3 to ppm:
mq 24.45
3.68 ppm = 63.0 —- x
HH m3 418.62
F.2 DINP Non-cancer HED and HEC Calculations for Chronic Exposures
The chronic duration non-cancer POD is based on a NOAEL of 15 mg/kg-day, and the critical effect is
liver toxicity (i.e., increased relative liver weight, increased serum chemistry (AST, ALT, ALP),
histopathologic findings (e.g., focal necrosis, spongiosis hepatis)) in F344 rats following two years of
dietary exposure to DINP (Lington etai. 1997; Bio/dynamics. 1986). EPA used Equation Apx F-l to
determine a DAF specific to rats (0.236), which was in turn used in the following calculation of the daily
HED using Equation Apx F-2:
mq mq
3.55 — = 15- — x 0.236
kg — day kg — day
EPA then calculated the continuous HEC for an individual at rest using Equation Apx F-3:
mq mq 80 kq
19.3-|= 3.55 x( ^ )
m kg day 0.6125 * 24 hr
hr
Equation Apx F-4 was used to convert the HEC from mg/m3 to ppm:
mg 24.45
1.13 ppm = 19.3 —7 x ^ ^ ^
m3 418.62
Page 184 of 184
------- |